Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific nTPM"	"RNA single cell type specificity"	"RNA single cell type distribution"	"RNA single cell type specificity score"	"RNA single cell type specific nTPM"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific nTPM"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific nTPM"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific nTPM"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific nTPM"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific nTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific nTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"CCD Protein"	"CCD Transcript"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [nTPM]"	"Tissue RNA - adrenal gland [nTPM]"	"Tissue RNA - amygdala [nTPM]"	"Tissue RNA - appendix [nTPM]"	"Tissue RNA - basal ganglia [nTPM]"	"Tissue RNA - bone marrow [nTPM]"	"Tissue RNA - breast [nTPM]"	"Tissue RNA - cerebellum [nTPM]"	"Tissue RNA - cerebral cortex [nTPM]"	"Tissue RNA - cervix [nTPM]"	"Tissue RNA - choroid plexus [nTPM]"	"Tissue RNA - colon [nTPM]"	"Tissue RNA - duodenum [nTPM]"	"Tissue RNA - endometrium 1 [nTPM]"	"Tissue RNA - epididymis [nTPM]"	"Tissue RNA - esophagus [nTPM]"	"Tissue RNA - fallopian tube [nTPM]"	"Tissue RNA - gallbladder [nTPM]"	"Tissue RNA - heart muscle [nTPM]"	"Tissue RNA - hippocampal formation [nTPM]"	"Tissue RNA - hypothalamus [nTPM]"	"Tissue RNA - kidney [nTPM]"	"Tissue RNA - liver [nTPM]"	"Tissue RNA - lung [nTPM]"	"Tissue RNA - lymph node [nTPM]"	"Tissue RNA - medulla oblongata [nTPM]"	"Tissue RNA - midbrain [nTPM]"	"Tissue RNA - olfactory bulb [nTPM]"	"Tissue RNA - ovary [nTPM]"	"Tissue RNA - pancreas [nTPM]"	"Tissue RNA - parathyroid gland [nTPM]"	"Tissue RNA - pituitary gland [nTPM]"	"Tissue RNA - placenta [nTPM]"	"Tissue RNA - pons [nTPM]"	"Tissue RNA - prostate [nTPM]"	"Tissue RNA - rectum [nTPM]"	"Tissue RNA - retina [nTPM]"	"Tissue RNA - salivary gland [nTPM]"	"Tissue RNA - seminal vesicle [nTPM]"	"Tissue RNA - skeletal muscle [nTPM]"	"Tissue RNA - skin 1 [nTPM]"	"Tissue RNA - small intestine [nTPM]"	"Tissue RNA - smooth muscle [nTPM]"	"Tissue RNA - spinal cord [nTPM]"	"Tissue RNA - spleen [nTPM]"	"Tissue RNA - stomach 1 [nTPM]"	"Tissue RNA - testis [nTPM]"	"Tissue RNA - thalamus [nTPM]"	"Tissue RNA - thymus [nTPM]"	"Tissue RNA - thyroid gland [nTPM]"	"Tissue RNA - tongue [nTPM]"	"Tissue RNA - tonsil [nTPM]"	"Tissue RNA - urinary bladder [nTPM]"	"Tissue RNA - vagina [nTPM]"	"Tissue RNA - white matter [nTPM]"	"Cell RNA - A-431 [nTPM]"	"Cell RNA - A549 [nTPM]"	"Cell RNA - AF22 [nTPM]"	"Cell RNA - AN3-CA [nTPM]"	"Cell RNA - ASC diff [nTPM]"	"Cell RNA - ASC TERT1 [nTPM]"	"Cell RNA - BEWO [nTPM]"	"Cell RNA - BJ [nTPM]"	"Cell RNA - BJ hTERT+ [nTPM]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [nTPM]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [nTPM]"	"Cell RNA - CACO-2 [nTPM]"	"Cell RNA - CAPAN-2 [nTPM]"	"Cell RNA - Daudi [nTPM]"	"Cell RNA - EFO-21 [nTPM]"	"Cell RNA - fHDF/TERT166 [nTPM]"	"Cell RNA - GAMG [nTPM]"	"Cell RNA - HaCaT [nTPM]"	"Cell RNA - HAP1 [nTPM]"	"Cell RNA - HBEC3-KT [nTPM]"	"Cell RNA - HBF TERT88 [nTPM]"	"Cell RNA - HDLM-2 [nTPM]"	"Cell RNA - HEK 293 [nTPM]"	"Cell RNA - HEL [nTPM]"	"Cell RNA - HeLa [nTPM]"	"Cell RNA - Hep G2 [nTPM]"	"Cell RNA - HHSteC [nTPM]"	"Cell RNA - HL-60 [nTPM]"	"Cell RNA - HMC-1 [nTPM]"	"Cell RNA - HSkMC [nTPM]"	"Cell RNA - hTCEpi [nTPM]"	"Cell RNA - hTEC/SVTERT24-B [nTPM]"	"Cell RNA - hTERT-HME1 [nTPM]"	"Cell RNA - hTERT-RPE1 [nTPM]"	"Cell RNA - HUVEC TERT2 [nTPM]"	"Cell RNA - JURKAT [nTPM]"	"Cell RNA - K-562 [nTPM]"	"Cell RNA - Karpas-707 [nTPM]"	"Cell RNA - LHCN-M2 [nTPM]"	"Cell RNA - MCF7 [nTPM]"	"Cell RNA - MOLT-4 [nTPM]"	"Cell RNA - NB-4 [nTPM]"	"Cell RNA - NTERA-2 [nTPM]"	"Cell RNA - OE19 [nTPM]"	"Cell RNA - PC-3 [nTPM]"	"Cell RNA - REH [nTPM]"	"Cell RNA - RH-30 [nTPM]"	"Cell RNA - RPMI-8226 [nTPM]"	"Cell RNA - RPTEC TERT1 [nTPM]"	"Cell RNA - RT4 [nTPM]"	"Cell RNA - SCLC-21H [nTPM]"	"Cell RNA - SH-SY5Y [nTPM]"	"Cell RNA - SiHa [nTPM]"	"Cell RNA - SK-BR-3 [nTPM]"	"Cell RNA - SK-MEL-30 [nTPM]"	"Cell RNA - SuSa [nTPM]"	"Cell RNA - T-47d [nTPM]"	"Cell RNA - THP-1 [nTPM]"	"Cell RNA - TIME [nTPM]"	"Cell RNA - U-138 MG [nTPM]"	"Cell RNA - U-2 OS [nTPM]"	"Cell RNA - U-2197 [nTPM]"	"Cell RNA - U-251 MG [nTPM]"	"Cell RNA - U-266/70 [nTPM]"	"Cell RNA - U-266/84 [nTPM]"	"Cell RNA - U-698 [nTPM]"	"Cell RNA - U-87 MG [nTPM]"	"Cell RNA - U-937 [nTPM]"	"Cell RNA - WM-115 [nTPM]"	"Blood RNA - basophil [nTPM]"	"Blood RNA - classical monocyte [nTPM]"	"Blood RNA - eosinophil [nTPM]"	"Blood RNA - gdT-cell [nTPM]"	"Blood RNA - intermediate monocyte [nTPM]"	"Blood RNA - MAIT T-cell [nTPM]"	"Blood RNA - memory B-cell [nTPM]"	"Blood RNA - memory CD4 T-cell [nTPM]"	"Blood RNA - memory CD8 T-cell [nTPM]"	"Blood RNA - myeloid DC [nTPM]"	"Blood RNA - naive B-cell [nTPM]"	"Blood RNA - naive CD4 T-cell [nTPM]"	"Blood RNA - naive CD8 T-cell [nTPM]"	"Blood RNA - neutrophil [nTPM]"	"Blood RNA - NK-cell [nTPM]"	"Blood RNA - non-classical monocyte [nTPM]"	"Blood RNA - plasmacytoid DC [nTPM]"	"Blood RNA - T-reg [nTPM]"	"Blood RNA - total PBMC [nTPM]"	"Brain RNA - amygdala [nTPM]"	"Brain RNA - basal ganglia [nTPM]"	"Brain RNA - cerebellum [nTPM]"	"Brain RNA - cerebral cortex [nTPM]"	"Brain RNA - hippocampal formation [nTPM]"	"Brain RNA - hypothalamus [nTPM]"	"Brain RNA - medulla oblongata [nTPM]"	"Brain RNA - midbrain [nTPM]"	"Brain RNA - olfactory bulb [nTPM]"	"Brain RNA - pons [nTPM]"	"Brain RNA - spinal cord [nTPM]"	"Brain RNA - thalamus [nTPM]"	"Brain RNA - white matter [nTPM]"	"Single Cell Type RNA - Adipocytes [nTPM]"	"Single Cell Type RNA - Alveolar cells type 1 [nTPM]"	"Single Cell Type RNA - Alveolar cells type 2 [nTPM]"	"Single Cell Type RNA - Astrocytes [nTPM]"	"Single Cell Type RNA - B-cells [nTPM]"	"Single Cell Type RNA - Basal keratinocytes [nTPM]"	"Single Cell Type RNA - Basal prostatic cells [nTPM]"	"Single Cell Type RNA - Basal respiratory cells [nTPM]"	"Single Cell Type RNA - Basal squamous epithelial cells [nTPM]"	"Single Cell Type RNA - Bipolar cells [nTPM]"	"Single Cell Type RNA - Breast glandular cells [nTPM]"	"Single Cell Type RNA - Breast myoepithelial cells [nTPM]"	"Single Cell Type RNA - Cardiomyocytes [nTPM]"	"Single Cell Type RNA - Cholangiocytes [nTPM]"	"Single Cell Type RNA - Club cells [nTPM]"	"Single Cell Type RNA - Collecting duct cells [nTPM]"	"Single Cell Type RNA - Cone photoreceptor cells [nTPM]"	"Single Cell Type RNA - Cytotrophoblasts [nTPM]"	"Single Cell Type RNA - dendritic cells [nTPM]"	"Single Cell Type RNA - Distal enterocytes [nTPM]"	"Single Cell Type RNA - Distal tubular cells [nTPM]"	"Single Cell Type RNA - Ductal cells [nTPM]"	"Single Cell Type RNA - Early spermatids [nTPM]"	"Single Cell Type RNA - Endometrial ciliated cells [nTPM]"	"Single Cell Type RNA - Endometrial stromal cells [nTPM]"	"Single Cell Type RNA - Endothelial cells [nTPM]"	"Single Cell Type RNA - Enteroendocrine cells [nTPM]"	"Single Cell Type RNA - Erythroid cells [nTPM]"	"Single Cell Type RNA - Excitatory neurons [nTPM]"	"Single Cell Type RNA - Exocrine glandular cells [nTPM]"	"Single Cell Type RNA - Extravillous trophoblasts [nTPM]"	"Single Cell Type RNA - Fibroblasts [nTPM]"	"Single Cell Type RNA - Gastric mucus-secreting cells [nTPM]"	"Single Cell Type RNA - Glandular and luminal cells [nTPM]"	"Single Cell Type RNA - granulocytes [nTPM]"	"Single Cell Type RNA - Granulosa cells [nTPM]"	"Single Cell Type RNA - Hepatic stellate cells [nTPM]"	"Single Cell Type RNA - Hepatocytes [nTPM]"	"Single Cell Type RNA - Hofbauer cells [nTPM]"	"Single Cell Type RNA - Horizontal cells [nTPM]"	"Single Cell Type RNA - Inhibitory neurons [nTPM]"	"Single Cell Type RNA - Intestinal goblet cells [nTPM]"	"Single Cell Type RNA - Ionocytes [nTPM]"	"Single Cell Type RNA - Kupffer cells [nTPM]"	"Single Cell Type RNA - Langerhans cells [nTPM]"	"Single Cell Type RNA - Late spermatids [nTPM]"	"Single Cell Type RNA - Leydig cells [nTPM]"	"Single Cell Type RNA - Macrophages [nTPM]"	"Single Cell Type RNA - Melanocytes [nTPM]"	"Single Cell Type RNA - Microglial cells [nTPM]"	"Single Cell Type RNA - monocytes [nTPM]"	"Single Cell Type RNA - Muller glia cells [nTPM]"	"Single Cell Type RNA - NK-cells [nTPM]"	"Single Cell Type RNA - Oligodendrocyte precursor cells [nTPM]"	"Single Cell Type RNA - Oligodendrocytes [nTPM]"	"Single Cell Type RNA - Pancreatic endocrine cells [nTPM]"	"Single Cell Type RNA - Paneth cells [nTPM]"	"Single Cell Type RNA - Peritubular cells [nTPM]"	"Single Cell Type RNA - Plasma cells [nTPM]"	"Single Cell Type RNA - Prostatic glandular cells [nTPM]"	"Single Cell Type RNA - Proximal enterocytes [nTPM]"	"Single Cell Type RNA - Proximal tubular cells [nTPM]"	"Single Cell Type RNA - Respiratory ciliated cells [nTPM]"	"Single Cell Type RNA - Rod photoreceptor cells [nTPM]"	"Single Cell Type RNA - Sertoli cells [nTPM]"	"Single Cell Type RNA - Skeletal myocytes [nTPM]"	"Single Cell Type RNA - Smooth muscle cells [nTPM]"	"Single Cell Type RNA - Spermatocytes [nTPM]"	"Single Cell Type RNA - Spermatogonia [nTPM]"	"Single Cell Type RNA - Squamous epithelial cells [nTPM]"	"Single Cell Type RNA - Suprabasal keratinocytes [nTPM]"	"Single Cell Type RNA - Syncytiotrophoblasts [nTPM]"	"Single Cell Type RNA - T-cells [nTPM]"	"Single Cell Type RNA - Theca cells [nTPM]"	"Single Cell Type RNA - Undifferentiated cells [nTPM]"	"Single Cell Type RNA - Urothelial cells [nTPM]"
UPK2	"MGC138598, UP2, UPII"	ENSG00000110375	"Uroplakin 2"	O00526	11	118925164-118958559	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	28	"urinary bladder: 70.7"	"Group enriched"	"Detected in some"	7	"Club cells: 3.2;Cytotrophoblasts: 10.5;Syncytiotrophoblasts: 9.6;Urothelial cells: 6.9"	"Cancer enriched"	"Detected in many"	72	"urothelial cancer: 339.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"MCF7: 144.4;RT4: 160.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA043312, HPA061106"	Enhanced					NA	NA					"HPA043312: AB_2678420, HPA061106: AB_2684429"	"unprognostic (6.04e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.02e-1)"	"unprognostic (3.97e-2)"	"unprognostic (1.21e-1)"	"unprognostic (4.12e-4)"	"unprognostic (1.65e-1)"	"prognostic unfavorable (9.57e-4)"	"unprognostic (3.13e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.05e-3)"	"unprognostic (6.35e-3)"	"prognostic unfavorable (7.30e-7)"	"unprognostic (6.69e-2)"	"unprognostic (7.45e-2)"	"unprognostic (2.98e-1)"	"unprognostic (1.00e-1)"	1.4	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.2	0.2	0.0	0.0	0.0	0.0	0.5	2.5	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.5	0.0	0.0	0.3	0.1	0.5	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.5	0.0	0.0	0.2	70.7	2.4	0.2	4.0	0.4	0.1	0.4	0.0	0.1	26.2	0.0	0.0	0.0	0.1	0.2	9.0	0.0	0.2	0.4	0.2	6.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	144.4	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.1	0.1	160.9	0.0	0.1	0.3	0.0	0.0	0.1	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.3	0.6	0.0	0.2	0.9	0.0	0.4	0.6	1.0	0.0	0.0	3.2	0.0	0.0	10.5	0.4	0.0	0.0	0.1	0.5	0.3	0.1	0.5	0.0	0.0	0.1	0.2	0.8	0.1	0.0	0.2	0.0	1.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.3	0.0	0.6	0.0	0.2	0.0	0.0	0.6	0.9	1.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.3	0.1	0.0	0.0	0.0	0.1	0.2	0.2	0.5	0.1	9.6	0.1	0.4	0.0	6.9
UPK1A	TSPAN21	ENSG00000105668	"Uroplakin 1A"	O00322	19	35666516-35678483	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 43.5;urinary bladder: 207.4;vagina: 52.8"	"Cell type enriched"	"Detected in some"	4	"Urothelial cells: 29.1"	"Cancer enriched"	"Detected in many"	41	"urothelial cancer: 148.1"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"RT4: 39.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			HPA049879	Enhanced					NA	NA					"HPA049879: AB_2680929"	"unprognostic (3.29e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.19e-3)"	"unprognostic (3.40e-4)"	"unprognostic (4.05e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.74e-2)"	"unprognostic (3.11e-3)"	"unprognostic (2.30e-1)"	"unprognostic (1.78e-1)"	"unprognostic (4.62e-2)"	"unprognostic (2.34e-1)"	"unprognostic (2.48e-9)"	"unprognostic (1.48e-1)"	"unprognostic (4.14e-2)"	"unprognostic (2.45e-2)"	"unprognostic (1.72e-1)"	0.8	0.0	0.2	0.1	0.2	0.1	0.3	0.5	0.4	15.2	0.2	0.1	0.0	0.0	0.0	43.5	0.5	0.2	0.1	0.3	0.3	0.5	0.2	0.1	0.1	0.2	0.2	0.3	0.1	0.0	0.0	0.1	0.1	0.3	6.9	0.0	0.1	4.3	0.2	0.1	19.7	0.1	0.0	0.2	0.1	0.1	0.8	0.3	0.1	0.0	0.0	0.3	207.4	52.8	0.2	0.0	0.4	0.2	0.2	0.4	0.1	0.4	0.0	0.1	0.2	0.6	1.1	0.0	0.0	0.1	0.2	0.1	0.1	0.1	0.0	0.2	3.8	0.3	0.0	0.2	0.2	0.2	0.1	0.5	0.1	0.4	0.2	0.0	0.6	0.0	0.0	0.1	0.1	0.0	0.7	0.0	0.2	0.5	8.1	0.0	0.0	0.0	0.1	0.0	39.2	0.1	0.1	0.2	0.2	0.5	0.2	0.3	0.0	0.0	0.0	1.2	0.0	0.0	0.2	0.5	0.0	0.0	0.1	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.2	0.0	0.1	0.3	0.2	0.0	0.1	0.0	0.1	0.2	0.2	0.5	0.4	0.3	0.3	0.2	0.2	0.3	0.3	0.2	0.3	0.2	0.1	0.0	0.0	0.3	0.0	0.3	0.9	0.2	0.0	0.0	0.2	0.4	0.7	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	6.4	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.6	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.2	0.0	0.1	0.0	0.0	0.0	0.3	0.2	0.4	1.3	0.0	0.4	0.1	0.1	0.0	0.0	29.1
PM20D1	"Cps1, FLJ32569"	ENSG00000162877	"Peptidase M20 domain containing 1"	Q6GTS8	1	205828025-205850132	"Enzymes, Predicted secreted proteins"		"Hydrolase, Lyase, Protease"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"pancreas: 78.7"	"Cell type enhanced"	"Detected in some"		"Exocrine glandular cells: 20.9;Gastric mucus-secreting cells: 7.1;Proximal tubular cells: 7.1"	"Cancer enriched"	"Detected in some"	32	"urothelial cancer: 30.2"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in some"		"T-reg: 2.2"	"Lineage enriched"	"Detected in single"	6	"T-cells: 2.2"	"Cell line enriched"	"Detected in single"	9	"Karpas-707: 1.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Secreted to digestive system"	NA	NA		3300000				"unprognostic (1.16e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.07e-2)"	"unprognostic (4.83e-1)"	"unprognostic (4.08e-3)"	"unprognostic (1.17e-3)"	"unprognostic (3.11e-1)"	"unprognostic (1.20e-1)"	"unprognostic (5.50e-2)"	"unprognostic (5.81e-2)"	"unprognostic (4.57e-2)"	"unprognostic (7.79e-3)"	"unprognostic (9.77e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.48e-1)"	"unprognostic (1.68e-2)"	0.8	0.0	0.4	0.1	0.3	0.0	1.2	0.1	0.9	0.1	1.2	0.1	0.1	0.1	0.6	0.0	0.4	0.0	0.3	0.3	0.5	6.4	0.2	0.2	1.1	0.8	0.7	0.2	0.3	78.7	0.0	0.0	0.1	0.9	0.0	0.1	0.3	0.0	0.0	0.0	19.2	0.1	0.0	0.3	1.0	3.0	0.0	0.6	0.1	0.1	0.0	0.4	2.2	0.1	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.3	0.0	0.5	0.1	0.4	1.3	0.0	0.1	0.1	0.4	0.0	0.0	0.1	0.0	2.2	0.3	0.4	0.3	0.1	0.9	0.3	0.5	0.8	0.7	0.2	0.9	0.3	0.6	0.4	0.8	0.0	0.0	1.6	1.1	0.0	0.0	0.0	0.6	0.5	0.0	0.0	1.5	0.0	0.0	0.0	2.1	0.0	0.9	0.1	0.0	0.1	0.0	0.1	0.1	0.3	0.0	0.4	3.2	20.9	0.3	0.5	7.1	0.0	0.0	0.0	0.7	0.3	0.1	0.0	3.5	0.2	0.0	1.3	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	1.0	1.5	1.5	0.6	0.0	0.0	1.8	0.2	0.0	7.1	0.0	0.8	0.0	0.2	0.2	0.1	0.1	0.0	0.1	0.0	0.9	2.4	0.0	0.1
CRH	"CRF, CRH1"	ENSG00000147571	"Corticotropin releasing hormone"	P06850	8	66176376-66178464	"Plasma proteins, Predicted secreted proteins"		Hormone		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	16	"brain: 104.6"	"Cell type enriched"	"Detected in some"	5	"Syncytiotrophoblasts: 160.6"	"Cancer enriched"	"Detected in some"	28	"urothelial cancer: 34.5"	"Region enriched"	"Detected in many"	4	"medulla oblongata: 104.6"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"SuSa: 1.3"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"pons: 25.1"						"Secreted to blood"	NA	NA	10000									"unprognostic (1.62e-1)"						"unprognostic (9.68e-2)"				"unprognostic (1.00e-1)"	"unprognostic (9.55e-2)"	"unprognostic (7.22e-3)"	1.5	0.2	9.7	0.0	2.8	0.1	0.0	0.1	6.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	7.5	0.0	0.0	0.0	0.0	104.6	10.7	1.9	0.0	1.6	0.7	0.2	6.6	17.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.1	0.9	24.3	0.0	0.1	0.0	0.0	0.0	0.0	13.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.7	2.8	0.1	6.4	1.4	7.5	104.6	10.7	1.9	17.0	0.3	24.3	13.1	0.1	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	20.4	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	31.5	0.0	0.0	0.0	0.0	18.8	0.0	0.0	0.0	2.8	0.0	0.0	0.0	1.5	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.4	0.0	0.0	160.6	0.0	0.0	0.0	0.1
CYP1A1	"CP11, CYP1, P1-450, P450-C, P450DX"	ENSG00000140465	"Cytochrome P450 family 1 subfamily A member 1"	P04798	15	74719542-74725536	"Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis"	"Lyase, Monooxygenase, Oxidoreductase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 66.6;urinary bladder: 64.1"	"Cell type enhanced"	"Detected in some"		"Adipocytes: 21.9;Endothelial cells: 13.7;Glandular and luminal cells: 5.9;Hepatocytes: 9.9;Urothelial cells: 16.4"	"Group enriched"	"Detected in some"	24	"liver cancer: 18.6;urothelial cancer: 54.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CACO-2: 36.9;hTCEpi: 19.5;HUVEC TERT2: 19.1;SK-BR-3: 14.7;SuSa: 35.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB018654	Uncertain					NA	NA					"CAB018654: AB_2088699"	"unprognostic (1.71e-2)"	"unprognostic (7.86e-2)"	"unprognostic (2.57e-2)"	"unprognostic (2.89e-1)"	"unprognostic (5.45e-3)"	"unprognostic (6.34e-2)"	"unprognostic (3.08e-1)"	"unprognostic (6.24e-3)"	"unprognostic (1.11e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.03e-1)"	"unprognostic (4.21e-2)"	"unprognostic (6.70e-2)"	"unprognostic (2.20e-1)"	"unprognostic (4.77e-1)"	"unprognostic (1.28e-1)"	15.9	0.6	0.2	0.0	0.2	0.0	14.8	0.1	0.4	2.0	0.0	1.9	0.6	2.4	0.6	1.9	1.2	0.7	6.4	0.2	0.4	1.4	66.6	12.3	0.0	0.3	0.3	0.2	0.5	0.6	0.0	0.5	0.3	0.2	0.7	0.1	0.3	1.8	0.6	4.2	11.8	19.9	0.0	0.1	0.1	1.9	0.3	0.2	0.2	2.0	0.2	0.1	64.1	2.3	0.3	0.3	2.1	0.2	0.0	0.5	0.1	11.7	0.0	0.1	0.7	0.3	36.9	1.6	0.3	9.6	0.0	8.8	11.4	0.7	7.3	0.3	0.0	1.0	0.5	2.6	5.5	0.2	0.3	11.5	0.0	19.5	0.3	1.4	0.4	19.1	0.3	2.3	0.3	0.1	0.7	0.1	0.4	0.2	12.1	2.9	1.2	0.0	0.4	0.0	2.4	0.6	0.3	1.7	14.7	3.8	35.6	0.4	0.2	1.0	1.6	0.5	5.2	0.0	0.7	0.2	0.5	0.0	0.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.1	0.4	0.2	0.4	0.3	0.3	0.2	0.2	0.1	0.2	0.3	21.9	0.0	0.0	0.0	0.1	0.5	2.4	0.0	0.0	0.0	0.4	0.5	0.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	3.4	1.1	13.7	0.0	0.0	0.1	0.2	0.0	0.2	0.0	5.9	0.0	0.0	0.0	9.9	0.0	0.0	0.4	0.0	0.0	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.1	0.0	0.4	0.0	0.1	0.0	0.0	16.4
GATA3	HDR	ENSG00000107485	"GATA binding protein 3"	P23771	10	8045378-8075198	"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Deafness, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 110.7;skin 1: 160.3"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 267.1;Cytotrophoblasts: 323.5;Extravillous trophoblasts: 746.6;Suprabasal keratinocytes: 198.9;Syncytiotrophoblasts: 1134.9"	"Group enriched"	"Detected in many"	24	"breast cancer: 190.0;urothelial cancer: 87.0"	"Group enriched"	"Detected in many"	4	"medulla oblongata: 3.6;midbrain: 9.6;pons: 6.6;thalamus: 4.3;white matter: 3.0"	"Group enriched"	"Detected in many"	41	"gdT-cell: 19.9;MAIT T-cell: 26.9;memory CD4 T-cell: 36.7;memory CD8 T-cell: 28.8;naive CD4 T-cell: 19.9;naive CD8 T-cell: 18.3;NK-cell: 36.1;T-reg: 43.6"	"Group enriched"	"Detected in many"	57	"NK-cells: 36.1;T-cells: 43.6"	"Cell line enhanced"	"Detected in many"		"BEWO: 190.2;MCF7: 473.4;RT4: 194.3;SH-SY5Y: 161.2;T-47d: 605.2"	"Region enriched"	"Detected in single"	6	"midbrain: 6.1"	"Group enriched"	"Detected in some"	11	"medulla oblongata: 5.2;midbrain: 14.0;pons: 11.8;thalamus: 13.1"	"CAB016217, HPA029730"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB016217: AB_2108591, HPA029730: AB_10601907"	"unprognostic (1.70e-1)"	"unprognostic (7.23e-2)"	"unprognostic (3.58e-2)"	"unprognostic (2.00e-1)"	"unprognostic (7.03e-3)"	"unprognostic (4.68e-3)"	"unprognostic (4.23e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.55e-1)"	"unprognostic (3.83e-1)"	"unprognostic (1.17e-1)"	"prognostic unfavorable (3.13e-4)"	"unprognostic (1.48e-1)"	"unprognostic (5.16e-2)"	"unprognostic (6.31e-2)"	"unprognostic (1.82e-3)"	6.8	6.5	1.3	3.9	0.2	4.2	34.6	0.2	1.0	1.9	0.8	0.6	1.0	0.7	8.7	0.6	0.5	1.2	2.0	0.1	0.5	21.0	1.0	3.4	7.9	3.6	9.6	0.0	0.1	0.3	110.7	5.0	32.4	6.6	11.3	0.7	0.0	20.0	25.1	2.1	160.3	2.4	0.3	0.4	7.2	1.5	0.2	4.3	25.2	3.1	1.0	3.8	39.1	10.9	3.0	33.8	8.1	0.0	0.4	0.0	0.0	190.2	0.7	0.0	0.0	0.1	12.4	29.9	0.0	0.1	0.0	0.0	28.9	3.2	0.6	0.1	95.8	10.2	0.2	0.3	0.1	2.1	0.1	0.5	0.0	6.9	0.1	1.8	1.0	15.3	45.8	0.4	0.0	0.1	473.4	54.2	0.5	3.5	6.5	4.5	2.8	2.6	0.8	0.0	194.3	9.8	161.2	0.5	26.8	0.0	34.1	605.2	0.1	0.0	2.4	5.9	1.4	4.3	0.9	0.0	0.0	1.3	0.0	1.7	0.1	0.1	0.0	19.9	0.0	26.9	0.4	36.7	28.8	0.0	0.1	19.9	18.3	0.7	36.1	0.0	0.0	43.6	7.0	1.3	0.2	0.2	1.0	0.1	0.5	3.6	9.6	0.0	6.6	0.4	4.3	3.0	14.6	0.0	6.0	0.0	3.4	94.8	69.6	1.6	0.0	0.0	267.1	167.3	1.3	0.0	1.5	178.4	0.0	323.5	49.2	0.0	0.0	0.2	0.2	0.5	0.4	12.6	0.0	2.1	0.0	0.4	746.6	5.3	2.6	0.7	2.5	0.0	6.8	0.6	30.7	0.0	0.0	0.0	0.0	3.5	9.9	0.1	0.0	3.8	8.8	1.0	1.5	0.0	51.5	0.0	0.0	4.1	1.1	0.0	12.2	45.8	0.0	0.6	0.3	0.0	0.0	1.1	2.8	0.0	1.4	1.0	198.9	1134.9	93.4	0.5	0.0	106.1
CYP1A2	"CP12, P3-450"	ENSG00000140505	"Cytochrome P450 family 1 subfamily A member 2"	P05177	15	74748845-74756607	"Cancer-related genes, Enzymes, Metabolic proteins, Predicted membrane proteins"	"Fatty acid metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	"Lyase, Monooxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	311	"liver: 517.6"	"Cell type enriched"	"Detected in some"	57	"Hepatocytes: 85.7"	"Group enriched"	"Detected in some"	22	"liver cancer: 25.3;urothelial cancer: 6.5"	"Low region specificity"	"Detected in some"			"Immune cell enhanced"	"Detected in some"		"neutrophil: 2.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"SK-BR-3: 2.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB016531	Enhanced					NA	NA					"CAB016531: AB_629359"				"unprognostic (1.54e-4)"			"unprognostic (1.29e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.59e-2)"		"unprognostic (1.76e-1)"	"unprognostic (1.17e-2)"	"unprognostic (5.48e-2)"	"unprognostic (2.33e-2)"	"unprognostic (7.41e-2)"	"unprognostic (2.53e-1)"	0.2	0.3	0.6	0.2	0.5	1.0	0.1	1.6	0.9	0.0	0.2	0.0	0.2	0.2	0.4	0.2	0.2	0.2	0.1	0.5	0.3	0.2	517.6	0.4	0.3	0.5	0.5	0.8	0.1	0.0	0.0	0.0	0.7	0.8	0.1	0.1	0.4	0.2	0.3	0.3	0.6	0.2	0.0	0.2	0.3	0.2	0.3	0.5	0.1	1.4	0.0	0.1	0.1	0.0	1.6	0.4	0.3	0.8	0.5	0.1	0.0	0.6	0.2	0.0	0.0	0.1	0.3	0.4	0.8	0.1	0.0	0.6	0.4	0.0	0.0	0.0	0.1	0.4	0.9	0.6	0.1	0.0	0.7	0.3	0.1	0.1	0.0	0.0	0.3	0.1	1.3	0.7	1.3	0.0	0.2	0.9	0.3	0.4	0.3	0.2	0.9	0.8	0.3	0.1	0.7	0.7	0.3	0.6	2.3	0.1	0.6	0.5	0.2	0.2	0.3	0.4	0.3	0.3	0.3	0.2	0.5	0.3	0.9	0.3	1.5	0.3	0.5	0.2	0.2	0.1	0.3	0.2	0.1	0.1	0.5	0.2	0.2	2.1	0.4	0.2	0.4	0.1	0.1	0.6	0.5	1.6	0.9	0.5	0.3	0.5	0.5	0.8	0.8	0.2	0.5	1.6	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	85.7	0.1	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2
SNX31	MGC39715	ENSG00000174226	"Sorting nexin 31"	Q8N9S9	8	100572889-100663415	"Predicted intracellular proteins, Transporters"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 6.6;urinary bladder: 16.5"	"Cell type enriched"	"Detected in some"	4	"Early spermatids: 81.8"	"Cancer enriched"	"Detected in many"	22	"urothelial cancer: 24.2"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	49	"RT4: 80.7"	"Region enriched"	"Detected in single"	5	"thalamus: 2.6"	"Not detected"	"Not detected"			"HPA024284, HPA053466"	Uncertain		Approved	"Nucleoplasm,Golgi apparatus,Cytosol"		NA	NA			"Nucleoplasm, Golgi apparatus"	Cytosol	"HPA024284: AB_1853894, HPA053466: AB_2682161"	"unprognostic (1.39e-1)"	"unprognostic (3.83e-2)"	"unprognostic (7.99e-2)"	"unprognostic (1.52e-1)"	"unprognostic (7.20e-5)"	"unprognostic (1.04e-1)"	"unprognostic (1.01e-2)"	"unprognostic (2.44e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.21e-1)"	"unprognostic (2.09e-2)"	"unprognostic (1.69e-1)"	"unprognostic (7.79e-3)"	"unprognostic (1.66e-1)"	"prognostic favorable (1.47e-4)"	"unprognostic (2.54e-1)"	"unprognostic (4.05e-2)"	0.5	0.1	1.5	0.0	1.4	0.2	0.4	0.9	3.3	0.4	0.4	0.2	0.0	0.3	0.2	6.6	0.3	1.1	1.7	2.3	0.8	0.2	0.5	0.1	0.4	1.6	0.1	0.9	0.4	0.3	0.3	0.2	0.0	1.8	1.4	0.1	0.2	1.2	0.2	0.6	0.6	0.1	0.5	0.3	0.1	0.7	4.0	1.6	0.3	0.5	0.5	3.6	16.5	1.7	1.7	0.0	0.0	0.0	0.3	0.4	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.2	0.3	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.2	0.1	0.1	0.0	0.0	0.0	0.6	0.1	0.1	0.1	0.1	0.0	0.0	0.0	80.7	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.3	1.6	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	1.5	1.4	0.9	3.3	2.3	0.8	1.6	0.1	0.9	1.8	0.3	1.6	1.7	0.5	0.0	0.0	6.2	0.1	0.4	3.3	0.2	9.6	0.0	0.2	0.6	0.6	0.0	0.3	0.0	0.0	0.0	0.1	0.0	1.9	0.0	81.8	0.2	0.1	0.4	0.0	0.0	12.8	0.0	0.0	0.1	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	19.7	0.6	0.2	0.0	1.0	0.0	0.0	0.0	1.0	0.9	0.0	0.0	1.2	0.1	0.8	0.0	0.1	0.0	0.0	0.0	0.3	3.7	0.3	0.5	9.7	0.4	0.0	0.1	0.0	0.0	6.0
KRTAP8-1	KAP8.1	ENSG00000183640	"Keratin associated protein 8-1"	Q8IUC2	21	30812697-30813274	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	99	"skin 1: 39.5"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in single"	21	"urothelial cancer: 1.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"													NA	NA																							0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	39.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PLA2G2F		ENSG00000158786	"Phospholipase A2 group IIF"	Q9BZM2	1	20139323-20150381	"Enzymes, Metabolic proteins, Predicted membrane proteins, RAS pathway related proteins"	"Immunity, Innate immunity, Lipid degradation, Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	25	"lymphoid tissue: 8.0;skin 1: 14.6;urinary bladder: 11.8"	"Cell type enhanced"	"Detected in some"		"Cardiomyocytes: 1.0;Collecting duct cells: 1.8;Suprabasal keratinocytes: 1.7"	"Cancer enriched"	"Detected in some"	18	"urothelial cancer: 17.1"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	69	"RT4: 139.2"	"Region enriched"	"Detected in single"	4	"hippocampal formation: 3.0"	"Not detected"	"Not detected"								"Intracellular and membrane"	NA	NA						"unprognostic (1.95e-1)"	"unprognostic (1.18e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.79e-2)"		"unprognostic (5.11e-2)"		"unprognostic (4.63e-2)"	"unprognostic (4.83e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.61e-2)"	"unprognostic (3.36e-5)"		"unprognostic (7.06e-2)"	"unprognostic (1.84e-1)"	"unprognostic (4.69e-1)"	"prognostic favorable (3.86e-4)"	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	14.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	8.0	11.8	0.4	0.1	0.1	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	139.2	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.8	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.7	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.7	0.8	0.0	0.0	0.0	0.9
KRTAP7-1	KAP7.1	ENSG00000274749	"Keratin associated protein 7-1"	Q8IUC3	21	30829039-30829759	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	100	"skin 1: 15.8"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in single"	16	"urothelial cancer: 1.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"													NA	NA																							0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	15.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NNAT	Peg5	ENSG00000053438	Neuronatin	Q16517	20	37521206-37523690	"Predicted membrane proteins"		"Developmental protein"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enriched"	"Detected in many"	10	"pituitary gland: 1599.2"	"Cell type enhanced"	"Detected in many"		"Early spermatids: 42.0;Excitatory neurons: 33.9;Late spermatids: 65.5;Muller glia cells: 177.1"	"Group enriched"	"Detected in many"	16	"glioma: 87.5;testis cancer: 55.0;urothelial cancer: 37.4"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	22	"SH-SY5Y: 720.8"					"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.18e-2)"	"unprognostic (7.41e-3)"	"unprognostic (1.85e-2)"	"unprognostic (1.04e-2)"	"prognostic unfavorable (9.66e-4)"	"unprognostic (7.08e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.36e-1)"	"unprognostic (4.05e-2)"	"unprognostic (7.52e-2)"	"unprognostic (4.94e-2)"	"unprognostic (1.64e-2)"	"unprognostic (1.77e-1)"	"unprognostic (5.91e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.15e-3)"	"unprognostic (5.90e-2)"	27.6	15.3	118.3	2.5	153.1	2.5	32.8	21.5	66.4	6.0	55.6	51.3	4.0	5.0	0.2	3.4	3.6	4.7	2.4	105.9	89.6	1.4	2.0	2.2	1.4	49.4	47.2	71.0	1.6	1.4	0.0	1599.2	107.3	49.6	4.4	4.0	31.6	6.6	0.6	13.6	4.5	14.7	5.2	30.8	1.4	17.0	5.0	71.4	11.2	2.0	0.3	0.1	14.6	5.6	50.1	2.2	1.7	12.6	1.7	0.0	0.0	4.5	0.5	0.0	0.1	0.0	4.2	2.2	1.0	0.7	0.0	0.2	10.2	0.0	0.0	0.0	0.1	0.3	0.3	12.9	2.4	3.2	1.3	1.1	2.9	0.0	0.0	0.0	0.2	32.5	0.3	0.2	2.4	0.1	1.0	5.7	1.3	0.9	0.3	1.6	0.5	4.0	0.5	0.0	20.6	1.9	720.8	1.1	5.0	0.0	0.6	1.3	0.2	0.8	5.7	0.8	1.6	1.1	0.9	0.2	0.1	1.7	0.6	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	118.3	153.1	21.5	66.4	105.9	89.6	49.4	47.2	71.0	49.6	30.8	71.4	50.1	0.3	0.0	0.0	1.6	0.2	4.0	0.8	0.1	19.9	4.5	0.3	5.8	0.1	0.0	0.7	0.0	0.0	0.6	0.3	0.1	0.0	0.2	42.0	0.1	3.0	21.6	0.0	0.0	33.9	0.0	1.1	3.1	0.0	0.1	1.3	2.2	0.0	0.0	1.6	0.0	9.6	0.2	0.0	0.3	1.1	65.5	0.6	0.1	1.8	4.7	0.0	177.1	0.0	2.0	1.8	0.0	0.0	1.2	0.0	2.5	0.0	0.0	1.1	6.5	0.0	1.4	1.9	1.5	5.6	3.6	1.0	0.3	0.1	0.1	0.0	4.8
BTBD16	"C10orf87, Em:AC061711.1, FLJ25359"	ENSG00000138152	"BTB domain containing 16"	Q32M84	10	122271296-122338159	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"skin 1: 8.4;testis: 7.9;urinary bladder: 20.4"	"Group enriched"	"Detected in some"	9	"Early spermatids: 123.2;Late spermatids: 69.9"	"Cancer enriched"	"Detected in many"	14	"urothelial cancer: 18.4"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	8	"RT4: 33.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA040529, HPA057638"	Uncertain		Uncertain	Nucleoli,Cytosol		Yes	NA			Nucleoli	Cytosol	"HPA040529: AB_2677022, HPA057638: "	"unprognostic (1.41e-4)"	"unprognostic (1.33e-1)"	"unprognostic (5.97e-2)"	"unprognostic (5.98e-3)"	"unprognostic (2.08e-1)"	"unprognostic (2.09e-3)"	"unprognostic (2.88e-1)"	"unprognostic (4.54e-2)"	"unprognostic (1.76e-1)"	"unprognostic (6.85e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.77e-1)"	"prognostic unfavorable (1.50e-4)"	"unprognostic (1.08e-1)"	"unprognostic (1.60e-1)"	"unprognostic (9.12e-2)"	"unprognostic (9.44e-3)"	0.1	0.0	1.5	0.0	1.8	0.0	0.5	1.7	2.1	0.3	1.2	0.4	0.0	0.1	0.3	0.1	0.4	0.2	0.0	1.6	1.7	0.3	4.0	0.3	0.0	1.8	1.9	1.4	0.0	0.1	0.0	0.4	0.1	2.1	0.8	0.0	0.0	0.4	0.0	0.3	8.4	0.1	0.1	1.7	0.0	0.1	7.9	1.7	0.0	0.4	0.0	0.1	20.4	0.5	2.6	0.0	0.3	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.3	0.0	0.5	0.0	0.1	0.0	0.0	0.1	4.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.4	0.0	1.5	33.7	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.5	1.8	1.7	2.1	1.6	1.7	1.8	1.9	1.4	2.1	1.7	1.7	2.6	0.0	0.0	0.0	0.0	0.0	2.8	0.4	0.2	0.0	0.0	0.2	0.0	0.6	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	1.4	123.2	0.6	0.0	0.2	0.0	0.0	0.9	0.7	0.1	0.0	0.0	0.4	0.0	0.0	0.0	4.5	0.0	0.0	1.2	0.0	0.0	0.0	0.4	69.9	0.6	0.0	0.0	1.0	0.0	0.0	0.0	0.5	9.8	1.1	3.8	0.4	0.0	0.1	0.2	1.0	3.1	0.0	0.0	0.4	0.2	10.0	0.8	0.0	3.1	0.1	0.4	0.0	0.0	2.9
UPK3B	"FLJ32198, MGC10902, p35, UPIIIb"	ENSG00000243566	"Uroplakin 3B"	Q9BT76	7	76510525-76516522	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"adipose tissue: 55.2;esophagus: 65.3;lung: 50.4;urinary bladder: 42.6"	"Cell type enriched"	"Detected in some"	5	"Alveolar cells type 1: 121.8"	"Group enriched"	"Detected in many"	12	"ovarian cancer: 64.6;urothelial cancer: 78.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 13.2;CAPAN-2: 48.2;HaCaT: 10.0;RT4: 34.7;T-47d: 27.1"	"Not detected"	"Not detected"							HPA010506	Approved					NA	NA					"HPA010506: AB_1080479"	"unprognostic (8.33e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.62e-3)"	"unprognostic (2.26e-3)"	"unprognostic (7.87e-2)"	"unprognostic (8.60e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.63e-1)"	"unprognostic (4.03e-1)"	"unprognostic (5.92e-2)"	"unprognostic (1.37e-2)"	"unprognostic (4.06e-2)"	"unprognostic (8.37e-9)"	"unprognostic (3.56e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.66e-1)"	"unprognostic (6.34e-2)"	55.2	0.7	0.1	0.1	0.4	0.1	1.5	0.0	0.3	4.6	0.8	1.0	0.0	0.7	0.2	65.3	10.1	0.1	5.8	0.0	0.2	0.6	1.0	50.4	0.1	0.1	0.2	0.0	7.0	1.3	0.0	1.8	0.0	0.1	2.7	0.0	0.2	8.3	0.0	0.5	4.1	1.0	0.0	0.0	2.1	2.9	4.3	0.6	0.0	1.4	0.0	1.9	42.6	12.2	0.1	1.1	13.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	48.2	0.0	0.4	0.0	0.1	10.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.1	0.0	2.9	0.1	0.0	0.0	0.0	0.0	34.7	0.0	0.0	0.3	3.9	0.0	0.1	27.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.3	0.0	0.2	0.1	0.2	0.0	0.1	0.0	0.6	0.1	0.3	121.8	3.3	0.0	0.3	1.7	0.4	18.3	4.6	0.4	0.2	0.0	0.3	20.0	20.4	3.7	4.2	0.1	0.0	0.2	0.0	0.1	0.0	0.5	0.0	0.9	0.0	0.0	0.0	0.0	0.0	13.9	1.1	0.5	1.3	0.1	0.7	0.1	0.1	1.7	0.0	0.0	6.1	0.3	2.5	0.0	12.2	0.3	3.6	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.7	0.1	0.0	11.1	0.2	0.0	0.0	1.1	0.0	0.1	2.1	2.8	0.1	0.4	0.0	0.2	14.2
TP63	"EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L"	ENSG00000073282	"Tumor protein p63"	Q9H3D4	3	189631389-189897276	"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease variant, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 70.2;skin 1: 138.4;vagina: 54.8"	"Group enriched"	"Detected in many"	4	"Basal keratinocytes: 275.4;Basal squamous epithelial cells: 335.2;Squamous epithelial cells: 173.4;Suprabasal keratinocytes: 283.1"	"Group enriched"	"Detected in many"	11	"cervical cancer: 37.9;head and neck cancer: 73.3;lung cancer: 37.3;urothelial cancer: 21.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"HaCaT: 87.1;HBEC3-KT: 167.3;hTCEpi: 124.0;hTERT-HME1: 117.3;RT4: 185.1"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000083, HPA006288, HPA006289, HPA007009, HPA007010"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000083: AB_2207187, HPA006288: AB_1080334, HPA006289: , HPA007009: , HPA007010: AB_1080336"	"prognostic favorable (1.07e-4)"	"unprognostic (1.30e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.02e-1)"	"unprognostic (4.38e-2)"	"unprognostic (3.50e-1)"	"unprognostic (1.29e-1)"	"unprognostic (5.17e-2)"	"unprognostic (2.78e-1)"	"unprognostic (5.37e-2)"	"unprognostic (2.09e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.87e-5)"	"unprognostic (1.86e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.74e-3)"	0.3	0.3	0.3	0.6	0.4	0.5	18.2	0.8	0.6	12.0	0.6	0.2	0.1	0.3	10.6	70.2	1.0	0.3	0.6	0.5	0.6	0.3	0.4	1.9	1.0	0.3	0.4	0.3	0.1	0.3	0.0	0.5	10.9	0.5	17.6	0.2	0.0	21.0	18.2	42.7	138.4	0.2	0.3	0.2	0.3	0.4	3.4	0.6	23.3	0.3	12.5	17.9	18.8	54.8	0.4	2.3	4.6	0.0	0.1	0.2	0.1	1.2	0.1	0.0	0.0	0.0	0.0	0.0	16.6	0.6	0.1	0.2	87.1	0.0	167.3	0.0	1.4	0.0	1.9	1.3	0.4	0.0	0.0	0.3	0.2	124.0	0.2	117.3	0.1	0.0	0.0	0.0	0.1	0.1	0.4	0.1	0.2	0.3	0.2	0.0	1.0	0.3	0.0	0.2	185.1	0.2	0.1	0.2	0.0	0.0	2.5	0.9	0.2	0.3	0.2	0.1	0.2	0.0	25.3	0.3	1.1	0.5	0.1	0.8	0.6	0.0	0.2	0.1	0.0	0.0	0.7	0.2	0.1	0.0	0.3	0.1	0.1	0.4	0.2	0.0	0.2	0.1	0.0	0.3	0.4	0.8	0.6	0.5	0.6	0.3	0.4	0.3	0.5	0.2	0.6	0.4	0.2	0.0	5.3	1.0	0.9	275.4	26.8	61.9	335.2	0.0	0.9	30.1	0.7	0.0	8.5	0.0	0.0	24.9	0.1	0.1	0.0	0.2	1.8	0.0	0.1	1.1	0.0	0.0	1.3	0.2	2.8	1.4	0.0	0.1	0.0	0.0	0.0	0.1	2.4	0.0	4.8	0.0	2.0	0.0	11.9	0.4	0.3	0.7	8.8	14.0	0.6	0.0	0.0	0.5	1.4	1.6	0.0	1.2	1.6	5.6	0.0	0.0	2.8	0.0	0.0	5.3	0.9	0.5	2.4	173.4	283.1	8.9	0.6	0.2	0.0	15.2
GABBR2	"GABABR2, GPR51, GPRC3B, HG20"	ENSG00000136928	"Gamma-aminobutyric acid type B receptor subunit 2"	O75899	9	98288109-98708935	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease variant, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	10	"brain: 90.5"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 386.5;Inhibitory neurons: 395.1"	"Group enriched"	"Detected in many"	10	"glioma: 7.2;thyroid cancer: 11.6;urothelial cancer: 3.9"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 14.6;fHDF/TERT166: 7.3;HUVEC TERT2: 29.5;U-138 MG: 11.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013820, HPA031684, CAB079065"	Enhanced	Approved				NA	NA					"CAB079065: , HPA013820: AB_1849364, HPA031684: AB_2673993"	"unprognostic (2.00e-1)"	"unprognostic (7.56e-2)"	"unprognostic (3.75e-1)"	"unprognostic (3.09e-5)"	"unprognostic (2.52e-1)"	"unprognostic (1.16e-1)"	"unprognostic (2.81e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.66e-1)"	"unprognostic (4.43e-2)"	"unprognostic (1.43e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.68e-2)"	"unprognostic (3.45e-2)"	0.0	3.6	16.3	0.2	39.7	0.0	0.0	10.1	90.5	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.3	33.0	17.8	0.0	0.0	0.3	0.0	12.1	19.6	42.1	0.0	0.1	0.2	0.6	0.1	20.2	0.0	0.0	8.6	0.0	0.1	2.9	0.1	0.0	0.1	0.4	0.0	0.2	0.6	40.7	0.0	1.4	0.5	0.2	0.5	0.0	36.2	0.0	0.0	0.0	0.0	0.1	0.1	1.2	14.6	2.9	3.0	5.5	0.1	0.1	0.0	0.9	7.3	0.6	0.0	0.1	0.2	1.0	0.0	0.5	0.0	0.0	0.0	1.3	0.0	0.0	0.4	0.0	0.9	0.2	0.0	29.5	0.0	0.3	0.1	0.0	0.4	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	4.0	0.0	0.1	3.5	0.0	0.0	0.0	0.1	1.2	11.5	0.7	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	16.3	39.7	10.1	90.5	33.0	17.8	12.1	19.6	42.1	20.2	0.4	40.7	36.2	0.1	0.0	0.0	14.0	0.0	0.1	0.0	0.0	0.0	86.4	0.5	0.1	1.9	0.0	0.1	0.0	0.0	0.5	0.0	0.1	0.0	0.0	90.3	0.1	0.0	0.6	0.0	0.0	386.5	0.2	1.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	395.1	0.0	0.0	0.0	0.0	34.5	0.3	0.1	1.8	11.2	0.0	1.8	0.0	26.2	7.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	7.4	0.0	0.3	1.3	0.7	0.9	0.0	0.1	0.4	0.0	0.3	0.1	0.0
TNNI2	"AMCD2B, DA2B, FSSV"	ENSG00000130598	"Troponin I2, fast skeletal type"	P48788	11	1838981-1841680	"Disease related genes, Human disease related genes, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	25	"skeletal muscle: 8045.8;tongue: 2645.6"	"Group enriched"	"Detected in many"	6	"Extravillous trophoblasts: 449.4;Skeletal myocytes: 598.7"	"Group enriched"	"Detected in many"	10	"cervical cancer: 12.7;head and neck cancer: 33.6;pancreatic cancer: 12.9;urothelial cancer: 39.8"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in many"		"plasmacytoid DC: 86.4"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"CAPAN-2: 35.7;hTCEpi: 101.2"	"Region enriched"	"Detected in single"	6	"olfactory bulb: 5.1"	"Not detected"	"Not detected"			"CAB018697, HPA055938"	Enhanced		Approved	"Plasma membrane,Intermediate filaments"		NA	NA		110000	"Plasma membrane"	"Intermediate filaments"	"CAB018697: AB_628400, HPA055938: AB_2682976"	"unprognostic (2.03e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.29e-2)"	"unprognostic (3.70e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.02e-2)"	"unprognostic (9.99e-3)"	"unprognostic (1.01e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.70e-1)"	"unprognostic (1.23e-3)"	"unprognostic (5.92e-3)"	"unprognostic (5.62e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.79e-2)"	2.3	1.8	0.3	1.1	0.3	6.1	8.0	0.3	0.6	0.9	0.4	1.2	0.3	0.8	0.3	67.4	0.9	5.6	1.5	0.3	0.3	0.7	1.6	7.9	1.6	0.4	0.3	0.3	0.7	8.8	0.0	0.9	3.0	0.4	14.1	0.2	0.0	217.9	3.2	8045.8	55.6	2.7	0.2	0.4	5.8	1.1	0.7	0.4	1.9	2.8	2645.6	1.0	27.7	3.2	0.5	0.0	0.0	0.1	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	2.4	35.7	1.0	0.2	0.0	0.0	1.7	0.0	1.3	0.0	0.0	0.0	0.1	0.0	2.1	0.2	0.0	0.1	8.1	101.2	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	3.1	0.0	0.1	1.2	2.4	0.0	1.0	0.0	1.0	0.0	0.7	0.0	0.0	12.3	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.6	0.0	13.8	5.8	53.3	0.1	12.5	0.1	3.8	0.0	0.0	8.0	4.8	0.0	0.0	39.7	0.4	17.6	86.4	0.0	2.5	0.3	0.3	0.3	0.6	0.3	0.3	0.4	0.3	0.3	0.4	0.4	0.4	0.5	1.2	3.2	4.4	0.0	9.1	25.1	2.6	1.8	15.4	0.0	0.5	23.7	5.6	21.5	3.0	0.0	0.0	33.8	15.7	0.1	0.0	1.4	0.0	1.4	0.2	2.0	0.0	0.0	0.0	0.6	449.4	2.4	1.1	0.1	10.8	0.4	0.4	0.3	39.6	0.0	0.0	0.0	2.0	18.8	10.7	0.0	0.3	25.9	0.0	0.0	16.0	0.0	1.0	0.0	0.0	1.4	0.0	0.0	4.2	0.1	0.0	0.2	13.2	0.0	0.0	598.7	2.4	0.0	0.6	2.7	6.5	87.2	1.9	4.3	0.0	0.9
KRTAP11-1	KAP11.1	ENSG00000182591	"Keratin associated protein 11-1"	Q8IUC1	21	30880644-30881580	"Metabolic proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	70	"skin 1: 116.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"endometrial cancer: 1.3;urothelial cancer: 0.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA054008	Enhanced					NA	NA		2700000			"HPA054008: AB_2682341"																		1.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	116.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TNNT3	"AMCD2B, DA2B, DKFZp779M2348, FSSV"	ENSG00000130595	"Troponin T3, fast skeletal type"	P45378	11	1919703-1938706	"Disease related genes, Human disease related genes, Predicted intracellular proteins"		"Muscle protein"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	43	"skeletal muscle: 14039.2;tongue: 4547.7"	"Cell type enriched"	"Detected in many"	4	"Skeletal myocytes: 542.6"	"Group enriched"	"Detected in many"	9	"head and neck cancer: 28.8;urothelial cancer: 19.0"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in single"	17	"basophil: 5.3"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 5.3"	"Cell line enriched"	"Detected in some"	21	"HSkMC: 24.0"	"Region enhanced"	"Detected in some"		"olfactory bulb: 5.1"	"Low region specificity"	"Detected in single"			"CAB002451, HPA037810, HPA056909"	Enhanced					NA	NA		470000			"CAB002451: AB_564151, HPA037810: AB_10966217, HPA056909: AB_2683273"	"unprognostic (1.01e-2)"	"prognostic favorable (7.37e-4)"	"unprognostic (2.17e-2)"	"unprognostic (2.30e-3)"	"unprognostic (1.23e-2)"	"unprognostic (1.29e-2)"	"unprognostic (4.53e-3)"	"unprognostic (1.20e-1)"	"unprognostic (5.88e-2)"	"unprognostic (4.29e-3)"	"unprognostic (3.53e-2)"	"unprognostic (4.34e-1)"	"unprognostic (1.42e-5)"	"unprognostic (2.99e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.79e-2)"	"unprognostic (2.90e-2)"	27.8	2.4	0.2	1.4	0.4	1.5	20.2	0.2	0.4	12.4	0.1	4.5	0.2	6.6	2.8	63.0	14.6	1.9	126.5	0.3	0.2	0.7	1.4	3.7	1.4	0.2	0.1	0.2	1.7	2.3	0.3	2.5	41.7	0.2	20.8	0.5	0.0	217.8	3.1	14039.2	8.5	3.1	1.3	0.1	2.9	3.3	5.3	0.1	5.5	7.7	4547.7	2.1	20.4	12.1	0.2	0.0	0.0	0.0	0.0	0.5	0.7	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	24.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.2	0.4	0.2	0.4	0.3	0.2	0.2	0.1	0.2	0.2	0.1	0.1	0.2	33.1	0.0	1.9	0.0	0.8	2.9	3.9	5.9	2.2	0.0	0.4	0.3	17.8	0.0	10.1	0.0	0.0	24.5	1.5	0.0	0.0	0.1	0.3	2.4	0.3	33.9	0.0	0.0	0.1	0.0	6.7	42.0	0.0	0.1	0.0	3.0	0.0	0.0	2.7	0.0	0.0	0.0	6.1	0.0	2.3	2.5	110.9	2.2	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	94.8	0.3	0.2	0.0	0.0	42.5	0.0	0.0	542.6	11.2	0.1	0.6	2.9	3.4	18.3	2.0	0.7	0.0	17.1
ATP1A4	ATP1AL2	ENSG00000132681	"ATPase Na+/K+ transporting subunit alpha 4"	Q13733	1	160151586-160186980	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport"	Translocase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"placenta: 6.3;testis: 16.4;urinary bladder: 5.1"	"Cell type enhanced"	"Detected in some"		"Cytotrophoblasts: 26.1;Early spermatids: 87.4;Extravillous trophoblasts: 14.4;Syncytiotrophoblasts: 38.2"	"Group enriched"	"Detected in some"	8	"breast cancer: 0.8;urothelial cancer: 1.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	11	"BEWO: 18.4;HDLM-2: 49.0;RT4: 57.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.33e-1)"	"unprognostic (4.01e-3)"	"unprognostic (2.20e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.09e-1)"	"unprognostic (8.55e-2)"	"unprognostic (1.22e-1)"	"unprognostic (7.48e-3)"	"unprognostic (2.45e-1)"	"unprognostic (8.77e-3)"	"unprognostic (1.98e-2)"	"unprognostic (3.17e-2)"	"unprognostic (2.43e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.09e-2)"	"prognostic favorable (2.20e-4)"	0.2	0.1	0.1	0.4	0.1	0.0	1.6	0.1	0.4	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.1	0.7	0.3	0.1	0.2	0.0	0.0	0.1	3.3	0.2	0.1	0.1	0.0	0.0	0.4	0.0	6.3	0.1	0.3	0.1	2.5	0.3	1.3	3.0	0.0	0.2	0.1	0.1	1.1	0.1	16.4	0.1	0.4	0.0	0.0	1.3	5.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	18.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	57.0	0.0	0.0	0.0	0.1	0.0	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.4	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.6	1.6	0.0	0.3	7.3	0.0	0.0	0.0	2.2	1.7	0.9	0.0	0.0	1.8	0.0	26.1	0.1	0.0	0.0	0.0	87.4	0.0	0.0	0.2	0.0	0.0	0.4	0.0	14.4	0.3	0.0	0.0	1.3	0.1	0.0	0.0	2.7	0.0	0.2	0.0	0.0	0.0	0.0	9.7	0.0	0.2	0.0	0.0	6.5	0.1	0.0	0.5	0.0	0.0	0.0	0.4	0.0	1.1	0.0	0.1	0.0	2.2	0.0	1.4	0.3	2.8	0.2	0.0	0.0	38.2	0.7	0.1	0.0	10.4
HAS3		ENSG00000103044	"Hyaluronan synthase 3"	O00219	16	69105653-69118719	"Enzymes, Metabolic proteins, Predicted membrane proteins"		"Glycosyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 33.8;urinary bladder: 93.7"	"Cell type enhanced"	"Detected in many"		"Basal keratinocytes: 162.3;Basal prostatic cells: 51.6;Basal respiratory cells: 107.1;Suprabasal keratinocytes: 158.6;Urothelial cells: 115.5"	"Group enriched"	"Detected in many"	8	"cervical cancer: 17.1;head and neck cancer: 44.9;lung cancer: 23.3;urothelial cancer: 31.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HaCaT: 52.5;PC-3: 270.5;RT4: 111.6"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"HPA031554, CAB033850"	Supported		Approved	Microtubules		NA	NA			Microtubules		"CAB033850: AB_2116418, HPA031554: AB_10670703"	"unprognostic (3.26e-2)"	"unprognostic (1.22e-1)"	"unprognostic (5.12e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.16e-1)"	"unprognostic (7.59e-3)"	"unprognostic (2.86e-3)"	"unprognostic (1.84e-1)"	"unprognostic (3.70e-1)"	"unprognostic (1.77e-1)"	"prognostic unfavorable (5.36e-4)"	"unprognostic (2.46e-1)"	"unprognostic (3.27e-3)"	"unprognostic (3.25e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.21e-2)"	"unprognostic (3.40e-3)"	0.8	0.5	0.8	0.8	1.0	0.9	7.5	1.1	1.1	2.8	0.7	5.4	2.9	0.9	1.2	33.8	1.2	4.9	0.7	0.5	0.9	1.1	1.3	20.2	0.4	0.9	0.9	0.7	1.4	1.3	0.4	1.7	3.4	1.2	3.7	3.1	0.8	5.4	1.5	1.2	7.8	2.3	0.6	0.3	0.8	12.9	3.6	0.9	0.6	6.0	1.0	2.9	93.7	10.4	1.0	3.5	17.1	1.0	0.9	0.3	0.4	6.6	1.1	0.4	1.0	0.4	3.4	9.0	0.7	2.0	0.4	4.0	52.5	2.9	31.5	1.0	0.2	1.3	0.0	0.2	0.6	0.1	0.3	0.9	0.5	8.6	1.0	3.0	4.0	0.7	0.6	0.1	0.4	0.3	1.8	1.2	0.7	15.5	18.7	270.5	2.0	0.1	0.2	28.3	111.6	19.2	0.8	1.8	0.1	0.3	3.1	0.6	0.8	0.3	0.9	0.9	29.9	1.8	1.0	0.9	0.2	1.0	0.0	0.6	0.1	0.2	0.3	0.2	0.0	0.1	0.1	0.1	0.0	0.1	0.2	0.2	0.1	0.0	0.0	0.1	0.1	0.2	0.2	0.8	1.0	1.1	1.1	0.5	0.9	0.9	0.9	0.7	1.2	0.3	0.9	1.0	4.2	0.0	30.8	0.7	0.2	162.3	51.6	107.1	8.6	1.1	1.6	6.1	1.4	0.0	12.2	0.0	2.1	1.0	0.1	16.4	0.0	4.5	10.2	0.7	0.3	2.4	0.0	0.4	1.0	3.6	0.9	1.1	5.1	2.7	0.0	0.4	1.1	0.2	0.3	0.0	2.1	0.7	2.0	0.0	6.5	22.7	1.2	0.5	3.6	0.0	0.0	0.1	0.0	0.5	0.8	2.4	0.2	0.4	0.6	18.4	0.1	0.7	3.0	1.0	0.0	0.9	1.9	0.5	0.7	25.6	158.6	0.3	1.1	0.1	2.2	115.5
HCAR2	"GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG"	ENSG00000182782	"Hydroxycarboxylic acid receptor 2"	Q8TDS4	12	122701293-122703357	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	Apoptosis	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 41.2"	"Cell type enhanced"	"Detected in many"		"Basal keratinocytes: 94.4;Basal prostatic cells: 84.7;Basal respiratory cells: 52.0;Basal squamous epithelial cells: 120.1;Ionocytes: 87.5;Langerhans cells: 124.0;Suprabasal keratinocytes: 106.1"	"Group enriched"	"Detected in many"	8	"cervical cancer: 12.6;head and neck cancer: 16.1;lung cancer: 6.4;urothelial cancer: 9.2"	"Group enriched"	"Detected in some"	11	"cerebral cortex: 5.3;pons: 1.3"	"Immune cell enriched"	"Detected in many"	5	"neutrophil: 176.7"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 176.7"	"Cell line enriched"	"Detected in some"	6	"HaCaT: 118.4"									HPA028660	Approved		Supported	"Cell Junctions"		NA	NA			"Cell Junctions"		"HPA028660: AB_10602139"	"unprognostic (5.43e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.77e-1)"	"unprognostic (2.05e-1)"	"unprognostic (6.65e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.33e-3)"	"unprognostic (7.26e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.77e-2)"	"unprognostic (7.10e-2)"	"unprognostic (7.33e-2)"	"unprognostic (4.83e-4)"	"unprognostic (5.76e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.54e-1)"	"unprognostic (4.63e-2)"	22.4	0.3	0.1	9.9	0.1	22.3	7.6	0.1	5.3	4.9	0.3	0.6	0.9	0.2	0.3	41.2	0.7	0.8	0.7	0.2	0.2	3.8	2.9	12.0	0.6	0.1	0.1	0.1	0.1	0.2	5.5	0.3	4.6	1.3	3.5	0.3	0.2	14.3	14.8	0.2	27.8	1.0	0.3	0.1	26.2	1.5	2.8	0.2	10.6	0.5	1.9	10.2	7.0	14.2	0.2	4.5	0.4	0.1	0.1	1.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	118.4	0.0	7.3	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.3	0.1	3.8	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	1.0	0.0	0.3	0.0	0.0	0.4	0.1	0.0	0.0	0.0	19.5	0.2	0.0	0.4	0.1	0.0	0.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.3	0.0	0.0	38.7	2.5	2.6	0.0	5.3	0.0	0.1	0.0	0.0	1.7	0.0	0.0	0.0	176.7	0.0	23.9	0.0	0.0	1.4	0.1	0.1	0.1	5.3	0.2	0.2	0.1	0.1	0.1	1.3	0.1	0.2	0.2	0.4	0.0	4.3	0.0	0.5	94.4	84.7	52.0	120.1	0.5	3.4	1.1	0.1	0.0	40.3	0.0	0.0	1.5	0.0	0.0	0.0	0.0	24.9	0.4	0.2	1.2	0.0	0.0	0.0	0.0	26.3	2.4	0.0	0.3	2.5	0.0	0.0	0.0	3.7	0.0	0.0	0.0	87.5	4.1	124.0	2.7	0.0	17.8	8.8	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.3	0.0	0.0	8.5	0.1	0.0	0.1	1.4	0.0	0.1	47.2	106.1	2.6	1.5	0.0	0.0	32.5
KRT38	KRTHA8	ENSG00000171360	"Keratin 38"	O76015	17	41436154-41440983	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	15	"skin 1: 9.2"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"head and neck cancer: 1.1;urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																	NA	NA		160000000									"unprognostic (1.37e-1)"				"unprognostic (4.05e-1)"								0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	9.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SNCG	"BCSG1, persyn, SR"	ENSG00000173267	"Synuclein gamma"	O76070	10	86958599-86963258	"Predicted intracellular proteins, Transporters"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 270.5;brain: 577.0"	"Cell type enhanced"	"Detected in many"		"Adipocytes: 164.9;Breast myoepithelial cells: 156.1;Endothelial cells: 143.3;Hepatic stellate cells: 206.0;Smooth muscle cells: 234.3;Urothelial cells: 358.3"	"Group enriched"	"Detected in all"	8	"ovarian cancer: 84.1;urothelial cancer: 301.2"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 748.2;RT4: 483.5;T-47d: 151.7;TIME: 160.9"	"Region enhanced"	"Detected in all"		"pons and medulla: 279.9"	"Low region specificity"	"Detected in many"			"CAB001452, HPA014404, CAB040581, CAB080022"	Enhanced	Supported				NA	NA		23000			"CAB001452: AB_564020, CAB040581: , CAB080022: , HPA014404: AB_1857715"	"unprognostic (2.06e-1)"	"unprognostic (2.58e-1)"	"unprognostic (6.87e-3)"	"unprognostic (1.45e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.91e-1)"	"unprognostic (4.76e-3)"	"unprognostic (8.99e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.85e-3)"	"unprognostic (3.75e-1)"	"prognostic unfavorable (2.29e-8)"	"prognostic unfavorable (7.15e-4)"	"unprognostic (2.35e-1)"	"unprognostic (2.36e-2)"	"unprognostic (3.77e-3)"	210.0	270.5	237.3	12.1	145.0	0.0	99.0	193.6	316.0	32.3	42.1	24.3	9.3	23.1	15.2	25.7	65.1	12.8	26.1	179.2	224.3	17.1	4.4	14.0	11.7	344.4	277.1	167.5	42.5	5.3	3.4	11.2	12.0	354.5	36.9	4.9	53.2	23.1	102.6	14.7	27.9	19.0	10.2	160.2	64.7	16.5	5.4	328.5	9.1	20.4	13.8	25.8	206.6	39.2	577.0	2.6	6.8	0.7	1.1	0.3	3.9	0.7	0.8	0.0	0.0	0.0	1.1	748.2	0.0	22.6	1.4	0.0	71.0	0.0	3.4	0.0	0.1	1.4	3.6	109.6	2.0	1.4	0.0	1.8	2.8	55.5	0.0	0.6	0.2	49.8	0.0	5.3	0.0	0.0	0.6	0.2	0.4	11.3	0.0	0.4	0.0	0.4	0.3	0.2	483.5	0.1	0.0	6.5	8.7	0.9	1.0	151.7	0.3	160.9	1.1	3.7	0.3	0.0	0.2	0.0	0.0	0.8	3.6	0.5	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.1	237.3	145.0	193.6	316.0	179.2	224.3	344.4	277.1	167.5	354.5	160.2	328.5	577.0	164.9	0.0	0.0	7.5	1.5	28.8	65.9	16.3	11.4	32.2	61.1	156.1	1.9	8.6	14.6	55.2	6.2	19.4	2.8	0.1	125.2	3.6	0.6	0.4	0.8	143.3	0.0	2.7	9.9	1.1	0.6	14.2	0.5	0.6	0.0	0.1	206.0	0.8	5.5	87.5	28.0	0.0	20.3	1.8	27.3	3.7	59.0	2.2	23.2	6.5	0.9	66.4	0.0	4.5	7.5	4.7	2.2	9.8	0.0	14.2	0.3	1.3	2.4	109.3	92.1	2.5	234.3	0.6	0.7	2.6	19.7	6.2	2.7	16.9	0.0	358.3
ACSM6	"bA310E22.3, C10orf129"	ENSG00000173124	"Acyl-CoA synthetase medium chain family member 6"	Q6P461	10	95194200-95228928	"Enzymes, Predicted membrane proteins"	"Fatty acid metabolism, Lipid metabolism"	Ligase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Group enriched"	"Detected in some"	5	"lymphoid tissue: 3.6;pancreas: 4.1;skin 1: 1.2;stomach 1: 1.9;urinary bladder: 1.1"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 2.0;Cone photoreceptor cells: 2.1;Early spermatids: 2.4;Excitatory neurons: 3.8;Inhibitory neurons: 3.4;Oligodendrocytes: 2.1;Rod photoreceptor cells: 5.3"	"Cancer enriched"	"Detected in single"	7	"urothelial cancer: 1.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	30	"RT4: 3.7"									HPA044593	Uncertain					NA	NA					"HPA044593: AB_10960261"	"unprognostic (2.91e-2)"				"unprognostic (2.87e-1)"	"unprognostic (3.64e-2)"	"unprognostic (5.73e-2)"	"unprognostic (2.48e-2)"		"unprognostic (6.34e-2)"	"unprognostic (1.41e-2)"	"unprognostic (1.91e-1)"	"unprognostic (3.75e-3)"	"unprognostic (2.25e-1)"	"unprognostic (2.37e-1)"	"unprognostic (1.11e-1)"	"prognostic favorable (7.71e-4)"	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	4.1	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	1.9	0.1	0.1	3.6	0.4	0.0	0.0	1.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.4	0.4	0.0	0.0	2.0	0.2	0.0	0.3	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	2.4	0.6	1.2	0.6	0.0	0.0	3.8	0.0	0.0	0.1	1.1	1.1	0.0	0.0	0.0	0.0	0.1	0.0	3.4	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	2.1	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	5.3	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1
CYP4F22	FLJ39501	ENSG00000171954	"Cytochrome P450 family 4 subfamily F member 22"	Q6NT55	19	15508525-15552317	"Disease related genes, Human disease related genes, Metabolic proteins, Predicted membrane proteins"		"Monooxygenase, Oxidoreductase"	Ichthyosis	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 19.0;skin 1: 55.3;vagina: 23.0"	"Cell type enhanced"	"Detected in some"		"Breast glandular cells: 8.8;Breast myoepithelial cells: 5.5;granulocytes: 7.0;Prostatic glandular cells: 4.0;Suprabasal keratinocytes: 3.0"	"Group enriched"	"Detected in many"	7	"breast cancer: 4.5;head and neck cancer: 5.7;liver cancer: 8.5;melanoma: 4.5;urothelial cancer: 13.9"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"intermediate monocyte: 6.1;MAIT T-cell: 4.3;non-classical monocyte: 14.1"	"Group enriched"	"Detected in many"	8	"monocytes: 14.1;T-cells: 4.3"	"Cell line enhanced"	"Detected in some"		"MCF7: 1.7;T-47d: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA058960	Uncertain					NA	NA					"HPA058960: AB_2683862"	"unprognostic (2.32e-3)"	"unprognostic (1.17e-2)"	"unprognostic (6.81e-2)"	"unprognostic (2.47e-2)"	"unprognostic (1.03e-1)"	"unprognostic (7.02e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.43e-1)"	"unprognostic (3.33e-1)"	"unprognostic (1.89e-2)"	"unprognostic (9.33e-2)"	"unprognostic (3.00e-2)"	"unprognostic (2.21e-5)"	"unprognostic (8.10e-2)"	"unprognostic (3.16e-1)"	"unprognostic (7.25e-3)"	"unprognostic (2.03e-2)"	0.9	0.0	0.0	0.0	0.0	0.1	3.7	0.0	0.0	5.1	0.0	0.0	0.2	0.3	0.0	19.0	0.1	0.1	0.0	0.0	0.0	0.0	7.0	0.3	0.3	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.2	8.5	0.0	0.0	3.2	6.4	0.2	55.3	0.1	0.0	0.0	0.3	1.4	1.0	0.0	0.1	0.0	0.0	1.8	6.3	23.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.7	6.1	4.3	0.0	0.5	1.5	0.2	0.0	0.0	0.4	0.0	1.1	14.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	8.8	5.5	0.4	1.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.4	0.0	0.0	0.1	0.0	0.0	7.0	0.0	0.0	1.5	0.0	0.0	0.4	0.0	0.0	0.8	0.0	0.4	0.0	0.3	0.0	0.0	0.5	0.0	1.0	0.0	0.3	0.0	0.0	0.0	0.1	4.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	1.8	0.0	3.0	0.0	1.8	0.0	0.0	0.3
FABP4	"A-FABP, aP2"	ENSG00000170323	"Fatty acid binding protein 4"	P15090	8	81478419-81483236	"Cancer-related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	12	"adipose tissue: 3821.0;breast: 2214.1"	"Cell type enriched"	"Detected in many"	17	"Adipocytes: 24359.7"	"Group enriched"	"Detected in all"	7	"breast cancer: 42.1;cervical cancer: 141.7;head and neck cancer: 133.8;urothelial cancer: 65.5"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	171	"ASC diff: 4051.5;RT4: 2107.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA002188, CAB024961"	Enhanced					NA	NA		22000000			"CAB024961: , HPA002188: AB_1078822"	"unprognostic (4.81e-2)"	"unprognostic (2.30e-3)"	"unprognostic (1.64e-3)"	"unprognostic (2.63e-2)"	"unprognostic (2.58e-1)"	"unprognostic (8.70e-3)"	"unprognostic (1.78e-3)"	"unprognostic (1.67e-1)"	"unprognostic (2.00e-1)"	"unprognostic (2.36e-1)"	"unprognostic (9.32e-2)"	"unprognostic (1.56e-1)"	"unprognostic (8.76e-2)"	"unprognostic (1.13e-3)"	"unprognostic (4.48e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.39e-1)"	3821.0	42.6	0.8	47.1	0.9	2.8	2214.1	0.9	1.6	10.0	29.3	53.4	2.8	4.7	0.6	15.3	11.0	68.8	93.4	1.2	0.9	7.0	5.2	114.5	13.7	0.9	0.8	0.7	4.2	16.7	59.6	1.5	188.5	0.9	4.3	33.8	2.6	59.2	5.1	67.2	57.7	45.1	14.3	0.8	6.7	26.7	1.1	3.1	30.1	83.7	168.2	2.0	245.2	19.1	0.9	0.0	0.0	0.0	0.0	4051.5	0.0	0.0	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.7	0.0	17.9	0.0	0.1	1.3	0.0	0.4	0.0	0.0	2.0	0.7	0.0	0.0	0.0	0.8	1.2	0.1	3.0	0.0	9.4	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.1	0.0	2107.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.3	0.2	5.7	0.0	0.2	0.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.9	0.9	1.6	1.2	0.9	0.9	0.8	0.7	0.9	0.8	3.1	0.9	24359.7	35.3	64.3	0.0	19.4	14.4	1.1	0.9	4.6	0.5	71.7	196.2	42.1	0.0	26.7	0.0	0.0	0.5	73.6	0.0	0.0	0.2	1.6	0.4	8.8	1132.7	0.0	0.0	0.0	5.6	0.7	53.1	1.1	0.2	27.8	0.1	23.2	0.4	114.2	0.0	0.0	0.0	0.0	50.4	15.7	10.9	1.5	192.7	16.0	0.0	0.6	0.9	0.0	0.0	0.0	0.2	2.2	1.2	2.7	0.5	0.0	0.3	21.9	2.4	716.6	62.2	1364.8	0.0	0.1	1.2	13.9	0.7	18.7	2.3	0.0	55.3
GHRH	GHRF	ENSG00000118702	"Growth hormone releasing hormone"	P01286	20	37251086-37261814	"Human disease related genes, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	14	"brain: 130.9"	"Cell type enriched"	"Detected in single"	7	"Cardiomyocytes: 5.2"	"Cancer enriched"	"Detected in some"	7	"urothelial cancer: 8.5"	"Region enriched"	"Detected in some"	12	"hypothalamus: 130.9"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"NTERA-2: 2.1;U-266/84: 7.9"	"Region enriched"	"Detected in many"	9	"hypothalamus: 32.9"	"Region enhanced"	"Detected in some"		"hypothalamus: 3.7"						"Secreted in other tissues"	NA	NA						"unprognostic (4.78e-2)"				"unprognostic (2.57e-2)"									"unprognostic (1.58e-1)"	"unprognostic (3.10e-1)"			0.0	1.0	0.7	0.0	0.3	0.0	0.3	0.3	0.5	0.0	0.1	0.0	3.5	0.0	0.0	0.3	0.0	0.0	6.3	0.3	130.9	0.0	0.0	0.0	0.0	0.2	0.4	0.3	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.1	0.0	1.2	0.0	0.2	0.0	0.6	0.1	11.2	9.3	0.2	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.3	0.5	0.3	130.9	0.2	0.4	0.3	0.3	0.2	11.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0
GUCA2A	"GUCA2, STARA"	ENSG00000197273	"Guanylate cyclase activator 2A"	Q02747	1	42162690-42164745	"Plasma proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	54	"intestine: 935.3"	"Cell type enhanced"	"Detected in some"		"Distal enterocytes: 3728.7;Paneth cells: 17085.1;Proximal enterocytes: 12113.5"	"Group enriched"	"Detected in many"	7	"colorectal cancer: 31.6;urothelial cancer: 8.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"OE19: 52.1"	"Not detected"	"Not detected"							HPA018215	Enhanced				"Secreted to blood"	NA	NA		18000000			"HPA018215: AB_1850443"			"unprognostic (7.98e-3)"		"unprognostic (1.60e-1)"		"unprognostic (1.16e-1)"	"unprognostic (9.07e-2)"			"unprognostic (1.14e-1)"			"unprognostic (8.06e-2)"	"unprognostic (2.89e-1)"	"unprognostic (3.10e-1)"	"unprognostic (9.15e-2)"	0.8	0.1	0.0	3.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	723.6	57.0	0.9	0.0	0.2	0.5	0.3	0.1	0.0	0.0	0.4	0.3	1.2	0.7	0.0	0.0	0.0	0.1	1.2	0.0	0.2	7.3	0.0	0.1	732.7	0.0	0.1	2.0	0.1	0.0	935.3	17.4	0.0	0.2	0.7	0.2	0.0	0.3	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	52.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	3728.7	0.0	2.6	0.1	0.0	0.0	0.0	47.7	0.0	0.0	1.1	4.4	0.0	0.0	0.0	22.3	0.0	0.0	0.0	0.0	0.0	0.0	421.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	17085.1	0.0	0.0	0.0	12113.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.9	3.8	0.0	206.6	0.2
IGFL1	UNQ644	ENSG00000188293	"IGF like family member 1"	Q6UW32	19	46229742-46231243	"Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	12	"esophagus: 113.9;salivary gland: 34.8;vagina: 31.8"	"Cell type enhanced"	"Detected in some"		"Basal keratinocytes: 1.7;Basal respiratory cells: 12.5;Prostatic glandular cells: 4.4;Squamous epithelial cells: 2.1;Suprabasal keratinocytes: 3.4"	"Group enriched"	"Detected in many"	7	"cervical cancer: 47.6;head and neck cancer: 60.7;melanoma: 23.3;urothelial cancer: 84.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"HaCaT: 6.9;RT4: 25.6;SK-BR-3: 8.6"									HPA014001	Uncertain				"Secreted in other tissues"	NA	NA					"HPA014001: AB_2668919"	"unprognostic (1.35e-1)"	"unprognostic (9.70e-2)"	"unprognostic (2.89e-1)"	"unprognostic (1.01e-1)"		"unprognostic (1.64e-2)"		"unprognostic (2.67e-2)"	"unprognostic (3.06e-1)"	"unprognostic (4.50e-3)"	"unprognostic (6.70e-3)"	"unprognostic (1.67e-1)"		"unprognostic (1.80e-1)"		"unprognostic (1.64e-1)"	"unprognostic (3.23e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	3.2	0.0	0.0	0.0	0.0	0.0	113.9	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.2	34.8	0.0	0.0	3.0	0.0	0.0	0.0	0.3	0.1	1.0	0.0	0.8	0.0	0.0	4.9	0.4	31.8	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	6.9	0.0	1.9	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	25.6	0.0	0.0	0.2	8.6	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.3	12.5	0.0	0.0	0.5	0.4	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	4.4	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.4	0.3	2.1	3.4	0.0	0.0	0.0	0.0	0.2
LY6D	E48	ENSG00000167656	"Lymphocyte antigen 6 family member D"	Q14210	8	142784882-142786539	"Plasma proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 2091.0;skin 1: 855.3;vagina: 495.3"	"Group enriched"	"Detected in many"	9	"Basal keratinocytes: 1171.6;Squamous epithelial cells: 1913.0;Suprabasal keratinocytes: 3866.1"	"Group enriched"	"Detected in many"	7	"cervical cancer: 409.8;head and neck cancer: 444.6;urothelial cancer: 242.3"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	14	"A-431: 162.0"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA024755, HPA064317"	Enhanced					NA	NA		210000			"HPA024755: AB_1853410, HPA064317: AB_2685244"	"unprognostic (2.13e-2)"	"unprognostic (7.48e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.08e-2)"		"unprognostic (8.97e-2)"		"unprognostic (1.51e-2)"	"unprognostic (3.84e-1)"	"unprognostic (5.11e-2)"	"prognostic unfavorable (1.94e-6)"	"unprognostic (8.68e-2)"	"prognostic unfavorable (1.20e-4)"	"unprognostic (2.50e-1)"	"unprognostic (3.97e-1)"	"unprognostic (5.40e-4)"	"unprognostic (1.06e-1)"	1.1	48.0	0.4	0.2	0.5	0.0	20.7	0.4	1.4	143.5	0.4	0.9	0.0	0.3	0.0	2091.0	1.0	1.4	0.7	0.6	0.4	0.3	0.8	0.5	0.0	0.4	0.4	0.4	0.5	1.0	0.0	1.0	2.6	0.5	15.4	0.2	0.0	237.3	0.3	2.6	855.3	0.5	0.0	0.4	0.5	12.5	0.4	0.4	4.7	0.4	0.0	76.2	65.7	495.3	0.6	162.0	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.1	6.0	0.0	1.3	0.0	0.2	0.0	0.0	4.0	11.9	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.9	0.0	0.0	1.2	4.0	0.2	0.0	0.0	0.8	0.0	0.0	0.2	0.0	0.2	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.4	1.4	0.6	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.6	0.1	3.2	0.0	0.0	0.0	1171.6	9.4	244.9	138.3	0.0	14.8	14.1	0.2	0.0	154.0	1.8	0.0	0.9	0.1	0.4	1.9	1.1	0.0	0.4	0.1	10.7	0.0	0.0	0.3	0.2	5.7	9.8	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	22.4	0.0	137.3	0.0	0.0	0.8	163.7	0.0	0.0	0.0	0.0	0.0	0.1	7.0	0.0	0.0	2.5	18.9	0.0	1.2	12.2	0.0	0.0	0.6	16.1	0.0	0.0	1913.0	3866.1	8.2	4.0	0.0	0.4	164.6
SLC1A6	EAAT4	ENSG00000105143	"Solute carrier family 1 member 6"	P48664	19	14950034-15022990	"Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Amino-acid transport, Symport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"brain: 91.5;testis: 28.2"	"Cell type enhanced"	"Detected in some"		"Bipolar cells: 17.1;Early spermatids: 35.3;Horizontal cells: 23.5;Late spermatids: 31.8;Syncytiotrophoblasts: 40.0"	"Cancer enriched"	"Detected in some"	7	"urothelial cancer: 5.2"	"Region enhanced"	"Detected in all"		"cerebellum: 91.5"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HAP1: 7.4;NTERA-2: 6.1;U-698: 28.3"	"Region enriched"	"Detected in all"	6	"cerebellum: 136.3"	"Region enhanced"	"Detected in all"		"cerebellum: 53.8"	"HPA041505, HPA044066"	Enhanced	Supported	Supported	"Plasma membrane,Intermediate filaments"		NA	NA			"Plasma membrane"	"Intermediate filaments"	"HPA041505: AB_2677520, HPA044066: AB_2678796"	"unprognostic (3.62e-2)"	"unprognostic (1.35e-1)"		"unprognostic (4.41e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.12e-1)"		"unprognostic (5.94e-3)"	"unprognostic (8.90e-2)"	"unprognostic (6.52e-4)"	"unprognostic (1.55e-1)"	"unprognostic (5.40e-3)"	"unprognostic (1.11e-2)"	"unprognostic (9.92e-2)"	"unprognostic (1.35e-1)"	"unprognostic (5.57e-2)"	"prognostic unfavorable (6.88e-6)"	0.1	0.2	8.6	0.2	11.1	0.9	0.4	91.5	15.1	0.1	1.3	0.2	0.3	0.4	1.7	0.1	0.2	0.2	0.2	15.2	7.4	0.1	0.2	0.2	0.3	3.9	7.3	10.2	0.3	0.6	0.9	0.3	0.7	29.7	0.5	0.3	2.3	0.4	0.5	0.3	8.3	0.3	0.2	2.5	0.4	0.2	28.2	6.3	0.2	0.3	0.1	0.3	0.1	0.1	5.7	0.1	0.1	0.3	0.4	0.2	0.2	0.9	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.1	1.4	7.4	0.2	0.1	0.2	0.1	0.2	0.4	0.3	0.0	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.2	0.1	0.6	0.1	0.6	0.0	0.5	6.1	0.0	0.1	0.1	0.1	0.1	0.1	0.3	0.5	0.2	0.2	2.8	0.0	1.1	0.3	0.1	0.0	0.3	1.1	0.3	0.1	0.5	0.1	28.3	0.1	0.3	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.1	0.3	0.0	0.0	0.1	0.0	0.0	8.6	11.1	91.5	15.1	15.2	7.4	3.9	7.3	10.2	29.7	2.5	6.3	5.7	0.0	0.0	0.0	0.7	0.0	3.2	0.7	0.0	0.0	17.1	0.0	0.1	2.1	0.0	0.0	1.8	0.0	1.9	0.0	0.0	0.0	0.0	35.3	0.0	0.1	0.1	0.0	0.0	8.2	0.4	9.9	0.4	0.0	0.0	0.0	5.8	0.0	0.0	0.5	23.5	8.6	0.0	0.0	0.0	0.7	31.8	0.6	0.0	0.0	1.0	0.0	0.7	0.0	4.5	0.9	0.0	0.0	0.7	0.0	0.2	0.0	0.2	0.0	0.8	0.0	0.0	0.4	2.2	6.3	0.0	6.8	40.0	0.0	0.0	0.0	0.1
SPOCD1	"FLJ25348, PPP1R146"	ENSG00000134668	"SPOC domain containing 1"	Q6ZMY3	1	31790422-31816051	"Predicted intracellular proteins"	"Differentiation, RNA-mediated gene silencing, Spermatogenesis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 19.7;testis: 9.8;urinary bladder: 9.6"	"Cell type enhanced"	"Detected in some"		"Hofbauer cells: 13.2;Pancreatic endocrine cells: 30.9;Smooth muscle cells: 10.4;Spermatogonia: 13.1;Urothelial cells: 48.6"	"Group enriched"	"Detected in many"	7	"glioma: 13.9;urothelial cancer: 5.6"	"Region enhanced"	"Detected in many"		"hypothalamus: 19.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 49.9;hTEC/SVTERT24-B: 51.5;RT4: 89.2;TIME: 46.2;U-87 MG: 84.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA031713, HPA031714, HPA031715"	Enhanced		Approved	Nucleoplasm,Nucleoli,Cytosol		NA	NA			Cytosol	"Nucleoplasm, Nucleoli"	"HPA031713: AB_10604099, HPA031714: AB_2674007, HPA031715: AB_2674008"	"unprognostic (7.78e-2)"	"unprognostic (2.58e-2)"	"unprognostic (1.85e-3)"	"unprognostic (2.70e-3)"	"unprognostic (1.29e-2)"	"unprognostic (1.56e-2)"	"unprognostic (2.15e-3)"	"unprognostic (2.60e-2)"	"unprognostic (3.51e-1)"	"unprognostic (2.18e-1)"	"unprognostic (3.01e-2)"	"unprognostic (3.00e-1)"	"unprognostic (0.00e+0)"	"unprognostic (1.97e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.54e-2)"	"prognostic favorable (4.05e-5)"	2.3	0.4	1.6	3.1	1.7	0.1	1.6	1.2	3.5	2.7	2.2	0.4	0.9	2.2	0.3	0.3	1.2	0.9	0.1	1.3	19.7	0.3	0.1	7.3	0.1	7.8	2.3	0.8	0.3	0.0	0.0	1.5	0.3	2.9	1.6	0.5	0.0	0.3	0.1	0.1	0.2	0.9	1.4	2.2	1.9	0.9	9.8	9.4	0.2	0.3	0.0	0.0	9.6	0.9	6.4	29.8	0.8	0.1	0.1	0.5	4.0	1.4	37.7	49.9	35.8	23.7	0.5	1.7	0.5	5.0	42.7	14.7	3.9	0.0	0.7	11.2	0.1	0.1	0.0	5.8	0.2	1.7	0.0	0.6	17.7	0.6	51.5	1.7	28.9	24.4	2.0	0.7	0.6	21.5	0.1	0.2	0.0	0.7	0.4	0.8	0.0	3.8	0.0	0.1	89.2	0.0	0.0	0.9	0.2	2.6	1.2	21.6	0.0	46.2	37.4	3.9	24.6	14.3	0.2	0.3	0.1	84.6	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	3.1	1.6	1.7	1.2	3.5	1.3	19.7	7.8	2.3	0.8	2.9	2.2	9.4	6.4	0.2	0.0	3.7	0.3	0.0	0.1	6.5	4.5	0.0	0.0	0.3	0.1	0.5	0.0	1.7	0.0	0.0	0.2	0.0	0.0	0.0	8.3	0.3	1.7	0.6	2.3	1.8	0.0	0.4	9.8	0.6	1.0	0.0	5.9	1.3	0.2	0.4	0.0	13.2	0.0	0.1	0.0	0.0	0.6	0.2	0.5	0.0	5.7	0.0	0.0	0.1	0.0	0.0	0.0	1.6	30.9	0.0	0.4	0.1	2.5	0.0	0.1	0.3	0.0	0.0	5.1	10.4	0.0	13.1	0.0	0.0	0.3	0.4	0.1	0.0	48.6
TAC3	"LncZBTB39, LncZBTB39-1:2, NK3, NKB, NKNB, ZNEUROK1"	ENSG00000166863	"Tachykinin precursor 3"	Q9UHF0	12	57010000-57028883	"Disease related genes, Human disease related genes, Predicted secreted proteins"		Neuropeptide	"Disease variant, Hypogonadotropic hypogonadism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	19	"placenta: 435.3"	"Group enriched"	"Detected in some"	5	"Cytotrophoblasts: 13.9;Extravillous trophoblasts: 19.6;Inhibitory neurons: 40.0;Syncytiotrophoblasts: 18.3"	"Cancer enriched"	"Detected in many"	7	"urothelial cancer: 40.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"K-562: 14.4;SuSa: 13.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			HPA045919	Supported	Supported	Approved	Vesicles	"Secreted in female reproductive system"	NA	NA		130000	Vesicles		"HPA045919: AB_10960533"	"unprognostic (4.53e-2)"	"unprognostic (1.97e-2)"	"unprognostic (8.41e-2)"	"unprognostic (3.00e-2)"	"unprognostic (3.61e-2)"	"unprognostic (1.76e-2)"	"unprognostic (5.99e-2)"	"unprognostic (8.41e-2)"		"unprognostic (1.34e-1)"	"unprognostic (2.03e-1)"	"unprognostic (5.28e-2)"	"unprognostic (4.71e-14)"	"unprognostic (1.58e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.39e-1)"	0.1	0.3	13.4	2.5	11.7	1.0	0.1	5.6	16.6	0.1	6.1	3.5	3.0	0.3	0.0	0.1	0.1	0.3	0.1	11.0	23.4	0.1	0.1	0.1	0.2	17.3	8.3	11.2	0.2	0.6	0.0	0.7	435.3	8.6	0.2	1.5	6.2	0.0	0.0	0.2	0.5	6.5	4.9	15.4	0.1	13.3	1.9	9.0	0.5	0.1	0.0	0.4	3.1	0.3	17.4	0.0	0.1	0.0	0.4	0.0	0.0	1.2	0.0	1.1	0.3	0.0	1.6	0.0	0.7	0.0	0.1	0.0	0.0	0.2	0.0	0.3	0.0	0.0	1.3	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.3	14.4	0.3	0.0	0.0	0.0	0.2	1.6	0.5	0.0	0.0	0.0	0.0	0.0	1.5	2.1	0.6	0.0	0.8	0.0	13.5	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.4	11.7	5.6	16.6	11.0	23.4	17.3	8.3	11.2	8.6	15.4	9.0	17.4	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.5	0.3	0.0	0.0	0.0	0.0	13.9	0.0	1.4	0.0	0.0	0.1	0.0	0.4	0.1	1.2	2.7	0.5	0.0	19.6	2.6	0.0	0.1	0.0	4.3	0.7	0.0	2.2	0.0	40.0	0.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.9	0.0	0.0	0.0	1.5	2.8	0.0	0.3	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.4	2.6	1.0	0.0	0.0	18.3	0.0	0.0	1.8	0.0
ACOXL	FLJ11042	ENSG00000153093	"Acyl-CoA oxidase like"	Q9NUZ1	2	110732539-111120610	"Predicted intracellular proteins"		Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in many"		"epididymis: 7.3;lung: 9.3"	"Cell type enriched"	"Detected in some"	5	"Alveolar cells type 2: 41.9"	"Group enriched"	"Detected in some"	6	"lung cancer: 0.6;prostate cancer: 1.1;testis cancer: 2.1;urothelial cancer: 2.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"A-431: 12.1;RPMI-8226: 22.0;RT4: 29.3;U-266/70: 18.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA035392, HPA035393"			Supported	Nucleoli,Cytosol		NA	NA			Cytosol	Nucleoli	"HPA035392: AB_2674604, HPA035393: AB_2674605"	"unprognostic (1.62e-1)"	"unprognostic (7.30e-2)"	"unprognostic (6.77e-4)"	"unprognostic (2.93e-7)"	"unprognostic (1.32e-2)"	"unprognostic (7.84e-5)"	"unprognostic (1.28e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.31e-2)"	"unprognostic (7.24e-2)"	"unprognostic (3.24e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.72e-1)"	"prognostic favorable (6.48e-4)"	1.1	0.6	0.6	0.5	0.7	1.5	0.1	0.2	0.5	0.4	0.1	0.5	0.5	0.5	7.3	0.4	0.3	0.6	1.2	0.4	0.1	0.5	0.3	9.3	0.9	0.4	0.3	0.5	0.2	1.0	2.9	0.3	0.7	0.5	3.2	0.3	0.7	0.6	0.0	1.3	0.7	0.6	0.1	0.0	0.6	0.5	3.2	0.3	0.3	0.8	0.0	1.2	4.7	0.1	0.6	12.1	0.2	0.3	0.2	0.1	0.0	0.8	0.1	0.0	0.0	0.0	0.9	0.7	0.3	0.5	0.1	0.3	1.3	0.0	0.1	0.0	0.3	3.5	0.2	0.5	0.5	0.0	0.0	0.3	0.1	1.2	0.0	0.1	0.3	0.0	0.6	1.8	1.8	0.1	4.4	0.9	0.4	4.2	0.0	0.3	0.6	0.2	22.0	0.0	29.3	2.5	1.0	0.3	0.5	0.1	0.6	0.4	1.2	0.3	0.2	1.0	0.2	0.1	18.7	4.8	0.7	0.0	0.1	0.1	0.7	0.3	0.3	0.1	0.1	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.0	0.9	0.2	0.2	0.2	0.1	0.1	0.6	0.7	0.2	0.5	0.4	0.1	0.4	0.3	0.5	0.5	0.0	0.3	0.6	0.3	0.0	41.9	0.0	1.0	0.3	0.3	0.0	0.0	0.6	0.1	0.3	0.5	0.0	0.7	0.0	0.0	0.0	0.1	1.3	0.0	0.2	5.4	0.2	0.1	0.2	1.2	0.0	2.2	0.0	0.0	0.4	0.0	0.8	0.0	5.9	0.0	0.0	0.1	0.0	2.0	0.3	0.0	0.0	0.8	8.1	0.0	0.2	0.0	0.0	0.0	0.1	1.0	1.0	1.3	0.1	2.3	0.0	7.5	0.8	0.0	0.1	0.1	0.3	0.0	0.2	0.3	1.6	2.7	0.0	0.3	0.0	1.1	0.0	0.2	0.8
AKR1C2	"BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD"	ENSG00000151632	"Aldo-keto reductase family 1 member C2"	P52895	10	4987400-5018031	"Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins"	"Lipid metabolism, Steroid metabolism"	Oxidoreductase	"Disease variant, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 324.5;liver: 485.9;skeletal muscle: 289.2"	"Cell type enhanced"	"Detected in many"		"Basal respiratory cells: 141.7;Club cells: 128.8;Gastric mucus-secreting cells: 133.5;Hepatocytes: 397.4;Urothelial cells: 271.9"	"Group enriched"	"Detected in many"	6	"cervical cancer: 21.7;head and neck cancer: 31.5;liver cancer: 50.2;lung cancer: 69.0;urothelial cancer: 35.7"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"A549: 2054.8;ASC diff: 2439.5;Hep G2: 3926.2;OE19: 2684.9;RT4: 1178.9"									"CAB047304, HPA068265"	Enhanced		Approved	"Nucleoplasm,Nucleoli fibrillar center,Endoplasmic reticulum,Cytosol"		NA	NA			"Nucleoplasm, Cytosol"	"Nucleoli fibrillar center, Endoplasmic reticulum"	"CAB047304: , HPA068265: AB_2685966"	"unprognostic (6.77e-2)"	"unprognostic (8.88e-3)"	"unprognostic (3.02e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.72e-2)"	"unprognostic (2.86e-2)"	"unprognostic (8.65e-2)"	"unprognostic (5.03e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.02e-1)"	"unprognostic (6.25e-3)"	"unprognostic (8.58e-2)"	"unprognostic (1.09e-2)"	"unprognostic (8.60e-3)"	"unprognostic (1.46e-2)"	"unprognostic (8.30e-2)"	324.5	21.0	12.3	10.1	11.0	1.0	207.4	10.9	10.8	11.4	8.8	26.1	29.9	5.7	3.3	204.1	8.7	99.0	54.4	7.2	11.9	16.3	485.9	23.7	2.1	18.2	13.4	7.3	10.4	11.9	1.1	8.2	0.8	17.6	11.8	13.4	15.3	117.4	13.1	289.2	39.3	34.0	9.3	12.6	2.1	138.2	12.0	18.8	4.5	38.6	36.8	9.3	256.4	47.4	18.8	0.0	2054.8	2.4	214.1	2439.5	83.4	0.1	0.7	8.6	0.9	2.0	8.1	0.2	0.4	11.5	14.2	10.0	57.8	0.2	10.7	1.2	0.6	0.2	0.7	516.4	3926.2	4.6	0.4	0.9	218.3	126.4	10.5	10.4	0.7	0.9	0.3	81.9	0.3	20.4	3.3	0.2	0.0	0.7	2684.9	0.8	0.3	0.6	34.6	19.0	1178.9	1.2	0.4	21.2	0.3	0.1	0.4	0.5	4.0	8.6	5.1	1.8	74.6	0.8	0.6	0.6	0.3	25.9	30.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	12.3	11.0	10.9	10.8	7.2	11.9	18.2	13.4	7.3	17.6	12.6	18.8	18.8	15.2	12.8	2.8	0.0	0.9	11.9	9.5	141.7	20.5	1.9	0.8	1.4	5.5	102.9	128.8	0.0	0.0	0.0	0.0	10.3	0.0	18.3	17.3	0.7	0.5	7.5	1.8	8.0	2.6	103.3	0.1	44.2	133.5	0.8	0.0	0.1	10.8	397.4	0.1	3.3	4.2	5.4	46.8	12.0	7.8	7.8	79.2	1.0	8.8	19.7	0.6	39.6	0.0	5.5	0.3	90.0	6.6	78.6	0.8	23.7	15.9	3.6	40.3	3.0	0.0	5.3	13.9	0.2	0.3	112.9	13.5	0.0	1.3	0.4	8.5	271.9
CALML5	CLSP	ENSG00000178372	"Calmodulin like 5"	Q9NZT1	10	5498697-5499570	"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"skin 1: 2852.4"	"Group enriched"	"Detected in some"	4	"Breast glandular cells: 172.1;Breast myoepithelial cells: 156.1;Suprabasal keratinocytes: 390.7"	"Group enriched"	"Detected in many"	6	"breast cancer: 97.6;cervical cancer: 189.1;head and neck cancer: 206.0;melanoma: 222.1;urothelial cancer: 82.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	21	"A-431: 400.3"					"Not detected"	"Not detected"			HPA040725	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA		48000000	"Plasma membrane, Cytosol"		"HPA040725: AB_10793863"	"unprognostic (7.68e-3)"	"unprognostic (5.06e-3)"		"unprognostic (5.64e-2)"		"prognostic favorable (2.59e-5)"		"unprognostic (4.82e-2)"	"unprognostic (2.67e-1)"	"unprognostic (1.37e-1)"	"unprognostic (8.27e-2)"	"unprognostic (1.14e-1)"		"unprognostic (2.79e-1)"	"unprognostic (1.71e-1)"		"unprognostic (4.99e-2)"	2.5	0.5	0.0	0.0	0.0	0.1	41.6	0.0	0.0	45.1	0.0	0.7	0.0	0.3	0.7	68.0	0.1	0.0	1.2	0.0	0.0	0.3	1.8	0.8	0.0	0.0	0.0	0.0	0.4	1.1	0.0	0.5	0.0	0.0	0.6	0.0	0.0	558.9	0.0	11.8	2852.4	0.6	0.0	0.0	0.4	0.8	1.0	0.0	9.3	0.6	0.0	13.5	0.1	309.1	0.0	400.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	7.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.6	0.0	0.0	1.2	0.4	0.0	0.0	0.0	0.8	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.4	27.3	0.3	2.2	0.0	0.0	172.1	156.1	0.2	0.0	1.8	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0	11.1	0.0	0.0	0.4	56.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.5	0.0	0.0	0.0	1.3	0.2	0.3	6.8	390.7	0.0	1.2	0.0	0.0	3.3
CDH26	VR20	ENSG00000124215	"Cadherin 26"	Q8IXH8	20	59958423-60034011	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 8.0"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 17.9;Club cells: 18.7;Oligodendrocytes: 14.9;Respiratory ciliated cells: 39.6;Syncytiotrophoblasts: 14.9"	"Group enriched"	"Detected in some"	6	"cervical cancer: 1.5;head and neck cancer: 0.9;lung cancer: 2.3;prostate cancer: 3.6;urothelial cancer: 3.2"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"RT4: 36.4"	"Low region specificity"	"Detected in some"							"HPA015722, HPA047578"	Uncertain		Supported	"Plasma membrane,Microtubules"		NA	NA			"Plasma membrane"	Microtubules	"HPA015722: AB_2077659, HPA047578: AB_2680091"	"unprognostic (2.42e-1)"	"prognostic favorable (7.62e-4)"	"unprognostic (4.71e-4)"	"unprognostic (8.17e-2)"	"unprognostic (9.40e-2)"	"unprognostic (9.95e-3)"	"unprognostic (6.65e-2)"	"prognostic favorable (3.75e-4)"	"unprognostic (1.37e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.26e-4)"	"unprognostic (8.24e-3)"	"unprognostic (9.96e-7)"	"unprognostic (1.85e-2)"	"unprognostic (2.73e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.04e-1)"	0.8	0.4	1.2	0.3	1.6	1.0	0.8	1.3	1.9	2.1	0.5	0.6	0.4	0.6	0.5	3.4	2.0	0.4	0.7	1.1	0.9	0.4	0.3	2.1	0.4	1.6	1.6	1.0	0.3	0.5	0.3	1.7	0.4	1.9	8.0	0.3	0.4	2.0	0.5	1.0	0.5	0.8	0.4	0.8	0.8	1.2	0.7	1.5	0.9	0.6	0.3	3.0	2.7	1.3	2.9	0.0	0.7	0.2	0.0	0.6	0.2	0.4	0.2	0.0	0.1	0.0	0.8	0.8	0.1	0.5	0.0	0.0	1.9	0.0	0.0	0.0	0.2	0.1	7.9	0.1	0.1	0.0	0.3	0.3	0.1	1.1	0.1	0.0	0.0	0.0	0.4	0.0	0.3	0.3	0.3	0.3	0.4	0.4	0.0	0.1	0.0	0.0	0.7	0.1	36.4	0.8	0.1	0.4	0.2	0.1	0.4	0.2	0.4	0.2	0.0	0.0	1.0	0.0	0.3	0.2	0.0	0.0	1.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.6	1.3	1.9	1.1	0.9	1.6	1.6	1.0	1.9	0.8	1.5	2.9	4.3	6.4	6.1	17.9	0.1	0.1	1.2	6.6	0.0	0.5	1.6	0.5	0.7	0.0	18.7	0.0	0.0	1.7	0.0	0.2	0.0	0.0	3.2	2.1	0.4	2.1	0.0	2.5	9.3	0.0	0.0	0.3	0.0	0.4	1.3	0.0	0.7	0.1	0.6	0.0	8.4	0.0	6.1	1.3	0.4	1.7	0.0	1.4	0.0	7.5	0.6	0.2	1.0	7.1	14.9	0.0	0.0	0.0	0.4	10.9	0.2	0.1	39.6	0.0	0.0	0.5	2.4	0.9	0.2	0.2	0.0	14.9	0.2	0.1	0.2	7.4
DHRS2	"HEP27, SDR25C1"	ENSG00000100867	"Dehydrogenase/reductase 2"	Q13268	14	23630115-23645639	"Metabolic proteins, Predicted intracellular proteins"		Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 339.6;urinary bladder: 395.9"	"Cell type enhanced"	"Detected in some"		"Extravillous trophoblasts: 15.1;Syncytiotrophoblasts: 24.8;Theca cells: 12.6;Urothelial cells: 30.6"	"Cancer enriched"	"Detected in many"	6	"urothelial cancer: 141.4"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"Hep G2: 719.8;RT4: 828.1;SK-BR-3: 4047.2;U-2 OS: 1286.3"	"Region enriched"	"Detected in single"	4	"cerebellum: 2.4"					"HPA053915, HPA069551"	Enhanced		Supported	Nucleoplasm,Mitochondria		No	NA			Mitochondria	Nucleoplasm	"HPA053915: AB_2682307, HPA069551: AB_2686150"	"unprognostic (3.07e-1)"	"unprognostic (4.91e-2)"	"unprognostic (3.44e-2)"	"prognostic unfavorable (3.23e-4)"	"unprognostic (9.97e-2)"	"unprognostic (5.03e-3)"	"unprognostic (5.62e-2)"	"unprognostic (1.86e-1)"	"unprognostic (4.08e-1)"	"unprognostic (6.91e-2)"	"unprognostic (6.66e-2)"	"unprognostic (4.59e-2)"	"prognostic unfavorable (3.75e-5)"	"unprognostic (1.83e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.76e-1)"	"prognostic favorable (6.45e-4)"	1.2	1.6	0.3	0.1	0.2	0.0	339.6	0.2	0.4	1.2	0.2	0.2	0.0	0.2	0.4	0.1	0.3	0.0	0.0	0.3	0.9	1.6	23.7	0.2	0.0	0.5	0.5	0.2	25.7	10.4	2.1	2.5	3.3	1.2	3.3	0.4	0.4	98.6	3.1	0.0	1.7	0.1	0.2	0.2	19.2	4.8	3.4	0.8	0.0	0.1	0.0	0.0	395.9	13.7	0.5	1.2	2.2	0.2	199.9	0.3	0.3	3.1	0.3	0.2	6.4	0.1	14.4	1.1	0.8	1.9	0.3	10.4	2.0	0.7	1.2	1.4	289.5	21.6	2.8	1.0	719.8	0.0	4.3	25.1	1.7	0.2	2.5	1.7	0.0	0.1	0.4	1.8	0.7	1.4	8.0	2.5	0.3	1.1	6.9	31.7	2.6	6.3	2.7	0.0	828.1	3.5	5.0	5.9	4047.2	4.9	0.7	3.9	1.0	0.0	2.4	1286.3	7.7	4.3	2.0	0.6	11.3	1.7	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.2	0.4	0.3	0.9	0.5	0.5	0.2	1.2	0.2	0.8	0.5	0.1	0.0	0.0	0.0	0.4	0.0	2.1	0.2	0.0	0.8	7.4	1.3	0.4	0.0	0.0	0.0	0.0	7.9	0.1	0.1	7.9	0.1	5.0	0.1	0.0	0.2	3.5	0.0	0.1	0.2	15.1	3.5	0.0	0.0	0.0	1.4	0.0	4.9	1.7	0.0	0.1	0.2	0.0	0.3	0.8	3.7	0.0	0.1	0.0	0.0	0.6	0.4	0.0	0.0	0.0	4.8	0.2	1.2	0.0	0.3	0.0	0.2	0.0	1.2	6.6	0.0	0.7	0.3	7.4	0.0	0.1	24.8	0.2	12.6	0.7	30.6
FAT2	"CDHF8, CDHR9, HFAT2, MEGF1"	ENSG00000086570	"FAT atypical cadherin 2"	Q9NYQ8	5	151504093-151568944	"Disease related genes, Human disease related genes, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"Disease variant, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 104.8;esophagus: 51.3;skin 1: 56.4"	"Cell type enhanced"	"Detected in some"		"Basal keratinocytes: 18.0;Basal respiratory cells: 31.6;Basal squamous epithelial cells: 27.9;Early spermatids: 16.0;Extravillous trophoblasts: 20.6;Squamous epithelial cells: 53.2;Suprabasal keratinocytes: 19.6"	"Group enriched"	"Detected in many"	6	"cervical cancer: 13.9;head and neck cancer: 21.4;lung cancer: 6.1;urothelial cancer: 5.6"	"Group enriched"	"Detected in many"	6	"cerebellum: 104.8;pons: 32.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"BEWO: 35.1;EFO-21: 21.0;HaCaT: 51.7;HBEC3-KT: 23.6;hTCEpi: 70.5"	"Region enriched"	"Detected in some"	18	"cerebellum: 32.0"	"Region enriched"	"Detected in many"	56	"cerebellum: 224.4"	CAB033680	Enhanced					NA	NA		300000			"CAB033680: AB_2100956"	"unprognostic (8.06e-3)"	"unprognostic (6.01e-2)"	"unprognostic (3.47e-1)"	"unprognostic (4.80e-3)"	"unprognostic (1.33e-1)"	"unprognostic (4.43e-1)"	"unprognostic (9.78e-3)"	"unprognostic (2.28e-1)"	"unprognostic (8.25e-2)"	"unprognostic (2.65e-1)"	"unprognostic (2.96e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.84e-7)"	"unprognostic (2.38e-1)"	"unprognostic (1.47e-1)"	"unprognostic (6.77e-2)"	"unprognostic (3.64e-3)"	0.3	0.2	0.2	0.0	3.6	0.1	3.7	104.8	3.6	6.2	0.0	0.1	0.1	0.1	1.7	51.3	1.0	0.0	0.1	0.5	1.0	0.2	0.1	0.2	0.0	11.7	6.4	0.1	0.1	0.2	0.2	0.5	0.9	32.7	5.3	0.0	0.1	9.0	4.8	0.2	56.4	0.2	0.0	0.3	0.1	0.1	13.3	1.2	2.2	0.1	0.0	3.5	2.9	24.6	6.6	1.7	0.0	0.0	0.1	0.0	0.0	35.1	0.2	0.0	0.0	0.0	0.1	0.0	0.1	21.0	0.0	0.2	51.7	0.0	23.6	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	70.5	0.0	3.8	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.7	0.1	0.0	0.1	1.1	0.2	0.5	0.0	0.0	0.1	0.1	0.4	0.0	0.1	0.0	0.0	1.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	3.6	104.8	3.6	0.5	1.0	11.7	6.4	0.1	32.7	0.3	1.2	6.6	0.1	0.0	0.0	0.7	0.0	18.0	5.8	31.6	27.9	0.0	3.4	12.8	1.9	0.0	11.1	1.8	0.0	0.4	0.0	0.0	0.0	0.0	16.0	0.1	0.0	0.3	0.0	0.0	5.0	0.0	20.6	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.8	0.0	2.9	0.0	0.0	0.0	1.5	7.8	0.0	0.0	7.2	0.0	0.0	0.0	0.0	4.0	0.9	0.0	0.0	0.0	0.0	1.2	0.0	0.1	3.0	0.0	0.0	0.0	0.4	0.5	0.1	53.2	19.6	1.0	0.1	0.0	0.0	13.0
GNAT3	"GDCA, gustducin"	ENSG00000214415	"G protein subunit alpha transducin 3"	A8MTJ3	7	80458635-80512064	"Predicted intracellular proteins"		Transducer		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	6	"intestine: 1.8"	"Cell type enhanced"	"Detected in single"		"Early spermatids: 2.8"	"Group enriched"	"Detected in some"	6	"breast cancer: 0.8;urothelial cancer: 1.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	6	"SCLC-21H: 3.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA071345	Enhanced					NA	NA					"HPA071345: "											"unprognostic (2.01e-1)"							0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
GPR87	GPR95	ENSG00000138271	"G protein-coupled receptor 87"	Q9BY21	3	151294086-151316820	"G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 36.2;skin 1: 33.0;vagina: 24.0"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 139.2;Basal respiratory cells: 150.0;Suprabasal keratinocytes: 68.2;Syncytiotrophoblasts: 205.0;Urothelial cells: 211.4"	"Group enriched"	"Detected in many"	6	"cervical cancer: 44.1;head and neck cancer: 40.1;lung cancer: 22.0;urothelial cancer: 23.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 110.8;CAPAN-2: 40.8;HaCaT: 90.6;HBEC3-KT: 116.7;hTCEpi: 152.8;hTERT-HME1: 62.2;RT4: 46.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA066313			Approved	"Nucleoplasm,Lipid droplets,Mitochondria"		No	No			"Lipid droplets, Mitochondria"	Nucleoplasm	"HPA066313: AB_2685656"	"unprognostic (5.81e-2)"	"unprognostic (2.12e-1)"		"unprognostic (4.07e-3)"	"unprognostic (8.60e-2)"	"unprognostic (1.28e-2)"		"unprognostic (4.61e-3)"	"unprognostic (3.28e-2)"	"unprognostic (1.27e-1)"	"prognostic unfavorable (4.62e-6)"	"unprognostic (8.64e-2)"	"unprognostic (1.50e-3)"	"unprognostic (3.66e-4)"	"unprognostic (8.73e-2)"	"unprognostic (3.80e-2)"	"unprognostic (2.17e-1)"	0.0	0.0	0.1	0.0	0.2	0.0	3.3	0.1	0.9	5.1	2.4	0.0	0.0	0.0	3.3	36.2	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.5	9.6	0.1	4.4	0.0	0.0	13.8	5.6	0.1	33.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	3.5	0.0	0.0	12.5	13.3	24.0	0.5	110.8	0.0	0.0	0.0	0.0	0.0	24.0	0.0	0.0	0.9	0.2	0.0	40.8	0.0	0.0	0.0	0.6	90.6	0.0	116.7	1.1	0.0	0.1	0.0	1.1	0.0	0.8	0.0	0.0	0.0	152.8	0.1	62.2	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.5	0.1	6.1	0.0	0.0	0.0	3.8	46.7	0.0	0.0	19.0	0.5	0.0	3.1	0.4	0.1	0.0	0.0	10.9	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.9	0.2	0.0	0.1	0.0	0.2	0.1	0.0	0.1	0.5	0.0	0.0	1.1	1.0	0.0	59.3	139.2	150.0	46.7	0.0	2.8	1.8	0.1	0.0	49.9	3.7	0.0	59.0	0.4	0.0	0.0	1.2	0.7	3.3	0.0	1.5	0.0	0.0	1.1	0.7	8.7	1.1	0.0	2.4	1.3	0.0	0.0	0.0	4.2	0.0	0.4	0.0	28.5	0.0	3.6	0.1	0.0	0.6	10.6	0.0	0.0	0.0	0.0	1.0	0.0	12.9	0.0	0.0	0.0	60.6	0.0	0.1	19.6	0.0	0.0	0.0	4.1	0.0	0.0	52.7	68.2	205.0	0.9	0.0	0.0	211.4
IFNK		ENSG00000147896	"Interferon kappa"	Q9P0W0	9	27524290-27526498	"Predicted intracellular proteins, Predicted secreted proteins"	"Antiviral defense"	Cytokine		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	29	"brain: 3.9;choroid plexus: 1.9"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"cervical cancer: 0.5;head and neck cancer: 0.6;urothelial cancer: 0.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"								"Secreted to blood"	NA	NA							"unprognostic (5.58e-3)"				"unprognostic (4.64e-3)"								"unprognostic (1.06e-1)"				0.0	0.0	0.9	0.0	3.3	0.0	0.0	1.3	1.4	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.6	0.0	0.0	0.0	0.0	2.9	2.1	0.2	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.1	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	3.3	1.3	1.4	0.5	1.6	2.9	2.1	0.2	2.3	2.1	2.5	3.9	0.1	0.0	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KRT20	"CK20, K20, MGC35423"	ENSG00000171431	"Keratin 20"	P35900	17	40875889-40885242	"Plasma proteins, Predicted intracellular proteins"	Apoptosis			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"intestine: 652.3"	"Group enriched"	"Detected in some"	6	"Distal enterocytes: 1328.5;Intestinal goblet cells: 421.7;Paneth cells: 1606.6;Proximal enterocytes: 1107.3"	"Group enriched"	"Detected in many"	6	"colorectal cancer: 159.5;stomach cancer: 52.7;urothelial cancer: 99.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"NB-4: 1.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB000032, HPA024309, HPA024684, HPA027236"	Enhanced		Supported	Cytosol		NA	NA		30000000	Cytosol		"CAB000032: AB_2133718, HPA024309: AB_1852220, HPA024684: AB_1852222, HPA027236: AB_1852224"	"unprognostic (3.49e-1)"	"unprognostic (3.13e-1)"	"unprognostic (1.71e-1)"	"unprognostic (6.38e-3)"	"unprognostic (5.12e-2)"	"unprognostic (2.66e-3)"	"prognostic unfavorable (7.05e-4)"	"unprognostic (2.63e-2)"			"unprognostic (4.87e-3)"	"unprognostic (2.37e-2)"	"prognostic unfavorable (1.32e-4)"	"unprognostic (5.71e-2)"	"unprognostic (6.30e-2)"		"unprognostic (7.27e-2)"	1.3	0.0	0.0	50.4	0.0	0.0	1.6	0.0	0.0	0.0	0.0	603.3	298.6	2.1	0.0	0.3	0.3	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	484.6	0.0	0.0	1.2	0.0	0.1	652.3	27.3	0.0	0.0	126.0	0.0	0.0	0.0	0.0	0.0	0.0	21.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	4.4	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1328.5	0.0	0.1	0.0	0.0	0.0	0.0	43.9	0.0	0.1	0.0	0.0	0.0	115.7	0.1	13.4	0.0	0.0	0.0	0.1	0.0	0.0	421.7	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1606.6	0.0	0.6	1.9	1107.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	1.6	0.0	160.4	1.4
PRR9		ENSG00000203783	"Proline rich 9"	Q5T870	1	153217584-153219310	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	13	"skin 1: 37.9"	"Group enriched"	"Detected in some"	5	"Early spermatids: 4.1;Late spermatids: 10.2;Syncytiotrophoblasts: 8.9"	"Group enriched"	"Detected in many"	6	"cervical cancer: 4.2;endometrial cancer: 4.1;head and neck cancer: 11.8;melanoma: 3.4;urothelial cancer: 6.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	8	"SuSa: 17.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA027714	Approved		Approved	Nucleoplasm,Vesicles,Cytosol		NA	NA			Cytosol	"Nucleoplasm, Vesicles"	"HPA027714: AB_10602194"		"unprognostic (1.45e-1)"	"unprognostic (1.46e-1)"			"unprognostic (4.17e-1)"			"unprognostic (3.48e-1)"	"unprognostic (7.02e-2)"					"unprognostic (8.27e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.23e-2)"	0.7	0.0	0.1	0.0	0.1	0.4	0.4	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	37.9	0.0	0.0	0.1	0.0	0.0	2.9	0.1	0.7	0.1	0.0	0.1	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	17.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	4.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.3	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	8.9	0.0	0.0	0.0	0.0
PSCA		ENSG00000167653	"Prostate stem cell antigen"	O43653	8	142670308-142682725	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"stomach 1: 3043.6"	"Cell type enriched"	"Detected in many"	4	"Gastric mucus-secreting cells: 5332.3"	"Cancer enriched"	"Detected in many"	6	"urothelial cancer: 785.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 22.4;HeLa: 45.7;OE19: 17.6;RT4: 61.7"	"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	8	"spinal cord: 38.2"	"HPA030783, HPA056418"	Approved		Supported	"Plasma membrane"		NA	NA		18000	"Plasma membrane"		"HPA030783: AB_2673611, HPA056418: AB_2683123"	"unprognostic (1.21e-3)"	"unprognostic (1.76e-3)"	"unprognostic (3.20e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.77e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.93e-2)"	"unprognostic (7.81e-3)"	"unprognostic (8.25e-3)"	"unprognostic (2.13e-1)"	"prognostic unfavorable (5.60e-5)"	"unprognostic (6.82e-2)"	"unprognostic (2.38e-3)"	"unprognostic (4.93e-2)"	"unprognostic (2.68e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.06e-3)"	2.7	0.4	0.4	0.5	0.4	0.2	1.9	0.2	0.9	33.4	0.1	5.0	4.0	0.4	0.6	336.7	8.0	10.1	0.3	0.5	0.2	5.7	0.7	6.4	0.1	0.4	0.2	0.3	0.6	3.2	0.0	0.6	2.4	0.4	232.6	4.8	0.0	23.6	2.0	0.3	10.2	2.5	0.1	0.1	0.4	3043.6	1.4	0.3	0.4	0.4	0.0	15.2	634.3	169.1	0.4	10.7	0.7	0.0	0.0	2.1	6.8	10.6	4.9	1.1	2.1	1.8	0.1	22.4	0.0	0.4	0.4	8.1	2.1	0.0	0.4	1.3	0.6	0.0	0.0	45.7	0.0	0.1	0.0	1.5	6.0	7.8	4.6	0.0	0.6	0.0	0.0	0.0	0.0	1.7	5.8	1.7	0.6	1.2	17.6	1.2	0.7	0.0	0.9	1.0	61.7	0.2	0.5	5.1	15.6	3.5	0.3	0.2	0.2	1.0	1.5	1.7	2.7	0.0	1.9	0.1	0.0	2.9	0.8	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.2	0.9	0.5	0.2	0.4	0.2	0.3	0.4	0.1	0.3	0.4	0.2	3.2	1.5	1.6	7.7	0.9	26.0	120.0	0.0	0.0	3.9	2.7	1.2	71.4	894.2	1.8	0.0	2.3	0.0	1.9	7.9	3.2	0.3	1.3	0.1	1.1	275.1	0.0	0.3	1.2	5.0	3.3	5332.3	0.3	0.0	0.3	0.0	0.0	0.6	0.0	0.2	12.9	179.0	0.6	1.0	0.4	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	57.1	0.2	0.0	13.4	238.7	0.3	0.4	994.9	0.0	0.0	0.0	48.9	0.0	0.5	13.1	1.3	28.5	4.6	0.0	0.9	1241.5
TMPRSS11E	"DESC1, TMPRSS11E2"	ENSG00000087128	"Transmembrane serine protease 11E"	Q9UL52	4	68447463-68497604	"Enzymes, Predicted membrane proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 221.9;vagina: 157.6"	"Cell type enriched"	"Detected in some"	14	"Ionocytes: 476.0"	"Group enriched"	"Detected in many"	6	"cervical cancer: 22.0;head and neck cancer: 25.3;lung cancer: 11.5;urothelial cancer: 7.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HaCaT: 1.5;OE19: 1.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA043816, HPA051062"	Enhanced		Approved	"Golgi apparatus"	"Secreted in other tissues"	NA	NA			"Golgi apparatus"		"HPA043816: , HPA051062: AB_2681329"	"unprognostic (2.53e-1)"	"unprognostic (3.10e-1)"	"unprognostic (1.84e-1)"	"unprognostic (9.14e-2)"		"unprognostic (5.03e-2)"		"prognostic unfavorable (6.73e-4)"	"unprognostic (2.22e-1)"		"unprognostic (9.70e-3)"	"unprognostic (2.16e-1)"	"unprognostic (3.74e-2)"	"unprognostic (4.03e-2)"	"unprognostic (8.39e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.08e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	42.8	0.0	0.0	0.0	0.0	18.4	221.9	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	2.2	0.0	0.0	57.1	0.7	0.0	3.2	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.1	0.0	0.0	24.7	6.5	157.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.5	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.4	12.9	0.7	0.0	0.0	0.5	0.3	0.3	0.0	2.8	0.0	0.0	0.0	0.3	0.0	0.0	0.3	6.5	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	476.0	0.0	0.3	1.4	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.2	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.1	0.2	6.6	0.3	1.1	0.7	0.0	0.0	32.6
UPK3A	UPK3	ENSG00000100373	"Uroplakin 3A"	O75631	22	45284949-45295874	"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"			"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"prostate: 21.5;skeletal muscle: 35.4;urinary bladder: 48.4"	"Cell type enhanced"	"Detected in some"		"Basal prostatic cells: 15.0;monocytes: 22.6;Prostatic glandular cells: 54.1;Proximal enterocytes: 29.8;Urothelial cells: 24.5"	"Group enriched"	"Detected in many"	6	"prostate cancer: 35.3;urothelial cancer: 78.0"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in many"		"myeloid DC: 86.6"	"Group enriched"	"Detected in many"	16	"dendritic cells: 86.6;monocytes: 32.0"	"Group enriched"	"Detected in some"	5	"Hep G2: 29.9;RT4: 48.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA018407, HPA018415"	Enhanced		Uncertain	"Nuclear membrane,Nuclear bodies"		NA	NA			"Nuclear membrane"	"Nuclear bodies"	"HPA018407: AB_1858641, HPA018415: AB_1858640"	"unprognostic (1.27e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.21e-1)"	"unprognostic (9.42e-2)"	"unprognostic (3.98e-5)"	"unprognostic (1.69e-2)"	"unprognostic (4.82e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.18e-1)"	"unprognostic (6.49e-5)"	"unprognostic (2.01e-2)"	"unprognostic (5.45e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.05e-3)"	0.2	0.1	0.1	0.5	0.1	1.5	0.2	0.1	0.4	0.0	0.3	1.0	0.0	0.1	0.1	0.3	0.3	0.9	0.1	0.1	0.4	0.0	0.0	0.2	0.9	0.3	0.2	0.0	0.1	0.2	5.0	0.7	0.0	0.2	21.5	0.7	0.0	2.8	0.2	35.4	0.0	1.3	0.1	0.2	1.1	0.1	0.1	0.1	0.7	2.3	4.6	0.9	48.4	1.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.9	0.0	4.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	8.5	0.0	4.6	0.0	0.1	0.0	0.2	0.0	48.9	0.1	0.0	0.2	0.8	0.0	0.0	0.1	5.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.1	0.0	0.0	0.0	0.0	21.2	0.0	0.0	25.8	0.0	1.2	0.0	0.1	86.6	0.5	0.0	0.0	3.6	0.4	32.0	32.9	0.0	7.4	0.1	0.1	0.1	0.4	0.1	0.4	0.3	0.2	0.0	0.2	0.2	0.1	0.3	0.2	0.0	0.0	0.7	1.2	0.1	15.0	0.1	0.0	0.1	4.6	3.6	0.2	2.8	0.1	0.0	0.0	0.0	4.0	3.3	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	1.7	0.0	0.1	3.5	0.0	4.8	8.7	1.7	0.3	6.4	0.0	0.0	22.6	0.8	2.1	0.0	0.0	0.0	9.3	0.0	0.1	54.1	29.8	0.0	0.1	0.0	0.0	1.6	0.5	0.0	0.4	0.0	0.4	0.1	0.2	0.0	4.4	24.5
ACP7	"FLJ16165, PAPL, PAPL1"	ENSG00000183760	"Acid phosphatase 7, tartrate resistant (putative)"	Q6ZNF0	19	39083913-39111493	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted secreted proteins"		Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 6.3;lymphoid tissue: 2.6;skin 1: 6.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"cervical cancer: 0.8;head and neck cancer: 2.6;lung cancer: 1.4;melanoma: 1.0;urothelial cancer: 1.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"GAMG: 33.3;U-87 MG: 45.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA042613	Uncertain				"Secreted - unknown location"	NA	NA					"HPA042613: AB_10963214"	"unprognostic (6.35e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.48e-1)"	"unprognostic (6.74e-3)"	"unprognostic (1.92e-3)"	"unprognostic (1.41e-1)"	"unprognostic (3.41e-1)"	"unprognostic (4.94e-3)"	"unprognostic (2.66e-1)"	"unprognostic (2.15e-1)"	"unprognostic (1.50e-1)"	"unprognostic (9.81e-2)"	"unprognostic (1.51e-5)"	"unprognostic (4.36e-3)"	"unprognostic (5.08e-2)"	"unprognostic (2.31e-2)"	"unprognostic (2.42e-1)"	0.0	0.0	2.5	0.0	3.3	0.0	0.2	6.3	3.0	0.5	0.9	0.0	0.0	0.0	0.4	0.8	0.0	0.2	0.0	2.0	2.4	0.0	0.0	0.0	0.0	4.0	3.8	1.8	0.0	0.0	0.3	0.0	0.0	5.1	0.3	0.0	0.0	0.5	0.0	0.0	6.0	0.0	0.0	2.2	0.0	0.1	0.0	3.1	0.0	0.0	0.0	2.6	0.1	0.6	4.7	5.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.2	0.6	0.8	0.4	5.2	0.0	0.0	0.0	33.3	0.3	0.0	1.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	9.5	0.3	0.0	0.1	0.0	0.0	0.0	0.2	2.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	6.1	1.1	0.0	0.0	0.0	0.0	0.0	45.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	3.3	6.3	3.0	2.0	2.4	4.0	3.8	1.8	5.1	2.2	3.1	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.2	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1
ANXA10	ANX14	ENSG00000109511	"Annexin A10"	Q9UJ72	4	168092537-168187736	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"stomach 1: 490.8"	"Group enriched"	"Detected in some"	5	"Exocrine glandular cells: 172.6;Gastric mucus-secreting cells: 667.7;Pancreatic endocrine cells: 315.0"	"Group enriched"	"Detected in many"	5	"pancreatic cancer: 62.4;stomach cancer: 42.2;urothelial cancer: 19.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"OE19: 284.8;PC-3: 125.5;RT4: 172.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA005469, HPA074650"	Enhanced		Approved	Nucleoplasm,Nucleoli,Vesicles		NA	NA			"Nucleoplasm, Nucleoli"	Vesicles	"HPA005469: AB_1844849, HPA074650: "	"unprognostic (2.29e-2)"	"unprognostic (8.71e-3)"	"unprognostic (2.48e-2)"	"unprognostic (1.71e-1)"	"unprognostic (4.69e-1)"	"unprognostic (2.29e-2)"	"prognostic favorable (3.64e-6)"	"unprognostic (1.18e-3)"	"unprognostic (2.88e-1)"	"unprognostic (8.61e-4)"	"unprognostic (3.43e-2)"	"unprognostic (1.84e-1)"	"unprognostic (1.69e-3)"	"unprognostic (8.41e-2)"	"unprognostic (4.01e-1)"	"unprognostic (2.04e-1)"	"unprognostic (8.89e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	19.8	0.0	0.0	0.3	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	490.8	0.9	0.1	0.0	0.0	0.0	0.0	90.4	0.1	0.1	0.0	4.6	0.0	0.0	0.3	0.1	0.0	0.1	0.2	0.6	0.5	0.0	0.1	0.0	0.0	0.0	0.7	0.9	0.0	0.0	0.4	0.0	0.0	0.0	22.5	0.0	0.0	0.0	0.0	0.4	0.1	9.7	0.0	4.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	284.8	125.5	0.0	0.6	0.0	0.0	172.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	7.3	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.0	0.5	0.0	1.5	0.0	0.5	15.5	0.0	0.4	0.1	0.0	0.2	7.2	3.2	0.0	2.1	0.0	0.0	0.1	0.0	21.1	11.0	0.1	0.1	0.3	0.0	2.7	0.2	172.6	0.0	0.4	667.7	0.1	0.0	0.0	1.8	72.6	0.0	0.0	0.2	0.5	0.0	2.8	0.0	0.8	0.0	0.4	0.0	0.0	0.6	0.0	0.0	0.5	0.0	315.0	1.1	0.0	1.4	0.6	0.0	0.2	0.3	0.6	0.0	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.6	0.0	0.1	14.7
AQP3	GIL	ENSG00000165272	"Aquaporin 3 (Gill blood group)"	Q92482	9	33441156-33447596	"Blood group antigen proteins, Metabolic proteins, Plasma proteins, Predicted membrane proteins"	Transport	"Blood group antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"esophagus: 1538.3;urinary bladder: 695.4"	"Cell type enhanced"	"Detected in many"		"Basal keratinocytes: 1923.3;Basal prostatic cells: 982.0;Collecting duct cells: 1609.3;Prostatic glandular cells: 1430.8;Squamous epithelial cells: 2189.3;Suprabasal keratinocytes: 2485.4;Urothelial cells: 2455.4"	"Group enriched"	"Detected in all"	5	"cervical cancer: 319.0;head and neck cancer: 283.7;lung cancer: 146.8;urothelial cancer: 221.3"	"Region enhanced"	"Detected in many"		"pons: 21.3"	"Immune cell enhanced"	"Detected in many"		"MAIT T-cell: 181.7;T-reg: 205.4"	"Lineage enriched"	"Detected in many"	18	"T-cells: 205.4"	"Cell line enhanced"	"Detected in many"		"HaCaT: 127.1;HeLa: 213.2;JURKAT: 130.7;RT4: 216.6;SK-BR-3: 149.7;U-266/70: 151.2;U-266/84: 213.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA014924	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA014924: AB_2669120"	"unprognostic (4.29e-2)"	"prognostic favorable (5.31e-4)"	"unprognostic (1.15e-1)"	"unprognostic (3.26e-2)"	"unprognostic (1.84e-2)"	"unprognostic (1.11e-2)"	"unprognostic (9.95e-2)"	"unprognostic (1.64e-1)"	"unprognostic (3.46e-1)"	"unprognostic (9.06e-2)"	"unprognostic (4.87e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.54e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.59e-1)"	"unprognostic (3.73e-2)"	"unprognostic (4.51e-2)"	8.4	2.1	1.6	16.9	1.0	19.9	37.0	1.9	3.4	90.8	1.3	10.4	74.0	11.0	3.0	1538.3	25.6	9.5	23.2	4.6	1.4	113.2	119.6	115.0	16.2	13.7	7.1	1.1	12.2	43.5	2.0	2.8	6.1	21.3	86.4	10.2	1.7	403.2	37.1	5.3	514.5	101.3	3.3	0.3	111.0	36.1	2.8	1.0	236.0	2.3	26.9	174.0	695.4	534.2	6.7	0.6	38.6	1.9	0.0	67.7	12.2	1.0	0.3	0.9	0.9	1.1	20.5	12.0	0.5	9.1	0.0	0.5	127.1	6.2	0.7	0.2	61.6	6.0	4.3	213.2	1.9	0.4	1.3	1.3	1.9	6.5	0.5	0.2	0.2	0.5	130.7	67.4	58.8	6.9	29.1	60.4	23.0	5.3	88.6	0.7	0.9	94.3	10.8	1.3	216.6	1.7	4.7	32.3	149.7	0.1	8.0	0.9	10.6	1.2	0.0	1.0	0.4	0.4	151.2	213.6	14.5	0.5	0.4	0.2	1.6	0.5	0.1	20.2	0.4	181.7	11.3	171.9	52.8	0.3	3.0	97.3	47.1	2.3	3.0	0.5	11.1	205.4	43.0	1.6	1.0	1.9	3.4	4.6	1.4	13.7	7.1	1.1	21.3	0.3	1.0	6.7	9.2	38.5	249.9	0.0	42.4	1923.3	982.0	381.4	811.0	9.7	56.8	27.8	3.4	157.3	436.3	1609.3	2.1	0.9	21.6	2.7	0.0	37.4	2.2	82.3	21.4	37.1	8.3	71.4	0.3	48.9	2.0	27.5	16.3	96.2	20.8	0.2	16.4	137.3	2.2	0.0	0.1	104.0	315.3	3.5	122.9	0.6	33.2	15.3	158.3	0.0	1.6	0.4	4.1	0.5	0.2	28.5	8.1	1.2	246.9	1430.8	343.1	31.9	546.0	0.5	0.0	10.2	35.8	0.7	1.9	2189.3	2485.4	50.2	73.4	1.6	7.3	2455.4
ARL14	"ARF7, FLJ22595"	ENSG00000179674	"ADP ribosylation factor like GTPase 14"	Q8N4G2	3	160677160-160678448	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"gallbladder: 130.2;intestine: 51.7;stomach 1: 77.9"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 588.3;Gastric mucus-secreting cells: 377.7;Intestinal goblet cells: 154.6;Paneth cells: 519.2;Proximal enterocytes: 174.5"	"Group enriched"	"Detected in many"	5	"colorectal cancer: 6.6;pancreatic cancer: 26.0;stomach cancer: 14.3;urothelial cancer: 8.1"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in single"	15	"memory B-cell: 1.8"	"Lineage enriched"	"Detected in single"	18	"B-cells: 1.8"	"Cell line enhanced"	"Detected in some"		"A-431: 9.7;CAPAN-2: 36.2;HaCaT: 9.0;OE19: 25.3;RT4: 17.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (2.65e-1)"	"unprognostic (7.26e-3)"	"unprognostic (2.64e-2)"	"unprognostic (3.70e-3)"		"unprognostic (6.36e-2)"	"unprognostic (2.47e-3)"	"prognostic unfavorable (2.64e-5)"	"unprognostic (2.30e-1)"	"unprognostic (8.67e-2)"	"prognostic unfavorable (6.71e-4)"	"unprognostic (4.74e-2)"	"unprognostic (4.91e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.70e-2)"	0.2	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	43.3	51.7	0.1	0.0	1.0	0.1	130.2	0.0	0.0	0.0	0.4	1.4	0.0	0.2	0.0	0.0	0.0	0.0	16.1	0.0	0.0	0.0	0.0	0.1	36.4	0.0	0.1	0.0	0.0	0.2	34.4	2.8	0.0	0.1	77.9	0.0	0.0	0.3	0.6	0.0	3.3	24.0	0.3	0.0	9.7	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.5	36.2	0.0	0.8	0.0	4.2	9.0	0.0	0.9	0.3	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.3	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.2	0.0	25.3	2.0	0.0	0.0	0.3	2.9	17.7	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.9	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	3.0	1.9	4.5	2.6	0.0	0.0	0.2	0.1	0.0	18.6	1.2	0.0	0.0	0.0	0.0	588.3	0.0	12.6	0.0	5.6	0.4	0.1	89.1	0.0	0.0	41.4	0.1	0.5	377.7	10.7	8.9	0.0	0.0	0.0	0.0	0.0	0.0	154.6	2.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.3	519.2	0.0	1.0	1.2	174.5	0.0	1.7	0.0	0.0	0.0	0.2	0.0	0.0	1.4	0.9	0.0	1.4	0.0	112.0	25.9
CCER2		ENSG00000262484	"Coiled-coil glutamate rich protein 2"	I3L3R5	19	38908980-38912158	"Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"testis: 4.9"	"Cell type enriched"	"Detected in some"	8	"Melanocytes: 617.2"	"Group enriched"	"Detected in many"	5	"glioma: 5.1;testis cancer: 1.9;urothelial cancer: 5.1"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 1.4;THP-1: 1.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA069716	Uncertain				"Secreted - unknown location"	NA	NA		8800			"HPA069716: AB_2686183"	"unprognostic (6.58e-2)"	"unprognostic (2.24e-2)"	"unprognostic (5.03e-3)"	"unprognostic (2.49e-2)"	"unprognostic (1.05e-1)"	"unprognostic (2.76e-3)"	"unprognostic (3.88e-2)"	"unprognostic (2.16e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.08e-3)"	"unprognostic (3.82e-2)"	"unprognostic (1.01e-9)"	"unprognostic (1.75e-2)"	"unprognostic (3.87e-2)"	"unprognostic (3.61e-1)"	"prognostic favorable (2.32e-4)"	0.5	0.6	2.2	0.2	2.3	0.7	0.8	2.2	3.4	0.9	1.8	0.8	0.3	0.7	0.3	1.2	1.1	0.1	0.6	2.2	2.1	1.3	3.0	0.5	0.3	2.8	2.2	2.1	0.8	0.5	0.2	2.5	0.1	2.4	1.4	0.1	1.0	0.9	0.2	2.3	3.9	0.9	0.1	2.0	1.1	0.6	4.9	2.2	0.4	1.2	0.0	0.1	0.9	0.8	2.3	0.1	1.4	0.3	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.5	1.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.4	0.4	0.0	0.3	0.0	0.0	0.6	0.5	0.1	0.2	0.1	0.0	0.0	0.0	0.9	0.2	0.9	0.0	0.9	0.2	0.4	0.3	0.0	0.2	0.7	0.1	0.2	0.1	0.6	0.4	0.2	0.1	0.1	0.0	0.1	1.0	1.4	0.0	0.0	0.7	0.0	0.0	0.6	0.5	0.2	0.1	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	2.3	2.2	3.4	2.2	2.1	2.8	2.2	2.1	2.4	2.0	2.2	2.3	0.1	3.2	0.0	3.9	0.1	76.9	0.1	0.1	0.0	2.5	0.4	0.5	0.4	1.5	0.1	1.8	4.2	0.4	0.4	0.3	0.0	0.0	1.4	0.3	0.2	0.6	1.2	0.4	2.3	0.0	0.1	0.8	0.0	0.5	0.0	0.3	0.0	0.6	0.2	0.0	3.3	0.2	0.0	0.3	7.2	4.9	0.3	0.2	617.2	0.0	0.0	1.3	0.0	3.5	2.2	0.1	0.2	0.0	0.0	0.1	0.2	0.2	0.4	3.8	0.0	0.4	0.7	1.1	2.1	0.0	3.0	0.3	0.4	0.2	0.6	0.1
CST6		ENSG00000175315	"Cystatin E/M"	Q15828	11	66012008-66013505	"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Thiol protease inhibitor"	"Cancer-related genes, Disease variant, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	17	"skin 1: 599.0"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 93.0;Club cells: 115.2;Pancreatic endocrine cells: 368.1;Respiratory ciliated cells: 404.0"	"Group enriched"	"Detected in many"	5	"thyroid cancer: 171.0;urothelial cancer: 43.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"A-431: 130.2;CAPAN-2: 364.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB019316, HPA044963"	Enhanced		Approved	"Plasma membrane,Cytosol"	"Secreted in other tissues"	NA	NA		82000000	"Plasma membrane"	Cytosol	"CAB019316: , HPA044963: AB_2679158"	"unprognostic (3.01e-2)"	"unprognostic (5.10e-2)"	"unprognostic (1.14e-1)"	"unprognostic (3.59e-2)"	"unprognostic (5.00e-2)"	"unprognostic (2.60e-1)"	"unprognostic (1.65e-1)"	"unprognostic (8.38e-2)"	"unprognostic (5.02e-1)"	"unprognostic (8.89e-3)"	"unprognostic (1.29e-3)"	"unprognostic (1.46e-1)"	"unprognostic (1.74e-3)"	"unprognostic (5.89e-3)"	"unprognostic (1.83e-1)"	"unprognostic (1.64e-2)"	"unprognostic (2.59e-2)"	1.7	0.3	0.1	0.3	0.2	0.2	28.8	0.8	0.4	4.1	0.9	0.4	0.0	0.3	0.6	34.9	15.0	0.5	1.9	0.1	0.7	2.3	0.3	18.5	0.0	0.2	0.2	0.0	0.7	0.7	2.1	1.6	8.2	0.5	0.9	0.0	0.0	7.5	4.9	2.0	599.0	0.3	0.1	0.1	0.2	0.6	1.9	0.3	2.7	21.6	0.0	2.3	1.2	22.7	0.2	130.2	0.0	0.0	0.6	0.0	0.0	37.6	1.4	0.0	0.3	0.2	1.0	364.6	0.0	1.8	5.1	0.1	4.5	0.0	32.3	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.8	0.6	0.2	0.1	0.0	0.3	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	1.5	0.5	0.8	0.2	0.7	0.0	0.0	35.8	0.4	0.1	0.8	0.1	0.0	0.2	2.5	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.2	0.8	0.4	0.1	0.7	0.2	0.2	0.0	0.5	0.1	0.3	0.2	0.1	93.0	6.1	0.0	0.6	1.1	1.7	41.4	0.6	0.0	5.3	7.1	1.2	0.0	115.2	58.8	0.0	33.3	0.0	0.1	0.0	57.4	0.2	7.7	0.1	0.9	0.0	0.0	0.0	21.6	24.4	2.0	0.0	0.6	21.6	0.1	0.4	0.1	41.1	0.0	0.0	0.0	24.4	1.4	10.0	0.8	0.0	5.3	5.4	0.0	1.1	1.3	0.0	0.0	0.0	368.1	1.1	0.4	9.8	1.9	0.0	0.5	404.0	0.1	0.0	0.3	16.0	5.2	17.6	1.0	27.6	64.2	0.7	0.0	0.4	6.1
FXYD4	CHIF	ENSG00000150201	"FXYD domain containing ion transport regulator 4"	P59646	10	43371636-43376335	"Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel"		"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at transcript level"	"Tissue enriched"	"Detected in some"	18	"kidney: 129.1"	"Cell type enriched"	"Detected in some"	107	"Collecting duct cells: 5039.3"	"Group enriched"	"Detected in many"	5	"renal cancer: 10.7;urothelial cancer: 20.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	29	"SuSa: 10.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA058421	Enhanced		Uncertain	Cytosol		NA	NA			Cytosol		"HPA058421: AB_2683714"	"unprognostic (2.92e-3)"	"unprognostic (5.25e-1)"	"unprognostic (9.46e-2)"	"unprognostic (2.60e-2)"	"unprognostic (2.56e-1)"	"unprognostic (1.85e-1)"		"unprognostic (2.32e-1)"		"unprognostic (2.00e-1)"	"unprognostic (5.17e-2)"	"unprognostic (2.19e-1)"	"unprognostic (6.12e-2)"	"unprognostic (7.88e-2)"	"unprognostic (1.26e-1)"	"unprognostic (3.20e-1)"	"unprognostic (2.09e-2)"	0.1	0.0	2.2	0.0	2.7	0.0	0.0	2.0	2.7	0.0	1.5	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.3	1.9	2.2	129.1	0.0	1.1	0.0	2.4	2.6	1.7	0.0	0.0	0.0	0.1	0.0	3.4	0.1	0.0	0.0	5.7	2.7	1.3	0.0	0.0	0.0	1.8	0.0	7.0	0.8	2.5	0.0	0.0	0.4	0.0	1.7	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	2.7	2.0	2.7	1.9	2.2	2.4	2.6	1.7	3.4	1.8	2.5	3.3	0.0	6.4	1.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.1	5039.3	0.0	0.5	0.0	0.5	46.9	0.0	2.6	6.4	2.6	0.0	0.0	0.0	0.0	0.2	0.1	0.4	9.2	15.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.9	0.0	0.0	0.0	11.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.1	0.0	0.2	0.1	0.1	8.0	0.0	0.0	0.0	0.0	0.1	1.4	0.1	0.0	0.0	0.4	0.3	0.1	1.0	1.4
GATA2	NFE1B	ENSG00000179348	"GATA binding protein 2"	P23769	3	128479427-128493201	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Phagocytosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Extravillous trophoblasts: 261.6;Glandular and luminal cells: 116.5;granulocytes: 638.7;Syncytiotrophoblasts: 321.4"	"Group enriched"	"Detected in all"	5	"endometrial cancer: 12.7;prostate cancer: 36.7;urothelial cancer: 13.2"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in some"	330	"basophil: 513.2"	"Lineage enriched"	"Detected in single"	4344	"granulocytes: 513.2"	"Cell line enhanced"	"Detected in many"		"BEWO: 281.0;HEL: 360.7;HMC-1: 187.4;SH-SY5Y: 325.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005633, CAB024847"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB024847: , HPA005633: AB_1078954"	"unprognostic (1.71e-1)"	"unprognostic (8.90e-2)"	"unprognostic (1.12e-1)"	"unprognostic (8.61e-2)"	"unprognostic (8.67e-2)"	"unprognostic (4.17e-2)"	"unprognostic (5.96e-3)"	"unprognostic (7.30e-2)"	"unprognostic (3.98e-2)"	"unprognostic (4.12e-2)"	"unprognostic (3.58e-2)"	"unprognostic (3.04e-1)"	"prognostic favorable (2.04e-4)"	"unprognostic (2.50e-1)"	"unprognostic (8.07e-2)"	"unprognostic (2.08e-1)"	"prognostic favorable (5.22e-5)"	15.1	9.9	8.2	2.8	4.2	5.1	12.9	3.5	4.8	31.7	4.0	6.0	4.4	43.0	7.2	4.9	50.1	10.8	15.1	3.6	2.9	18.1	1.3	35.1	2.8	6.9	6.2	1.6	4.3	13.8	7.0	9.8	22.7	8.0	54.8	2.9	0.1	4.9	52.7	6.5	8.1	8.6	10.9	3.5	11.5	6.7	2.8	7.0	0.8	7.4	5.3	1.3	34.1	24.1	5.6	24.4	5.9	1.3	15.9	2.0	0.6	281.0	53.8	45.2	18.0	6.5	10.0	10.7	0.5	14.8	31.9	1.5	25.5	14.7	0.0	7.6	0.0	8.3	360.7	42.9	16.0	4.0	36.8	187.4	0.3	0.3	0.7	0.3	2.9	28.6	0.2	96.7	0.5	0.4	9.0	0.1	74.2	1.0	0.2	1.8	0.1	7.0	0.4	0.5	21.5	21.8	325.9	13.6	70.1	2.4	14.4	13.5	15.0	52.0	1.2	0.7	12.7	7.4	0.1	0.0	0.2	0.6	2.5	3.7	513.2	0.0	1.5	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	3.9	8.2	4.2	3.5	4.8	3.6	2.9	6.9	6.2	1.6	8.0	3.5	7.0	5.6	69.0	6.4	27.7	0.0	0.9	4.8	25.5	0.0	1.2	0.2	1.5	1.5	5.7	0.0	1.8	75.4	0.0	63.4	2.3	0.5	1.9	0.2	10.1	74.2	43.2	75.4	3.0	62.4	0.0	14.2	261.6	8.8	0.5	116.5	638.7	0.9	57.5	0.2	10.8	0.0	0.0	0.3	0.0	0.3	4.6	6.4	0.6	7.9	8.8	15.9	0.7	0.1	0.0	0.0	0.0	0.9	0.0	0.4	5.4	29.5	0.0	0.2	0.7	0.2	0.0	2.2	11.0	0.6	4.7	0.9	2.4	321.4	14.0	0.2	0.3	10.5
HTR7	5-HT7	ENSG00000148680	"5-hydroxytryptamine receptor 7"	P34969	10	90740823-90858039	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 7.9;parathyroid gland: 13.2;testis: 8.8"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 7.0;Excitatory neurons: 5.9;Inhibitory neurons: 24.2;Spermatocytes: 13.1"	"Group enriched"	"Detected in some"	5	"cervical cancer: 0.9;head and neck cancer: 3.3;lung cancer: 0.9;urothelial cancer: 1.3"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	12	"myeloid DC: 1.4"	"Lineage enriched"	"Detected in single"	12	"dendritic cells: 1.4"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 11.3;hTCEpi: 10.1;hTERT-HME1: 33.4;LHCN-M2: 13.5;U-251 MG: 9.6;U-87 MG: 10.2;WM-115: 13.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB022708, HPA073617"	Approved	Supported	Supported	"Nuclear speckles,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nuclear speckles, Cytosol"	"CAB022708: , HPA073617: AB_2732228"	"unprognostic (1.17e-1)"	"unprognostic (1.24e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.33e-1)"	"unprognostic (5.51e-3)"	"unprognostic (1.71e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.15e-1)"	"unprognostic (4.58e-3)"	"unprognostic (3.32e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.89e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.84e-2)"	"unprognostic (6.49e-2)"	0.4	0.2	2.4	0.9	1.4	0.3	0.3	0.1	2.6	0.4	0.8	0.6	0.6	0.2	0.1	0.7	0.2	0.9	0.1	2.9	6.3	0.1	0.4	0.2	0.6	1.5	3.1	1.3	0.1	0.2	13.2	0.1	0.3	2.0	0.2	0.9	0.1	0.3	0.1	0.9	0.4	1.4	0.3	0.8	1.1	0.7	8.8	7.9	0.2	0.1	0.5	0.4	2.3	0.6	1.5	0.3	0.0	0.0	0.0	0.2	0.9	0.0	0.7	0.3	0.7	1.0	0.0	1.2	0.0	0.0	0.1	2.0	4.7	1.3	11.3	2.8	0.0	0.2	0.0	0.0	0.0	5.1	0.0	0.6	7.8	10.1	3.3	33.4	6.3	0.0	0.0	0.1	0.0	13.5	0.0	0.0	0.2	1.2	0.0	1.6	1.0	0.1	0.0	0.0	1.2	0.4	0.0	0.5	0.0	5.4	0.6	0.0	0.2	0.3	6.1	0.0	0.1	9.6	0.0	0.0	0.0	10.2	0.0	13.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.4	1.4	0.1	2.6	2.9	6.3	1.5	3.1	1.3	2.0	0.8	7.9	1.5	0.1	0.0	0.0	0.7	0.3	0.0	0.2	0.7	0.0	0.0	0.0	0.3	0.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.3	0.0	0.0	0.4	5.9	0.0	0.0	0.1	0.0	0.1	0.0	0.4	0.4	0.0	1.7	0.0	24.2	0.0	2.0	2.2	0.0	2.7	0.0	2.5	0.0	0.0	0.4	0.0	0.0	0.5	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.2	0.1	13.1	1.3	0.0	0.1	0.1	0.2	0.0	0.0	0.3
IVL		ENSG00000163207	Involucrin	P07476	1	152908546-152911886	"Plasma proteins, Predicted intracellular proteins"	Keratinization			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"cervix: 77.5;esophagus: 300.7;salivary gland: 95.3;skin 1: 145.7;vagina: 237.1"	"Cell type enhanced"	"Detected in some"		"Club cells: 10.4;Squamous epithelial cells: 30.8;Suprabasal keratinocytes: 71.0;Urothelial cells: 13.3"	"Group enriched"	"Detected in many"	5	"cervical cancer: 44.0;head and neck cancer: 145.4;melanoma: 50.9;urothelial cancer: 47.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	25	"HaCaT: 292.9;RT4: 76.9;SK-BR-3: 86.3"					"Not detected"	"Not detected"			"CAB002243, HPA055211"	Enhanced		Supported	"Nuclear bodies,Centrosome,Cytosol"		NA	NA		4700000	Cytosol	"Nuclear bodies, Centrosome"	"CAB002243: AB_563785, HPA055211: AB_2682739"	"unprognostic (3.29e-4)"	"unprognostic (1.91e-1)"		"unprognostic (2.92e-2)"		"unprognostic (2.31e-2)"		"unprognostic (7.60e-2)"	"unprognostic (2.22e-1)"		"unprognostic (4.82e-2)"	"unprognostic (3.11e-1)"		"unprognostic (3.66e-1)"		"unprognostic (1.22e-2)"	"unprognostic (1.32e-1)"	0.2	0.1	0.0	0.0	0.0	0.0	5.7	0.0	0.0	77.5	0.0	0.0	0.0	0.0	18.4	300.7	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.6	0.0	0.0	95.3	0.1	0.4	145.7	0.1	0.0	0.0	0.1	0.2	0.1	0.0	3.6	0.1	0.0	37.2	17.6	237.1	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	6.0	0.0	0.0	0.2	0.0	292.9	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	3.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	76.9	0.0	0.0	0.0	86.3	0.0	0.2	3.6	0.0	0.0	0.0	0.2	0.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	3.1	3.5	0.0	0.0	0.0	0.0	0.1	0.0	10.4	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	1.2	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.0	0.0	0.6	0.0	0.0	30.8	71.0	0.0	0.1	0.0	0.0	13.3
KRT13	"CK13, K13, MGC161462, MGC3781"	ENSG00000171401	"Keratin 13"	P13646	17	41500981-41505705	"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 41253.5;vagina: 13518.8"	"Cell type enriched"	"Detected in many"	4	"Squamous epithelial cells: 16844.0"	"Group enriched"	"Detected in many"	5	"cervical cancer: 899.2;head and neck cancer: 758.7;urothelial cancer: 504.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	93	"A-431: 2462.5;HaCaT: 1626.2"									"CAB000133, HPA030877, HPA069771"	Enhanced		Enhanced	"Intermediate filaments"		NA	NA		680000000	"Intermediate filaments"		"CAB000133: , HPA030877: AB_2673641, HPA069771: AB_2732141"	"unprognostic (1.45e-1)"	"unprognostic (6.23e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.19e-2)"	"unprognostic (9.30e-5)"	"unprognostic (7.30e-3)"		"unprognostic (1.95e-1)"	"unprognostic (1.77e-1)"	"unprognostic (5.81e-3)"	"prognostic unfavorable (1.02e-4)"	"unprognostic (3.16e-1)"	"prognostic unfavorable (1.45e-6)"	"unprognostic (1.80e-1)"	"unprognostic (2.76e-1)"	"unprognostic (3.04e-2)"	"unprognostic (4.33e-1)"	6.8	7.5	0.0	0.0	0.1	6.9	5.2	0.0	0.0	3290.9	0.0	4.9	0.1	10.3	0.0	41253.5	7.1	8.9	9.3	0.0	0.1	5.5	12.9	6.0	0.3	0.0	0.0	0.0	9.9	17.3	0.0	27.1	0.0	0.0	116.2	0.0	0.0	6935.6	3.9	9.9	13.5	8.6	14.3	0.0	7.8	31.5	7.0	0.0	13.7	6.1	0.0	1871.4	933.9	13518.8	0.0	2462.5	0.6	0.0	0.0	0.0	0.0	0.4	0.6	0.0	0.0	0.0	0.6	0.8	7.1	0.6	0.0	0.0	1626.2	0.0	0.4	0.0	1.4	0.0	4.5	21.8	0.0	0.0	1.7	1.3	0.0	0.8	0.0	0.0	0.3	0.0	0.0	5.4	1.2	0.0	1.3	0.1	0.1	0.1	14.8	0.3	0.2	1.2	0.3	0.0	10.7	0.0	0.0	1.9	2.0	7.7	0.0	2.3	6.4	5.1	0.0	0.4	0.0	6.6	0.3	6.3	5.8	1.9	4.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	16.0	1.1	0.0	0.9	2.8	545.6	17.1	146.8	0.0	2.3	4.6	0.6	1.5	94.5	0.0	0.0	0.1	0.2	0.6	0.0	0.0	1.2	2.7	0.2	11.4	1.2	5.5	0.0	0.0	0.5	12.6	0.0	4.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.8	8.2	0.0	0.0	3.2	55.9	13.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.7	286.6	27.1	227.9	0.1	0.1	3.3	0.0	0.0	0.0	16.9	0.2	0.6	16844.0	1.6	0.4	8.8	0.0	0.4	3645.4
KRT4	"CK4, CYK4, K4"	ENSG00000170477	"Keratin 4"	P19013	12	52806549-52814116	"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	9	"esophagus: 19918.5"	"Cell type enriched"	"Detected in some"	18	"Squamous epithelial cells: 5828.7"	"Group enriched"	"Detected in many"	5	"cervical cancer: 94.3;head and neck cancer: 151.8;stomach cancer: 73.1;urothelial cancer: 38.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	33	"HaCaT: 734.9;SK-BR-3: 361.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB002154, HPA034881"	Enhanced		Supported	"Intermediate filaments"		NA	NA		600000000	"Intermediate filaments"		"CAB002154: AB_563803, HPA034881: AB_2674370"	"unprognostic (4.04e-1)"	"unprognostic (3.22e-3)"	"unprognostic (5.16e-3)"	"unprognostic (8.52e-3)"		"unprognostic (1.20e-1)"		"unprognostic (2.64e-1)"	"unprognostic (1.84e-1)"	"prognostic unfavorable (3.26e-4)"	"unprognostic (2.85e-3)"	"unprognostic (2.84e-2)"	"unprognostic (2.58e-11)"	"unprognostic (1.64e-1)"	"unprognostic (6.97e-2)"	"unprognostic (1.16e-1)"	"prognostic unfavorable (6.26e-4)"	1.3	1.5	0.0	0.0	0.0	0.0	0.9	0.0	0.0	246.0	0.0	1.0	0.0	1.2	0.0	19918.5	9.6	3.2	7.2	0.0	0.0	0.9	2.6	17.5	0.0	0.0	0.0	0.0	1.8	2.8	0.0	8.9	0.0	0.0	4.4	0.0	0.0	2140.9	0.0	2.6	3.2	1.7	0.9	0.0	1.6	8.7	0.8	0.0	2.0	1.0	0.1	1430.5	4.4	1048.7	0.0	0.0	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	1.8	0.0	0.1	0.0	734.9	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.5	1.3	0.0	0.9	0.0	0.0	0.0	0.0	0.0	1.9	0.3	0.0	1.4	0.0	0.2	0.0	15.5	0.0	0.1	0.3	0.0	0.0	0.0	0.2	0.0	1.0	361.6	0.0	0.0	2.0	0.0	2.0	0.0	0.2	0.0	0.0	0.0	1.0	0.9	0.5	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	3.3	0.0	0.0	0.0	6.5	36.9	23.3	0.0	0.5	2.9	0.5	0.0	308.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.6	0.2	2.9	0.0	0.0	0.0	0.0	0.0	2.6	0.0	1.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	28.5	0.0	0.0	0.1	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	9.9	6.9	0.0	0.1	53.7	0.0	0.0	0.0	5.3	0.0	0.1	5828.7	0.0	0.0	2.0	0.0	0.0	54.4
KRT79	"K6L, KRT6L"	ENSG00000185640	"Keratin 79"	Q5XKE5	12	52821408-52834311	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	13	"skin 1: 43.8"	"Cell type enhanced"	"Detected in some"		"granulocytes: 4.5;Late spermatids: 1.1;Melanocytes: 3.6"	"Group enriched"	"Detected in some"	5	"breast cancer: 1.4;cervical cancer: 2.6;head and neck cancer: 2.7;melanoma: 1.6;urothelial cancer: 3.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	19	"HMC-1: 425.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA059347	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Cytosol"		NA	NA		1900000000	"Nucleoplasm, Nuclear membrane, Cytosol"		"HPA059347: AB_2683986"	"unprognostic (5.19e-3)"	"unprognostic (1.56e-3)"	"unprognostic (5.24e-2)"	"unprognostic (2.38e-2)"		"unprognostic (6.85e-2)"		"unprognostic (6.36e-2)"	"unprognostic (3.17e-1)"	"unprognostic (7.92e-2)"	"unprognostic (1.88e-2)"			"unprognostic (1.60e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.72e-1)"	"unprognostic (3.99e-2)"	0.1	0.0	0.0	0.0	0.0	0.1	3.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	43.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	1.0	0.0	0.0	0.0	0.0	425.5	0.0	0.0	5.1	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	0.1	6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	21.8	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	4.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	1.1	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0
PNMT	PENT	ENSG00000141744	"Phenylethanolamine N-methyltransferase"	P11086	17	39667981-39670475	"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins"	"Catecholamine biosynthesis"	"Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"adrenal gland: 159.8"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 20.1;Breast myoepithelial cells: 15.1;Cardiomyocytes: 13.4;Endometrial ciliated cells: 24.0;Erythroid cells: 16.6;Hepatic stellate cells: 27.5;Skeletal myocytes: 48.0"	"Group enriched"	"Detected in many"	5	"breast cancer: 7.7;cervical cancer: 27.0;urothelial cancer: 9.8"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEL: 5.3;K-562: 12.8;NB-4: 24.1;NTERA-2: 4.5;SCLC-21H: 6.4;SH-SY5Y: 5.8"	"Region enhanced"	"Detected in single"		"basal ganglia: 1.4"	"Not detected"	"Not detected"			"CAB017029, HPA043412, HPA051005"	Enhanced					NA	NA					"CAB017029: , HPA043412: AB_2630373, HPA051005: AB_2681306"	"unprognostic (1.50e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.08e-1)"	"prognostic unfavorable (3.95e-5)"	"unprognostic (4.27e-2)"	"unprognostic (3.02e-1)"	"unprognostic (2.98e-2)"	"unprognostic (5.75e-2)"	"unprognostic (5.29e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.52e-4)"	"unprognostic (1.58e-1)"	"unprognostic (1.97e-1)"	"unprognostic (4.72e-2)"	"unprognostic (1.87e-2)"	4.5	159.8	15.1	0.2	23.1	2.1	8.5	17.5	13.8	5.9	6.1	4.0	0.5	4.4	1.4	3.0	9.1	0.3	18.3	8.7	14.9	2.4	0.5	9.0	0.3	25.7	20.2	9.6	3.0	1.8	7.5	30.9	3.3	20.0	8.6	0.0	0.1	3.2	21.5	21.3	3.0	7.3	0.2	9.2	2.2	7.0	4.5	19.8	0.1	1.8	17.7	0.0	6.6	5.9	10.6	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.6	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	1.9	5.3	0.2	0.4	2.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	12.8	0.0	0.0	0.0	0.0	24.1	4.5	0.5	0.1	0.1	0.0	0.3	0.0	0.0	6.4	5.8	0.1	2.3	0.2	0.1	0.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	15.1	23.1	17.5	13.8	8.7	14.9	25.7	20.2	9.6	20.0	9.2	19.8	10.6	3.1	0.0	0.0	1.0	0.5	0.5	0.7	0.0	0.0	0.3	20.1	15.1	13.4	1.5	0.0	5.5	0.0	0.1	1.1	0.1	1.9	0.0	0.7	24.0	2.6	5.0	3.0	16.6	0.5	0.0	0.9	1.1	0.0	9.0	0.0	0.7	27.5	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.0	1.5	2.1	0.2	0.0	1.0	0.0	3.5	0.0	0.0	0.0	0.1	0.0	0.4	0.3	0.2	0.1	0.1	0.0	0.5	0.0	48.0	0.8	1.0	2.3	0.0	0.4	0.0	11.0	0.0	0.3	1.8
PSAPL1		ENSG00000178597	"Prosaposin like 1"	Q6NUJ1	4	7430285-7434930	"Predicted secreted proteins"	"Lipid metabolism, Sphingolipid metabolism"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	13	"skin 1: 93.8;stomach 1: 38.9"	"Cell type enriched"	"Detected in some"	13	"Gastric mucus-secreting cells: 41.8"	"Group enriched"	"Detected in some"	5	"head and neck cancer: 0.7;melanoma: 2.5;pancreatic cancer: 2.0;stomach cancer: 3.0;urothelial cancer: 1.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"CACO-2: 16.6;OE19: 32.2;RPMI-8226: 24.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA038013, HPA038482"	Approved		Enhanced	Cytosol	"Secreted - unknown location"	NA	NA		31000	Cytosol		"HPA038013: AB_10673652, HPA038482: AB_2676037"		"unprognostic (2.64e-2)"				"unprognostic (2.40e-1)"		"unprognostic (9.33e-2)"	"unprognostic (2.40e-1)"	"unprognostic (2.61e-1)"	"unprognostic (7.90e-3)"	"unprognostic (2.52e-1)"		"unprognostic (2.08e-2)"	"unprognostic (2.75e-1)"		"unprognostic (2.63e-3)"	0.2	0.0	0.0	0.0	0.2	0.0	5.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	93.8	0.0	0.0	0.0	0.0	38.9	3.5	0.1	0.2	0.0	0.0	3.1	0.0	0.2	0.7	0.0	0.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.2	0.0	0.0	0.0	24.7	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.2	0.0	0.2	0.1	0.0	0.6	0.0	0.1	0.7	0.0	0.0	0.0	0.3	0.2	0.1	0.0	1.8	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	41.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0
RHBG	SLC42A2	ENSG00000132677	"Rh family B glycoprotein"	Q9H310	1	156369211-156385219	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Ammonia transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"kidney: 9.6"	"Group enriched"	"Detected in some"	4	"Granulosa cells: 89.9;Theca cells: 91.3"	"Group enriched"	"Detected in some"	5	"liver cancer: 14.2;renal cancer: 5.1;urothelial cancer: 4.1"	"Region enhanced"	"Detected in single"		"cerebellum: 2.1"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"CACO-2: 2.9;Hep G2: 3.0;RT4: 5.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA042726, HPA048489"	Enhanced		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA042726: AB_2678131, HPA048489: AB_2680417"	"unprognostic (1.20e-1)"	"unprognostic (2.05e-1)"	"unprognostic (4.55e-3)"	"unprognostic (5.04e-2)"	"unprognostic (2.95e-2)"	"unprognostic (3.76e-3)"	"unprognostic (2.00e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.45e-1)"	"unprognostic (3.72e-1)"	"unprognostic (3.63e-2)"	"unprognostic (4.91e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.91e-3)"	"prognostic favorable (8.06e-4)"	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	9.6	1.9	0.0	0.0	0.0	0.2	0.0	2.1	0.1	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	22.0	0.0	0.0	0.0	0.0	19.6	0.3	10.3	0.3	0.0	0.1	0.0	0.0	0.2	0.6	0.1	1.3	0.0	0.1	0.0	89.9	0.0	10.5	0.1	0.0	0.1	0.0	0.0	0.0	0.0	12.4	0.3	0.1	0.0	0.0	0.6	1.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.1	0.1	1.3	0.2	0.0	0.0	0.0	0.8	2.3	0.4	0.0	0.4	0.0	0.0	91.3	0.0	0.1
S1PR5	"Edg-8, EDG8"	ENSG00000180739	"Sphingosine-1-phosphate receptor 5"	Q9H228	19	10512742-10517931	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 67.6"	"Cell type enhanced"	"Detected in some"		"dendritic cells: 93.9;NK-cells: 164.8;Oligodendrocytes: 26.6;T-cells: 33.1"	"Group enriched"	"Detected in many"	5	"cervical cancer: 11.7;head and neck cancer: 8.0;lung cancer: 3.7;urothelial cancer: 6.2"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"gdT-cell: 299.4;MAIT T-cell: 184.9;memory CD8 T-cell: 144.9;naive CD8 T-cell: 109.3"	"Lineage enriched"	"Detected in many"	7	"T-cells: 299.4"	"Cell line enhanced"	"Detected in many"		"HaCaT: 28.5;HBEC3-KT: 10.9;RT4: 18.7;T-47d: 11.6;U-2 OS: 10.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA029683	Enhanced					NA	NA					"HPA029683: AB_10603237"	"unprognostic (9.07e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.28e-2)"	"unprognostic (5.55e-4)"	"unprognostic (4.21e-1)"	"unprognostic (4.85e-2)"	"unprognostic (9.30e-2)"	"unprognostic (1.55e-1)"	"unprognostic (3.48e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.27e-1)"	"prognostic unfavorable (6.71e-7)"	"unprognostic (2.46e-2)"	"unprognostic (2.90e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.52e-1)"	0.6	0.4	29.7	0.8	41.5	19.9	0.6	39.0	38.2	2.8	17.3	0.3	0.2	0.3	4.4	12.9	0.2	0.2	0.5	26.8	34.0	0.7	1.6	3.0	1.0	45.3	42.3	22.4	0.2	1.5	0.1	0.4	1.7	43.9	2.5	0.1	0.0	2.5	0.5	0.6	18.9	0.3	0.2	36.5	11.2	0.3	0.7	38.1	0.9	0.5	0.2	2.1	2.3	11.0	67.6	1.9	2.8	0.6	0.0	0.0	0.1	0.2	0.6	0.5	0.9	0.5	0.3	0.1	0.0	7.6	0.3	1.2	28.5	1.8	10.9	2.0	0.0	1.8	0.2	2.3	0.0	0.1	0.0	0.1	0.0	5.0	3.0	0.6	0.2	0.0	0.0	0.2	0.0	0.0	3.7	1.1	0.0	4.5	0.6	0.5	0.0	2.1	0.0	0.0	18.7	0.0	0.0	4.7	0.0	0.5	1.9	11.6	3.3	0.0	1.5	10.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	3.3	0.5	0.5	1.2	299.4	0.2	184.9	0.6	36.3	144.9	0.6	0.5	10.8	109.3	3.9	44.5	1.1	0.8	0.6	64.2	29.7	41.5	39.0	38.2	26.8	34.0	45.3	42.3	22.4	43.9	36.5	38.1	67.6	1.0	3.2	1.9	0.0	0.6	3.6	2.2	10.9	7.4	0.0	0.1	0.9	0.9	1.5	0.9	0.0	0.0	0.1	93.9	0.0	0.0	0.0	6.2	0.1	0.2	0.6	0.0	0.8	0.1	0.2	0.3	1.7	0.5	0.0	2.5	0.0	1.8	0.3	0.2	0.0	0.1	0.0	0.0	0.8	0.3	2.3	0.0	0.6	0.0	2.8	1.2	0.0	164.8	0.0	26.6	0.2	0.0	0.0	14.7	0.2	0.0	0.1	0.4	0.0	0.0	0.1	1.9	0.0	0.2	4.8	5.1	0.1	33.1	0.0	0.0	0.4
SIGLEC5	"CD170, CD33L2, OB-BP2, SIGLEC-5"	ENSG00000105501	"Sialic acid binding Ig like lectin 5"	O15389	19	51611927-51645545	"CD markers, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"bone marrow: 14.9;lymphoid tissue: 12.5"	"Cell type enhanced"	"Detected in some"		"granulocytes: 8.2;Hofbauer cells: 5.6;Kupffer cells: 10.4;Macrophages: 4.4;monocytes: 3.0"	"Cancer enriched"	"Detected in single"	5	"urothelial cancer: 1.7"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	4	"neutrophil: 152.5;non-classical monocyte: 49.3"	"Group enriched"	"Detected in many"	6	"granulocytes: 152.5;monocytes: 49.3"	"Group enriched"	"Detected in some"	5	"HMC-1: 59.2;U-937: 25.6"									"HPA009085, CAB024900"	Supported					NA	NA					"CAB024900: , HPA009085: AB_1079965"	"unprognostic (1.83e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.02e-2)"	"unprognostic (1.03e-2)"	"unprognostic (4.39e-2)"	"unprognostic (1.62e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.01e-1)"	"unprognostic (3.28e-1)"	"unprognostic (7.44e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.05e-1)"	"unprognostic (3.71e-4)"	"unprognostic (4.37e-2)"	"unprognostic (3.55e-3)"	"unprognostic (4.02e-1)"	"unprognostic (1.95e-1)"	1.5	0.4	0.3	6.7	0.6	14.9	0.2	0.3	1.1	0.2	0.1	0.7	0.1	0.3	0.0	0.3	0.7	0.7	0.4	0.3	0.3	0.3	1.5	3.4	3.1	0.4	0.3	0.2	0.1	0.2	0.3	0.1	0.9	0.6	0.3	0.7	0.2	0.3	0.1	0.0	0.0	2.0	0.9	0.4	12.5	0.6	0.8	0.4	0.7	0.2	0.4	2.2	1.5	0.1	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.2	59.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	7.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.6	0.0	15.5	22.2	0.5	0.0	24.2	0.0	2.5	0.0	0.0	15.6	2.0	0.0	0.0	152.5	0.7	49.3	5.0	0.0	8.4	0.3	0.6	0.3	1.1	0.3	0.3	0.4	0.3	0.2	0.6	0.4	0.4	0.7	0.0	0.0	0.0	0.3	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	0.0	8.2	0.0	0.0	0.0	5.6	0.0	0.2	0.0	0.0	10.4	1.2	0.5	0.3	4.4	0.0	1.0	3.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0
SLC14A1	"HsT1341, JK, RACH1, RACH2"	ENSG00000141469	"Solute carrier family 14 member 1 (Kidd blood group)"	Q13336	18	45687025-45752520	"Blood group antigen proteins, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	"Blood group antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 136.7;prostate: 79.0;urinary bladder: 91.8"	"Group enriched"	"Detected in many"	7	"Adipocytes: 136.6;Astrocytes: 228.5;Basal prostatic cells: 313.4;Erythroid cells: 102.5;Prostatic glandular cells: 192.6;Urothelial cells: 249.9"	"Group enriched"	"Detected in many"	5	"glioma: 5.3;prostate cancer: 8.6;urothelial cancer: 16.1"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"T-reg: 4.1"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"GAMG: 273.4;RT4: 113.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA059570, HPA077233"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA059570: AB_2684066, HPA077233: "	"unprognostic (2.04e-1)"	"unprognostic (2.56e-3)"	"unprognostic (5.20e-2)"	"unprognostic (1.27e-1)"	"unprognostic (6.86e-2)"	"unprognostic (1.84e-2)"	"unprognostic (1.70e-2)"	"unprognostic (7.97e-2)"	"unprognostic (8.17e-2)"	"unprognostic (9.99e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.02e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.52e-1)"	"unprognostic (9.09e-2)"	"unprognostic (6.93e-2)"	2.1	1.7	66.3	1.0	89.5	15.3	2.1	119.5	63.7	2.1	23.7	1.3	1.3	0.5	0.7	0.4	0.3	10.2	15.5	60.1	91.9	11.1	1.1	4.3	2.3	123.0	113.5	26.2	0.3	1.7	0.9	1.0	1.6	110.3	79.0	1.3	0.3	2.3	3.1	4.0	4.0	3.4	0.5	86.7	4.6	1.8	0.2	136.7	7.8	6.4	7.9	2.3	91.8	2.3	103.9	0.0	0.4	0.0	0.1	0.0	0.2	0.7	0.4	8.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	273.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.2	0.1	0.2	0.0	0.0	0.0	0.0	38.3	0.0	0.2	0.0	0.2	0.3	0.1	0.9	0.3	0.0	0.3	0.2	0.0	0.0	0.2	3.0	113.8	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.3	0.0	1.8	0.5	0.9	0.1	4.1	0.2	0.1	2.7	1.3	1.3	0.0	0.0	1.1	0.8	0.0	0.0	0.3	0.9	0.9	0.0	0.3	0.2	1.5	0.0	0.9	0.0	0.1	4.1	0.6	66.3	89.5	119.5	63.7	60.1	91.9	123.0	113.5	26.2	110.3	86.7	136.7	103.9	136.6	0.0	0.6	228.5	3.1	0.3	313.4	0.1	0.6	0.3	5.4	1.5	10.9	5.7	0.0	0.0	0.0	0.0	8.6	0.0	0.0	0.2	0.6	0.0	0.1	28.7	0.0	102.5	0.6	0.2	0.1	3.8	0.0	0.1	0.0	0.2	21.4	0.3	0.1	0.0	0.7	0.2	18.3	0.6	0.3	0.4	0.0	2.0	12.4	5.6	0.1	0.0	5.2	3.5	0.7	0.3	0.0	1.2	2.1	192.6	0.0	0.0	0.0	0.2	0.0	1.7	3.7	0.1	0.2	0.2	0.4	0.0	6.1	0.1	0.0	249.9
SYT8	DKFZp434K0322	ENSG00000149043	"Synaptotagmin 8"	Q8NBV8	11	1828307-1837521	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 29.5;skin 1: 63.8;urinary bladder: 40.9"	"Group enriched"	"Detected in many"	4	"Basal keratinocytes: 184.7;Basal squamous epithelial cells: 520.2;Breast myoepithelial cells: 192.9;Cholangiocytes: 183.0;Extravillous trophoblasts: 201.8;Respiratory ciliated cells: 163.8;Squamous epithelial cells: 132.5"	"Group enriched"	"Detected in many"	5	"cervical cancer: 10.5;pancreatic cancer: 21.7;urothelial cancer: 33.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"CAPAN-2: 32.2;hTCEpi: 50.2;T-47d: 13.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA047239, HPA052700"	Uncertain		Approved	"Nucleoli fibrillar center,Endoplasmic reticulum"		NA	NA			"Nucleoli fibrillar center, Endoplasmic reticulum"		"HPA047239: , HPA052700: AB_2681920"	"unprognostic (1.66e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.12e-2)"	"unprognostic (2.14e-1)"	"unprognostic (6.31e-2)"	"unprognostic (2.06e-1)"	"unprognostic (3.10e-2)"	"unprognostic (1.36e-2)"	"unprognostic (1.02e-1)"	"unprognostic (8.25e-2)"	"unprognostic (7.09e-2)"	"unprognostic (2.48e-1)"	"unprognostic (2.33e-6)"	"unprognostic (2.87e-2)"	"unprognostic (1.75e-1)"	"unprognostic (5.52e-2)"	"unprognostic (2.77e-2)"	0.1	0.2	0.0	0.0	0.0	0.0	5.1	0.0	0.0	1.1	0.0	0.2	0.5	0.0	0.5	29.5	1.0	8.7	0.0	0.0	0.0	0.3	0.6	4.7	0.0	0.0	0.0	0.0	0.0	15.0	0.0	0.2	1.6	0.0	2.5	0.0	0.0	21.0	3.0	0.0	63.8	2.6	0.0	0.0	0.1	2.3	0.2	0.0	0.0	0.0	0.0	0.1	40.9	3.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	32.2	0.0	0.0	0.0	0.6	0.6	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	50.2	0.0	5.8	0.8	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	5.7	0.0	0.0	0.3	0.0	0.1	1.0	0.0	0.3	0.0	2.7	0.0	0.0	13.7	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	16.0	3.9	0.0	0.3	184.7	5.6	24.9	520.2	0.0	3.2	192.9	0.6	183.0	39.1	5.5	0.0	28.7	0.7	3.4	0.0	31.1	0.0	15.6	0.1	1.7	0.0	0.0	0.0	9.7	201.8	1.6	12.2	0.6	1.3	0.0	0.0	0.1	7.1	0.0	0.0	1.3	16.2	0.0	14.7	0.0	0.0	1.3	10.6	0.0	0.0	0.0	0.0	0.0	0.0	28.3	3.5	0.0	6.2	1.3	18.3	0.0	163.8	0.0	0.0	0.0	7.0	0.0	0.0	132.5	47.2	36.8	0.6	0.1	1.7	31.5
TH	DYT5b	ENSG00000180176	"Tyrosine hydroxylase"	P07101	11	2163929-2171815	"Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins"	"Catecholamine biosynthesis, Neurotransmitter biosynthesis"	"Monooxygenase, Oxidoreductase"	"Disease variant, Dystonia, FDA approved drug targets, Parkinson disease, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	55	"adrenal gland: 198.4;brain: 177.6"	"Cell type enhanced"	"Detected in some"		"Endometrial stromal cells: 9.0;Extravillous trophoblasts: 12.4;Leydig cells: 3.4;Syncytiotrophoblasts: 2.2"	"Cancer enriched"	"Detected in some"	5	"urothelial cancer: 4.0"	"Group enriched"	"Detected in many"	6	"midbrain: 167.5;pons: 177.6;white matter: 69.0"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	30	"PC-3: 60.8;SK-BR-3: 21.0"	"Region enhanced"	"Detected in many"		"olfactory bulb: 178.8"	"Region enriched"	"Detected in many"	20	"midbrain: 594.4"	"CAB002522, HPA013768, HPA014010, HPA061003, CAB072340"	Enhanced	Supported	Approved	Cytosol		NA	NA			Cytosol		"CAB002522: AB_564047, CAB072340: , HPA013768: , HPA014010: , HPA061003: AB_2630374"	"unprognostic (1.31e-1)"	"unprognostic (1.30e-1)"	"unprognostic (9.08e-2)"	"unprognostic (1.75e-4)"	"unprognostic (8.82e-3)"	"unprognostic (5.88e-2)"	"unprognostic (1.93e-1)"	"unprognostic (1.74e-3)"	"unprognostic (3.83e-2)"	"unprognostic (4.39e-4)"	"unprognostic (4.97e-1)"	"unprognostic (3.61e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.43e-1)"	"unprognostic (2.70e-2)"	"unprognostic (2.18e-2)"	3.3	198.4	7.7	0.1	2.2	0.0	0.0	0.2	9.5	0.5	0.0	0.1	0.0	0.5	0.1	0.7	0.2	0.4	0.1	1.3	23.5	0.1	0.4	0.0	0.0	15.9	167.5	0.5	0.7	0.2	0.0	1.7	0.1	177.6	0.3	0.0	0.1	0.1	0.0	0.0	0.8	0.5	0.0	0.7	0.2	0.3	0.5	15.8	0.0	0.0	0.0	0.0	1.4	1.5	69.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.6	60.8	0.0	0.0	0.0	0.1	0.1	1.1	0.2	0.0	21.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.7	2.2	0.2	9.5	1.3	23.5	15.9	167.5	0.5	177.6	0.7	15.8	69.0	0.3	0.0	0.0	0.0	0.5	0.1	0.1	0.2	0.0	0.0	0.0	0.1	0.9	0.0	0.2	1.8	0.0	0.2	0.0	0.1	0.0	0.1	0.1	0.4	9.0	0.4	0.0	0.0	0.1	0.0	12.4	0.4	0.0	0.3	0.0	0.0	1.1	0.2	0.5	0.0	0.3	0.1	0.0	0.0	0.3	0.2	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	1.6	0.0	0.0	2.2	0.1	0.3	0.2	0.2
TRIM31	"C6orf13, HCG1, HCGI, RNF"	ENSG00000204616	"Tripartite motif containing 31"	Q9BZY9	6	30102897-30113090	"Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 12.2;stomach 1: 6.0;urinary bladder: 8.6"	"Group enriched"	"Detected in some"	4	"Distal enterocytes: 409.1;Paneth cells: 404.9;Proximal enterocytes: 193.3;Urothelial cells: 227.9"	"Group enriched"	"Detected in many"	5	"cervical cancer: 6.7;colorectal cancer: 25.8;pancreatic cancer: 11.4;stomach cancer: 19.8;urothelial cancer: 12.8"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	726	"RT4: 294.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA074175	Enhanced					NA	NA					"HPA074175: "	"unprognostic (1.37e-1)"	"unprognostic (7.78e-3)"	"unprognostic (1.83e-1)"	"unprognostic (7.05e-3)"	"unprognostic (1.75e-1)"	"unprognostic (9.37e-2)"	"unprognostic (6.13e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.97e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.43e-3)"	"unprognostic (5.84e-3)"	"unprognostic (6.20e-2)"	"unprognostic (1.60e-1)"	"unprognostic (2.50e-3)"	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	12.2	0.9	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	1.2	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	2.0	0.2	0.0	0.0	0.0	0.0	0.3	12.2	0.1	0.0	0.0	6.0	3.3	0.0	0.0	0.0	0.0	0.0	8.6	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	294.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	0.6	0.1	12.3	2.5	0.0	0.0	0.4	0.3	5.7	4.3	3.0	0.0	0.0	0.0	0.2	409.1	0.0	2.7	0.2	25.7	0.2	0.4	5.4	2.7	0.0	1.7	0.0	0.3	73.9	1.1	4.5	0.0	0.0	0.0	0.1	0.0	0.0	52.3	0.0	0.0	0.0	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	404.9	0.0	0.2	2.7	193.3	0.6	14.2	0.0	0.0	0.2	0.5	1.8	0.2	0.0	0.0	0.0	0.8	0.0	25.6	227.9
UGT1A6	"GNT1, HLUGP, UGT1F"	ENSG00000167165	"UDP glucuronosyltransferase family 1 member A6"	P19224	2	233691607-233773300	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Glycosyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"kidney: 72.0;liver: 144.4;urinary bladder: 89.6"	"Cell type enhanced"	"Detected in some"		"Basal squamous epithelial cells: 12.5;Early spermatids: 52.4;Gastric mucus-secreting cells: 14.3;Late spermatids: 23.3;Squamous epithelial cells: 17.3"	"Group enriched"	"Detected in many"	5	"liver cancer: 7.2;lung cancer: 3.1;renal cancer: 7.6;urothelial cancer: 3.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	4	"OE19: 1194.0"	"Not detected"	"Not detected"							"CAB009819, HPA054065, HPA056023"	Enhanced		Supported	"Endoplasmic reticulum,Vesicles"		NA	NA			Vesicles	"Endoplasmic reticulum"	"CAB009819: AB_2241481, HPA054065: AB_2682367, HPA056023: "		"unprognostic (9.09e-2)"	"unprognostic (6.07e-2)"	"unprognostic (5.43e-2)"		"unprognostic (6.03e-2)"	"prognostic unfavorable (2.89e-6)"	"unprognostic (2.79e-1)"	"unprognostic (6.18e-2)"		"unprognostic (2.09e-3)"	"unprognostic (9.97e-2)"	"unprognostic (2.16e-2)"	"unprognostic (3.52e-1)"	"unprognostic (7.50e-2)"		"unprognostic (2.01e-2)"	0.1	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.0	0.9	0.0	1.8	5.9	0.1	2.6	16.2	0.0	3.5	0.0	0.0	0.0	72.0	144.4	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.1	1.4	0.0	2.6	3.6	0.0	11.2	2.6	0.0	0.0	0.0	17.5	0.4	0.0	1.2	0.5	0.0	5.8	89.6	5.6	0.0	4.2	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	53.8	1.6	0.0	80.2	0.1	0.8	294.5	0.1	4.0	0.0	0.0	0.0	0.0	0.3	1.3	0.0	0.0	0.3	0.0	31.2	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	6.2	0.0	0.0	0.0	1194.0	0.0	0.1	0.2	0.1	3.2	149.0	0.0	0.0	7.1	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.6	1.2	12.5	0.0	0.0	0.0	0.3	0.0	2.9	1.8	0.0	0.0	0.0	0.4	0.0	0.0	52.4	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	14.3	0.5	0.0	0.0	0.4	5.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	23.3	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.9	0.5	1.8	0.1	0.0	0.0	0.0	0.0	1.2	0.2	17.3	1.1	0.0	0.0	0.0	0.1	3.0
UGT1A8	UGT1H	ENSG00000242366	"UDP glucuronosyltransferase family 1 member A8"	Q9HAW9	2	233617645-233773310	"Enzymes, Metabolic proteins, Predicted membrane proteins"		"Glycosyltransferase, Transferase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 16.1;liver: 20.2;urinary bladder: 30.3"	"Cell type enhanced"	"Detected in some"		"Basal respiratory cells: 4.5;Club cells: 1.0;Ionocytes: 2.0;Paneth cells: 2.5;Proximal enterocytes: 1.3;Squamous epithelial cells: 1.1"	"Cancer enriched"	"Detected in some"	5	"urothelial cancer: 2.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	64	"RT4: 121.4"															NA	NA								"unprognostic (1.27e-2)"			"unprognostic (1.35e-1)"	"unprognostic (1.42e-3)"				"unprognostic (1.23e-1)"	"unprognostic (4.78e-1)"	"unprognostic (9.71e-12)"	"unprognostic (9.26e-2)"			"unprognostic (1.96e-1)"	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.1	2.8	0.0	0.0	1.9	0.0	6.6	0.0	0.0	0.0	1.8	20.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	8.9	0.0	0.5	0.0	0.0	0.1	4.4	1.0	0.0	0.0	0.1	0.0	0.0	1.0	0.0	0.0	0.4	30.3	0.8	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	121.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	1.3	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.6	0.0	0.0	0.0	0.4	0.2
ANXA8	ANX8	ENSG00000265190	"Annexin A8"	P13928	10	47460162-47484158	"Predicted intracellular proteins"	"Blood coagulation, Hemostasis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 219.4;skin 1: 268.4;vagina: 111.6"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 99.3;Astrocytes: 38.8;Club cells: 40.7;Excitatory neurons: 47.8;Fibroblasts: 34.5;Inhibitory neurons: 41.0;Microglial cells: 35.6;Oligodendrocyte precursor cells: 50.8;Oligodendrocytes: 48.1;Squamous epithelial cells: 63.6"	"Group enriched"	"Detected in many"	4	"cervical cancer: 14.3;head and neck cancer: 16.1;lung cancer: 4.3;urothelial cancer: 11.1"	"Low region specificity"	"Detected in single"			"Immune cell enhanced"	"Detected in single"		"myeloid DC: 1.6"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"HaCaT: 394.3;HBEC3-KT: 622.3;hTCEpi: 357.6;hTERT-HME1: 134.2;RT4: 159.6"									"HPA045246, HPA047451"			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA045246: AB_2679271, HPA047451: AB_2680052"	"unprognostic (8.32e-4)"	"unprognostic (2.52e-1)"	"unprognostic (2.44e-1)"	"unprognostic (6.15e-2)"	"unprognostic (1.82e-1)"	"prognostic unfavorable (6.07e-4)"	"unprognostic (5.94e-2)"	"unprognostic (2.88e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.50e-2)"	"prognostic unfavorable (2.68e-4)"	"unprognostic (1.19e-1)"	"unprognostic (7.55e-15)"	"unprognostic (1.04e-2)"	"unprognostic (9.94e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.39e-1)"	33.4	0.7	0.4	0.1	0.3	0.7	11.8	0.8	1.0	24.8	0.4	0.4	0.0	0.1	1.0	219.4	3.8	0.4	2.5	0.5	0.1	0.0	1.8	13.2	0.0	0.8	0.5	0.2	1.3	0.3	0.0	0.3	31.2	0.6	12.5	0.1	0.0	47.7	9.9	0.4	268.4	0.2	0.0	0.5	0.2	0.4	0.8	0.9	4.8	0.2	0.2	47.0	67.0	111.6	0.8	123.4	16.2	0.0	0.0	0.0	0.0	33.7	2.3	0.3	0.0	0.0	8.7	35.0	0.0	2.5	1.0	1.8	394.3	0.0	622.3	0.0	27.9	0.0	0.0	39.6	0.0	26.2	0.0	1.3	0.2	357.6	0.2	134.2	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	37.2	0.1	4.0	0.0	0.0	0.5	0.0	0.0	159.6	0.0	0.0	56.4	16.4	0.3	8.7	0.1	3.5	0.0	0.0	39.5	0.7	2.4	0.2	0.1	0.2	4.4	0.3	0.0	0.0	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.3	0.8	1.0	0.5	0.1	0.8	0.5	0.2	0.6	0.5	0.9	0.8	0.1	99.3	7.3	38.8	0.0	1.1	10.3	1.6	2.8	0.0	4.9	3.4	2.6	7.2	40.7	3.7	0.0	14.7	0.1	1.0	0.0	3.1	0.6	2.1	0.0	0.5	0.0	0.0	47.8	0.4	6.7	34.5	0.0	0.2	1.3	0.1	0.0	0.0	0.6	0.0	41.0	0.1	0.0	0.0	0.0	1.7	0.0	0.2	0.0	35.6	0.1	0.0	0.0	50.8	48.1	17.3	0.0	0.0	0.0	8.5	1.5	0.0	14.2	0.0	0.0	0.0	0.6	0.2	1.4	63.6	2.0	6.2	0.3	0.1	0.2	17.2
BMP3		ENSG00000152785	"Bone morphogenetic protein 3"	P12645	4	81030708-81057627	"Plasma proteins, Predicted secreted proteins"	"Chondrogenesis, Differentiation, Osteogenesis"	"Cytokine, Developmental protein, Growth factor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 8.1;lung: 5.5;urinary bladder: 9.5"	"Cell type enhanced"	"Detected in some"		"Alveolar cells type 2: 32.2;Distal enterocytes: 68.9;Granulosa cells: 104.0;Paneth cells: 32.8;Proximal enterocytes: 25.2"	"Group enriched"	"Detected in some"	4	"lung cancer: 4.2;urothelial cancer: 7.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"AF22: 10.3;Daudi: 16.3;RT4: 13.5;SK-BR-3: 5.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"								"Secreted in other tissues"	NA	NA						"unprognostic (5.21e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.23e-2)"	"unprognostic (2.07e-1)"	"unprognostic (3.36e-2)"		"unprognostic (2.73e-3)"		"unprognostic (9.11e-2)"	"unprognostic (2.35e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.16e-4)"	"unprognostic (2.26e-2)"	"unprognostic (3.86e-1)"	"unprognostic (1.11e-1)"	"unprognostic (4.22e-2)"	1.2	0.4	0.6	0.3	0.3	0.8	1.2	0.2	0.3	0.4	0.1	8.1	3.2	0.0	0.1	0.0	0.9	2.0	0.0	0.1	0.6	0.1	0.0	5.5	0.3	0.5	0.8	0.3	2.5	0.0	0.0	0.0	0.0	0.5	0.2	6.8	0.5	1.3	0.0	0.0	0.3	7.3	0.5	0.6	0.0	1.1	0.1	0.8	0.0	0.0	0.6	1.5	9.5	0.2	0.5	0.0	0.0	10.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	16.3	0.0	0.0	0.0	1.9	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	13.5	0.1	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.6	0.3	0.2	0.3	0.1	0.6	0.5	0.8	0.3	0.5	0.6	0.8	0.5	0.0	3.2	32.2	0.0	0.2	0.1	0.5	0.7	0.0	2.2	0.1	0.0	1.3	0.0	15.1	0.0	0.0	0.0	0.0	68.9	0.0	0.0	0.0	0.9	0.1	0.3	0.0	0.0	1.6	0.0	0.0	2.1	0.0	0.0	0.0	104.0	0.0	0.0	0.0	0.0	5.6	5.0	6.1	0.0	1.2	0.0	0.9	0.2	0.0	1.0	0.0	0.2	0.0	0.0	0.1	0.2	32.8	0.0	0.0	0.5	25.2	0.1	9.4	0.1	0.0	0.3	1.2	0.2	0.3	0.0	0.4	0.0	0.0	0.1	14.1	3.8
FABP5	"E-FABP, KFABP, PA-FABP"	ENSG00000164687	"Fatty acid binding protein 5"	Q01469	8	81280536-81284777	"Cancer-related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	5	"esophagus: 3720.6;vagina: 2621.6"	"Cell type enhanced"	"Detected in all"		"Adipocytes: 2511.2;Alveolar cells type 2: 1891.0;Hofbauer cells: 2385.2;Squamous epithelial cells: 9211.0"	"Group enriched"	"Detected in all"	4	"cervical cancer: 268.3;head and neck cancer: 288.8;urothelial cancer: 73.7"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 1167.2;MOLT-4: 1213.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017831, CAB040577, HPA051895"	Enhanced		Supported	"Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA		14000000	Cytosol	"Plasma membrane"	"CAB017831: , CAB040577: , HPA051895: AB_2681654"	"unprognostic (8.76e-2)"	"unprognostic (7.28e-2)"	"unprognostic (1.54e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.33e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.95e-3)"	"unprognostic (4.03e-3)"	"unprognostic (2.71e-1)"	"unprognostic (3.13e-1)"	"unprognostic (6.16e-2)"	"unprognostic (3.57e-2)"	"prognostic unfavorable (4.69e-10)"	"unprognostic (1.99e-1)"	"unprognostic (3.72e-1)"	"unprognostic (1.61e-1)"	"unprognostic (6.60e-2)"	334.5	15.6	125.4	139.0	120.9	112.7	243.8	122.3	147.7	653.8	284.7	259.2	84.1	63.3	4.8	3720.6	22.6	88.5	248.7	124.3	151.1	16.5	27.8	274.9	193.0	179.1	125.6	109.3	12.2	73.8	447.2	33.0	341.7	163.4	23.1	212.6	33.6	519.0	17.2	120.3	612.9	123.3	52.9	143.2	128.4	182.9	45.5	126.6	138.9	75.5	308.8	295.3	366.0	2621.6	151.6	76.9	215.9	133.1	0.3	615.7	59.0	0.3	158.0	8.9	123.2	153.3	2.2	100.3	1167.2	86.7	38.3	1.1	69.2	328.9	254.8	103.7	597.6	603.2	449.0	136.2	345.0	54.2	421.6	107.9	45.0	507.0	146.8	306.1	121.3	708.9	328.6	125.9	124.1	73.7	69.3	1213.7	199.9	170.5	785.1	732.1	526.0	0.4	127.7	198.9	951.4	514.4	190.7	74.1	24.7	61.0	230.2	1.2	201.6	97.0	0.1	331.3	1.6	1.4	155.6	70.1	902.2	52.2	396.8	184.9	8.1	14.3	0.9	6.1	16.6	9.3	17.2	6.9	13.7	55.9	10.4	3.1	11.9	5.2	22.3	5.5	54.8	9.8	13.4	125.4	120.9	122.3	147.7	124.3	151.1	179.1	125.6	109.3	163.4	143.2	126.6	151.6	2511.2	288.4	1891.0	30.7	93.0	121.0	90.0	881.2	727.3	23.7	22.3	48.6	5.7	2.8	649.8	22.0	45.9	28.0	97.5	420.3	3.9	35.4	29.5	55.7	579.5	662.2	197.2	74.4	7.7	23.8	272.4	140.6	278.8	29.6	55.8	70.1	35.3	1.4	2385.2	21.9	10.9	216.3	175.0	182.2	764.3	46.0	6.2	405.5	206.3	4.7	697.1	273.0	15.5	6.0	16.3	43.3	561.0	5.3	132.9	71.3	10.4	2.3	115.7	43.5	361.6	140.0	336.8	179.4	182.5	9211.0	168.6	27.0	102.3	68.8	419.2	232.6
GNA15	GNA16	ENSG00000060558	"G protein subunit alpha 15"	P30679	19	3136033-3163749	"Plasma proteins, Predicted intracellular proteins"		Transducer		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 76.2;esophagus: 109.7"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 141.5;Langerhans cells: 190.6;Macrophages: 78.3;Suprabasal keratinocytes: 95.8;Urothelial cells: 173.8"	"Group enriched"	"Detected in all"	4	"cervical cancer: 39.9;head and neck cancer: 46.4;lung cancer: 17.3;pancreatic cancer: 11.9;urothelial cancer: 31.2"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in many"		"plasmacytoid DC: 67.1"	"Group enriched"	"Detected in many"	4	"dendritic cells: 67.1;granulocytes: 19.4;monocytes: 29.1"	"Cell line enhanced"	"Detected in some"		"HBEC3-KT: 65.4;HMC-1: 152.1;MOLT-4: 162.4;NB-4: 59.8;REH: 119.3;THP-1: 62.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA043113	Approved					NA	NA					"HPA043113: AB_10967343"	"prognostic favorable (7.57e-5)"	"unprognostic (6.06e-2)"	"unprognostic (3.43e-1)"	"prognostic favorable (2.01e-4)"	"unprognostic (4.34e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.14e-2)"	"unprognostic (5.38e-3)"	"unprognostic (1.82e-1)"	"unprognostic (3.22e-2)"	"unprognostic (1.42e-3)"	"unprognostic (1.69e-1)"	"prognostic unfavorable (4.26e-6)"	"unprognostic (1.04e-1)"	"unprognostic (2.16e-3)"	"unprognostic (2.36e-1)"	"unprognostic (2.07e-1)"	5.7	3.2	3.6	12.5	3.7	76.2	4.7	3.8	6.6	7.3	5.5	2.4	1.7	1.3	0.4	109.7	2.4	4.7	1.9	4.6	5.7	2.0	1.4	13.2	4.2	5.2	4.0	3.2	0.8	1.2	0.4	1.4	7.7	4.5	11.7	1.8	0.1	19.6	2.5	0.6	47.7	2.5	3.1	4.8	8.8	4.4	1.4	5.7	32.3	1.2	0.9	12.2	28.3	42.0	5.3	44.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.1	0.1	0.0	18.7	0.1	0.1	0.0	0.1	36.2	0.0	65.4	0.0	0.1	0.0	19.1	0.1	0.0	0.0	27.2	152.1	0.0	40.0	0.2	26.2	0.0	0.0	16.6	0.1	0.3	0.0	0.0	162.4	59.8	0.1	2.9	0.0	119.3	0.0	0.2	0.0	23.6	0.2	0.0	4.6	0.2	0.2	0.0	0.0	62.1	0.1	0.0	0.2	0.2	0.3	0.2	0.0	0.1	0.3	29.8	0.1	19.4	29.1	14.3	0.0	21.8	1.1	0.0	2.0	0.3	28.8	0.0	0.0	0.0	6.9	4.4	15.5	67.1	8.7	13.3	3.6	3.7	3.8	6.6	4.6	5.7	5.2	4.0	3.2	4.5	4.8	5.7	5.3	1.0	9.6	8.8	0.0	2.2	67.2	141.5	65.5	9.1	0.2	7.4	3.7	0.5	0.0	39.0	3.7	0.0	0.5	27.6	0.5	0.0	0.7	0.5	1.4	0.5	3.1	6.6	21.0	1.3	0.0	0.8	2.5	3.6	3.9	34.3	0.0	0.7	0.0	66.5	0.0	0.4	2.2	57.0	36.2	190.6	0.8	0.0	78.3	21.4	7.5	32.0	0.0	0.0	0.0	0.2	13.2	0.3	0.0	3.6	69.3	0.0	0.1	21.7	0.1	19.7	0.3	3.3	4.0	2.0	38.0	95.8	0.4	19.6	0.1	1.4	173.8
GRHL3	"SOM, TFCP2L4"	ENSG00000158055	"Grainyhead like transcription factor 3"	Q8TE85	1	24319357-24364482	"Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 121.8;skin 1: 52.0;vagina: 48.1"	"Group enriched"	"Detected in some"	5	"Squamous epithelial cells: 113.5;Suprabasal keratinocytes: 99.3;Urothelial cells: 78.4"	"Group enriched"	"Detected in many"	4	"cervical cancer: 13.3;head and neck cancer: 16.1;urothelial cancer: 28.9"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 46.1;HaCaT: 36.6;MCF7: 58.5;OE19: 21.2;RT4: 64.8;SuSa: 33.3"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA059960	Enhanced		Approved	Nucleoplasm	"Intracellular and membrane"	NA	NA			Nucleoplasm		"HPA059960: AB_2684180"	"unprognostic (8.99e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.95e-2)"	"unprognostic (7.83e-3)"	"unprognostic (7.58e-3)"	"unprognostic (6.28e-3)"	"unprognostic (1.20e-1)"	"unprognostic (6.34e-2)"	"unprognostic (9.01e-3)"	"unprognostic (4.03e-2)"	"unprognostic (1.24e-1)"	"unprognostic (7.36e-2)"	"unprognostic (8.59e-4)"	"unprognostic (9.79e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.97e-3)"	"unprognostic (7.42e-2)"	0.2	0.1	0.5	0.3	0.5	0.1	1.9	1.4	2.1	11.1	0.1	0.1	0.6	0.1	1.6	121.8	0.6	0.7	0.0	0.4	1.2	0.2	0.3	0.1	0.0	5.2	2.1	0.0	0.0	0.2	0.9	0.2	1.4	5.0	1.5	0.3	0.1	16.8	1.6	0.1	52.0	0.3	0.0	2.2	0.0	0.5	2.4	1.1	1.0	0.0	0.0	25.3	35.0	48.1	1.8	1.2	2.7	1.0	0.0	0.0	0.0	46.1	0.0	0.0	0.3	0.0	0.0	0.5	0.2	0.0	0.0	0.0	36.6	0.1	3.3	0.0	1.2	0.6	0.0	0.3	0.0	0.0	0.0	0.1	0.0	14.2	0.2	2.7	0.0	0.0	0.0	0.2	0.1	0.0	58.5	0.0	0.2	2.4	21.2	0.0	0.0	0.0	0.2	4.6	64.8	0.3	0.0	0.2	6.3	0.0	33.3	4.2	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.5	1.4	2.1	0.4	1.2	5.2	2.1	0.0	5.0	2.2	1.1	1.8	0.0	0.0	0.6	0.0	0.0	14.4	13.2	5.2	8.6	0.0	1.1	0.3	0.5	0.0	6.4	1.8	0.0	4.1	0.0	0.9	0.0	0.4	0.5	3.8	0.1	0.3	0.0	0.0	0.1	0.0	0.8	0.3	0.0	1.3	0.0	0.0	0.0	0.3	0.2	0.0	0.1	0.1	2.0	0.3	2.1	0.3	0.0	0.3	12.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	11.1	0.2	0.0	3.3	0.0	0.0	0.0	0.3	2.6	0.0	113.5	99.3	18.5	0.0	0.0	0.1	78.4
HCAR3	"GPR109B, HCA3, HM74"	ENSG00000255398	"Hydroxycarboxylic acid receptor 3"	P49019	12	122714756-122716811	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 27.6;esophagus: 16.9;lymphoid tissue: 19.8"	"Cell type enhanced"	"Detected in many"		"Basal keratinocytes: 94.4;Basal prostatic cells: 81.1;Basal respiratory cells: 57.3;Basal squamous epithelial cells: 159.4;Langerhans cells: 57.4;Squamous epithelial cells: 66.9;Suprabasal keratinocytes: 106.3;Urothelial cells: 66.1"	"Group enriched"	"Detected in some"	4	"cervical cancer: 2.1;head and neck cancer: 2.5;lung cancer: 1.0;urothelial cancer: 1.9"	"Region enriched"	"Detected in some"	4	"cerebral cortex: 4.2"	"Group enriched"	"Detected in many"	6	"basophil: 58.6;neutrophil: 177.2;non-classical monocyte: 84.4"	"Group enriched"	"Detected in many"	50	"granulocytes: 177.2;monocytes: 84.4"	"Cell line enriched"	"Detected in some"	4	"RT4: 37.1"									HPA028660	Approved		Approved	"Cell Junctions"		NA	NA			"Cell Junctions"		"HPA028660: AB_10602139"	"unprognostic (2.32e-1)"	"unprognostic (5.82e-2)"	"unprognostic (8.23e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.17e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.64e-3)"	"unprognostic (1.60e-1)"	"unprognostic (6.29e-2)"	"unprognostic (9.87e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.80e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.30e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.16e-1)"	"unprognostic (9.28e-2)"	5.7	0.1	0.0	9.2	0.0	27.6	2.3	0.0	4.2	1.4	0.3	0.5	0.2	0.0	0.5	16.9	0.8	0.7	0.5	0.1	0.0	0.9	1.8	8.3	0.4	0.1	0.1	0.0	0.1	0.0	3.4	0.2	1.9	1.0	1.5	0.1	0.1	3.5	2.7	0.1	15.0	0.2	0.2	0.0	19.8	0.4	0.1	0.1	4.0	0.4	1.1	7.8	7.2	4.4	0.2	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	9.2	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.2	0.0	0.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	37.1	0.2	0.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.4	0.0	0.0	0.0	0.1	58.6	2.2	0.8	0.0	16.7	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.1	177.2	0.0	84.4	0.0	0.0	2.9	0.0	0.0	0.0	4.2	0.1	0.0	0.1	0.1	0.0	1.0	0.0	0.1	0.2	0.1	3.2	6.7	0.0	0.7	94.4	81.1	57.3	159.4	0.2	0.7	0.3	0.0	0.0	24.6	0.0	0.0	1.3	0.2	0.0	0.0	0.0	0.7	0.0	0.0	1.0	0.0	0.0	0.0	0.0	21.5	1.4	0.0	0.1	3.8	0.0	0.0	0.1	6.0	0.0	0.0	0.0	12.2	10.6	57.4	0.2	0.0	20.1	8.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	14.7	0.0	0.1	2.2	0.2	0.0	0.0	1.4	0.1	0.0	66.9	106.3	13.8	1.0	0.0	0.0	66.1
HSD17B2	"HSD17, SDR9C2"	ENSG00000086696	"Hydroxysteroid 17-beta dehydrogenase 2"	P37059	16	82035004-82098534	"Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis"	Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"intestine: 432.9;liver: 219.6;placenta: 384.9"	"Cell type enhanced"	"Detected in many"		"Cholangiocytes: 155.8;Distal enterocytes: 203.4;Hepatocytes: 121.9;Paneth cells: 284.2;Proximal enterocytes: 390.7"	"Group enriched"	"Detected in many"	4	"liver cancer: 10.9;pancreatic cancer: 6.5;stomach cancer: 4.2;urothelial cancer: 5.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 57.9;Hep G2: 47.5;hTERT-HME1: 27.1;OE19: 87.1;RT4: 96.8;TIME: 54.0"	"Group enriched"	"Detected in some"	5	"midbrain: 2.2;pons and medulla: 3.4"	"Not detected"	"Not detected"			"HPA021826, HPA050235"	Enhanced		Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA021826: AB_10961148, HPA050235: AB_2681059"	"unprognostic (1.50e-1)"	"unprognostic (2.53e-2)"	"unprognostic (1.42e-1)"	"unprognostic (6.48e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.77e-1)"	"unprognostic (4.29e-2)"	"unprognostic (2.60e-1)"	"unprognostic (7.35e-2)"	"unprognostic (6.05e-3)"	"unprognostic (4.98e-2)"	"unprognostic (7.35e-2)"	"unprognostic (6.31e-4)"	"unprognostic (5.39e-2)"	"unprognostic (1.14e-1)"	"unprognostic (4.30e-2)"	"prognostic favorable (3.83e-4)"	0.9	0.0	0.4	4.3	0.3	0.7	26.6	0.9	0.5	4.3	0.2	75.5	432.9	1.2	0.1	9.7	0.1	21.3	0.2	0.3	0.2	5.0	219.6	2.3	0.3	0.1	0.1	0.2	0.3	23.4	0.0	1.2	384.9	0.5	2.0	57.4	17.5	22.3	0.2	0.1	3.1	190.1	2.4	0.0	0.2	20.3	0.3	0.1	0.4	0.1	0.0	3.4	79.3	1.4	0.5	0.4	0.1	0.4	0.0	0.0	0.7	0.7	0.2	57.9	0.0	0.0	10.9	1.7	0.1	11.4	0.0	0.1	0.4	0.0	2.4	0.0	0.1	0.1	0.3	0.3	47.5	0.4	0.3	0.3	0.0	3.1	0.0	27.1	0.6	0.9	0.1	0.1	0.4	8.6	0.1	0.0	0.9	0.2	87.1	21.4	0.1	0.2	1.3	1.0	96.8	0.4	1.5	0.0	2.7	0.2	0.0	0.1	0.1	54.0	0.6	0.5	0.3	0.0	0.2	0.2	0.3	0.0	0.2	0.0	0.3	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.5	0.1	0.1	0.2	0.0	0.0	0.4	0.3	0.9	0.5	0.3	0.2	0.1	0.1	0.2	0.5	0.0	0.1	0.5	1.0	3.2	3.9	0.3	0.7	0.4	2.7	16.4	2.2	0.5	45.7	12.3	0.6	155.8	21.4	0.0	0.0	2.7	0.3	203.4	0.0	73.6	0.5	5.9	5.4	21.3	3.0	2.7	0.1	6.0	1.8	38.3	15.3	41.3	0.0	0.0	2.5	121.9	3.5	0.0	0.1	26.3	6.1	3.1	0.0	0.9	0.0	0.4	1.8	0.0	0.0	45.1	0.0	0.0	0.1	20.1	284.2	0.0	0.1	2.7	390.7	1.4	5.6	0.7	0.0	0.4	2.0	0.0	0.1	0.8	1.1	6.4	0.7	0.0	47.1	14.8
HSD3B1	"HSD3B, HSDB3, SDR11E1"	ENSG00000203857	"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1"	P14060	1	119507198-119515054	"Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Steroid metabolism, Steroidogenesis"	"Isomerase, Multifunctional enzyme, Oxidoreductase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"placenta: 78.4"	"Group enriched"	"Detected in some"	8	"Extravillous trophoblasts: 140.8;Syncytiotrophoblasts: 502.0"	"Cancer enriched"	"Detected in single"	4	"urothelial cancer: 1.6"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"CACO-2: 64.1;SuSa: 26.5"									"HPA043261, HPA043264, HPA044028"	Supported		Approved	"Nucleoli,Endoplasmic reticulum,Cytokinetic bridge"		Yes	NA			"Nucleoli, Endoplasmic reticulum"	"Cytokinetic bridge"	"HPA043261: AB_2630368, HPA043264: AB_2678398, HPA044028: AB_2678781"			"unprognostic (1.53e-1)"				"unprognostic (7.11e-2)"					"unprognostic (1.15e-1)"		"unprognostic (1.04e-1)"			"prognostic favorable (4.59e-5)"	0.1	1.2	0.3	0.0	1.0	0.0	1.5	0.0	1.3	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.3	0.4	0.0	1.2	0.0	0.0	0.4	0.0	0.8	0.0	1.2	0.0	0.0	78.4	0.2	0.1	0.5	0.0	0.1	0.0	0.2	2.5	8.7	0.5	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	1.7	0.2	0.0	0.0	0.0	64.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	7.0	0.7	0.8	26.5	0.0	0.0	0.2	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.0	0.0	1.3	0.3	0.4	0.4	0.0	0.8	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	23.6	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	140.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	37.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	502.0	0.0	0.1	1.0	0.0
IL9R	CD129	ENSG00000124334	"Interleukin 9 receptor"	Q01113	X	155997581-156010817	"CD markers, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 3.5;urinary bladder: 4.5"	"Group enriched"	"Detected in some"	5	"granulocytes: 4.5;T-cells: 2.7"	"Group enriched"	"Detected in some"	4	"cervical cancer: 0.7;urothelial cancer: 1.4"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in some"		"eosinophil: 3.4"	"Group enriched"	"Detected in many"	23	"B-cells: 1.8;granulocytes: 3.4;T-cells: 1.4"	"Cell line enriched"	"Detected in some"	10	"HMC-1: 247.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA063240, HPA064557"	Approved				"Intracellular and membrane"	NA	NA					"HPA063240: AB_2732700, HPA064557: AB_2732716"	"unprognostic (1.07e-2)"	"unprognostic (3.27e-3)"	"unprognostic (9.52e-3)"	"unprognostic (4.13e-2)"	"unprognostic (7.35e-2)"	"unprognostic (3.26e-4)"	"unprognostic (8.94e-2)"	"unprognostic (3.56e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.90e-2)"	"unprognostic (2.04e-1)"	"unprognostic (3.98e-8)"	"unprognostic (2.06e-1)"	"unprognostic (2.38e-1)"	"unprognostic (4.07e-1)"	"prognostic favorable (1.90e-7)"	0.1	0.0	0.2	1.0	0.2	0.5	0.2	0.1	0.2	0.2	0.0	0.4	0.6	0.2	0.1	0.5	0.3	0.8	0.0	0.2	0.1	0.1	0.2	1.1	2.4	0.1	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.3	0.3	0.9	0.1	0.4	0.1	0.1	0.5	1.7	0.1	0.1	1.7	0.7	0.0	0.1	3.5	0.3	0.0	2.2	4.5	0.2	0.2	0.0	0.3	0.0	0.3	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.2	0.5	0.3	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.3	0.3	23.8	0.0	0.0	0.0	0.5	247.8	0.0	0.2	0.0	0.0	0.0	0.0	5.6	3.7	0.8	0.0	1.1	9.5	4.9	0.0	0.1	0.0	0.6	0.1	0.0	0.0	19.2	0.2	0.1	0.0	0.4	0.2	0.0	0.3	0.4	0.0	0.1	0.6	0.1	0.1	1.2	0.6	0.9	0.2	0.3	0.1	0.0	0.0	3.4	0.0	0.0	0.0	0.8	0.3	0.6	0.0	1.8	0.0	0.0	0.9	0.0	0.0	0.0	1.4	0.2	0.2	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.2	0.3	0.1	0.1	0.2	0.0	0.0	0.6	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	4.5	0.1	0.4	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.1
INA	"NEF5, NF-66"	ENSG00000148798	"Internexin neuronal intermediate filament protein alpha"	Q16352	10	103277138-103290346	"Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 304.2;retina: 98.1"	"Group enriched"	"Detected in some"	4	"Bipolar cells: 62.4;Cone photoreceptor cells: 22.9;Early spermatids: 41.4;Excitatory neurons: 28.7;Horizontal cells: 45.4;Inhibitory neurons: 39.8;Late spermatids: 26.5;Rod photoreceptor cells: 48.2;Spermatocytes: 20.3"	"Group enriched"	"Detected in many"	4	"glioma: 4.7;testis cancer: 18.2;urothelial cancer: 14.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 53.0;SCLC-21H: 103.3;SH-SY5Y: 58.7;SiHa: 71.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002059, HPA007572, HPA008057"	Enhanced	Supported	Approved	"Intermediate filaments,Cytosol"		NA	NA			"Intermediate filaments"	Cytosol	"CAB002059: AB_442031, HPA007572: , HPA008057: AB_1851833"	"unprognostic (1.77e-1)"	"unprognostic (2.50e-2)"	"unprognostic (9.54e-2)"	"unprognostic (5.49e-3)"	"unprognostic (3.91e-1)"	"unprognostic (1.45e-3)"	"unprognostic (1.31e-1)"	"unprognostic (2.29e-2)"	"unprognostic (2.08e-2)"	"unprognostic (1.98e-1)"	"unprognostic (8.09e-3)"	"unprognostic (3.07e-2)"	"unprognostic (1.78e-3)"	"unprognostic (1.66e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.07e-1)"	0.2	12.3	42.4	1.2	44.2	0.0	0.0	70.6	166.4	0.0	0.5	2.6	0.6	0.0	0.0	0.6	0.0	0.1	0.0	36.8	83.7	0.0	0.0	0.2	0.1	106.6	80.0	48.1	0.0	2.0	0.4	41.7	0.2	112.3	0.2	1.2	98.1	0.1	0.0	0.0	0.8	1.1	0.8	31.3	0.0	1.1	2.7	115.5	1.7	0.1	0.0	0.2	1.1	0.6	304.2	0.0	25.4	11.8	0.0	0.1	0.0	19.3	13.3	3.3	3.1	0.3	0.0	0.0	0.0	5.4	0.9	1.5	1.9	11.0	0.0	0.7	24.6	4.9	0.0	6.8	0.1	0.2	0.0	0.0	0.0	0.1	1.9	0.0	0.0	0.0	2.7	0.4	0.0	0.0	0.0	13.6	0.0	53.0	0.0	0.0	0.0	0.0	0.0	8.5	0.0	103.3	58.7	71.6	0.1	0.0	2.7	0.0	0.7	0.1	0.0	0.1	0.0	0.0	3.4	3.1	0.0	0.1	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	42.4	44.2	70.6	166.4	36.8	83.7	106.6	80.0	48.1	112.3	31.3	115.5	304.2	0.1	0.0	0.0	6.2	0.0	0.3	0.1	0.0	0.0	62.4	0.0	0.4	0.5	0.0	0.0	0.0	22.9	0.2	0.0	0.1	0.0	0.1	41.4	0.4	0.2	0.9	7.8	0.0	28.7	0.0	0.2	0.1	0.0	0.8	0.0	0.1	0.0	0.0	0.5	45.4	39.8	0.0	0.0	0.0	0.0	26.5	0.3	0.1	0.0	2.8	0.0	8.7	0.0	1.0	5.4	0.4	0.0	0.4	0.0	0.5	0.0	0.0	0.0	48.2	0.0	0.0	0.6	20.3	4.1	1.0	0.4	0.1	0.1	0.1	0.0	0.6
KLHDC7B	MGC16635	ENSG00000130487	"Kelch domain containing 7B"	Q96G42	22	50545899-50551023	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 5.2;parathyroid gland: 13.8"	"Cell type enhanced"	"Detected in some"		"B-cells: 5.2;Collecting duct cells: 5.5;granulocytes: 5.7;Kupffer cells: 5.2;monocytes: 21.1;NK-cells: 10.3;T-cells: 5.7"	"Group enriched"	"Detected in many"	4	"cervical cancer: 42.3;head and neck cancer: 11.4;urothelial cancer: 40.7"	"Not detected"	"Not detected"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	4	"HMC-1: 97.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA000518, HPA076540"	Uncertain		Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA000518: AB_1079213, HPA076540: "	"prognostic favorable (1.30e-4)"	"unprognostic (3.18e-2)"	"unprognostic (2.74e-2)"	"unprognostic (2.21e-1)"	"unprognostic (3.96e-2)"	"unprognostic (6.04e-3)"	"unprognostic (3.91e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.07e-2)"	"unprognostic (7.13e-2)"	"unprognostic (3.33e-3)"	"unprognostic (2.48e-1)"	"unprognostic (2.09e-3)"	"unprognostic (2.89e-1)"	"unprognostic (4.69e-2)"	"unprognostic (3.49e-1)"	"unprognostic (1.02e-1)"	0.2	0.2	0.1	2.1	0.2	1.1	0.3	0.1	0.1	0.5	0.1	0.3	0.4	0.2	0.3	0.4	0.1	0.3	0.0	0.2	0.3	3.6	0.4	0.7	2.3	0.3	0.2	0.1	0.0	0.1	13.8	1.0	0.1	0.2	0.4	0.1	0.0	1.3	0.2	0.0	0.3	1.1	0.1	0.2	2.7	0.5	0.2	0.3	5.2	2.0	0.0	1.3	1.6	0.2	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.2	0.0	0.1	0.0	0.8	0.0	0.8	0.1	0.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	22.0	0.2	97.7	0.1	1.2	0.0	0.2	0.1	0.0	0.0	0.0	11.6	0.0	0.0	0.0	8.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.7	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.8	0.3	0.0	0.1	1.1	1.1	0.1	2.0	1.9	1.4	1.9	2.1	2.6	0.9	1.3	2.3	2.0	0.2	0.7	1.4	0.3	2.0	1.5	0.1	0.2	0.1	0.1	0.2	0.3	0.3	0.2	0.1	0.2	0.2	0.3	0.3	0.0	0.0	0.6	0.0	5.2	0.1	0.0	1.6	0.0	0.0	3.0	1.4	0.5	0.0	1.6	5.5	0.0	0.0	2.5	0.1	0.0	0.8	0.0	0.2	0.0	0.1	0.0	0.4	0.0	0.7	0.1	0.2	0.5	0.3	5.7	0.0	0.0	0.1	1.6	0.0	0.0	0.0	0.0	5.2	1.2	0.0	0.0	2.7	0.0	0.0	21.1	0.0	10.3	0.0	0.0	1.3	0.0	0.0	2.8	0.1	0.0	0.3	1.6	0.0	0.0	0.1	0.3	0.1	0.1	0.0	0.0	0.0	5.7	0.0	0.0	0.2
KRT24	"FLJ20261, MGC138169, MGC138173"	ENSG00000167916	"Keratin 24"	Q2M2I5	17	40697991-40703752	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"esophagus: 179.4;lymphoid tissue: 76.9"	"Cell type enhanced"	"Detected in some"		"Cytotrophoblasts: 6.0;Fibroblasts: 4.6;Leydig cells: 3.1;Syncytiotrophoblasts: 4.0"	"Group enriched"	"Detected in some"	4	"cervical cancer: 9.6;head and neck cancer: 15.0;urothelial cancer: 6.1"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	14	"SK-BR-3: 7.0"	"Region enriched"	"Detected in single"	10	"cerebellum: 1.0"	"Low region specificity"	"Detected in some"			HPA022978	Uncertain		Approved	"Intermediate filaments,Cytosol"		No	NA		300000000	"Intermediate filaments, Cytosol"		"HPA022978: AB_1852230"	"unprognostic (2.74e-2)"	"unprognostic (1.05e-2)"		"unprognostic (1.45e-1)"		"unprognostic (3.16e-2)"		"unprognostic (2.47e-1)"			"unprognostic (3.75e-1)"	"unprognostic (2.74e-1)"		"unprognostic (2.95e-1)"			"unprognostic (3.37e-2)"	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.5	0.0	8.0	0.0	0.1	16.8	179.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	7.5	0.0	0.0	5.9	0.2	2.3	1.6	0.0	0.0	0.3	0.5	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	76.9	2.6	13.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.0	0.0	0.0	0.0	1.2	4.6	0.0	0.7	0.0	0.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	3.1	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.1	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.3	0.0	4.0	0.0	0.0	0.0	0.0
LRRC38		ENSG00000162494	"Leucine rich repeat containing 38"	Q5VT99	1	13474973-13514003	"Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	9	"adrenal gland: 19.7;skeletal muscle: 44.9;tongue: 14.8"	"Group enriched"	"Detected in some"	6	"Bipolar cells: 19.3;Inhibitory neurons: 10.6"	"Group enriched"	"Detected in some"	4	"head and neck cancer: 0.5;lung cancer: 0.8;testis cancer: 0.6;urothelial cancer: 0.6"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 4.2;MOLT-4: 16.7;PC-3: 11.5;U-138 MG: 18.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			HPA038778	Approved					NA	NA					"HPA038778: AB_10673294"	"unprognostic (5.13e-2)"	"unprognostic (3.98e-1)"	"unprognostic (3.12e-1)"	"unprognostic (3.88e-1)"	"unprognostic (5.49e-2)"	"unprognostic (1.45e-3)"		"unprognostic (1.72e-1)"		"unprognostic (2.70e-1)"	"unprognostic (9.70e-2)"	"unprognostic (4.23e-1)"		"unprognostic (7.81e-2)"	"unprognostic (4.47e-2)"		"unprognostic (1.05e-1)"	0.2	19.7	0.4	0.0	0.4	0.1	0.6	2.9	1.2	0.1	0.7	0.0	0.0	0.1	0.2	0.3	0.1	0.1	1.2	0.4	0.6	0.1	0.0	0.0	0.0	1.0	2.9	0.4	0.1	0.0	0.0	0.0	0.5	0.8	0.2	0.0	3.0	0.6	0.0	44.9	1.0	0.0	0.0	0.6	0.0	0.1	0.4	0.4	1.3	0.0	14.8	0.0	0.3	0.7	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	16.7	0.0	0.0	0.0	11.5	0.1	0.1	1.8	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.3	18.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.4	2.9	1.2	0.4	0.6	1.0	2.9	0.4	0.8	0.6	0.4	0.7	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	19.3	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.0	0.3	0.0	0.0	0.9	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	10.6	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.0	0.0	0.5	0.0	0.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	1.5	0.1	0.7	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1
NCCRP1	"FBXO50, LOC342897, NCCRP-1"	ENSG00000188505	"NCCRP1, F-box associated domain containing"	Q6ZVX7	19	39196964-39201884	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"esophagus: 457.0;lymphoid tissue: 126.0;skin 1: 257.3;vagina: 183.2"	"Cell type enriched"	"Detected in some"	12	"monocytes: 563.9"	"Group enriched"	"Detected in many"	4	"cervical cancer: 42.8;head and neck cancer: 48.5;melanoma: 28.3;urothelial cancer: 33.9"	"Low region specificity"	"Detected in many"			"Immune cell enhanced"	"Detected in single"		"basophil: 1.1"	"Lineage enriched"	"Detected in single"	6	"granulocytes: 1.1"	"Cell line enriched"	"Detected in some"	10	"SK-BR-3: 30.8"	"Region enhanced"	"Detected in single"		"olfactory bulb: 1.6"	"Low region specificity"	"Detected in some"			HPA052812	Approved					NA	NA		400000			"HPA052812: AB_2681960"	"unprognostic (3.56e-3)"	"unprognostic (3.69e-2)"	"unprognostic (2.08e-1)"	"prognostic unfavorable (1.01e-4)"	"unprognostic (4.59e-3)"	"unprognostic (3.73e-3)"	"unprognostic (2.78e-1)"	"unprognostic (3.37e-3)"	"unprognostic (1.00e-1)"	"unprognostic (3.53e-3)"	"unprognostic (2.04e-2)"	"unprognostic (1.90e-1)"	"unprognostic (6.37e-6)"	"unprognostic (2.12e-1)"	"unprognostic (3.00e-1)"	"unprognostic (2.13e-1)"	"unprognostic (1.57e-1)"	0.3	0.2	1.8	2.1	1.1	1.0	6.3	1.8	1.9	46.5	0.0	0.4	2.0	0.6	0.8	457.0	1.1	0.8	0.4	1.2	1.0	2.8	0.2	0.4	2.8	1.2	1.1	0.8	0.4	8.9	1.4	0.4	1.1	1.6	1.4	1.9	1.7	54.4	1.2	0.9	257.3	0.7	0.5	0.9	1.4	0.5	0.5	1.1	4.2	0.6	0.0	126.0	5.2	183.2	1.6	0.2	0.2	1.1	0.2	0.1	0.7	2.4	0.1	0.0	0.1	0.2	0.5	0.5	0.7	2.3	0.4	0.2	1.0	1.7	0.7	0.5	0.0	0.4	0.2	0.9	0.1	0.2	0.5	0.3	0.5	0.5	0.1	0.3	0.3	0.3	0.5	0.4	0.2	0.3	0.1	0.2	0.2	0.7	0.2	0.2	0.2	0.4	0.4	0.1	0.6	0.6	1.0	2.9	30.8	0.2	0.9	0.4	0.9	0.2	0.2	0.2	0.2	0.5	0.2	0.2	0.6	0.6	0.2	0.5	1.1	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.1	0.1	0.1	0.0	0.0	1.8	1.1	1.8	1.9	1.2	1.0	1.2	1.1	0.8	1.6	0.9	1.1	1.6	0.0	0.0	0.0	0.0	0.0	0.6	1.6	8.5	0.0	0.3	4.7	2.4	0.3	0.0	30.8	3.7	0.0	0.4	0.2	0.1	0.0	2.7	0.0	0.7	0.4	0.2	0.0	0.0	0.0	2.3	3.1	1.0	0.0	2.5	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	6.1	0.0	4.7	0.2	0.0	0.7	1.8	0.0	563.9	0.3	0.0	0.0	0.0	4.2	0.7	0.0	1.2	1.1	0.0	0.1	1.6	0.0	0.0	0.1	2.0	0.1	0.5	7.3	7.1	11.1	0.2	0.1	0.0	46.4
PADI3	PDI3	ENSG00000142619	"Peptidyl arginine deiminase 3"	Q9ULW8	1	17249098-17284233	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		Hydrolase	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"esophagus: 17.2;urinary bladder: 25.8"	"Cell type enhanced"	"Detected in some"		"Collecting duct cells: 1.8;Ionocytes: 6.1;Squamous epithelial cells: 1.1;Urothelial cells: 7.9"	"Cancer enriched"	"Detected in many"	4	"urothelial cancer: 48.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 14.0;RT4: 17.4;T-47d: 12.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA043739	Uncertain		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"HPA043739: AB_10959466"	"unprognostic (4.47e-2)"	"unprognostic (9.32e-2)"	"unprognostic (1.50e-1)"	"prognostic unfavorable (3.22e-4)"	"unprognostic (1.05e-3)"	"unprognostic (6.66e-2)"	"unprognostic (3.10e-3)"	"unprognostic (5.88e-2)"	"unprognostic (2.06e-4)"	"unprognostic (1.03e-1)"	"unprognostic (3.47e-4)"	"unprognostic (1.76e-1)"	"prognostic unfavorable (1.55e-11)"	"unprognostic (2.40e-2)"	"unprognostic (4.73e-3)"		"unprognostic (2.64e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5	17.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.9	3.5	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	25.8	3.6	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	14.0	0.0	1.4	0.3	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	1.7	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	17.4	0.0	0.0	0.0	2.5	0.1	0.1	12.8	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	3.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.2	1.8	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.0	0.0	0.2	0.0	7.9
PLA2G4D	cPLA2delta	ENSG00000159337	"Phospholipase A2 group IVD"	Q86XP0	15	42067009-42094562	"Enzymes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"prostate: 19.3;skin 1: 16.1;vagina: 22.7"	"Cell type enhanced"	"Detected in some"		"Cone photoreceptor cells: 2.1;Glandular and luminal cells: 1.1;Ionocytes: 2.0;Prostatic glandular cells: 3.0;Rod photoreceptor cells: 1.0;Suprabasal keratinocytes: 3.4"	"Group enriched"	"Detected in some"	4	"cervical cancer: 1.1;head and neck cancer: 2.0;melanoma: 1.8;prostate cancer: 1.3;urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	13	"RPMI-8226: 15.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA074206			Approved	"Plasma membrane,Cytosol"		NA	NA			Cytosol	"Plasma membrane"	"HPA074206: "	"unprognostic (1.16e-1)"	"unprognostic (1.10e-2)"	"unprognostic (2.91e-2)"	"unprognostic (9.16e-3)"	"unprognostic (9.33e-3)"	"unprognostic (4.35e-2)"		"unprognostic (5.39e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.28e-2)"	"unprognostic (2.75e-1)"	"unprognostic (2.64e-7)"	"unprognostic (2.54e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.47e-2)"	"unprognostic (4.32e-2)"	0.0	0.2	0.1	0.0	0.1	0.0	0.3	0.0	0.3	2.5	0.0	0.0	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.7	0.0	0.0	19.3	0.0	0.2	0.8	0.0	0.0	16.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.4	22.7	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	0.0	0.0	15.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.5	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	2.1	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.0	0.1	0.1	0.0	1.0	0.0	0.0	0.1	0.0	0.4	0.0	3.4	0.0	0.0	0.0	0.1	0.4
POU3F1	"OCT6, OTF6, SCIP"	ENSG00000185668	"POU class 3 homeobox 1"	Q03052	1	38043829-38046793	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"brain: 10.3;skin 1: 32.9"	"Cell type enhanced"	"Detected in many"		"Basal keratinocytes: 27.3;Breast myoepithelial cells: 39.1;Cone photoreceptor cells: 22.9;Suprabasal keratinocytes: 55.8"	"Group enriched"	"Detected in many"	4	"cervical cancer: 1.8;head and neck cancer: 4.4;melanoma: 4.8;testis cancer: 1.3;urothelial cancer: 2.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 24.1;HDLM-2: 23.9;NTERA-2: 7.5;SCLC-21H: 5.7;SK-MEL-30: 28.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA055980, HPA073824"			Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA055980: AB_2682995, HPA073824: AB_2686635"	"unprognostic (9.99e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.43e-2)"	"unprognostic (7.46e-3)"	"unprognostic (1.96e-2)"	"unprognostic (1.33e-2)"	"unprognostic (2.56e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.07e-2)"	"unprognostic (4.40e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.61e-4)"	"unprognostic (2.79e-2)"	"unprognostic (1.97e-1)"	"unprognostic (3.61e-2)"	"unprognostic (2.67e-3)"	0.1	1.5	1.5	0.2	5.7	0.0	0.3	1.0	10.3	0.1	0.2	0.0	0.0	0.0	0.1	2.6	0.0	0.0	0.0	9.4	2.2	0.0	0.0	0.0	1.0	2.0	2.4	2.7	0.1	0.1	0.2	0.0	0.0	3.4	0.2	0.0	0.3	0.3	0.1	0.9	32.9	0.0	0.0	0.5	0.1	0.1	0.8	1.9	0.3	0.0	0.5	1.0	0.8	0.3	2.5	0.0	0.0	24.1	0.4	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.3	0.1	0.0	23.9	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0.1	0.0	1.4	5.7	0.0	0.1	0.0	28.9	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	5.7	1.0	10.3	9.4	2.2	2.0	2.4	2.7	3.4	0.5	1.9	2.5	12.2	0.0	0.0	2.3	8.3	27.3	2.9	1.4	20.5	7.8	9.9	39.1	5.2	0.0	0.2	0.0	22.9	0.2	13.4	13.8	0.0	0.0	0.2	0.5	2.3	1.9	1.8	2.7	6.4	0.0	0.1	5.2	7.1	1.4	0.0	0.5	0.0	0.0	0.3	1.7	1.1	11.0	0.0	0.0	1.3	0.0	0.3	4.3	7.2	1.0	0.0	14.0	0.0	0.5	0.2	0.0	0.1	0.0	2.7	0.7	0.3	0.1	0.0	21.1	0.0	8.5	7.2	0.2	4.1	20.2	55.8	0.1	5.2	8.3	5.7	3.2
PRSS56		ENSG00000237412	"Serine protease 56"	P0CW18	2	232520388-232525716	"Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins"		"Hydrolase, Protease, Serine protease"	"Disease variant, Microphthalmia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"brain: 3.1;retina: 5.3;skeletal muscle: 9.8"	"Group enriched"	"Detected in some"	10	"Early spermatids: 29.0;Muller glia cells: 45.8"	"Group enriched"	"Detected in many"	4	"cervical cancer: 1.2;colorectal cancer: 2.5;endometrial cancer: 1.4;melanoma: 2.1;urothelial cancer: 4.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	5	"Daudi: 1.0"	"Group enriched"	"Detected in some"	10	"basal ganglia: 1.8;olfactory bulb: 4.2"	"Region enhanced"	"Detected in many"		"olfactory bulb: 14.9"							NA	NA								"unprognostic (3.26e-1)"	"unprognostic (1.98e-2)"	"unprognostic (1.31e-1)"	"unprognostic (3.73e-3)"			"unprognostic (2.28e-1)"	"unprognostic (7.15e-2)"				"unprognostic (4.64e-2)"	"unprognostic (1.20e-1)"			0.0	0.0	1.0	0.0	0.8	0.0	0.0	1.6	3.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.4	0.0	0.0	0.0	0.0	2.8	1.2	0.2	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	5.3	0.0	0.0	9.8	0.0	0.0	0.0	1.0	0.0	0.0	0.8	1.2	0.0	0.0	0.5	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.8	1.6	3.1	0.1	2.4	2.8	1.2	0.2	3.1	1.0	1.2	1.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.0	1.4	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.4	2.2	0.0	0.0	0.0	0.0	0.0	45.8	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.1	0.0	3.6	0.0	0.4	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0
RAET1G	ULBP5	ENSG00000203722	"Retinoic acid early transcript 1G"	Q6H3X3	6	149916878-149923121	"Predicted membrane proteins, Predicted secreted proteins"	"Host-virus interaction, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 8.5;esophagus: 15.2"	"Cell type enhanced"	"Detected in some"		"Basal respiratory cells: 42.9;Club cells: 14.8;Ionocytes: 12.2;Respiratory ciliated cells: 23.3;Squamous epithelial cells: 8.9;Urothelial cells: 8.1"	"Group enriched"	"Detected in many"	4	"cervical cancer: 4.5;head and neck cancer: 4.7;lung cancer: 1.2;thyroid cancer: 1.5;urothelial cancer: 4.2"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HeLa: 29.5;hTCEpi: 22.6;SiHa: 11.9;U-87 MG: 9.3"									"HPA062673, HPA066741"			Supported	"Vesicles,Plasma membrane"	"Secreted - unknown location"	NA	NA			"Vesicles, Plasma membrane"		"HPA062673: , HPA066741: "	"unprognostic (4.46e-3)"	"unprognostic (4.92e-2)"	"unprognostic (1.95e-1)"	"unprognostic (1.21e-1)"	"unprognostic (2.87e-3)"	"unprognostic (1.49e-1)"	"unprognostic (4.61e-3)"	"prognostic unfavorable (5.35e-4)"	"unprognostic (3.05e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.38e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.48e-1)"	"unprognostic (8.85e-2)"	"unprognostic (9.11e-2)"	1.5	8.5	0.6	0.4	0.6	0.0	0.6	0.1	0.7	2.3	0.0	0.2	0.1	0.3	0.7	15.2	0.6	0.7	0.4	0.5	0.3	0.5	0.1	0.5	0.1	1.0	0.6	0.4	0.7	0.1	0.2	0.3	0.1	0.6	0.7	0.1	0.1	3.7	1.0	0.2	2.7	0.2	0.6	0.1	0.1	0.4	0.3	0.6	0.0	0.5	0.1	1.1	1.8	6.1	0.3	1.0	1.4	0.0	1.7	2.3	1.7	0.0	0.8	3.0	1.3	1.9	0.0	1.5	0.0	0.6	1.7	1.4	2.7	0.9	5.3	1.1	0.3	1.6	0.5	29.5	0.0	0.7	0.0	0.0	3.3	22.6	3.5	1.7	1.5	0.3	0.7	0.3	0.2	0.6	1.3	0.0	0.0	0.0	0.3	2.3	0.0	0.0	0.0	1.0	3.2	0.3	0.3	11.9	0.5	0.0	0.1	0.4	0.4	1.6	0.6	0.5	1.6	0.8	0.0	0.0	0.0	9.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.1	0.7	0.5	0.3	1.0	0.6	0.4	0.6	0.1	0.6	0.3	1.4	0.0	0.0	0.0	0.0	3.1	5.1	42.9	2.8	0.0	0.4	0.4	0.1	1.5	14.8	0.0	0.0	0.0	0.2	0.1	0.0	0.2	0.1	0.4	0.1	1.3	0.0	0.0	0.0	1.3	0.0	1.9	0.0	0.1	0.0	0.0	0.7	0.0	0.1	0.0	0.0	0.0	12.2	0.0	0.7	0.1	0.9	0.0	3.6	0.0	0.0	0.8	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.4	0.0	0.0	23.3	0.0	0.0	0.2	1.1	0.0	0.3	8.9	1.7	0.1	0.3	0.5	0.0	8.1
RASL10A	RRP22	ENSG00000100276	"RAS like family 10 member A"	Q92737	22	29312933-29319679	"Enzymes, Predicted intracellular proteins"		Hydrolase	"Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 28.3"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 17.9;Breast glandular cells: 35.9;Breast myoepithelial cells: 58.3;Excitatory neurons: 35.1;Rod photoreceptor cells: 19.6"	"Group enriched"	"Detected in some"	4	"glioma: 2.5;testis cancer: 3.4;urothelial cancer: 1.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 1.6;NB-4: 2.5;U-2 OS: 1.1;U-266/70: 2.7;U-266/84: 1.0"	"Group enriched"	"Detected in many"	6	"amygdala: 33.7;basal ganglia: 16.7;cerebral cortex: 36.0;hippocampal formation: 26.3;white matter: 15.3"	"Group enriched"	"Detected in many"	4	"cerebral cortex: 35.6;hippocampal formation: 27.8"	HPA056169	Approved					NA	NA					"HPA056169: AB_2683053"	"unprognostic (1.94e-1)"	"unprognostic (2.51e-4)"	"unprognostic (3.78e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.94e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.16e-1)"	"unprognostic (7.99e-2)"	"unprognostic (9.42e-2)"	"unprognostic (1.61e-2)"	"unprognostic (5.00e-4)"	"unprognostic (2.44e-1)"	"unprognostic (7.00e-4)"	"unprognostic (3.12e-1)"	"unprognostic (1.19e-1)"	"unprognostic (6.61e-2)"	"unprognostic (3.61e-3)"	0.8	1.4	28.3	0.3	24.7	0.1	2.1	7.6	27.2	0.3	6.8	0.6	0.3	0.6	0.1	0.4	0.6	0.1	2.8	26.1	13.2	1.2	0.9	1.2	0.1	12.6	13.2	26.9	0.2	0.4	0.1	5.1	0.2	17.0	2.0	0.0	2.6	1.0	0.1	0.7	0.7	1.1	0.0	9.6	1.2	0.5	1.8	14.0	0.1	1.1	0.1	0.1	0.5	0.3	19.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.1	1.6	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.5	0.0	0.4	0.0	2.5	0.6	0.0	0.0	0.0	0.2	0.0	0.1	0.2	0.3	0.0	0.0	0.1	0.0	0.5	0.5	0.2	0.1	0.0	1.1	0.0	0.1	2.7	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.3	24.7	7.6	27.2	26.1	13.2	12.6	13.2	26.9	17.0	9.6	14.0	19.0	3.9	0.0	0.0	17.9	0.4	0.4	0.6	0.0	0.0	6.8	35.9	58.3	1.1	1.5	0.0	0.0	6.2	0.2	1.0	0.7	0.0	0.0	1.3	0.8	0.3	3.1	0.0	0.0	35.1	0.0	4.7	0.5	1.5	1.4	0.0	0.5	7.9	0.5	1.1	0.0	4.4	1.1	0.0	2.6	5.8	0.5	0.3	2.7	0.0	4.7	0.2	3.3	0.0	3.0	3.9	0.1	0.1	0.0	0.3	1.7	0.2	0.1	0.2	19.6	0.0	13.4	0.5	1.5	3.9	0.3	0.6	0.5	0.5	0.6	0.4	0.2
SLC39A2	ZIP2	ENSG00000165794	"Solute carrier family 39 member 2"	Q9NP94	14	20999255-21001871	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport, Zinc transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"esophagus: 18.9;prostate: 12.3;seminal vesicle: 33.5;skin 1: 36.6;vagina: 14.2"	"Cell type enhanced"	"Detected in some"		"Muller glia cells: 22.3;Squamous epithelial cells: 12.0;Suprabasal keratinocytes: 6.0;Urothelial cells: 4.4"	"Group enriched"	"Detected in many"	4	"cervical cancer: 5.1;colorectal cancer: 3.3;head and neck cancer: 6.1;melanoma: 1.9;urothelial cancer: 6.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	71	"HaCaT: 23.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA030489, HPA073231"	Uncertain		Approved	"Plasma membrane,Cytoplasmic bodies"		NA	NA			"Plasma membrane"	"Cytoplasmic bodies"	"HPA030489: AB_10601488, HPA073231: "	"unprognostic (2.76e-2)"	"unprognostic (4.86e-2)"	"unprognostic (9.72e-2)"	"unprognostic (2.37e-1)"	"unprognostic (2.46e-1)"	"unprognostic (2.71e-1)"	"unprognostic (3.42e-1)"	"unprognostic (1.70e-1)"	"unprognostic (4.43e-1)"	"unprognostic (6.20e-3)"	"unprognostic (3.31e-1)"	"unprognostic (2.80e-1)"	"unprognostic (3.62e-2)"	"unprognostic (1.91e-1)"	"unprognostic (5.80e-2)"	"unprognostic (3.71e-1)"	"unprognostic (2.30e-3)"	0.1	0.0	0.2	0.1	0.2	0.0	2.0	0.2	0.3	4.2	0.2	1.9	0.0	0.3	0.1	18.9	0.5	0.4	0.1	0.2	0.2	0.0	0.1	0.1	0.0	0.3	0.2	0.2	0.0	0.0	2.3	0.1	0.3	0.2	12.3	1.3	3.7	4.2	33.5	0.2	36.6	0.1	0.2	0.2	0.0	0.0	0.1	0.2	2.8	0.0	0.0	2.8	0.3	14.2	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	23.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.3	0.2	0.0	0.2	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.8	1.1	0.9	0.0	0.2	0.8	0.3	0.4	0.0	0.7	0.0	2.1	0.1	0.0	0.5	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.8	0.0	1.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	22.3	0.0	0.0	0.0	0.1	0.1	0.0	0.0	2.8	0.2	0.0	0.0	0.9	0.0	0.0	0.2	0.0	0.0	12.0	6.0	0.3	0.0	0.0	1.4	4.4
SPANXB1	"CT11.2, SPANXB2, SPANXF1, SPANXF2"	ENSG00000227234	"SPANX family member B1"	Q9NS25	X	141002594-141003706	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	81	"testis: 89.5"	"Group enriched"	"Detected in some"	160	"Early spermatids: 686.8;Late spermatids: 2015.4"	"Group enriched"	"Detected in some"	4	"breast cancer: 2.1;cervical cancer: 1.1;head and neck cancer: 2.1;lung cancer: 1.8;urothelial cancer: 3.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 81.9;GAMG: 16.6;U-2 OS: 27.4"									"HPA046423, HPA073647"	Supported		Approved	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"HPA046423: AB_2679660, HPA073647: AB_2732232"															"unprognostic (8.55e-2)"			0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	89.5	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.3	81.9	1.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	16.6	0.1	0.0	0.0	0.0	0.0	0.2	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.3	0.0	0.2	0.1	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.1	27.4	1.9	0.7	0.4	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.2	0.2	0.1	0.0	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	686.8	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2015.4	6.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.2	0.0	0.0	6.6	0.0	0.1	8.4	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TEPP		ENSG00000159648	"Testis, prostate and placenta expressed"	Q6URK8	16	57976435-57988116	"Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"testis: 14.3"	"Group enriched"	"Detected in many"	12	"Early spermatids: 317.5;Late spermatids: 440.1"	"Group enriched"	"Detected in some"	4	"thyroid cancer: 3.2;urothelial cancer: 1.5"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in some"		"naive CD8 T-cell: 1.7"	"Lineage enriched"	"Detected in single"	6	"T-cells: 1.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA062092	Enhanced				"Secreted in male reproductive system"	NA	NA					"HPA062092: AB_2684679"	"unprognostic (4.86e-2)"	"unprognostic (2.72e-1)"	"unprognostic (4.12e-2)"	"unprognostic (2.56e-2)"	"unprognostic (1.79e-2)"	"unprognostic (8.04e-2)"	"unprognostic (3.67e-1)"	"unprognostic (2.40e-2)"	"unprognostic (2.74e-1)"	"unprognostic (2.48e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.27e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.46e-1)"	"unprognostic (3.97e-3)"	"unprognostic (2.59e-1)"	0.0	0.4	0.2	0.0	0.3	0.0	0.2	0.1	0.4	0.4	0.1	0.1	0.0	0.2	0.2	0.4	0.3	0.0	0.2	0.2	0.3	0.1	0.0	0.5	0.0	0.2	0.2	0.2	0.4	0.2	0.0	0.2	0.0	0.2	0.4	0.0	0.2	0.3	0.4	0.0	0.2	0.1	0.0	0.1	0.1	0.0	14.3	0.3	0.1	2.2	0.0	0.1	0.9	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.9	0.0	1.1	0.8	0.0	0.2	1.1	1.7	0.0	0.1	0.0	0.1	0.6	0.4	0.2	0.3	0.1	0.4	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.3	0.1	0.5	12.8	5.9	0.0	0.2	0.1	8.2	24.4	2.2	0.1	1.0	8.6	30.4	1.5	8.7	1.8	0.0	2.7	0.5	0.0	0.0	0.0	317.5	0.4	0.1	1.4	0.0	0.0	0.2	0.6	4.1	1.4	0.0	0.2	2.5	0.2	2.5	0.0	0.5	0.0	0.1	0.0	4.1	0.0	0.6	440.1	3.7	0.3	1.8	0.0	0.0	0.8	0.0	0.5	0.1	0.1	0.0	0.4	0.0	1.6	0.0	0.0	3.0	1.1	0.0	0.2	3.1	2.7	3.3	0.3	0.0	1.1	1.7	2.9	0.0	3.6
TM4SF19		ENSG00000145107	"Transmembrane 4 L six family member 19"	Q96DZ7	3	196319342-196338503	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"testis: 4.7"	"Cell type enriched"	"Detected in some"	8	"Hofbauer cells: 74.6"	"Group enriched"	"Detected in some"	4	"cervical cancer: 1.4;head and neck cancer: 3.4;lung cancer: 1.4;melanoma: 1.0;urothelial cancer: 0.9"	"Region enhanced"	"Detected in single"		"thalamus: 1.8"	"Group enriched"	"Detected in some"	6	"gdT-cell: 14.8;memory CD8 T-cell: 3.9;naive CD8 T-cell: 4.9"	"Lineage enriched"	"Detected in single"	16	"T-cells: 14.8"	"Cell line enriched"	"Detected in many"	12	"GAMG: 427.6"															NA	NA						"unprognostic (9.90e-2)"	"unprognostic (1.17e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.89e-2)"	"unprognostic (1.67e-1)"	"unprognostic (7.19e-2)"	"unprognostic (8.90e-5)"	"unprognostic (8.86e-3)"	"unprognostic (1.30e-1)"	"unprognostic (3.21e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.86e-1)"	"unprognostic (1.06e-3)"	"unprognostic (4.23e-2)"	"unprognostic (4.20e-3)"	"unprognostic (2.60e-1)"	"unprognostic (1.18e-3)"	3.9	0.3	0.0	0.5	0.2	0.7	2.9	0.2	0.9	0.8	0.0	0.3	0.2	0.3	0.0	3.4	0.3	0.1	0.1	0.2	0.3	0.2	0.5	3.6	0.5	0.2	0.2	0.1	0.7	0.3	0.0	0.1	0.8	0.3	0.5	0.2	0.5	1.5	0.0	1.6	1.8	0.2	0.1	0.1	0.6	0.5	4.7	1.8	0.2	0.7	0.5	0.8	0.3	1.7	0.8	15.6	7.2	0.2	0.4	0.9	4.6	0.3	0.0	4.4	1.6	2.9	0.0	8.2	0.2	2.6	0.0	427.6	2.2	0.0	1.7	1.1	0.6	0.0	0.3	2.1	0.0	1.0	0.5	0.4	0.5	1.4	18.8	31.3	0.0	0.0	0.9	9.8	0.9	4.8	1.2	0.1	0.8	0.0	0.2	36.2	0.2	3.2	0.9	0.0	0.4	0.3	0.0	2.5	0.1	0.7	0.4	0.6	0.2	1.4	18.6	15.6	2.9	9.1	0.5	5.6	0.3	20.2	0.7	0.3	0.9	0.3	0.4	14.8	0.4	0.1	0.1	1.3	3.9	0.1	0.3	0.7	4.9	0.6	0.7	0.1	0.6	0.4	1.6	0.0	0.2	0.2	0.9	0.2	0.3	0.2	0.2	0.1	0.3	0.1	1.8	0.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.0	0.0	0.0	2.9	0.0	0.1	0.2	0.0	0.0	0.0	0.2	0.3	0.2	0.0	0.0	0.0	0.1	0.0	0.0	74.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	9.3	4.9	4.9	0.0	0.4	0.9	0.1	0.0	0.0
UPK1B	"TSPAN20, UPK1"	ENSG00000114638	"Uroplakin 1B"	O75841	3	119173517-119205143	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"stomach 1: 34.1;urinary bladder: 89.7"	"Cell type enhanced"	"Detected in many"		"Basal respiratory cells: 32.2;Club cells: 198.3;Glandular and luminal cells: 80.9;Urothelial cells: 46.3"	"Cancer enriched"	"Detected in many"	4	"urothelial cancer: 147.3"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 17.7;CACO-2: 40.6;RPTEC TERT1: 36.5;RT4: 147.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"HPA031799, HPA031800"	Enhanced					NA	NA					"HPA031799: AB_10671579, HPA031800: AB_10671580"	"unprognostic (1.20e-2)"	"unprognostic (7.18e-2)"		"prognostic favorable (3.87e-5)"	"unprognostic (2.22e-1)"	"unprognostic (1.39e-1)"		"unprognostic (8.77e-3)"	"unprognostic (3.67e-1)"	"unprognostic (2.71e-1)"	"unprognostic (3.26e-2)"	"unprognostic (2.03e-1)"	"unprognostic (1.92e-2)"	"prognostic unfavorable (7.76e-4)"	"unprognostic (1.68e-1)"	"unprognostic (6.76e-2)"	"unprognostic (2.95e-2)"	4.9	0.0	0.5	0.1	1.5	0.2	0.2	0.3	0.5	4.9	0.0	0.0	0.1	0.6	0.0	3.5	7.9	8.0	1.0	0.3	0.0	10.3	0.1	1.3	0.0	0.6	0.1	0.5	0.0	6.5	0.0	0.2	7.7	1.3	0.4	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	34.1	0.6	0.4	3.8	0.0	0.2	17.1	89.7	1.4	2.1	0.1	17.7	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	40.6	0.0	0.0	5.4	0.0	0.0	1.1	0.0	0.5	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	36.5	147.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.6	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.0	0.4	0.1	0.1	0.2	0.0	0.0	0.5	1.5	0.3	0.5	0.3	0.0	0.6	0.1	0.5	1.3	0.0	0.4	2.1	0.2	0.0	1.5	0.0	0.2	0.3	0.6	32.2	0.0	0.5	0.2	0.4	0.5	24.3	198.3	0.0	0.0	3.5	0.4	0.1	0.0	15.6	3.5	25.1	9.4	0.9	0.0	0.0	1.9	0.7	11.1	4.0	11.2	80.9	2.5	0.5	0.0	0.5	0.5	1.7	1.2	0.2	24.4	0.3	3.1	1.5	0.0	1.1	1.8	0.0	1.1	0.2	0.0	0.5	0.5	0.8	0.2	0.0	0.4	0.9	0.2	10.9	27.8	1.2	0.0	0.5	4.6	0.2	0.5	0.3	0.0	1.5	0.7	0.1	0.0	46.3
VGLL1	"TDU, TONDU"	ENSG00000102243	"Vestigial like family member 1"	Q99990	X	136532215-136556807	"Predicted intracellular proteins"	"Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	9	"placenta: 205.6"	"Group enriched"	"Detected in some"	11	"Cytotrophoblasts: 1282.0;Extravillous trophoblasts: 582.3;Syncytiotrophoblasts: 1788.6"	"Group enriched"	"Detected in many"	4	"ovarian cancer: 13.7;urothelial cancer: 47.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 130.7;BEWO: 189.5;CAPAN-2: 72.7;RT4: 328.6;SK-BR-3: 328.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA042403, HPA064616"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA042403: AB_2677980, HPA064616: AB_2685300"	"unprognostic (1.38e-1)"	"unprognostic (1.58e-1)"	"unprognostic (3.09e-1)"	"prognostic unfavorable (4.54e-4)"		"unprognostic (5.16e-2)"		"unprognostic (1.80e-1)"	"unprognostic (4.28e-1)"	"unprognostic (6.14e-3)"	"unprognostic (1.92e-3)"	"unprognostic (1.37e-2)"		"unprognostic (5.53e-2)"	"unprognostic (3.05e-1)"	"unprognostic (1.46e-2)"	"unprognostic (1.64e-2)"	0.6	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.1	0.1	0.0	0.0	0.2	0.1	0.4	1.5	1.3	0.6	0.1	0.0	0.0	3.8	0.1	2.2	0.0	0.0	0.0	0.0	0.1	1.5	0.0	1.4	205.6	0.0	1.4	0.0	0.0	5.2	6.7	0.0	0.2	0.2	0.0	0.0	0.1	0.9	0.1	0.0	0.2	0.0	0.0	1.1	22.9	1.6	0.0	130.7	0.0	0.0	0.1	0.0	0.0	189.5	0.0	0.0	0.0	0.0	18.1	72.7	0.0	0.0	0.0	0.0	5.9	0.0	7.5	0.0	0.0	0.3	0.0	0.2	0.3	0.0	0.0	0.1	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.3	0.4	0.1	2.1	0.0	0.1	0.0	0.1	0.0	328.6	0.2	0.2	0.0	328.7	0.3	13.2	5.6	0.4	0.0	0.0	0.1	0.2	0.4	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	0.0	0.0	0.0	0.0	2.3	1.7	0.0	0.0	4.9	1.8	0.2	0.0	16.6	36.8	0.0	1282.0	0.1	0.0	0.0	2.1	0.0	3.3	0.1	2.7	0.0	0.0	0.0	0.2	582.3	5.8	0.0	2.0	1.3	0.0	0.0	0.0	108.2	0.0	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	2.3	0.0	0.1	8.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1788.6	0.0	0.0	0.0	30.5
ACER2	"ALKCDase2, ASAH3L, FLJ41587"	ENSG00000177076	"Alkaline ceramidase 2"	Q5QJU3	9	19409009-19452505	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Lipid metabolism, Sphingolipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"stomach 1: 62.3;urinary bladder: 39.6"	"Cell type enhanced"	"Detected in some"		"Excitatory neurons: 19.7;Gastric mucus-secreting cells: 21.9;Inhibitory neurons: 10.3;Microglial cells: 26.2;Oligodendrocytes: 7.0"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 15.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"BEWO: 29.7;RT4: 73.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.94e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.06e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.95e-2)"	"unprognostic (2.03e-1)"	"unprognostic (3.90e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.13e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.42e-2)"	"unprognostic (8.46e-3)"	6.5	1.4	5.4	1.1	3.2	0.6	5.0	2.5	5.3	1.8	2.4	3.3	4.5	1.4	4.2	2.2	3.7	1.7	2.7	4.6	3.0	1.9	2.4	2.2	1.1	3.4	2.9	2.3	1.0	6.9	2.5	1.2	9.8	3.5	3.7	4.3	3.8	2.0	4.6	1.2	5.9	2.7	1.3	2.5	1.4	62.3	1.9	4.3	2.4	2.6	1.0	1.3	39.6	1.8	5.1	1.2	2.0	3.9	2.0	6.2	0.5	29.7	2.1	1.4	0.7	1.0	0.6	1.9	1.3	0.7	0.3	0.4	4.5	0.8	5.8	1.5	2.4	1.1	2.1	1.6	3.0	1.3	0.5	2.0	1.8	5.6	2.2	2.4	0.6	6.2	2.1	3.1	3.8	2.0	1.7	3.6	1.8	3.1	11.1	0.9	3.2	1.0	0.7	0.6	73.6	6.9	1.8	0.4	2.2	0.5	9.3	2.7	2.5	3.1	0.5	1.5	0.6	0.9	1.4	1.7	1.4	0.6	1.5	1.3	0.0	0.0	0.0	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.1	5.4	3.2	2.5	5.3	4.6	3.0	3.4	2.9	2.3	3.5	2.5	4.3	5.1	3.2	0.0	0.0	1.0	0.7	0.3	0.4	0.1	0.6	1.0	0.3	0.4	0.1	0.0	0.1	0.0	2.1	0.5	0.4	0.0	0.0	0.1	2.6	0.3	0.2	0.8	0.0	0.8	19.7	0.0	0.6	0.3	21.9	0.4	0.0	0.0	1.4	0.0	0.1	0.0	10.3	0.0	0.0	0.0	0.0	4.0	0.3	0.2	0.0	26.2	0.0	0.6	0.0	5.5	7.0	0.1	0.0	0.0	0.4	0.2	0.0	0.1	0.1	0.6	0.0	0.6	0.4	0.4	0.4	0.8	0.0	4.0	0.3	0.0	0.0	1.1
AMELX	"AIH1, AMG"	ENSG00000125363	"Amelogenin X-linked"	Q99217	X	11293413-11300761	"Disease related genes, Human disease related genes, Predicted secreted proteins"	Biomineralization		"Amelogenesis imperfecta, Disease variant"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Evidence at protein level"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in some"		"urothelial cancer: 1.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted in other tissues"	NA	NA								"unprognostic (1.76e-1)"									"unprognostic (1.00e-1)"		"unprognostic (2.00e-1)"				0.0	0.0	0.9	0.0	0.4	0.0	0.0	0.1	0.2	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.6	0.6	0.0	0.0	0.0	0.0	0.3	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.4	0.1	0.2	0.6	0.6	0.3	0.2	0.3	0.3	0.3	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
CAPNS2	"MGC12536, MGC14804"	ENSG00000256812	"Calpain small subunit 2"	Q96L46	16	55566684-55567687	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 86.4;skin 1: 96.0;vagina: 33.8"	"Group enriched"	"Detected in some"	7	"Basal keratinocytes: 87.8;Basal squamous epithelial cells: 117.3;Squamous epithelial cells: 108.6;Suprabasal keratinocytes: 149.3"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 26.3;urothelial cancer: 21.0"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	5	"eosinophil: 3.8;intermediate monocyte: 1.0"	"Group enriched"	"Detected in many"	9	"granulocytes: 3.8;monocytes: 1.0"	"Cell line enriched"	"Detected in some"	10	"hTCEpi: 223.0"	"Not detected"	"Not detected"							"HPA059749, HPA076768"	Enhanced		Approved	Cytosol		NA	NA			Cytosol		"HPA059749: AB_2732639, HPA076768: AB_2732322"	"unprognostic (3.26e-2)"	"unprognostic (6.85e-2)"	"unprognostic (2.57e-1)"	"unprognostic (1.77e-3)"	"unprognostic (4.14e-1)"	"unprognostic (3.32e-2)"		"unprognostic (1.79e-1)"	"unprognostic (2.98e-1)"	"unprognostic (7.21e-2)"	"unprognostic (3.38e-2)"	"unprognostic (3.62e-1)"	"unprognostic (2.42e-2)"	"unprognostic (4.48e-1)"	"unprognostic (4.11e-2)"	"unprognostic (2.82e-1)"	"unprognostic (1.69e-1)"	0.3	0.0	0.3	0.1	0.6	0.7	6.7	0.8	0.5	6.9	0.7	0.0	0.0	0.1	0.2	86.4	0.8	0.0	0.1	0.4	0.5	0.0	0.1	0.2	0.0	1.1	0.7	0.1	0.1	0.1	0.0	0.1	0.3	1.6	4.3	0.0	0.1	16.9	0.1	0.7	96.0	0.1	0.0	1.2	0.1	0.1	0.1	0.8	0.2	0.3	0.0	18.7	18.3	33.8	1.3	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.3	0.0	23.0	0.0	1.0	0.1	0.1	0.1	0.2	0.0	0.1	0.0	0.7	0.8	0.0	223.0	0.0	0.0	0.6	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.1	0.0	1.1	0.1	7.6	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.5	1.2	0.0	0.1	3.8	0.0	1.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.3	0.6	0.8	0.5	0.4	0.5	1.1	0.7	0.1	1.6	1.2	0.8	1.3	0.6	0.0	0.5	0.0	0.0	87.8	10.0	13.7	117.3	0.0	0.2	0.3	0.0	0.0	11.9	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.0	0.0	0.0	0.0	0.1	0.9	0.0	0.1	1.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	4.1	0.8	7.7	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.0	0.0	0.5	0.7	0.0	0.0	108.6	149.3	2.3	0.2	0.1	0.0	15.4
CBY2	"NURIT, SPERT"	ENSG00000174015	"Chibby family member 2"	Q8NA61	13	45702320-45714559	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	579	"testis: 99.8"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.8"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA039359, HPA040046"	Enhanced		Approved	"Plasma membrane,Cell Junctions"		NA	NA			"Plasma membrane, Cell Junctions"		"HPA039359: AB_10794088, HPA040046: AB_10796117"	"unprognostic (2.86e-1)"	"unprognostic (3.38e-1)"	"unprognostic (1.64e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.76e-2)"	"unprognostic (4.19e-4)"		"unprognostic (8.52e-2)"	"unprognostic (8.87e-2)"	"unprognostic (1.23e-1)"	"unprognostic (4.38e-1)"		"unprognostic (2.38e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.56e-2)"	"unprognostic (1.97e-2)"	"unprognostic (4.15e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	99.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CLCA4	CaCC2	ENSG00000016602	"Chloride channel accessory 4"	Q14CN2	1	86547078-86580754	"Predicted membrane proteins, Transporters"	Transport	"Hydrolase, Metalloprotease, Protease"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 376.9;intestine: 260.2"	"Group enriched"	"Detected in many"	6	"Distal enterocytes: 597.0;Paneth cells: 183.2;Squamous epithelial cells: 158.7;Urothelial cells: 176.9"	"Cancer enhanced"	"Detected in many"		"cervical cancer: 21.4;urothelial cancer: 15.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	1368	"RT4: 430.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA017045, HPA064770"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Aggresome"	"Intracellular and membrane"	NA	NA		150000	"Plasma membrane"	"Nucleoplasm, Aggresome"	"HPA017045: AB_2291679, HPA064770: "	"unprognostic (1.38e-4)"	"unprognostic (1.52e-1)"	"prognostic favorable (7.47e-4)"	"unprognostic (2.73e-2)"	"unprognostic (7.03e-2)"	"prognostic favorable (8.63e-4)"		"unprognostic (7.59e-2)"	"unprognostic (3.35e-1)"	"unprognostic (1.26e-1)"	"unprognostic (6.01e-2)"	"unprognostic (1.20e-1)"		"unprognostic (2.57e-2)"	"unprognostic (2.29e-1)"	"unprognostic (5.69e-2)"	"unprognostic (3.43e-2)"	0.6	0.0	6.3	14.0	9.1	0.0	2.2	6.8	8.1	21.4	3.4	260.2	0.1	0.1	0.1	376.9	0.2	0.2	0.1	6.1	6.6	0.1	0.1	0.0	0.0	9.3	7.5	5.3	0.0	0.1	0.0	0.5	0.0	8.5	2.5	144.9	0.0	23.3	0.2	0.1	17.3	29.3	3.0	7.0	0.1	0.6	0.3	7.4	0.1	0.0	0.0	30.3	100.3	67.4	13.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	430.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	9.1	6.8	8.1	6.1	6.6	9.3	7.5	5.3	8.5	7.0	7.4	13.1	0.1	0.0	0.0	0.0	2.9	3.3	40.3	6.5	2.8	0.0	1.9	1.8	0.4	0.0	17.5	1.8	0.0	0.0	0.2	597.0	0.0	0.0	0.4	7.3	0.1	0.3	8.3	0.0	0.1	0.0	0.0	0.4	0.0	3.5	8.9	0.0	0.0	0.0	0.0	0.0	0.1	9.8	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	27.1	0.0	183.2	0.0	1.2	9.7	4.7	0.0	1.9	0.0	0.0	0.0	0.4	0.1	0.0	158.7	11.9	0.0	1.5	0.0	12.0	176.9
CNGA1	"CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49"	ENSG00000198515	"Cyclic nucleotide gated channel subunit alpha 1"	P29973	4	47935977-48016681	"Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sensory transduction, Transport, Vision"	"Ion channel, Ligand-gated ion channel"	"Disease variant, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	11	"retina: 266.7"	"Cell type enriched"	"Detected in many"	6	"Rod photoreceptor cells: 1139.7"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 4.5"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 9.2;RT4: 7.2;U-2 OS: 3.0"	"Region enhanced"	"Detected in single"		"basal ganglia: 1.0"	"Not detected"	"Not detected"			HPA076168			Approved	"Nucleoplasm,Vesicles,Plasma membrane"		NA	NA			"Vesicles, Plasma membrane"	Nucleoplasm	"HPA076168: AB_2686781"	"unprognostic (2.68e-2)"	"unprognostic (4.90e-2)"	"unprognostic (1.33e-1)"	"unprognostic (8.59e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.76e-2)"	"unprognostic (3.85e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.98e-2)"	"unprognostic (3.18e-1)"	"unprognostic (2.91e-1)"	"unprognostic (5.48e-6)"	"unprognostic (1.86e-1)"	"unprognostic (1.04e-1)"	"unprognostic (4.66e-2)"	"unprognostic (8.23e-2)"	3.3	0.4	0.5	0.8	1.3	0.3	1.5	1.6	0.9	1.0	0.6	3.6	2.3	0.4	9.4	9.1	4.1	1.1	0.4	0.8	0.7	2.4	23.7	0.3	0.1	0.6	0.5	0.6	0.1	0.8	4.2	0.3	1.0	0.8	2.6	2.4	266.7	4.4	1.7	5.1	5.2	6.3	0.3	0.1	3.4	2.8	0.4	0.7	0.3	0.7	1.3	0.5	3.7	1.9	0.7	2.3	0.9	0.0	0.1	0.0	0.0	0.2	0.0	0.1	0.0	0.2	2.0	9.2	0.1	0.5	0.0	2.7	1.4	0.2	0.3	0.1	0.0	0.6	0.0	0.2	0.8	0.0	0.1	0.2	0.0	0.4	0.0	0.0	0.9	0.0	0.8	0.7	0.5	0.2	0.9	0.0	0.1	0.4	1.1	2.2	0.1	0.0	0.1	0.4	7.2	0.3	0.0	0.2	0.5	0.1	0.2	0.9	0.0	0.3	0.2	3.0	0.1	0.1	0.7	0.8	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.1	0.2	0.3	0.0	0.5	0.0	0.0	0.5	1.3	1.6	0.9	0.8	0.7	0.6	0.5	0.6	0.8	0.1	0.7	0.7	7.3	0.0	0.0	0.7	0.1	0.1	1.8	0.5	0.6	97.7	8.7	1.8	0.7	5.7	3.4	62.5	91.8	0.0	0.0	10.6	0.0	10.1	0.4	2.5	0.4	8.7	0.0	2.7	1.2	6.6	0.0	0.3	0.0	3.6	0.0	0.0	0.0	38.0	1.7	45.4	1.1	4.0	0.0	0.8	0.0	0.1	0.3	0.5	0.0	7.5	0.0	163.9	0.0	0.0	0.2	2.1	16.4	0.0	0.0	3.7	24.5	0.4	0.8	1139.7	0.0	0.6	17.1	0.6	1.3	10.3	2.7	0.3	0.2	0.1	4.7	35.1
CYP24A1	"CP24, CYP24, P450-CC24"	ENSG00000019186	"Cytochrome P450 family 24 subfamily A member 1"	Q07973	20	54153446-54173986	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		"Monooxygenase, Oxidoreductase"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"endometrium 1: 15.1;kidney: 35.5;lymphoid tissue: 10.6;placenta: 10.1;urinary bladder: 29.0"	"Cell type enhanced"	"Detected in some"		"Basal prostatic cells: 48.3;Basal respiratory cells: 142.7;Basal squamous epithelial cells: 74.0;Club cells: 47.0;Proximal tubular cells: 61.3;Urothelial cells: 36.7"	"Cancer enhanced"	"Detected in many"		"lung cancer: 18.3;urothelial cancer: 21.0"	"Region enhanced"	"Detected in some"		"midbrain: 2.0"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	17	"A549: 411.5;Hep G2: 122.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA022261, HPA063771"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Mitochondria"		NA	Yes			"Nucleoplasm, Mitochondria"	"Plasma membrane"	"HPA022261: AB_1847427, HPA063771: AB_2685120"	"unprognostic (1.19e-7)"	"unprognostic (1.73e-1)"	"unprognostic (2.24e-2)"	"unprognostic (7.69e-3)"	"unprognostic (3.30e-1)"	"unprognostic (2.30e-2)"		"unprognostic (1.11e-2)"	"unprognostic (2.12e-1)"	"unprognostic (2.09e-2)"	"unprognostic (5.37e-3)"	"unprognostic (1.23e-1)"	"unprognostic (6.05e-2)"	"unprognostic (5.98e-2)"	"unprognostic (1.36e-1)"	"unprognostic (4.38e-2)"	"unprognostic (2.12e-1)"	0.0	0.0	0.2	0.4	0.3	0.0	3.8	0.0	0.3	1.6	0.0	0.0	0.1	15.1	0.2	3.8	0.2	0.0	0.0	0.1	1.0	35.5	0.4	0.7	0.2	0.3	2.0	0.1	0.0	0.0	0.0	0.3	10.1	0.3	2.9	0.0	0.0	0.3	2.0	0.0	0.7	0.0	0.2	0.1	0.0	0.0	0.0	0.6	0.2	1.3	0.0	10.6	29.0	1.3	0.2	0.5	411.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	12.6	0.0	3.2	0.0	0.9	15.8	0.0	0.1	0.1	0.0	0.0	0.0	6.5	122.6	0.0	0.0	0.0	0.1	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.0	11.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.7	0.0	7.0	1.3	0.0	2.6	0.6	0.0	0.1	0.1	0.0	0.0	0.0	16.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.3	0.1	1.0	0.3	2.0	0.1	0.3	0.1	0.6	0.2	0.0	0.0	0.0	0.0	1.3	22.8	48.3	142.7	74.0	0.0	11.0	8.6	0.4	0.0	47.0	0.0	0.0	0.1	0.1	0.1	5.9	0.1	0.0	0.7	0.5	0.3	0.0	0.0	0.2	0.0	0.1	2.0	0.0	4.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	12.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	9.8	0.0	61.3	13.1	0.0	0.0	0.0	0.6	0.0	0.0	3.3	19.6	0.1	0.1	0.0	0.2	36.7
CYP4B1		ENSG00000142973	"Cytochrome P450 family 4 subfamily B member 1"	P13584	1	46757838-46819413	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Monooxygenase, Oxidoreductase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 244.3"	"Group enriched"	"Detected in many"	4	"Alveolar cells type 1: 1227.5;Club cells: 405.1;Respiratory ciliated cells: 763.9"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 56.9"	"Region enriched"	"Detected in single"	13	"hypothalamus: 8.6"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	8	"RT4: 286.7"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA004331	Approved		Supported	Vesicles		NA	NA			Vesicles		"HPA004331: AB_1078616"	"unprognostic (2.29e-2)"	"prognostic favorable (5.99e-4)"	"unprognostic (7.01e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.28e-1)"	"unprognostic (8.31e-2)"	"unprognostic (1.16e-2)"	"unprognostic (1.98e-2)"	"unprognostic (2.65e-1)"	"unprognostic (2.59e-1)"	"unprognostic (6.12e-2)"	"unprognostic (5.46e-2)"	"unprognostic (7.33e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.22e-3)"	"unprognostic (6.69e-3)"	78.3	4.9	0.3	0.0	0.2	0.0	62.5	0.2	0.6	10.5	1.1	14.1	1.3	9.6	1.7	44.3	48.4	0.5	24.9	0.2	8.6	2.4	0.1	244.3	0.5	0.4	0.2	0.1	1.8	3.5	0.7	9.4	1.2	0.3	22.9	0.7	0.0	16.8	16.0	24.2	39.5	15.4	0.1	0.2	0.4	11.6	0.5	0.3	3.2	22.5	24.9	15.3	82.4	30.8	0.2	0.0	0.0	0.0	0.0	20.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	16.5	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	35.6	0.0	0.1	0.0	0.3	0.0	0.2	0.0	0.1	0.0	0.0	0.0	286.7	0.1	0.0	0.0	11.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.2	0.6	0.2	8.6	0.4	0.2	0.1	0.3	0.2	0.3	0.2	60.8	1227.5	89.3	0.0	0.0	0.5	139.6	111.5	36.5	0.0	2.0	1.5	6.4	1.5	405.1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	1.7	93.8	12.5	23.5	0.0	0.0	0.1	0.0	0.2	47.9	1.1	8.5	6.3	0.0	1.4	0.0	0.6	0.0	0.1	0.0	48.8	0.0	0.3	0.9	0.6	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	6.9	0.0	1.1	763.9	0.0	0.0	3.0	23.3	0.1	0.1	71.4	4.1	0.8	1.8	0.0	0.0	163.0
CYP4F8		ENSG00000186526	"Cytochrome P450 family 4 subfamily F member 8"	P98187	19	15615218-15630639	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid metabolism, Lipid metabolism"	"Monooxygenase, Oxidoreductase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	15	"seminal vesicle: 217.7"	"Cell type enhanced"	"Detected in some"		"Basal prostatic cells: 1.2;Breast glandular cells: 1.7;granulocytes: 1.3;NK-cells: 1.0;Prostatic glandular cells: 1.3;Skeletal myocytes: 1.7;Urothelial cells: 2.5"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 10.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"SK-BR-3: 1.1"					"Low region specificity"	"Detected in all"			HPA058960	Approved					NA	NA					"HPA058960: AB_2683862"	"unprognostic (1.70e-2)"	"unprognostic (5.46e-3)"	"unprognostic (3.21e-2)"	"unprognostic (3.97e-6)"		"unprognostic (3.51e-3)"				"unprognostic (2.72e-1)"	"unprognostic (1.15e-1)"	"unprognostic (8.25e-2)"		"unprognostic (1.15e-2)"			"unprognostic (1.02e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.9	0.0	0.0	0.2	217.7	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.2	0.0	0.0	0.4	1.7	0.3	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.5	0.2	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.3	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.9	0.0	0.3	0.0	0.0	0.1	0.1	1.0	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.7	0.0	1.7	0.2	0.0	0.2	0.0	0.0	0.1	0.2	0.0	0.3	2.5
ERVV-1	"ENVV1, FLJ32214, HERV-V1"	ENSG00000269526	"Endogenous retrovirus group V member 1, envelope"	B6SEH8	19	53013921-53016122	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	37	"placenta: 16.2"	"Cell type enriched"	"Detected in some"	28	"Syncytiotrophoblasts: 260.9"	"Cancer enhanced"	"Detected in some"		"renal cancer: 0.6;urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"BEWO: 7.9;SuSa: 6.2"									HPA076115			Approved	Centrosome,Cytosol		NA	NA			Cytosol	Centrosome	"HPA076115: "	"unprognostic (1.04e-3)"			"unprognostic (7.32e-3)"	"unprognostic (2.97e-1)"	"unprognostic (2.70e-2)"		"unprognostic (1.67e-2)"		"unprognostic (9.92e-2)"		"unprognostic (6.75e-2)"	"unprognostic (4.34e-5)"	"unprognostic (3.48e-2)"	"unprognostic (5.80e-2)"	"unprognostic (3.18e-1)"	"unprognostic (1.35e-1)"	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	16.2	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	6.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.2	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	260.9	0.0	0.0	0.0	0.0
EVX1		ENSG00000106038	"Even-skipped homeobox 1"	P49640	7	27242700-27250493	"Predicted intracellular proteins, Transcription factors"		"Developmental protein, DNA-binding"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 2.9;prostate: 3.9;seminal vesicle: 3.0;urinary bladder: 3.3;vagina: 3.5"	"Group enriched"	"Detected in some"	33	"Early spermatids: 62.0;Late spermatids: 73.3"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 2.6"	"Region enhanced"	"Detected in some"		"medulla oblongata: 1.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	16	"OE19: 25.2;RT4: 16.1"	"Region enhanced"	"Detected in single"		"pons and medulla: 1.0"	"Not detected"	"Not detected"			HPA055132			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA055132: AB_2682707"	"unprognostic (2.73e-2)"	"unprognostic (3.59e-1)"	"unprognostic (4.31e-1)"		"unprognostic (5.16e-2)"		"unprognostic (1.76e-3)"	"unprognostic (2.08e-2)"			"unprognostic (8.48e-3)"	"unprognostic (5.94e-2)"	"unprognostic (1.26e-8)"	"unprognostic (2.94e-1)"	"unprognostic (1.39e-1)"	"unprognostic (9.12e-2)"	"unprognostic (1.83e-2)"	0.0	2.9	0.2	0.0	0.2	0.0	0.0	0.2	0.1	1.7	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.7	0.5	0.0	0.0	0.0	0.0	0.0	0.1	1.0	3.9	0.3	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	1.1	0.1	0.0	0.0	0.0	0.0	3.3	3.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.2	0.2	0.0	0.0	0.0	0.0	16.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.1	0.0	0.0	1.7	0.5	0.0	1.0	0.6	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.1	62.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	73.3	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.1	2.0
FCRLB	"FCRL2, FCRLM2, FCRLY, FLJ31052, FREB-2"	ENSG00000162746	"Fc receptor like B"	Q6BAA4	1	161721563-161728143	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in single"		"lymphoid tissue: 1.8"	"Cell type enhanced"	"Detected in many"		"Hepatic stellate cells: 7.5;NK-cells: 11.3;Proximal tubular cells: 14.7"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 7.8"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in many"		"basophil: 6.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 4.8;Daudi: 6.0;fHDF/TERT166: 8.8;HMC-1: 7.4;PC-3: 4.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB026139	Uncertain		Supported	Cytosol	"Intracellular and membrane"	NA	NA			Cytosol		"CAB026139: "	"unprognostic (1.87e-1)"	"unprognostic (1.20e-4)"	"unprognostic (5.77e-3)"	"unprognostic (7.49e-3)"	"unprognostic (1.73e-3)"	"unprognostic (2.95e-1)"	"unprognostic (2.98e-2)"	"unprognostic (1.18e-3)"	"unprognostic (1.89e-1)"	"unprognostic (3.59e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.22e-2)"	"unprognostic (2.25e-3)"	"unprognostic (1.27e-1)"	"unprognostic (9.92e-3)"	"unprognostic (3.14e-2)"	0.2	0.1	0.3	0.7	0.3	0.0	0.1	0.4	0.7	0.1	0.2	0.1	0.1	0.0	0.0	0.1	0.2	0.0	0.1	0.4	0.4	0.6	0.3	0.1	0.9	0.4	0.4	0.4	0.1	0.2	0.1	0.0	0.1	0.5	0.1	0.1	0.1	0.3	0.9	0.0	0.2	0.1	0.0	0.4	0.3	0.1	0.1	0.4	0.0	0.1	0.0	1.8	0.2	0.1	0.5	0.6	0.1	0.0	0.3	0.4	0.6	0.0	3.7	4.8	1.2	1.2	0.1	0.1	6.0	0.2	8.8	0.2	0.0	0.2	0.3	3.1	0.1	0.3	0.2	0.1	0.1	0.2	0.0	7.4	1.1	0.0	2.1	0.1	0.3	1.1	0.0	0.3	0.3	0.1	0.3	0.0	2.1	0.1	0.0	4.4	0.0	0.4	0.2	0.1	0.2	0.0	0.0	0.0	0.1	1.9	0.2	0.0	0.0	0.6	1.3	0.6	1.3	0.7	0.0	0.0	2.3	2.5	0.4	0.6	6.4	0.1	1.8	1.8	0.0	0.6	3.4	1.1	1.0	0.4	4.7	0.5	0.8	1.0	3.7	0.2	0.0	0.0	0.5	0.3	0.3	0.4	0.7	0.4	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.5	2.8	0.0	0.0	0.3	2.9	1.1	1.1	1.0	0.6	0.2	1.5	1.5	1.5	0.0	1.2	3.7	0.0	2.1	3.9	0.1	5.9	1.3	0.1	0.3	1.3	2.3	1.2	5.3	0.9	1.1	5.6	1.1	0.0	0.4	0.0	1.2	7.5	1.2	1.4	0.0	1.2	0.0	0.0	1.9	1.2	0.2	0.0	3.4	1.8	0.0	0.7	3.4	11.3	0.0	0.3	1.0	0.1	0.4	3.0	0.6	0.0	14.7	0.7	0.7	0.0	0.2	1.6	2.7	1.4	1.3	0.4	0.8	2.4	2.2	0.0	1.1
GDPD3	MGC4171	ENSG00000102886	"Glycerophosphodiester phosphodiesterase domain containing 3"	Q7L5L3	16	30104810-30113537	"Predicted intracellular proteins, Predicted membrane proteins"		Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 46.0"	"Cell type enriched"	"Detected in many"	4	"Late spermatids: 447.4"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 21.1"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in single"		"neutrophil: 2.4"	"Lineage enriched"	"Detected in single"	22	"granulocytes: 2.4"	"Cell line enhanced"	"Detected in many"		"Hep G2: 32.1;MCF7: 50.6;OE19: 53.3;SK-BR-3: 165.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA041148, HPA041470"	Uncertain		Approved	"Nucleoplasm,Cytokinetic bridge,Cytosol"		Yes	NA			Nucleoplasm	"Cytokinetic bridge, Cytosol"	"HPA041148: AB_10794545, HPA041470: AB_10795121"	"unprognostic (4.12e-1)"	"unprognostic (2.29e-2)"	"unprognostic (2.01e-1)"	"unprognostic (9.99e-2)"	"unprognostic (2.53e-1)"	"unprognostic (4.57e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.36e-1)"	"unprognostic (4.53e-1)"	"unprognostic (8.86e-3)"	"unprognostic (6.59e-3)"	"unprognostic (1.95e-1)"	"prognostic unfavorable (5.89e-9)"	"unprognostic (3.11e-1)"	"unprognostic (3.13e-1)"	"unprognostic (1.12e-1)"	"unprognostic (8.79e-3)"	6.5	2.4	6.4	6.1	6.4	1.8	5.4	7.0	11.5	13.5	6.4	26.1	8.5	5.4	9.4	46.0	5.8	2.5	4.7	6.2	6.4	18.1	2.1	6.5	4.3	7.7	6.3	6.1	6.8	2.2	0.4	4.8	11.5	8.2	5.7	17.3	6.6	9.1	2.2	2.1	10.2	10.2	5.3	6.5	9.1	18.9	1.8	6.4	4.2	4.8	0.9	21.1	5.5	19.3	7.1	21.8	0.3	5.2	1.5	1.6	5.5	5.5	0.6	1.3	1.8	1.7	1.0	15.2	0.6	2.9	1.5	0.6	1.8	1.6	0.5	1.8	2.5	4.0	0.2	1.0	32.1	1.0	0.7	1.3	0.2	1.6	4.5	0.3	4.1	5.1	4.2	1.0	2.3	2.2	50.6	1.5	2.0	2.6	53.3	0.6	6.3	1.4	7.1	2.6	7.4	1.1	2.2	0.2	165.0	0.5	1.6	3.0	2.7	2.7	0.9	1.1	1.9	1.8	2.7	0.9	1.5	4.2	2.7	0.7	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.4	0.0	0.0	0.0	0.1	0.0	6.4	6.4	7.0	11.5	6.2	6.4	7.7	6.3	6.1	8.2	6.5	6.4	7.1	5.9	6.4	1.1	1.6	1.0	1.3	0.9	4.4	1.2	1.6	4.1	3.0	1.5	0.0	22.2	5.5	0.0	24.2	1.2	98.2	5.9	0.9	67.8	2.6	3.8	4.3	3.5	0.0	0.6	1.3	71.9	2.1	30.1	4.1	0.0	2.0	3.9	0.3	3.1	1.7	0.8	34.2	6.1	1.9	1.0	447.4	3.4	1.4	1.8	1.9	1.2	0.6	0.0	1.5	1.2	19.2	36.7	3.0	0.1	1.1	46.0	100.6	9.0	1.7	6.6	0.6	2.7	1.4	1.3	5.1	2.0	9.3	1.9	1.3	13.9	4.8
GNG8		ENSG00000167414	"G protein subunit gamma 8"	Q9UK08	19	46634076-46634685	"Predicted intracellular proteins, RAS pathway related proteins"		Transducer		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 111.8;choroid plexus: 42.9"	"Cell type enhanced"	"Detected in some"		"Cardiomyocytes: 12.6;Langerhans cells: 5.1;Melanocytes: 32.0;monocytes: 9.5;Oligodendrocytes: 5.0;Smooth muscle cells: 9.0"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 6.1"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in many"		"naive B-cell: 10.8;T-reg: 5.7"	"Group enriched"	"Detected in many"	5	"B-cells: 10.8;T-cells: 5.7"	"Cell line enriched"	"Detected in some"	4	"SH-SY5Y: 1157.3"	"Region enhanced"	"Detected in all"		"white matter: 20.2"	"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (7.23e-4)"	"unprognostic (4.96e-6)"	"unprognostic (9.00e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.41e-1)"	"prognostic favorable (2.14e-5)"	"unprognostic (1.94e-1)"	"unprognostic (1.45e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.80e-1)"	"unprognostic (9.60e-2)"	"unprognostic (9.83e-2)"	"unprognostic (5.90e-8)"	"unprognostic (2.67e-2)"	"unprognostic (1.70e-1)"	"unprognostic (4.22e-2)"	"unprognostic (4.41e-1)"	0.7	22.2	54.6	5.6	60.0	0.8	0.4	53.3	66.9	4.4	42.9	3.6	1.9	2.5	0.0	0.9	2.4	0.7	10.1	52.4	64.6	2.0	0.4	1.3	4.4	60.7	111.8	51.5	1.4	0.1	2.9	7.8	0.2	61.5	1.4	2.1	0.9	0.1	1.7	0.0	0.2	2.7	3.0	52.7	2.9	1.2	1.1	57.8	16.2	0.3	0.0	6.0	1.0	1.4	75.9	0.0	1.6	1.7	0.7	0.0	0.0	0.0	0.8	0.7	0.6	0.6	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.9	0.0	0.0	0.0	0.0	89.3	1.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.0	0.6	0.3	0.0	0.0	0.0	0.0	0.6	0.8	0.0	1.3	0.9	0.0	0.8	0.0	0.0	264.0	1157.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.3	0.0	0.9	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.9	0.5	0.0	0.0	10.8	2.2	1.0	1.7	0.0	0.0	0.0	5.7	4.3	54.6	60.0	53.3	66.9	52.4	64.6	60.7	111.8	51.5	61.5	52.7	57.8	75.9	0.0	0.0	0.0	1.0	1.6	0.1	0.1	0.1	0.0	0.0	0.0	0.1	12.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.3	0.3	0.0	0.0	0.1	0.0	0.0	0.6	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	5.1	3.1	0.0	2.0	32.0	0.0	9.5	0.0	0.0	1.5	5.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	9.0	0.1	0.1	0.0	0.3	0.0	0.9	0.1	0.0	0.1
GPR78		ENSG00000155269	"G protein-coupled receptor 78"	Q96P69	4	8558725-8619761	"G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 1.4;placenta: 3.1"	"Cell type enriched"	"Detected in some"	4	"Extravillous trophoblasts: 5.2"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 1.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"BEWO: 25.8"									HPA013209	Uncertain					NA	NA					"HPA013209: AB_10601657"	"unprognostic (6.41e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.51e-1)"	"unprognostic (1.81e-2)"	"unprognostic (3.70e-2)"		"unprognostic (3.82e-4)"	"unprognostic (6.46e-3)"	"unprognostic (1.20e-1)"	"unprognostic (3.80e-2)"	"unprognostic (2.29e-1)"	"unprognostic (4.88e-15)"	"unprognostic (5.55e-3)"	"unprognostic (3.93e-2)"	"unprognostic (9.90e-3)"	"unprognostic (8.15e-2)"	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	3.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	4.9	0.0	0.0	0.0	0.0	0.0	25.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	2.9	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.3	0.8	0.0	0.1	0.0	0.4	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	5.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0
GSTM1	"GST1, H-B, MU"	ENSG00000134184	"Glutathione S-transferase mu 1"	P09488	1	109687814-109709039	"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins"		Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 349.5;liver: 614.4"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 9.6;Alveolar cells type 2: 6.8;Cardiomyocytes: 6.0;Club cells: 6.7;Hepatocytes: 5.5;Kupffer cells: 7.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 63.1"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 87.0;HeLa: 96.1;HHSteC: 78.6;hTEC/SVTERT24-B: 73.0;HUVEC TERT2: 62.4;MOLT-4: 115.4;U-266/84: 64.4"	"Low region specificity"	"Detected in all"							"CAB022669, CAB047357, HPA048652, HPA055972, HPA055973"	Approved		Approved	"Cytokinetic bridge,Cytosol"		Yes	NA			Cytosol	"Cytokinetic bridge"	"CAB022669: , CAB047357: , HPA048652: AB_2680478, HPA055972: AB_2682992, HPA055973: AB_2682993"	"unprognostic (2.22e-2)"	"unprognostic (5.35e-2)"	"unprognostic (3.87e-3)"	"unprognostic (3.20e-1)"	"unprognostic (4.95e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.56e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.41e-1)"	"unprognostic (6.55e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.45e-1)"	"unprognostic (3.17e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.36e-1)"	"unprognostic (2.18e-1)"	"unprognostic (4.72e-3)"	56.0	157.0	102.1	17.5	112.0	9.8	57.4	101.0	349.5	60.6	102.9	35.2	28.1	38.4	70.3	153.6	46.3	29.7	30.1	102.2	100.3	37.7	614.4	28.5	1.8	141.3	118.7	101.2	179.9	67.3	49.0	33.8	8.8	155.1	47.4	22.6	10.3	44.1	129.8	69.8	67.7	47.7	64.8	100.1	64.1	60.0	57.5	100.7	33.7	27.9	0.0	18.1	128.0	136.3	100.9	0.3	0.6	0.3	1.3	0.0	0.0	0.5	0.0	0.3	0.2	0.4	1.0	7.0	26.9	0.1	41.6	0.0	1.3	0.1	0.6	0.7	0.1	0.4	87.0	96.1	1.7	78.6	0.0	0.7	0.1	0.1	73.0	0.3	48.1	62.4	50.1	0.0	56.8	2.5	0.0	115.4	0.7	54.6	0.1	0.0	0.4	0.6	11.1	9.0	0.1	5.3	0.7	0.0	0.3	0.5	2.6	1.1	44.5	0.2	35.5	2.0	0.9	0.1	45.1	64.4	3.7	30.7	1.1	2.0	2.2	26.1	32.2	28.8	39.1	31.0	30.8	31.4	28.5	77.8	32.5	33.1	32.6	2.0	30.1	17.4	41.1	38.9	28.5	102.1	112.0	101.0	349.5	102.2	100.3	141.3	118.7	101.2	155.1	100.1	100.7	100.9	0.3	9.6	6.8	0.0	0.2	1.8	0.6	2.0	0.0	0.1	2.7	1.9	6.0	2.8	6.7	0.0	0.0	0.0	0.8	0.4	0.0	1.2	0.0	0.9	1.9	0.8	0.0	0.0	0.0	0.0	0.0	1.7	0.0	1.5	2.5	0.0	5.0	5.5	0.1	0.0	0.0	0.3	0.0	7.1	2.2	0.4	3.7	0.5	0.0	0.0	0.7	2.4	0.0	0.0	0.0	0.6	0.1	2.2	0.0	0.1	1.9	0.0	5.1	0.0	0.0	0.3	1.4	0.5	0.4	0.0	1.6	0.0	0.8	0.0	0.2	1.8
HPGD	SDR36C1	ENSG00000164120	"15-hydroxyprostaglandin dehydrogenase"	P15428	4	174490175-174523154	"Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid metabolism, Prostaglandin metabolism"	Oxidoreductase	"Cancer-related genes, Disease variant, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"stomach 1: 237.1;urinary bladder: 379.3"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 457.8;Extravillous trophoblasts: 701.7;granulocytes: 864.5;Proximal enterocytes: 500.6;Urothelial cells: 922.8"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 52.4"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"basophil: 123.7;T-reg: 45.0"	"Group enriched"	"Detected in many"	73	"granulocytes: 123.7;T-cells: 45.0"	"Cell line enhanced"	"Detected in many"		"A549: 157.8;ASC diff: 110.6;HEL: 355.0;OE19: 102.1;RT4: 565.7;SuSa: 121.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004919, HPA005679"	Enhanced		Supported	Nucleoplasm,Cytosol		No	NA		20000	Cytosol	Nucleoplasm	"HPA004919: AB_1079081, HPA005679: AB_1079080"	"unprognostic (1.23e-3)"	"unprognostic (1.61e-1)"	"unprognostic (5.96e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.09e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.27e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.08e-1)"	"unprognostic (4.28e-2)"	"unprognostic (3.54e-3)"	"unprognostic (2.34e-2)"	"prognostic favorable (3.20e-4)"	"unprognostic (2.44e-1)"	"unprognostic (2.59e-1)"	"unprognostic (1.37e-4)"	"unprognostic (2.33e-2)"	7.0	16.7	1.0	11.5	0.8	2.7	161.5	0.6	1.0	20.4	7.3	61.5	153.6	45.9	36.8	82.3	13.5	25.2	1.7	1.2	2.3	60.8	212.5	91.8	5.5	1.3	1.9	0.6	1.1	2.6	86.1	2.1	99.9	1.1	10.3	57.9	1.0	7.7	4.1	2.5	36.2	118.2	64.2	0.8	10.4	237.1	1.6	1.8	12.3	1.8	3.0	26.8	379.3	83.6	0.8	0.0	157.8	0.0	0.0	110.6	5.4	0.4	0.0	0.0	0.0	0.4	45.1	0.2	0.1	0.0	0.0	0.2	14.2	16.0	0.0	0.0	0.3	2.9	355.0	10.8	0.3	0.0	2.1	0.9	5.6	2.6	0.0	0.1	0.1	0.0	22.6	0.2	0.0	0.0	0.3	1.2	0.3	1.4	102.1	7.4	16.3	0.3	1.3	36.2	565.7	0.9	0.4	0.0	1.3	3.5	121.3	0.1	0.0	0.3	0.0	0.2	0.1	0.0	28.4	0.0	0.1	0.3	0.2	0.0	123.7	0.3	16.6	9.9	0.0	15.6	0.4	5.2	4.5	0.7	0.2	1.6	4.0	1.3	1.1	0.0	0.0	45.0	3.0	1.0	0.8	0.6	1.0	1.2	2.3	1.3	1.9	0.6	1.1	0.8	1.8	0.8	3.4	16.0	33.0	0.0	4.3	17.3	80.8	6.9	45.5	3.3	14.5	6.7	0.8	35.8	23.6	22.0	0.0	48.5	38.5	457.8	21.5	7.4	1.4	5.7	5.4	18.2	8.4	17.2	0.8	94.5	701.7	25.3	196.7	36.4	864.5	1.5	13.9	245.7	21.4	0.0	9.7	60.7	0.0	14.8	19.5	0.5	19.9	29.2	76.5	5.6	2.9	0.0	10.3	0.0	4.1	42.4	254.7	0.0	50.2	76.8	500.6	131.1	4.4	0.8	0.0	2.4	3.7	0.5	1.0	53.4	22.4	56.6	42.7	65.0	58.9	922.8
HS3ST6	HS3ST5	ENSG00000162040	"Heparan sulfate-glucosamine 3-sulfotransferase 6"	Q96QI5	16	1911475-1918415	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		Transferase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"skin 1: 74.8"	"Cell type enhanced"	"Detected in some"		"Endometrial ciliated cells: 10.7;Horizontal cells: 21.9;Suprabasal keratinocytes: 9.1;Urothelial cells: 24.9"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 4.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"A549: 1.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (5.72e-2)"	"prognostic favorable (3.73e-4)"		"unprognostic (1.30e-1)"		"unprognostic (1.20e-2)"		"unprognostic (1.19e-2)"	"unprognostic (3.10e-1)"	"unprognostic (4.99e-3)"		"unprognostic (2.10e-2)"		"unprognostic (6.55e-3)"	"unprognostic (2.42e-1)"	"unprognostic (3.61e-1)"	"unprognostic (2.26e-1)"	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	4.4	0.0	0.4	0.0	0.0	0.0	14.5	0.7	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.8	0.0	1.4	0.0	0.0	1.9	0.0	0.3	74.8	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.1	0.0	0.0	0.1	4.1	10.9	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.5	3.4	0.9	0.0	0.0	0.1	0.0	0.3	0.0	0.7	1.8	0.0	0.2	0.0	6.3	0.0	0.0	4.5	10.7	0.5	0.1	0.0	0.0	0.1	0.0	0.4	2.0	0.0	1.4	0.0	0.0	0.0	0.0	0.2	21.9	0.1	0.9	4.1	0.0	1.5	1.4	0.0	0.1	3.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	2.8	0.0	0.0	2.7	0.2	0.2	5.0	0.2	0.0	0.0	0.3	0.0	0.0	4.5	9.1	0.1	0.1	0.0	1.7	24.9
IL1A	"IL-1A, IL1, IL1-ALPHA, IL1F1"	ENSG00000115008	"Interleukin 1 alpha"	P01583	2	112773925-112784493	"Cancer-related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Cytokine, Mitogen, Pyrogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 13.4;testis: 10.5;urinary bladder: 26.2"	"Cell type enhanced"	"Detected in some"		"Basal respiratory cells: 22.6;Club cells: 9.8;Endometrial ciliated cells: 11.5;Glandular and luminal cells: 29.4;Macrophages: 30.6;Squamous epithelial cells: 9.4"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 22.3;urothelial cancer: 17.0"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"HBEC3-KT: 447.6;hTCEpi: 216.2;hTERT-HME1: 283.4"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"								"Secreted to blood"	NA	NA	10800					"unprognostic (3.41e-2)"	"prognostic unfavorable (9.52e-4)"	"unprognostic (1.99e-2)"	"unprognostic (4.28e-2)"	"unprognostic (2.08e-1)"	"unprognostic (8.03e-3)"	"unprognostic (4.42e-3)"	"prognostic unfavorable (1.54e-4)"	"unprognostic (1.62e-1)"	"unprognostic (2.45e-1)"	"unprognostic (4.57e-3)"	"unprognostic (1.22e-1)"	"unprognostic (4.30e-3)"	"prognostic unfavorable (4.03e-4)"	"unprognostic (1.66e-1)"	"unprognostic (2.44e-1)"	"unprognostic (8.62e-2)"	0.2	0.0	0.5	1.3	0.4	1.0	0.4	0.5	0.4	4.9	0.2	0.3	0.1	2.5	0.8	13.4	0.1	2.3	0.0	0.4	0.6	0.0	0.0	2.4	0.3	0.9	0.4	0.2	0.0	0.0	0.4	0.2	1.5	0.9	0.1	0.2	0.1	1.2	0.4	0.0	0.8	0.1	0.0	1.0	0.3	0.1	10.5	0.5	0.3	0.2	0.0	8.7	26.2	1.3	0.9	12.5	0.0	0.5	0.0	0.1	0.0	0.2	0.4	13.5	0.0	0.2	0.5	0.8	0.0	52.5	0.0	65.9	3.6	0.0	447.6	1.7	0.1	0.1	0.1	0.7	0.2	1.0	0.2	0.1	0.0	216.2	3.8	283.4	3.4	0.3	0.0	0.1	0.2	0.0	0.0	0.0	0.0	4.2	0.2	0.5	0.0	0.0	0.0	0.1	55.0	0.1	0.0	1.6	0.0	0.0	0.6	0.0	0.1	1.7	1.3	0.6	0.3	0.3	0.0	0.1	0.2	5.2	0.1	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.4	0.5	0.4	0.4	0.6	0.9	0.4	0.2	0.9	1.0	0.5	0.9	0.9	6.4	1.1	0.0	2.2	1.5	0.7	22.6	1.2	0.0	0.5	0.3	0.2	0.0	9.8	0.0	0.0	0.3	0.3	0.6	0.0	4.6	8.3	11.5	2.8	0.2	0.0	0.0	0.0	0.9	0.1	0.1	0.0	29.4	1.3	0.0	0.0	0.0	0.3	0.0	0.0	0.2	2.0	0.0	4.8	3.8	0.0	30.6	0.0	5.6	0.0	0.0	0.0	0.0	0.1	3.5	0.0	0.0	0.4	0.3	0.0	0.0	1.9	0.0	0.0	0.0	1.1	0.1	0.1	9.4	1.0	0.0	0.4	0.1	0.2	2.4
KCNG1	"K13, KCNG, kH2, Kv6.1"	ENSG00000026559	"Potassium voltage-gated channel modifier subfamily G member 1"	Q9UIX4	20	51003656-51023107	"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 28.0;endometrium 1: 88.2"	"Cell type enhanced"	"Detected in many"		"Cytotrophoblasts: 53.7;Granulosa cells: 34.0;Syncytiotrophoblasts: 97.0"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 8.9"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	20	"naive B-cell: 7.1"	"Lineage enriched"	"Detected in single"	71	"B-cells: 7.1"	"Cell line enhanced"	"Detected in many"		"hTCEpi: 53.5;U-138 MG: 40.4;WM-115: 34.6"	"Group enriched"	"Detected in many"	5	"amygdala: 20.6;basal ganglia: 19.1;cerebral cortex: 14.9;hippocampal formation: 18.1;white matter: 9.1"	"Group enriched"	"Detected in all"	5	"amygdala: 12.6;basal ganglia: 11.1;cerebral cortex: 22.4;hippocampal formation: 16.8"	"HPA039530, HPA040024"	Approved		Approved	Vesicles		NA	NA			Vesicles		"HPA039530: AB_10795144, HPA040024: AB_10796338"	"unprognostic (1.19e-1)"	"unprognostic (4.47e-2)"	"unprognostic (8.70e-2)"	"unprognostic (3.49e-2)"	"unprognostic (4.07e-2)"	"unprognostic (5.05e-4)"	"unprognostic (2.53e-2)"	"unprognostic (3.89e-3)"	"unprognostic (3.64e-2)"	"unprognostic (3.43e-2)"	"unprognostic (8.74e-2)"	"unprognostic (8.89e-2)"	"unprognostic (1.83e-9)"	"unprognostic (1.52e-1)"	"unprognostic (7.42e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.02e-2)"	0.3	3.1	16.8	2.3	28.0	0.0	0.4	0.6	10.1	11.8	0.2	4.3	0.2	88.2	0.8	6.7	19.4	0.9	1.0	15.5	5.3	0.3	0.2	0.3	2.3	24.8	10.1	18.8	0.7	2.7	4.2	0.8	7.2	6.8	5.6	0.8	0.1	2.2	12.9	0.0	0.5	5.3	4.2	2.5	2.8	0.7	9.6	5.5	0.2	0.2	0.0	0.9	3.5	6.3	5.0	0.9	3.6	2.7	13.3	1.5	3.4	0.2	11.6	0.1	6.7	5.3	0.2	0.2	0.0	7.1	3.5	18.8	3.4	1.7	3.5	6.9	0.4	4.7	0.0	13.6	0.0	23.2	0.0	0.4	6.8	53.5	25.7	26.1	1.3	1.8	0.1	0.2	0.0	0.6	13.4	0.0	0.4	13.7	0.0	25.0	0.0	0.0	0.0	0.0	4.1	3.9	15.0	25.5	29.3	19.9	4.3	2.1	1.9	0.7	40.4	23.9	0.3	3.4	0.1	0.0	0.0	11.8	1.0	34.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	16.8	28.0	0.6	10.1	15.5	5.3	24.8	10.1	18.8	6.8	2.5	5.5	5.0	0.2	3.2	1.1	0.3	10.5	1.1	11.0	0.6	13.6	0.3	1.1	2.3	1.1	7.2	0.9	0.0	0.0	53.7	0.0	7.5	0.0	2.6	18.2	9.3	2.0	1.2	0.0	0.0	2.0	0.0	2.7	1.5	0.5	15.9	0.0	34.0	0.4	0.3	3.3	1.7	2.2	0.6	0.0	0.0	0.3	20.3	1.5	0.3	0.0	1.0	0.0	0.2	1.0	0.0	0.6	0.2	3.4	4.1	0.0	18.1	12.8	0.1	0.9	0.2	0.0	1.1	7.1	12.7	0.7	5.4	0.3	97.0	0.4	0.3	0.4	9.9
KISS1		ENSG00000170498	"KiSS-1 metastasis suppressor"	Q15726	1	204190341-204196491	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted secreted proteins"			"Cancer-related genes, Disease variant, Hypogonadotropic hypogonadism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	24	"placenta: 235.3"	"Cell type enriched"	"Detected in many"	26	"Syncytiotrophoblasts: 1336.6"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 9.2"	"Region enriched"	"Detected in some"	8	"hypothalamus: 9.9"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	23	"BJ: 145.5;U-2 OS: 59.4"					"Not detected"	"Not detected"			"CAB017775, HPA035542"	Enhanced		Approved	Vesicles	"Secreted in female reproductive system"	NA	NA		860000	Vesicles		"CAB017775: , HPA035542: AB_2674677"	"unprognostic (9.64e-2)"	"unprognostic (1.78e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.18e-2)"	"unprognostic (3.89e-1)"	"unprognostic (6.87e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.28e-2)"		"unprognostic (1.28e-2)"	"unprognostic (4.51e-2)"	"unprognostic (1.63e-1)"	"unprognostic (8.98e-12)"	"unprognostic (2.25e-1)"	"unprognostic (2.91e-2)"	"unprognostic (1.76e-1)"	"prognostic favorable (6.29e-6)"	0.0	0.0	0.4	0.0	0.7	0.0	0.1	0.7	0.6	0.3	0.7	0.2	0.9	0.2	0.0	0.1	0.1	0.0	0.1	0.4	9.9	2.4	4.4	1.4	0.0	1.3	0.3	0.3	0.1	1.0	0.1	3.1	235.3	0.4	0.6	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.2	0.2	2.1	3.3	5.2	0.9	0.1	0.0	0.0	0.0	0.6	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.0	2.4	145.5	1.8	2.5	0.7	0.0	0.7	0.0	1.4	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.2	0.0	0.0	0.1	0.1	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.9	0.2	0.0	0.2	0.1	0.0	0.0	0.9	0.2	0.1	0.0	0.7	0.0	0.8	0.2	0.3	0.0	0.1	59.4	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.7	0.7	0.6	0.4	9.9	1.3	0.3	0.3	0.4	0.2	0.9	0.4	0.3	0.0	0.0	0.3	0.0	0.0	4.0	7.5	0.0	1.0	1.2	0.6	0.0	1.5	2.2	0.0	0.0	9.3	0.0	1.5	0.0	11.3	40.2	0.2	0.0	1.4	0.0	0.0	0.1	4.9	6.9	1.9	4.1	0.5	0.0	0.4	0.7	2.8	15.1	0.0	0.0	0.6	0.0	0.0	0.0	5.7	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	1.5	0.0	0.1	50.1	17.0	1.4	0.4	0.0	0.0	0.0	7.1	0.6	1.1	0.0	0.0	1336.6	0.1	0.1	2.1	14.3
KRT23	"CK23, DKFZP434G032, HAIK1, K23, MGC26158"	ENSG00000108244	"Keratin 23"	Q9C075	17	40922700-40937646	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"salivary gland: 149.0;skin 1: 161.7"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 1328.6;Cytotrophoblasts: 679.8;Prostatic glandular cells: 2203.0;Syncytiotrophoblasts: 3890.8;Urothelial cells: 1590.3"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 61.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	14	"HBEC3-KT: 9.6;Hep G2: 11.0;SuSa: 7.1;T-47d: 16.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA012050, HPA016959, CAB017091"	Approved		Approved	"Intermediate filaments,Cytosol"		NA	NA		590000	"Intermediate filaments"	Cytosol	"CAB017091: , HPA012050: AB_1852226, HPA016959: AB_1852228"	"unprognostic (1.62e-1)"	"unprognostic (5.29e-2)"	"unprognostic (4.35e-2)"	"unprognostic (6.18e-3)"	"unprognostic (1.45e-2)"	"unprognostic (2.83e-1)"	"unprognostic (5.22e-2)"	"unprognostic (6.84e-3)"	"unprognostic (2.74e-1)"	"unprognostic (2.15e-2)"	"unprognostic (8.96e-2)"	"unprognostic (1.56e-1)"	"unprognostic (8.22e-2)"	"unprognostic (6.78e-2)"	"unprognostic (1.40e-1)"	"unprognostic (2.99e-1)"	"prognostic unfavorable (8.26e-4)"	0.4	0.0	0.0	0.3	0.0	1.1	15.8	0.0	0.0	6.8	0.0	0.1	0.2	1.1	2.1	6.6	3.0	1.5	0.1	0.0	0.0	0.6	1.0	1.4	0.0	0.0	0.0	0.0	0.1	3.6	0.1	2.9	15.7	0.0	20.8	0.0	0.6	149.0	0.4	0.3	161.7	0.2	0.0	0.0	3.1	0.2	21.8	0.0	0.4	0.1	0.4	2.5	4.4	10.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.5	0.2	0.0	0.1	0.0	0.0	0.2	0.0	9.6	0.0	0.0	0.0	0.0	0.1	11.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.6	0.0	7.1	16.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.3	0.3	0.3	4.6	1328.6	242.1	0.6	0.0	78.0	27.9	0.4	12.8	390.5	3.7	0.0	679.8	1.1	0.1	1.9	462.9	66.2	49.8	7.8	15.1	7.1	0.0	0.5	0.8	109.3	15.0	0.0	66.4	0.0	0.0	0.0	0.0	63.8	0.0	0.3	0.7	57.0	0.0	0.7	10.6	0.6	3.0	5.4	0.0	5.4	15.8	0.0	0.5	0.3	17.7	1.1	0.7	0.0	2203.0	0.0	0.4	275.0	0.2	0.0	0.0	48.4	62.1	0.7	7.9	8.1	3890.8	7.6	0.1	0.9	1590.3
KRT33A	"Ha-3I, Krt1-3, KRTHA3A"	ENSG00000006059	"Keratin 33A"	O76009	17	41346092-41350828	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	11	"skin 1: 27.7"	"Group enriched"	"Detected in some"	8	"Basal squamous epithelial cells: 1.8;Early spermatids: 2.2;Late spermatids: 2.1;Squamous epithelial cells: 4.5"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 2.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA055194	Supported					NA	NA		160000000			"HPA055194: AB_2682733"	"unprognostic (1.93e-1)"	"unprognostic (1.30e-2)"				"unprognostic (4.58e-2)"		"unprognostic (4.34e-1)"									"unprognostic (2.16e-1)"	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	27.7	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0
KRT33B	"Ha-3II, KRTHA3B"	ENSG00000131738	"Keratin 33B"	Q14525	17	41363498-41369813	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	35	"skin 1: 49.9"	"Cell type enhanced"	"Detected in some"		"Extravillous trophoblasts: 2.9;Ionocytes: 2.0"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.8"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	27	"BJ: 4.3;BJ hTERT+ SV40 Large T+ RasG12V: 1.1"									HPA055194	Supported					NA	NA		350000000			"HPA055194: AB_2682733"		"unprognostic (3.34e-2)"				"unprognostic (5.19e-2)"		"unprognostic (3.04e-1)"					"unprognostic (1.55e-2)"				"unprognostic (6.28e-2)"	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	49.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.1
KRT7	"CK7, K2C7, K7, SCL"	ENSG00000135480	"Keratin 7"	P08729	12	52232520-52252186	"Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"salivary gland: 913.2;thyroid gland: 598.3"	"Cell type enhanced"	"Detected in many"		"Cytotrophoblasts: 1756.7;Ductal cells: 2931.3;Exocrine glandular cells: 2143.5;Extravillous trophoblasts: 4196.1;Pancreatic endocrine cells: 6163.7;Prostatic glandular cells: 2386.6;Urothelial cells: 1900.8"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 560.1"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in single"	4	"intermediate monocyte: 1.1"	"Lineage enriched"	"Detected in single"	4	"monocytes: 1.1"	"Cell line enhanced"	"Detected in many"		"A549: 2418.2;BEWO: 2737.9;HBEC3-KT: 6225.3;hTERT-HME1: 2433.8;RT4: 7463.2;SiHa: 5833.6;SK-BR-3: 3363.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000028, HPA007272, HPA007315, CAB079970"	Enhanced		Approved	"Intermediate filaments,Cytosol"		NA	NA		1300000000	"Intermediate filaments"	Cytosol	"CAB000028: AB_2134589, CAB079970: , HPA007272: AB_1079181, HPA007315: "	"unprognostic (2.71e-3)"	"unprognostic (3.09e-1)"	"unprognostic (2.20e-1)"	"prognostic unfavorable (1.99e-4)"	"unprognostic (2.22e-2)"	"unprognostic (8.59e-2)"	"unprognostic (1.27e-1)"	"unprognostic (5.44e-3)"	"unprognostic (2.74e-1)"	"prognostic unfavorable (9.42e-5)"	"prognostic unfavorable (7.78e-5)"	"unprognostic (4.54e-2)"	"prognostic favorable (2.77e-9)"	"unprognostic (2.82e-1)"	"unprognostic (1.43e-2)"	"unprognostic (3.28e-1)"	"unprognostic (3.98e-3)"	15.9	0.7	0.0	1.4	0.0	0.3	275.6	0.0	0.3	48.9	0.4	1.4	0.4	13.0	15.3	92.4	76.6	83.2	3.7	0.0	0.8	101.4	14.3	328.0	1.7	0.3	0.0	0.0	2.4	57.8	5.6	12.1	267.3	0.3	58.6	0.7	0.3	913.2	215.1	1.7	72.0	1.3	0.4	0.1	0.8	18.0	0.8	0.1	3.4	598.3	2.0	6.8	393.4	20.2	0.5	4.9	2418.2	0.6	1.7	2.8	0.0	2737.9	509.6	0.6	261.3	23.6	7.6	1683.1	0.3	1.4	176.3	0.8	1871.6	0.2	6225.3	13.3	3.0	0.0	2.2	1179.8	8.0	57.4	1.5	1.5	1.3	380.7	1.3	2433.8	1.0	267.4	0.0	0.7	2.2	0.1	13.7	1.8	3.7	7.6	1.1	2.6	2.0	4.8	38.6	1520.5	7463.2	3.5	2.4	5833.6	3363.4	0.0	27.5	130.3	0.0	2028.2	1.9	3.7	2.4	1.1	1.8	0.4	2.0	2.0	1.6	1.2	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.8	0.3	0.0	0.0	0.3	0.1	0.1	0.5	8.1	653.9	109.4	0.0	2.5	3.6	1172.6	173.6	8.0	0.0	451.3	426.3	0.8	724.9	684.8	360.5	0.0	1756.7	8.9	2.2	135.0	2931.3	16.1	106.2	20.4	30.6	6.6	0.0	0.1	2143.5	4196.1	29.9	14.3	253.2	3.8	0.1	4.2	2.9	189.9	0.0	0.0	3.5	954.2	3.4	4.6	140.0	3.7	11.0	131.6	0.0	35.6	0.0	0.0	0.0	0.0	6163.7	0.3	0.4	1.4	2386.6	0.2	8.5	249.2	0.0	0.0	7.6	72.1	0.6	1.3	35.3	2.3	1442.5	9.2	0.0	4.4	1900.8
KRTAP3-1	KAP3.1	ENSG00000212901	"Keratin associated protein 3-1"	Q9BYR8	17	41008521-41019324	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	285	"skin 1: 140.6"	"Cell type enriched"	"Detected in some"	4	"Basal prostatic cells: 581.4"	"Cancer enhanced"	"Detected in some"		"stomach cancer: 2.8;urothelial cancer: 2.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 2.0;BJ: 4.9;CACO-2: 12.7;HaCaT: 2.4;T-47d: 2.0"	"Not detected"	"Not detected"													NA	NA									"unprognostic (4.24e-1)"				"unprognostic (3.00e-2)"				"unprognostic (7.37e-2)"						0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	140.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	12.7	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	581.4	0.0	4.0	0.0	0.9	0.0	0.0	0.0	3.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	3.1	0.3	1.0	0.0	0.0	0.0	0.0	0.1	1.5	0.0	2.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	139.6	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	1.3	0.0	1.4	11.2	0.0	0.0	71.8
KRTAP3-3	KAP3.3	ENSG00000212899	"Keratin associated protein 3-3"	Q9BYR6	17	40993430-40994164	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	218	"skin 1: 77.6"	"Cell type enriched"	"Detected in single"	4	"Enteroendocrine cells: 1.8"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA042992	Supported					NA	NA					"HPA042992: AB_2678258"																		0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	77.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KRTAP5-10	KRTAP5.10	ENSG00000204572	"Keratin associated protein 5-10"	Q6L8G5	11	71565563-71566735	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in some"		"epididymis: 1.4;skin 1: 3.2"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 2.7;Late spermatids: 1.0;Respiratory ciliated cells: 1.0"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	10	"RT4: 3.5"															NA	NA						"unprognostic (4.05e-2)"	"unprognostic (5.64e-3)"	"unprognostic (1.39e-2)"	"unprognostic (6.47e-2)"	"unprognostic (7.81e-2)"	"unprognostic (4.70e-2)"	"unprognostic (5.55e-2)"	"unprognostic (1.68e-1)"	"unprognostic (3.53e-1)"	"unprognostic (9.81e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.53e-1)"	"unprognostic (8.39e-4)"	"unprognostic (9.43e-2)"	"unprognostic (1.37e-1)"	"unprognostic (6.21e-2)"	"unprognostic (2.27e-4)"	0.1	0.1	0.2	0.0	0.3	0.0	0.2	0.2	0.4	0.0	0.2	0.1	0.0	0.0	1.4	0.1	0.2	0.1	0.0	0.3	0.3	0.3	0.2	0.1	0.0	0.2	0.2	0.2	0.0	0.5	0.0	0.2	0.0	0.2	0.3	0.1	0.1	0.1	0.3	0.2	3.2	0.1	0.0	0.2	0.2	0.1	0.6	0.3	0.0	0.2	0.0	0.0	0.6	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.2	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.0	0.5	0.7	0.0	0.1	0.2	0.0	0.0	0.0	0.2	0.6	0.6	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.7	0.4	0.1	0.4	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.5	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	1.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.7	1.0	0.0	0.0	0.0	0.1	0.4	0.1	0.0	0.0	0.0	0.0	0.2	0.2	0.6
KRTAP5-9	"KRN1, KRTAP5-1, KRTAP5.9"	ENSG00000254997	"Keratin associated protein 5-9"	P26371	11	71548420-71549608	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"testis: 3.2"	"Group enriched"	"Detected in some"	7	"Early spermatids: 2.3;Late spermatids: 5.6"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 2.0"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	21	"RT4: 8.6"															NA	NA						"unprognostic (1.72e-3)"	"unprognostic (2.20e-1)"	"unprognostic (2.22e-2)"	"unprognostic (2.16e-1)"	"unprognostic (4.13e-1)"	"unprognostic (6.53e-2)"	"unprognostic (8.10e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.06e-1)"	"unprognostic (7.76e-2)"	"unprognostic (7.23e-2)"	"unprognostic (2.56e-1)"	"unprognostic (3.29e-1)"	"unprognostic (2.05e-2)"	"unprognostic (2.01e-1)"	"unprognostic (4.82e-4)"	"prognostic favorable (9.25e-4)"	0.3	0.3	0.7	0.0	0.7	0.2	0.3	0.4	1.2	0.2	0.3	0.4	0.1	0.2	1.7	0.5	0.4	0.3	0.1	0.7	0.5	0.5	0.8	0.4	0.1	0.6	0.6	0.4	0.1	0.2	0.2	0.8	0.1	0.5	0.6	0.2	0.3	0.3	0.4	0.4	0.8	0.5	0.0	0.4	0.6	0.2	3.2	0.5	0.0	0.3	0.0	0.1	1.3	0.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.4	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	8.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.4	1.2	0.7	0.5	0.6	0.6	0.4	0.5	0.4	0.5	0.6	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.3	0.4	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.1	0.4	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1
LRTM1	HT017	ENSG00000144771	"Leucine rich repeats and transmembrane domains 1"	Q9HBL6	3	54918231-54967088	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"retina: 79.6;skeletal muscle: 26.1"	"Cell type enriched"	"Detected in some"	12	"Bipolar cells: 389.8"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"HEL: 1.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"									NA	NA										"unprognostic (2.28e-1)"	"unprognostic (1.58e-2)"								"unprognostic (9.56e-2)"	"unprognostic (2.16e-1)"		"unprognostic (1.87e-3)"	0.1	0.0	1.4	0.0	3.0	0.1	0.5	0.5	3.5	0.2	2.7	0.4	0.0	0.0	0.3	4.0	0.1	0.0	0.1	2.2	3.3	0.0	0.3	0.2	0.1	1.0	5.8	2.4	0.0	0.1	0.1	0.0	0.6	1.7	1.1	0.1	79.6	1.0	0.5	26.1	0.0	0.2	0.0	0.1	6.7	0.1	0.5	1.1	0.1	0.3	2.5	0.1	0.1	0.0	3.0	0.1	0.0	0.3	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.4	0.0	0.3	0.0	0.1	0.1	0.0	0.2	0.0	0.4	0.1	0.2	0.0	1.1	0.3	0.2	0.0	0.0	0.2	0.4	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.5	0.3	0.0	0.1	0.0	0.0	0.3	0.0	0.2	0.1	0.1	0.0	0.5	0.0	0.1	0.2	0.0	0.0	0.2	0.2	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.1	0.5	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	0.3	0.0	0.1	0.1	1.4	3.0	0.5	3.5	2.2	3.3	1.0	5.8	2.4	1.7	0.1	1.1	3.0	0.2	0.0	0.0	5.9	0.0	0.4	0.6	0.1	0.0	389.8	0.0	0.0	0.5	0.0	0.0	1.8	16.7	9.3	0.0	0.1	0.0	0.0	3.0	0.1	0.2	1.0	0.0	0.0	27.1	0.4	1.3	1.2	0.0	0.3	0.0	0.2	0.0	0.0	0.7	1.7	10.9	0.0	0.0	0.0	0.6	0.7	5.9	0.1	0.0	1.9	0.1	17.2	0.0	4.0	0.5	2.0	0.0	4.5	0.0	0.6	0.0	0.0	0.0	30.8	0.0	3.2	1.6	3.1	3.7	0.0	0.4	22.2	0.1	0.5	0.0	0.4
MAGEA10	"CT1.10, MAGE10, MGC10599"	ENSG00000124260	"MAGE family member A10"	P43363	X	152133310-152138578	"Predicted intracellular proteins"		"Tumor antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	12	"placenta: 9.5;testis: 2.6"	"Cell type enhanced"	"Detected in some"		"Sertoli cells: 6.6;Spermatocytes: 57.3;Spermatogonia: 26.2;Syncytiotrophoblasts: 11.2"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 3.8"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	6	"GAMG: 78.6"					"Not detected"	"Not detected"			"HPA003333, HPA070780"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA003333: AB_10962837, HPA070780: AB_2686310"		"unprognostic (1.92e-1)"				"unprognostic (1.06e-1)"		"unprognostic (2.02e-1)"	"unprognostic (6.95e-2)"	"unprognostic (9.91e-2)"				"unprognostic (5.97e-3)"	"unprognostic (1.11e-1)"		"unprognostic (1.25e-1)"	0.1	0.1	0.1	0.1	0.1	0.3	0.0	0.3	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	9.5	0.3	0.0	0.0	0.1	0.1	0.0	0.1	0.5	0.1	0.0	0.0	0.1	0.0	2.6	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	78.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.2	0.0	0.0	0.1	0.0	0.0	8.2	0.0	0.1	0.0	0.0	0.0	0.2	4.9	0.0	0.1	0.0	0.2	0.1	0.0	0.1	0.0	0.1	0.0	0.0	1.0	6.0	0.0	0.4	0.0	12.7	0.5	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.4	0.2	0.1	0.1	0.0	0.0	0.1	0.1	0.3	0.3	0.1	0.3	0.0	0.1	0.0	0.3	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	57.3	26.2	0.0	0.0	11.2	0.0	0.0	0.0	0.1
MAGEA9B		ENSG00000267978	"MAGE family member A9B"	P43362	X	149581653-149587453	"Predicted intracellular proteins"		"Tumor antigen"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	29	"testis: 10.1"	"Group enriched"	"Detected in some"	4	"Spermatocytes: 39.6;Spermatogonia: 16.0"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 1.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	14	"OE19: 82.4;RT4: 131.1;U-266/70: 55.1;U-266/84: 73.7"									"HPA045401, HPA051687"			Approved	"Nucleoplasm,Golgi apparatus"		NA	NA			"Nucleoplasm, Golgi apparatus"		"HPA045401: AB_2679315, HPA051687: "															"unprognostic (6.12e-3)"		"unprognostic (3.26e-1)"	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.3	2.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.4	0.0	0.1	0.0	0.0	0.1	82.4	0.0	0.2	0.0	6.3	0.0	131.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	55.1	73.7	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	39.6	16.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
MROH2A	HEATR7B1	ENSG00000185038	"Maestro heat like repeat family member 2A"	A6NES4	2	233775679-233833423	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"testis: 1.8;thyroid gland: 1.6"	"Cell type enhanced"	"Detected in some"		"Basal squamous epithelial cells: 3.4;Early spermatids: 1.3;Hepatocytes: 1.0;Late spermatids: 1.7;Spermatocytes: 1.5"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 2.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	7	"RT4: 6.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA052107	Uncertain		Uncertain	Cytosol		NA	NA			Cytosol		"HPA052107: AB_2681729"	"unprognostic (7.00e-2)"	"unprognostic (3.37e-3)"	"unprognostic (4.77e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.03e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.87e-1)"	"unprognostic (4.41e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.67e-1)"	"unprognostic (4.32e-2)"	"unprognostic (5.05e-2)"	"unprognostic (4.06e-9)"	"unprognostic (5.65e-2)"	"unprognostic (3.90e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.41e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.8	0.1	0.0	1.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	6.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.1	0.4	3.4	0.0	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	1.5	0.6	0.6	0.1	0.0	0.0	0.0	0.0	0.3
MTUS2	"CAZIP, ICIS, KIAA0774, TIP150"	ENSG00000132938	"Microtubule associated scaffold protein 2"	Q5JR59	13	28820339-29505947	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"heart muscle: 50.7"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 548.4;Inhibitory neurons: 671.8"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 0.9"	"Region enhanced"	"Detected in many"		"cerebral cortex: 10.6"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"HaCaT: 13.2;HeLa: 5.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031473, HPA031474, HPA031475"	Enhanced		Supported	"Microtubules,Cytokinetic bridge"		Yes	NA			"Microtubules, Cytokinetic bridge"		"HPA031473: AB_2673901, HPA031474: AB_10600109, HPA031475: AB_10600442"	"unprognostic (1.67e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.96e-1)"	"unprognostic (3.33e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.22e-2)"	"unprognostic (2.79e-1)"	"unprognostic (1.35e-1)"	"unprognostic (2.87e-1)"	"unprognostic (4.97e-2)"	"unprognostic (1.30e-3)"	"unprognostic (3.45e-2)"	"unprognostic (3.91e-5)"	"unprognostic (2.51e-2)"	"unprognostic (5.46e-2)"	"unprognostic (5.93e-2)"	"unprognostic (9.62e-2)"	0.1	0.2	0.3	0.1	2.0	0.1	0.1	1.4	10.6	0.6	1.6	0.6	0.1	1.5	0.0	0.3	0.9	0.1	50.7	1.6	1.4	0.1	0.9	0.1	0.6	0.4	0.9	1.9	7.6	4.8	0.0	6.2	0.0	1.7	0.3	0.2	4.6	1.0	0.1	0.1	0.2	0.5	1.2	0.4	0.5	1.4	1.2	1.0	0.2	0.5	0.1	0.1	1.3	0.2	3.1	0.0	0.0	0.8	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.1	0.2	13.2	0.4	0.0	0.0	0.0	0.5	0.0	5.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.6	0.1	0.0	0.0	0.0	0.0	1.0	0.0	2.3	1.6	0.1	0.4	0.0	0.2	0.2	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.7	0.2	0.1	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	2.0	1.4	10.6	1.6	1.4	0.4	0.9	1.9	1.7	0.4	1.0	3.1	0.1	0.0	0.5	10.4	0.1	0.5	0.7	0.1	0.0	0.0	0.3	0.4	145.8	0.0	1.3	0.0	0.0	0.1	0.0	0.1	0.0	0.0	5.4	0.3	1.0	0.7	0.0	0.8	548.4	0.6	0.0	5.9	0.0	1.1	0.0	1.2	0.4	0.5	0.1	0.0	671.8	0.7	0.0	0.0	0.8	3.3	0.9	0.2	1.8	15.0	0.1	0.0	0.0	18.1	16.2	0.4	0.0	0.0	0.1	0.2	0.0	0.0	3.6	0.0	0.0	1.6	1.0	0.1	4.1	1.8	0.1	0.3	0.3	19.6	0.0	1.1
MYCL	"bHLHe38, LMYC, MYCL1"	ENSG00000116990	"MYCL proto-oncogene, bHLH transcription factor"	P12524	1	39895426-39902256	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 68.4;skin 1: 41.7"	"Cell type enhanced"	"Detected in many"		"Cytotrophoblasts: 34.9;Hepatocytes: 24.3;Intestinal goblet cells: 25.0;monocytes: 27.4;Squamous epithelial cells: 34.2;Urothelial cells: 27.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 28.9"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"classical monocyte: 17.3;intermediate monocyte: 8.2;myeloid DC: 18.7;plasmacytoid DC: 22.8"	"Group enriched"	"Detected in many"	72	"dendritic cells: 22.8;monocytes: 17.3"	"Group enriched"	"Detected in many"	7	"U-266/70: 444.0;U-266/84: 364.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA063132, HPA074515"			Enhanced	"Nucleoplasm,Mitotic chromosome"		Yes	NA			Nucleoplasm	"Mitotic chromosome"	"HPA063132: AB_2684946, HPA074515: "	"unprognostic (7.45e-2)"	"unprognostic (6.91e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.83e-3)"	"unprognostic (1.61e-2)"	"unprognostic (2.92e-3)"	"unprognostic (6.72e-3)"	"prognostic favorable (4.49e-4)"	"unprognostic (1.24e-1)"	"unprognostic (1.77e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.12e-1)"	"unprognostic (5.01e-3)"	"unprognostic (2.75e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.53e-2)"	"unprognostic (5.80e-2)"	0.8	0.3	1.6	4.7	1.8	0.6	3.4	1.2	2.1	2.7	1.8	6.2	4.8	0.9	7.2	22.3	3.1	1.5	0.5	2.3	1.6	1.0	11.4	3.4	6.4	1.5	1.5	1.7	0.4	68.4	0.3	3.0	6.7	1.7	4.2	6.7	0.2	6.4	7.5	0.5	41.7	5.7	1.1	1.9	7.7	6.2	1.3	2.0	6.6	5.4	0.5	9.6	16.1	12.9	2.0	1.2	0.4	14.4	3.5	0.2	0.1	31.8	0.5	0.2	1.0	0.7	0.4	0.8	2.2	1.4	0.1	0.4	3.3	10.4	2.7	0.8	2.0	4.9	0.5	0.3	0.5	0.4	0.3	7.5	1.0	12.1	0.4	1.3	0.2	1.2	5.4	3.2	0.4	0.6	1.2	0.2	0.3	13.4	2.2	0.4	1.3	15.5	2.9	1.1	58.0	2.5	3.1	1.4	2.1	0.8	5.5	3.7	18.7	0.0	0.0	4.6	6.2	0.5	444.0	364.6	1.0	0.1	2.3	0.3	0.0	17.3	0.0	0.0	8.2	0.0	0.0	0.0	0.0	18.7	0.0	0.0	0.0	0.2	0.0	3.4	22.8	0.0	6.7	1.6	1.8	1.2	2.1	2.3	1.6	1.5	1.5	1.7	1.7	1.9	2.0	2.0	0.4	0.0	1.1	0.0	0.8	6.6	10.0	2.1	13.1	0.4	3.8	6.0	3.7	0.0	5.5	9.2	0.0	34.9	20.1	13.4	0.0	1.5	0.1	5.1	0.6	0.5	17.3	0.0	0.2	5.8	15.4	0.9	5.1	6.3	0.0	0.0	1.4	24.3	5.1	0.0	0.3	25.0	8.2	8.3	13.1	0.4	0.0	10.6	1.8	0.0	27.4	0.8	0.0	1.0	0.0	2.9	6.5	0.0	3.6	5.3	6.4	0.1	4.9	0.1	0.0	1.4	0.7	0.0	1.2	34.2	11.8	17.5	0.3	0.0	10.8	27.1
NIPAL4	ICHYN	ENSG00000172548	"NIPA like domain containing 4"	Q0D2K0	5	157460213-157474722	"Disease related genes, Human disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	Receptor	"Disease variant, Ichthyosis"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 19.5;skin 1: 60.2"	"Cell type enhanced"	"Detected in some"		"Basal keratinocytes: 29.7;Basal prostatic cells: 9.8;Oligodendrocytes: 21.0;Squamous epithelial cells: 9.8;Suprabasal keratinocytes: 42.1"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 17.0;urothelial cancer: 11.8"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	25	"memory B-cell: 1.6;naive B-cell: 4.8"	"Lineage enriched"	"Detected in single"	37	"B-cells: 4.8"	"Group enriched"	"Detected in some"	8	"hTCEpi: 31.7;RT4: 108.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038259	Approved					NA	NA					"HPA038259: AB_10672510"	"unprognostic (6.74e-4)"	"unprognostic (9.54e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.61e-1)"	"unprognostic (6.56e-2)"	"unprognostic (3.55e-2)"	"unprognostic (5.20e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.99e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.76e-2)"	"unprognostic (5.28e-9)"	"unprognostic (3.12e-2)"	"unprognostic (8.66e-3)"	"unprognostic (1.18e-2)"	"prognostic favorable (6.82e-4)"	0.3	0.0	4.5	2.0	9.6	3.5	2.2	8.8	7.9	2.9	2.1	2.9	0.3	1.2	0.1	15.3	0.1	0.5	0.8	4.5	6.7	0.0	0.0	0.7	0.4	12.8	9.5	3.5	0.0	0.0	0.0	0.5	0.6	10.3	1.5	0.6	0.1	1.9	1.4	0.2	60.2	1.0	1.1	9.8	0.2	2.6	0.1	8.5	0.4	0.3	0.0	5.8	11.6	15.2	19.5	0.0	5.1	0.0	0.0	0.0	0.0	0.0	0.9	0.1	0.4	0.1	1.1	0.0	0.0	0.7	0.4	0.0	6.3	0.3	2.7	0.6	0.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.3	31.7	0.0	1.3	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.8	0.0	0.0	0.0	0.0	108.1	0.0	0.4	0.0	0.0	0.0	8.5	1.6	0.0	0.1	0.0	3.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.6	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.5	9.6	8.8	7.9	4.5	6.7	12.8	9.5	3.5	10.3	9.8	8.5	19.5	0.0	0.0	0.5	0.0	2.4	29.7	9.8	0.6	2.2	0.6	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	1.7	0.3	0.0	1.1	1.8	0.0	0.0	0.0	0.0	0.0	21.0	0.1	0.0	0.0	0.3	3.8	0.0	0.0	0.1	1.1	0.0	5.2	0.3	0.0	0.1	9.8	42.1	0.0	0.2	0.0	0.0	4.4
ODAPH	"AI2A4, C4orf26, FLJ23657"	ENSG00000174792	"Odontogenesis associated phosphoprotein"	Q17RF5	4	75556048-75565871	"Disease related genes, Human disease related genes, Predicted secreted proteins"			"Amelogenesis imperfecta"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 1.8;placenta: 5.9"	"Group enriched"	"Detected in some"	4	"Extravillous trophoblasts: 9.2;Syncytiotrophoblasts: 27.0"	"Cancer enhanced"	"Detected in some"		"head and neck cancer: 1.1;urothelial cancer: 0.7"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	33	"basophil: 10.7"	"Lineage enriched"	"Detected in single"	33	"granulocytes: 10.7"	"Cell line enriched"	"Detected in some"	6	"HDLM-2: 61.3"														"Secreted in other tissues"	NA	NA						"unprognostic (1.13e-1)"	"unprognostic (4.45e-3)"	"unprognostic (3.78e-1)"	"unprognostic (1.66e-1)"	"unprognostic (6.12e-2)"	"unprognostic (2.12e-2)"		"unprognostic (1.75e-2)"	"unprognostic (2.44e-1)"	"unprognostic (3.87e-2)"	"unprognostic (5.30e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.17e-7)"	"unprognostic (8.31e-2)"	"unprognostic (2.70e-2)"	"unprognostic (8.40e-4)"	"unprognostic (6.53e-3)"	0.1	0.1	1.0	0.2	1.0	0.3	0.1	1.1	1.5	0.1	0.8	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.9	0.8	0.1	0.1	0.1	0.2	1.1	1.0	0.8	0.1	0.0	0.0	0.4	5.9	1.1	0.1	0.2	0.5	0.1	0.1	0.9	0.3	0.2	0.0	0.8	0.1	0.1	0.4	0.9	0.1	0.0	0.0	0.3	0.1	0.1	1.8	0.9	0.0	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	1.3	0.5	0.1	0.2	0.0	0.1	0.1	0.0	0.2	0.3	61.3	0.0	0.2	0.2	0.3	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	2.9	0.0	0.2	0.1	0.1	0.2	0.0	0.0	0.0	0.1	0.1	0.7	0.1	0.0	0.1	0.0	2.8	0.0	2.1	0.3	0.1	0.0	0.1	2.6	0.1	0.9	9.6	0.1	0.1	0.6	0.2	0.0	10.7	0.1	0.0	0.0	0.1	0.3	0.1	0.1	0.1	0.0	0.3	0.0	0.0	0.3	0.1	0.1	0.1	0.0	0.1	1.0	1.0	1.1	1.5	0.9	0.8	1.1	1.0	0.8	1.1	0.8	0.9	1.8	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.0	0.0	0.0	1.8	0.0	1.9	0.1	0.0	0.0	3.9	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.2	9.2	0.1	0.0	0.2	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	27.0	0.1	0.1	0.0	0.0
OR13A1		ENSG00000256574	"Olfactory receptor family 13 subfamily A member 1"	Q8NGR1	10	45302298-45315608	"G-protein coupled receptors, Predicted membrane proteins"	"Olfaction, Sensory transduction"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in single"		"urinary bladder: 1.0"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.8"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	33	"Daudi: 10.4;U-698: 9.3"	"Not detected"	"Not detected"							HPA057237	Uncertain					NA	NA					"HPA057237: AB_2683378"	"unprognostic (7.88e-2)"	"unprognostic (1.90e-1)"	"unprognostic (5.52e-2)"	"unprognostic (2.33e-5)"	"unprognostic (6.43e-3)"	"unprognostic (6.04e-2)"		"unprognostic (8.65e-2)"	"unprognostic (3.59e-1)"	"unprognostic (2.45e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.67e-15)"	"unprognostic (6.54e-2)"	"unprognostic (2.87e-1)"	"unprognostic (8.55e-2)"	"unprognostic (4.09e-3)"	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.1	0.2	0.1	0.7	0.0	0.0	0.3	1.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	9.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.1
OSR1	ODD	ENSG00000143867	"Odd-skipped related transcription factor 1"	Q8TAX0	2	19351485-19358623	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"urinary bladder: 82.0"	"Cell type enhanced"	"Detected in some"		"Fibroblasts: 35.8;Leydig cells: 133.6;Peritubular cells: 45.9;Smooth muscle cells: 21.4"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 4.9"	"Region enhanced"	"Detected in some"		"hypothalamus: 8.4"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	11	"U-2197: 101.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA015525	Uncertain					NA	NA					"HPA015525: AB_1854822"	"unprognostic (1.71e-3)"	"unprognostic (1.23e-1)"	"unprognostic (6.85e-4)"	"unprognostic (1.42e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.45e-2)"	"unprognostic (8.47e-4)"	"unprognostic (2.79e-1)"	"unprognostic (1.91e-1)"	"unprognostic (6.87e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.21e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.74e-1)"	"unprognostic (2.51e-2)"	"unprognostic (1.62e-1)"	24.6	2.4	0.6	3.5	0.7	0.0	22.6	0.3	1.7	13.2	2.2	18.4	1.4	10.4	0.3	3.6	8.2	6.0	10.1	1.5	8.4	1.5	0.5	17.1	0.5	0.5	0.2	0.8	6.1	2.8	0.2	2.7	3.4	0.2	14.1	2.0	0.0	31.7	3.7	3.0	10.2	11.2	11.4	0.2	0.1	9.8	5.4	2.7	0.7	10.3	3.6	0.1	82.0	12.4	0.5	0.0	2.4	0.1	4.7	3.2	9.2	0.0	6.0	2.8	5.6	2.8	0.0	0.1	0.0	0.0	8.5	2.7	0.0	3.0	1.4	1.4	0.0	0.2	0.0	0.1	3.5	4.0	0.0	0.2	4.6	0.0	5.2	6.9	4.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.1	0.0	3.6	5.0	0.0	0.2	0.0	0.6	1.9	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	1.3	0.4	101.8	0.2	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.3	1.7	1.5	8.4	0.5	0.2	0.8	0.2	0.2	2.7	0.5	1.2	0.0	0.5	0.0	0.0	4.7	1.0	1.7	0.6	0.0	1.0	6.1	7.2	0.0	1.1	3.7	0.0	0.5	0.1	0.1	0.0	1.3	0.7	0.0	0.7	0.5	0.0	0.0	0.1	0.0	0.4	35.8	0.0	0.1	1.3	1.2	0.0	0.0	0.9	0.0	0.0	0.3	4.1	0.0	4.9	3.8	133.6	0.3	3.6	2.8	0.0	0.0	0.0	0.0	0.1	0.4	0.1	45.9	0.0	0.4	0.0	2.9	0.3	0.0	0.0	1.3	21.4	0.4	0.1	0.3	4.1	0.4	0.7	0.8	0.2	1.1
OVCH2	OVTN	ENSG00000183378	"Ovochymase 2"		11	7689437-7706421	"Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at transcript level"	"Evidence at transcript level"			"Group enriched"	"Detected in some"	15	"epididymis: 190.6;retina: 93.1"	"Group enriched"	"Detected in some"	7	"Collecting duct cells: 7.3;Rod photoreceptor cells: 16.6"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.5"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	7	"REH: 25.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted in male reproductive system"	NA	NA						"unprognostic (1.59e-2)"	"unprognostic (3.74e-1)"		"unprognostic (8.03e-2)"		"unprognostic (9.77e-2)"		"unprognostic (1.85e-1)"	"unprognostic (1.70e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.28e-1)"	"unprognostic (2.84e-2)"	"unprognostic (3.06e-1)"	"unprognostic (9.27e-2)"	"unprognostic (7.65e-2)"	"unprognostic (1.22e-2)"	0.0	0.0	0.1	0.0	0.6	0.4	3.4	0.7	0.3	0.1	0.0	0.0	0.0	0.2	190.6	0.1	0.3	0.0	0.0	0.0	0.1	5.4	0.0	2.4	0.0	0.6	0.4	0.0	0.0	0.0	0.0	0.0	1.4	1.0	1.1	0.0	93.1	0.8	5.8	0.4	9.1	0.1	0.0	0.0	0.0	0.5	0.5	0.7	0.0	0.0	0.0	0.1	0.9	0.2	0.7	3.4	0.0	0.3	0.0	0.0	0.0	0.5	0.8	0.6	0.1	0.3	0.2	0.0	0.1	0.2	0.0	0.1	0.1	0.0	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.9	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	25.2	0.0	0.2	0.2	2.7	0.0	0.2	0.0	0.1	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.7	0.3	0.0	0.1	0.6	0.4	0.0	1.0	0.0	0.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.4	0.1	1.3	0.1	0.0	0.0	7.3	0.0	1.4	0.0	0.0	0.0	0.0	1.7	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.6	0.0	0.0	0.7	0.0	0.1	0.0	0.7	0.0	16.6	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.4
PCP4L1	IQM1	ENSG00000248485	"Purkinje cell protein 4 like 1"	A6NKN8	1	161258745-161285450	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 70.5;pituitary gland: 85.0"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 35.8;Bipolar cells: 82.8;Inhibitory neurons: 34.0;Sertoli cells: 19.7;Squamous epithelial cells: 23.5;Urothelial cells: 39.9"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 21.8"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"RT4: 13.8;T-47d: 8.9"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"olfactory bulb: 206.6"	HPA052833	Enhanced	Supported	Approved	Nucleoplasm,Mitochondria		NA	NA			"Nucleoplasm, Mitochondria"		"HPA052833: AB_2681968"	"unprognostic (1.81e-2)"	"unprognostic (9.39e-2)"	"unprognostic (5.25e-2)"	"unprognostic (2.07e-1)"	"unprognostic (3.03e-2)"	"unprognostic (1.87e-2)"	"unprognostic (2.51e-1)"	"prognostic favorable (8.10e-5)"	"unprognostic (2.39e-1)"	"unprognostic (1.92e-1)"	"unprognostic (4.93e-2)"	"unprognostic (7.37e-2)"	"unprognostic (3.63e-5)"	"unprognostic (4.81e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.09e-1)"	"unprognostic (6.15e-2)"	2.8	0.4	16.4	0.8	70.5	0.1	1.8	21.8	29.5	3.6	2.3	4.9	1.7	1.8	2.6	18.9	2.1	2.0	0.8	9.1	21.5	0.5	4.0	4.6	0.2	37.6	24.2	14.7	2.2	0.5	0.4	85.0	0.3	42.8	11.1	2.6	39.6	1.9	16.5	0.5	4.6	2.8	6.6	22.1	0.4	2.0	1.8	20.3	2.0	0.7	1.6	2.6	35.9	17.2	65.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	1.7	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.3	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.1	0.0	0.1	0.0	13.8	1.9	0.0	0.0	0.2	0.0	0.2	8.9	0.3	0.2	0.0	0.0	0.0	0.0	0.8	0.9	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	16.4	70.5	21.8	29.5	9.1	21.5	37.6	24.2	14.7	42.8	22.1	20.3	65.9	0.0	3.2	6.4	2.0	0.0	0.0	35.8	8.3	12.5	82.8	3.2	1.0	0.2	0.0	7.6	0.0	6.2	0.4	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.3	0.0	0.0	3.1	1.3	1.9	0.2	4.6	0.3	1.3	0.0	0.0	0.9	0.1	0.0	34.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	2.8	0.0	3.5	0.0	5.0	1.4	0.2	0.0	1.9	0.0	2.5	0.0	0.6	0.9	5.9	19.7	0.0	10.0	1.3	1.5	23.5	0.3	1.8	0.0	0.0	0.0	39.9
POU4F3	"BRN3C, DFNA15, DFNA42, DFNA52"	ENSG00000091010	"POU class 4 homeobox 3"	Q15319	5	146338839-146341728	"Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Deafness, Disease variant, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA038215	Uncertain		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA038215: AB_10697245"	"unprognostic (8.41e-3)"	"unprognostic (9.46e-2)"	"unprognostic (1.84e-1)"	"unprognostic (6.26e-4)"	"unprognostic (1.86e-1)"	"unprognostic (1.12e-1)"		"unprognostic (1.03e-1)"	"unprognostic (9.54e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.09e-3)"	"unprognostic (1.20e-3)"	"unprognostic (1.24e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.87e-1)"	"unprognostic (8.84e-2)"	"unprognostic (7.82e-2)"	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.4	0.0	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PPARG	"NR1C3, PPARG1, PPARG2, PPARgamma"	ENSG00000132170	"Peroxisome proliferator activated receptor gamma"	P37231	3	12287368-12434356	"Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Diabetes mellitus, Disease variant, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 166.6"	"Cell type enhanced"	"Detected in many"		"Adipocytes: 284.1;Extravillous trophoblasts: 217.8;Granulosa cells: 232.9;Urothelial cells: 239.6"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 33.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 198.7;ASC TERT1: 113.7;BEWO: 247.5;CAPAN-2: 111.6;HSkMC: 118.9;PC-3: 112.0;RT4: 157.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB004282, HPA051239, HPA063663"	Approved		Enhanced	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"CAB004282: AB_628115, HPA051239: AB_2681400, HPA063663: AB_2685081"	"unprognostic (7.35e-3)"	"unprognostic (3.27e-2)"	"unprognostic (4.05e-2)"	"unprognostic (8.37e-2)"	"unprognostic (2.41e-2)"	"unprognostic (5.27e-3)"	"prognostic unfavorable (3.41e-5)"	"unprognostic (9.13e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.77e-1)"	"prognostic favorable (1.59e-8)"	"unprognostic (1.51e-2)"	"unprognostic (1.46e-1)"	"unprognostic (9.68e-3)"	"prognostic favorable (5.52e-5)"	166.6	3.9	4.5	8.7	3.5	3.0	75.0	3.5	5.7	8.2	1.7	49.2	23.8	7.0	1.2	6.2	7.1	10.6	12.7	4.4	3.5	14.4	17.3	28.7	4.9	4.2	3.6	3.0	14.6	2.8	8.0	0.5	44.0	3.8	5.6	41.0	1.0	5.8	1.7	5.2	5.8	15.2	8.8	5.7	12.1	35.8	7.0	3.5	4.1	13.3	8.2	2.2	68.3	9.2	5.1	44.0	38.6	0.0	0.2	198.7	113.7	247.5	3.7	44.7	5.4	2.1	7.8	111.6	0.0	0.1	4.0	72.9	17.3	14.4	0.7	1.0	106.4	20.3	0.0	8.1	10.3	51.8	0.2	0.1	118.9	9.7	9.8	37.5	20.6	0.7	1.0	0.0	0.0	8.3	11.0	0.1	0.8	0.7	99.2	112.0	0.0	0.0	0.2	30.6	157.5	0.1	1.2	18.8	6.7	2.2	6.7	0.0	34.2	35.0	7.8	10.6	4.6	0.2	0.0	0.1	0.3	3.2	0.5	1.2	0.0	0.3	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	4.5	3.5	3.5	5.7	4.4	3.5	4.2	3.6	3.0	3.8	5.7	3.5	5.1	284.1	3.2	7.2	1.6	0.6	1.0	50.5	0.4	4.6	0.9	1.9	2.8	9.2	1.5	2.5	5.5	0.0	110.4	1.8	93.4	1.9	1.1	4.9	5.2	1.4	26.1	8.4	0.0	39.3	0.7	217.8	12.3	83.1	20.8	8.9	232.9	25.7	3.4	49.9	0.0	74.1	21.3	0.0	19.4	4.8	2.2	4.1	19.1	3.6	38.4	1.8	0.6	0.0	6.6	1.2	17.3	84.1	0.0	1.6	42.1	17.0	14.3	1.5	0.2	13.1	1.9	31.3	10.9	22.8	4.6	1.1	88.9	2.2	0.8	24.5	239.6
PSG5	"FL-NCA-3, PSG"	ENSG00000204941	"Pregnancy specific beta-1-glycoprotein 5"	Q15238	19	43166256-43186536	"Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	68	"placenta: 112.8"	"Cell type enriched"	"Detected in some"	44	"Syncytiotrophoblasts: 724.4"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.5"	"Region enhanced"	"Detected in single"		"cerebellum: 1.6"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"BJ: 427.9;fHDF/TERT166: 1485.4"									HPA046327	Supported				"Secreted in female reproductive system"	NA	NA		22000000			"HPA046327: AB_2679624"	"unprognostic (1.59e-1)"	"unprognostic (3.38e-2)"				"unprognostic (4.69e-2)"		"unprognostic (1.62e-2)"	"unprognostic (2.18e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.75e-2)"		"unprognostic (1.12e-2)"	"unprognostic (2.62e-2)"		"unprognostic (1.03e-1)"	"unprognostic (7.92e-2)"	0.1	0.0	0.1	0.0	0.1	0.0	0.0	1.6	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.5	0.0	0.1	0.0	0.1	0.0	0.3	0.0	0.1	0.3	0.0	112.8	0.8	0.0	0.0	0.3	0.1	0.1	0.1	0.6	0.0	0.9	0.0	0.3	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.3	0.3	0.0	0.0	0.2	0.6	0.1	427.9	122.3	7.0	57.8	0.0	0.3	0.0	0.0	1485.4	1.8	16.4	0.1	0.0	65.8	0.0	0.0	0.1	0.3	0.0	0.4	0.0	0.1	0.8	0.0	1.1	7.8	2.3	0.0	0.0	0.0	0.0	0.6	1.6	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	10.2	0.0	0.0	0.1	0.5	1.6	54.9	0.3	0.1	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	1.6	0.3	0.3	0.0	0.1	0.0	0.3	0.8	0.0	0.1	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.2	2.3	0.0	1.2	0.0	0.1	0.1	0.0	0.5	1.8	0.0	14.2	0.0	0.1	0.0	6.0	0.8	0.0	0.0	0.2	0.0	0.0	3.3	0.0	16.2	0.4	0.0	0.2	0.0	0.0	0.0	0.0	2.5	0.0	3.4	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.0	0.6	0.0	0.0	0.5	1.5	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.2	0.0	0.0	1.0	0.0	0.0	0.0	0.0	724.4	0.0	0.1	0.0	0.1
PSORS1C2	"C6orf17, SPR1"	ENSG00000204538	"Psoriasis susceptibility 1 candidate 2"	Q9UIG4	6	31137534-31139066	"Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	47	"skin 1: 166.8"	"Group enriched"	"Detected in some"	8	"Endometrial ciliated cells: 3.3;Glandular and luminal cells: 9.0;Melanocytes: 8.8;Suprabasal keratinocytes: 7.0"	"Cancer enhanced"	"Detected in many"		"testis cancer: 14.6;urothelial cancer: 20.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA061228	Enhanced				"Secreted in other tissues"	NA	NA					"HPA061228: AB_2684455"	"unprognostic (8.86e-2)"	"unprognostic (7.73e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.67e-2)"	"unprognostic (5.20e-3)"	"unprognostic (1.67e-1)"		"unprognostic (1.75e-1)"	"unprognostic (2.03e-2)"	"unprognostic (3.78e-1)"	"unprognostic (1.64e-2)"	"unprognostic (1.06e-1)"	"unprognostic (9.40e-5)"	"unprognostic (2.09e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.66e-1)"	1.0	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.4	0.0	0.3	0.0	0.2	0.0	3.5	0.1	0.0	0.1	0.0	0.0	0.2	0.1	0.3	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.0	0.1	166.8	0.4	0.0	0.0	0.0	0.4	1.8	0.0	0.0	0.3	0.0	0.2	0.2	2.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.8	0.0	0.0	0.8	0.4	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	7.0	0.0	0.0	0.1	0.0	0.5
PTGES	"MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12"	ENSG00000148344	"Prostaglandin E synthase"	O14684	9	129738331-129753042	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	"Isomerase, Oxidoreductase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"seminal vesicle: 85.0;urinary bladder: 79.3"	"Cell type enhanced"	"Detected in many"		"Basal respiratory cells: 101.2;Cytotrophoblasts: 146.0;Extravillous trophoblasts: 293.1;Syncytiotrophoblasts: 276.2"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 69.6"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in some"	7	"basophil: 28.9"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 28.9"	"Cell line enhanced"	"Detected in many"		"ASC diff: 147.7;BEWO: 162.7;GAMG: 292.8;HaCaT: 216.3;SK-BR-3: 157.6;U-2197: 404.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA045064	Enhanced		Supported	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA045064: AB_10795889"	"unprognostic (2.92e-3)"	"unprognostic (1.09e-1)"	"prognostic unfavorable (2.32e-4)"	"unprognostic (2.54e-2)"	"unprognostic (1.94e-3)"	"unprognostic (1.25e-1)"	"unprognostic (5.38e-3)"	"unprognostic (1.24e-3)"	"unprognostic (2.92e-1)"	"unprognostic (1.61e-1)"	"prognostic unfavorable (7.97e-5)"	"unprognostic (2.22e-1)"	"unprognostic (4.66e-2)"	"unprognostic (9.78e-3)"	"unprognostic (3.19e-2)"	"unprognostic (1.30e-1)"	"unprognostic (5.20e-2)"	27.3	1.4	4.0	14.0	3.3	7.8	25.7	3.5	4.6	24.0	3.0	7.9	2.9	3.7	19.2	18.0	5.5	9.1	6.1	3.9	4.3	8.1	0.7	7.9	7.6	5.3	5.0	3.1	2.2	1.6	42.4	1.9	58.9	5.9	13.8	4.3	0.0	31.0	85.0	1.3	39.9	9.1	4.1	3.7	2.5	7.2	17.0	4.6	4.2	3.7	1.2	31.0	79.3	20.2	4.4	1.5	94.9	0.1	46.6	147.7	51.9	162.7	7.4	64.2	1.1	1.7	5.6	71.7	0.1	2.7	18.0	292.8	216.3	0.7	7.2	0.6	0.3	0.5	0.0	62.5	0.4	3.5	0.0	0.0	30.9	49.0	0.9	0.3	1.4	0.0	0.9	0.0	0.1	0.7	1.7	0.2	0.0	1.2	46.7	8.2	0.2	0.0	0.3	5.3	102.2	0.8	3.6	87.1	157.6	0.8	6.3	83.3	0.0	0.5	0.1	0.4	404.8	0.0	0.0	0.0	0.0	78.8	0.1	0.7	28.9	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	4.0	0.0	0.0	0.3	4.0	3.3	3.5	4.6	3.9	4.3	5.3	5.0	3.1	5.9	3.7	4.6	4.4	3.4	0.0	0.0	0.3	0.3	17.8	8.9	101.2	10.8	0.0	29.7	19.7	0.1	0.0	53.2	3.7	0.0	146.0	0.6	0.0	1.9	13.4	0.6	1.6	2.3	4.0	7.3	0.0	1.0	1.1	293.1	70.7	0.0	5.0	1.3	61.5	0.0	0.0	17.5	0.0	2.8	6.6	30.5	0.0	21.6	0.4	0.3	13.2	14.2	7.5	7.2	0.0	0.0	0.0	0.2	8.1	0.2	0.0	0.3	8.2	0.3	0.5	6.7	0.0	0.0	0.8	13.5	0.3	0.0	5.5	43.0	276.2	0.8	0.2	0.4	49.2
PTPRR	"EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ"	ENSG00000153233	"Protein tyrosine phosphatase receptor type R"	Q15256	12	70638073-70920738	"Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 15.7;endometrium 1: 5.6;intestine: 7.7"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 199.5;Inhibitory neurons: 160.7"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 3.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"HDLM-2: 20.0;RT4: 37.4"	"Region enriched"	"Detected in all"	5	"cerebellum: 89.6"					"CAB011461, HPA011851, HPA071067"	Uncertain		Supported	"Plasma membrane,Cell Junctions,Cytosol"		NA	NA			"Plasma membrane, Cell Junctions, Cytosol"		"CAB011461: AB_298890, HPA011851: AB_1855939, HPA071067: AB_2686340"	"unprognostic (4.98e-2)"	"unprognostic (1.91e-2)"	"unprognostic (1.55e-1)"	"unprognostic (2.04e-1)"	"unprognostic (3.63e-3)"	"unprognostic (3.48e-5)"	"unprognostic (5.44e-3)"	"unprognostic (1.77e-3)"	"unprognostic (1.13e-1)"	"unprognostic (9.01e-2)"	"unprognostic (1.37e-3)"	"unprognostic (8.06e-2)"	"unprognostic (1.10e-2)"	"unprognostic (1.92e-2)"	"unprognostic (4.78e-2)"	"unprognostic (2.72e-1)"	"prognostic favorable (1.40e-5)"	0.0	2.2	3.0	1.0	6.5	0.0	0.0	15.7	4.4	0.2	0.0	7.5	3.3	5.6	0.0	0.0	0.1	1.1	0.0	6.6	4.4	0.0	0.0	0.0	0.0	0.9	0.5	6.1	0.0	0.1	0.0	0.3	0.2	3.7	0.0	5.1	2.5	0.0	1.1	0.0	0.0	7.7	3.0	0.6	0.0	2.8	0.0	0.5	0.0	0.0	0.0	0.0	1.7	0.2	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.9	0.0	0.4	0.0	0.0	0.7	0.0	0.0	0.0	20.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.2	37.4	0.1	5.8	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	6.5	15.7	4.4	6.6	4.4	0.9	0.5	6.1	3.7	0.6	0.5	2.8	1.7	0.0	0.0	3.9	0.2	0.5	0.1	0.5	0.0	16.5	0.2	0.1	3.5	0.0	3.4	0.0	0.0	0.0	0.7	43.2	0.0	2.6	1.7	2.2	1.3	4.0	0.0	0.0	199.5	0.2	0.3	0.3	10.2	14.6	0.0	0.0	0.7	0.0	0.0	16.8	160.7	1.8	0.0	0.0	0.3	0.4	0.0	0.2	0.0	3.7	0.0	0.2	1.0	2.0	4.0	2.8	23.0	0.0	0.0	0.4	17.3	0.0	0.1	0.8	0.0	0.1	0.8	0.0	0.1	0.0	0.1	0.8	0.4	0.0	0.7	0.4
RADX	"CXorf57, FLJ10178, FLJ14191"	ENSG00000147231	"RPA1 related single stranded DNA binding protein, X-linked"	Q6NSI4	X	106611930-106679439	"Predicted intracellular proteins"		DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 21.6;pituitary gland: 20.5"	"Cell type enhanced"	"Detected in some"		"Cytotrophoblasts: 12.3;Extravillous trophoblasts: 4.7;Syncytiotrophoblasts: 22.6"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 4.5"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Group enriched"	"Detected in many"	10	"B-cells: 1.8;NK-cells: 1.0;T-cells: 1.6"	"Cell line enhanced"	"Detected in many"		"HEK 293: 37.2;RT4: 39.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA000896, HPA001010, HPA001374"	Uncertain		Supported	"Nuclear speckles"		NA	No			"Nuclear speckles"		"HPA000896: AB_1078880, HPA001010: , HPA001374: AB_2666288"	"unprognostic (3.30e-2)"	"unprognostic (5.59e-3)"	"unprognostic (2.67e-2)"	"unprognostic (1.46e-3)"	"unprognostic (4.85e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.02e-1)"	"unprognostic (5.49e-2)"	"unprognostic (3.81e-3)"	"unprognostic (1.17e-1)"	"unprognostic (4.20e-3)"	"unprognostic (1.63e-1)"	"unprognostic (2.70e-1)"	"unprognostic (2.21e-2)"	"unprognostic (1.23e-3)"	0.9	7.3	6.7	1.4	6.0	0.6	1.4	2.9	4.8	3.5	2.1	1.1	1.1	3.2	2.2	1.0	3.8	0.6	0.9	3.7	21.6	2.5	1.4	2.4	3.3	4.7	4.7	3.8	6.8	1.9	0.8	20.5	3.6	5.4	0.9	0.8	1.8	0.9	1.2	1.9	2.5	1.8	0.9	3.6	2.4	2.6	3.9	15.1	2.4	3.0	1.0	2.2	2.5	1.9	5.7	7.2	0.0	7.2	10.1	4.0	3.4	10.8	0.3	1.4	0.0	0.1	1.6	1.5	15.0	0.0	0.8	7.7	2.0	18.6	3.2	0.0	0.0	37.2	5.0	0.0	0.4	0.2	0.0	3.2	2.0	2.2	0.5	1.3	1.9	0.0	13.1	0.2	19.1	1.6	0.0	14.0	0.0	6.5	4.8	1.1	0.0	6.7	0.0	3.1	39.9	11.8	0.0	0.7	0.2	4.3	5.5	1.8	0.2	0.0	3.1	2.6	0.0	4.5	6.8	3.1	18.5	5.5	0.0	5.3	0.0	0.0	0.0	1.5	0.0	1.1	1.8	1.3	1.0	0.0	1.3	1.6	1.3	0.1	1.0	0.0	0.1	0.5	0.4	6.7	6.0	2.9	4.8	3.7	21.6	4.7	4.7	3.8	5.4	3.6	15.1	5.7	0.8	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	12.3	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.7	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	22.6	1.0	0.0	0.0	0.0
RARRES1	"LXNL, TIG1"	ENSG00000118849	"Retinoic acid receptor responder 1"	P49788	3	158696892-158732489	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"fallopian tube: 208.1;salivary gland: 166.6"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 217.1;Club cells: 621.4;Prostatic glandular cells: 312.9;Urothelial cells: 737.7"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 93.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	10	"CAPAN-2: 1319.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003892	Uncertain		Approved	"Endoplasmic reticulum,Golgi apparatus"	"Intracellular and membrane"	NA	NA			"Golgi apparatus"	"Endoplasmic reticulum"	"HPA003892: AB_1856079"	"unprognostic (5.76e-3)"	"unprognostic (2.13e-1)"	"unprognostic (8.85e-2)"	"unprognostic (1.19e-2)"	"prognostic unfavorable (9.29e-4)"	"unprognostic (7.09e-2)"	"unprognostic (8.93e-2)"	"unprognostic (3.86e-1)"	"unprognostic (7.16e-3)"	"unprognostic (1.47e-2)"	"unprognostic (6.42e-2)"	"unprognostic (2.15e-1)"	"prognostic unfavorable (5.88e-6)"	"unprognostic (3.49e-1)"	"unprognostic (1.33e-1)"	"unprognostic (7.73e-2)"	"unprognostic (1.15e-1)"	106.0	21.5	1.0	65.7	1.4	0.6	44.9	1.5	1.7	56.5	9.3	32.0	5.2	26.1	27.3	11.3	208.1	19.9	49.9	1.4	2.5	24.7	4.3	53.1	19.1	0.7	0.5	1.5	61.0	10.1	0.2	27.9	3.6	0.8	79.2	36.6	0.9	166.6	37.5	5.6	8.4	38.8	51.7	0.2	2.8	23.9	4.6	0.8	1.8	20.5	2.8	6.2	93.0	32.5	1.4	19.2	6.9	0.2	1.0	4.0	12.6	0.3	1.8	5.7	1.0	1.4	1.4	1319.3	0.0	1.2	0.9	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	2.0	0.1	12.0	0.0	0.0	131.3	0.0	0.5	0.0	8.9	2.8	0.0	0.0	0.0	0.4	0.0	0.0	0.2	1.7	5.8	0.0	0.0	0.0	0.1	0.3	22.9	0.5	1.7	16.7	1.3	0.3	0.0	1.9	2.3	1.3	1.1	0.0	4.6	0.0	0.0	0.0	0.0	1.5	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	1.0	1.4	1.5	1.7	1.4	2.5	0.7	0.5	1.5	0.8	0.2	0.8	1.4	5.2	0.0	0.6	2.3	0.9	0.5	217.1	92.7	11.4	0.4	99.7	35.6	0.9	11.5	621.4	14.7	0.0	2.9	1.6	59.0	0.0	10.5	29.5	14.4	98.4	18.1	37.5	3.6	14.2	4.7	0.8	101.3	1.1	16.9	29.9	0.3	31.8	6.0	10.8	0.0	10.6	102.3	40.7	1.6	1.7	33.1	10.8	11.0	5.4	1.9	0.0	4.2	0.0	4.5	7.6	2.3	106.1	1.2	1.2	312.9	140.7	19.7	149.3	0.7	0.0	7.7	46.7	3.8	0.7	7.8	0.4	11.4	3.3	0.1	88.3	737.7
S100A3	S100E	ENSG00000188015	"S100 calcium binding protein A3"	P33764	1	153547329-153549258	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skin 1: 63.8"	"Cell type enhanced"	"Detected in many"		"Basal respiratory cells: 15.4;Ductal cells: 21.7;Endometrial stromal cells: 18.4;Exocrine glandular cells: 24.0;Pancreatic endocrine cells: 24.2;Skeletal myocytes: 24.7"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 26.6"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"intermediate monocyte: 3.1;non-classical monocyte: 6.2;plasmacytoid DC: 7.4"	"Group enriched"	"Detected in many"	11	"dendritic cells: 7.4;monocytes: 6.2"	"Cell line enhanced"	"Detected in many"		"A549: 87.0;HBEC3-KT: 45.7;HeLa: 51.4;U-2197: 47.4"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"spinal cord: 15.8"	"HPA042674, HPA056140"	Enhanced		Enhanced	"Golgi apparatus,Plasma membrane,Cytosol"		NA	NA		240000	Cytosol	"Golgi apparatus, Plasma membrane"	"HPA042674: AB_10796581, HPA056140: AB_2683050"	"unprognostic (3.90e-2)"	"unprognostic (1.60e-1)"	"unprognostic (3.59e-2)"	"unprognostic (1.21e-2)"	"unprognostic (4.53e-2)"	"unprognostic (5.37e-3)"	"unprognostic (1.48e-1)"	"unprognostic (2.36e-1)"	"unprognostic (2.46e-1)"	"unprognostic (2.08e-1)"	"unprognostic (5.34e-3)"	"unprognostic (3.97e-3)"	"prognostic unfavorable (1.61e-6)"	"unprognostic (8.13e-2)"	"unprognostic (3.46e-1)"	"unprognostic (6.21e-2)"	"unprognostic (8.10e-2)"	5.6	1.1	0.8	3.6	1.0	1.8	4.2	0.8	1.3	6.1	0.7	2.5	0.5	3.9	0.2	17.4	3.3	1.7	2.1	0.7	1.3	5.8	0.2	16.7	1.8	1.3	1.4	0.6	1.1	0.8	0.1	0.7	2.2	1.2	3.1	1.2	0.0	4.3	1.7	1.0	63.8	1.9	2.1	1.2	0.8	1.4	0.5	2.4	0.4	1.5	1.9	5.2	6.9	9.6	1.1	7.3	87.0	0.1	0.1	8.1	5.2	0.0	6.1	31.4	7.9	12.8	2.6	2.8	0.1	19.0	16.1	10.7	22.2	0.1	45.7	3.7	0.3	0.0	0.3	51.4	15.3	2.2	0.0	0.3	4.1	24.9	17.9	19.9	4.5	1.7	0.0	0.0	0.0	39.8	0.5	0.0	0.0	0.6	0.2	11.5	0.0	5.9	4.7	26.0	18.3	1.2	0.0	5.4	6.1	2.0	24.7	0.2	0.6	8.6	2.9	4.8	47.4	6.3	1.4	1.6	0.2	38.2	0.7	19.1	0.0	0.1	0.0	0.0	3.1	0.2	0.6	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	6.2	7.4	0.1	0.4	0.8	1.0	0.8	1.3	0.7	1.3	1.3	1.4	0.6	1.2	1.2	2.4	1.1	2.0	3.2	0.5	0.7	0.0	10.3	2.3	15.4	4.0	0.0	0.3	0.4	0.3	1.5	5.9	0.0	0.0	0.3	0.0	0.0	1.9	21.7	0.0	2.3	18.4	7.4	0.0	1.3	0.0	24.0	4.4	8.4	0.0	1.3	0.0	0.0	2.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	11.1	0.1	4.1	0.4	1.8	0.0	3.6	0.0	0.0	0.0	0.0	24.2	0.0	0.4	0.0	1.5	0.0	0.3	1.1	0.0	0.0	24.7	9.6	0.1	0.0	5.6	6.5	1.5	0.5	1.1	0.0	2.0
S100P		ENSG00000163993	"S100 calcium binding protein P"	P25815	4	6693878-6697170	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 1423.9;stomach 1: 1757.5;urinary bladder: 1794.1"	"Cell type enhanced"	"Detected in many"		"Club cells: 1088.3;Gastric mucus-secreting cells: 2306.9;Syncytiotrophoblasts: 2773.6;Urothelial cells: 4448.3"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 564.7"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	46	"basophil: 1789.3;eosinophil: 836.9;neutrophil: 2961.8"	"Lineage enriched"	"Detected in many"	73	"granulocytes: 2961.8"	"Cell line enhanced"	"Detected in many"		"BEWO: 879.0;Hep G2: 1283.2;hTCEpi: 1185.6;OE19: 4335.4;RT4: 2619.8;SK-BR-3: 1057.4"									"HPA019502, HPA075251"	Enhanced		Supported	Nucleoplasm		NA	NA		1600000	Nucleoplasm		"HPA019502: AB_1856530, HPA075251: "	"unprognostic (1.46e-1)"	"unprognostic (1.50e-1)"	"unprognostic (7.52e-2)"	"unprognostic (1.44e-1)"	"unprognostic (2.22e-1)"	"unprognostic (7.34e-2)"	"unprognostic (1.60e-3)"	"unprognostic (3.92e-2)"	"unprognostic (7.19e-2)"	"unprognostic (9.24e-2)"	"prognostic unfavorable (2.00e-4)"	"unprognostic (3.87e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.72e-1)"	"unprognostic (9.24e-2)"	"unprognostic (3.65e-1)"	"unprognostic (1.12e-2)"	14.2	1.7	1.1	42.8	1.2	1423.9	7.5	1.7	5.7	15.1	2.1	157.0	13.3	6.0	0.0	343.7	6.9	52.6	2.7	1.4	1.0	2.1	8.8	14.8	1.0	1.2	1.3	0.8	0.5	4.7	0.4	1.7	478.8	3.3	25.7	177.7	0.1	8.3	0.5	0.4	20.2	24.0	16.7	0.8	34.6	1757.5	1.4	1.0	10.7	0.6	12.3	97.7	1794.1	34.8	1.8	115.2	89.1	0.0	0.1	0.0	0.5	879.0	0.0	1.0	0.0	0.0	5.2	17.6	0.7	40.1	0.6	1.2	137.6	0.5	1.1	0.0	54.7	0.0	1.9	106.7	1283.2	0.0	53.4	3.2	0.6	1185.6	0.0	1.1	0.2	0.2	0.8	3.1	0.0	0.0	214.5	1.6	126.5	1.5	4335.4	149.6	0.9	0.5	0.5	0.0	2619.8	1.1	0.7	156.8	1057.4	2.4	39.9	31.0	169.6	0.5	0.0	1.4	0.2	0.9	1.2	0.7	0.8	0.1	479.1	0.2	1789.3	40.6	836.9	1.4	9.5	1.1	0.4	1.7	1.1	1.6	0.5	0.3	0.8	2961.8	0.1	5.7	0.4	1.1	16.7	1.1	1.2	1.7	5.7	1.4	1.0	1.2	1.3	0.8	3.3	0.8	1.0	1.8	0.9	9.6	48.6	0.0	6.2	1.1	318.3	568.6	4.0	0.0	3.4	3.6	1.2	27.1	1088.3	1.8	0.0	550.7	2.2	322.2	0.0	4.8	12.3	37.5	38.9	8.7	16.6	0.0	0.0	31.1	783.4	13.8	2306.9	202.5	31.6	0.0	1.4	7.4	69.2	0.0	0.0	443.7	152.5	11.8	1.0	7.4	0.0	11.0	8.8	0.0	5.6	0.0	2.1	0.0	0.1	828.1	580.9	0.0	5.9	288.4	2.2	0.5	301.5	0.0	0.0	0.1	32.1	0.5	0.6	18.6	6.3	2773.6	9.8	0.1	173.2	4448.3
SCNN1B	ENaCbeta	ENSG00000168447	"Sodium channel epithelial 1 subunit beta"	P51168	16	23278231-23381294	"Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Sensory transduction, Sodium transport, Taste, Transport"	"Ion channel, Sodium channel"	"Disease variant, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 83.5;intestine: 56.8;vagina: 56.9"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 99.3;Club cells: 64.8;Collecting duct cells: 57.0;Distal enterocytes: 262.8;Ionocytes: 107.8;Paneth cells: 73.7"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 26.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"hTCEpi: 33.3;RPMI-8226: 9.2;RT4: 18.5;U-266/70: 55.4;U-266/84: 20.2"	"Region enriched"	"Detected in single"	5	"cerebellum: 1.0"	"Low region specificity"	"Detected in many"			HPA015612	Uncertain					NA	NA					"HPA015612: AB_1856629"	"unprognostic (7.45e-2)"	"unprognostic (1.76e-3)"	"unprognostic (1.39e-1)"	"unprognostic (6.74e-3)"	"unprognostic (1.74e-2)"	"unprognostic (5.11e-3)"	"unprognostic (7.74e-2)"	"unprognostic (5.49e-3)"	"unprognostic (2.60e-1)"	"unprognostic (2.40e-1)"	"unprognostic (3.68e-1)"	"unprognostic (2.84e-1)"	"prognostic unfavorable (2.09e-6)"	"unprognostic (2.32e-1)"	"unprognostic (4.66e-2)"	"unprognostic (3.93e-3)"	"unprognostic (1.25e-2)"	14.6	0.4	0.0	1.2	0.0	0.2	17.9	0.9	0.0	48.9	0.0	56.8	2.5	2.8	0.1	83.5	3.7	0.5	0.2	0.0	0.2	23.2	0.2	24.1	0.8	0.0	0.0	0.0	0.7	2.1	0.3	1.0	3.6	0.3	10.6	36.0	0.0	39.9	2.4	1.5	36.2	4.3	0.8	0.0	3.8	24.3	0.3	0.0	0.7	9.3	0.8	5.4	8.4	56.9	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	33.3	0.0	0.1	0.0	0.0	0.0	0.0	2.0	0.0	1.8	0.0	0.0	0.0	0.0	7.0	0.0	0.0	9.2	0.0	18.5	0.2	0.0	0.0	0.5	0.0	0.1	3.6	0.0	0.0	0.0	0.0	0.0	0.0	55.4	20.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	25.7	99.3	28.3	0.0	7.1	3.1	15.4	27.8	5.7	0.0	4.4	3.0	0.7	0.0	64.8	57.0	0.0	0.7	0.1	262.8	0.0	0.0	0.1	11.9	1.6	6.2	7.7	0.0	0.3	0.4	0.3	1.0	36.7	23.4	8.2	0.0	1.1	0.1	0.1	0.0	0.3	21.4	107.8	0.0	0.0	0.2	0.0	1.0	10.6	0.0	0.0	0.0	0.0	0.0	0.1	0.4	73.7	0.0	38.7	6.1	0.0	0.1	9.2	0.0	0.0	0.1	0.7	0.1	0.4	29.8	5.4	2.2	1.4	0.0	15.2	19.7
SCNN1G	"ENaCgamma, SCNEG"	ENSG00000166828	"Sodium channel epithelial 1 subunit gamma"	P51170	16	23182745-23216883	"Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters"	"Ion transport, Sensory transduction, Sodium transport, Taste, Transport"	"Ion channel, Sodium channel"	"Disease variant, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 42.8"	"Cell type enriched"	"Detected in some"	4	"Collecting duct cells: 90.1"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 15.6"	"Region enhanced"	"Detected in some"		"cerebellum: 3.9"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"hTCEpi: 46.8;RT4: 21.7"	"Region enriched"	"Detected in single"	13	"cerebellum: 2.5"	"Not detected"	"Not detected"			HPA071194			Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"HPA071194: AB_2686359"	"unprognostic (2.90e-1)"	"unprognostic (5.21e-3)"	"unprognostic (5.79e-2)"	"unprognostic (4.31e-2)"	"unprognostic (1.92e-3)"	"unprognostic (1.71e-3)"		"unprognostic (1.97e-1)"	"unprognostic (4.85e-2)"	"unprognostic (7.84e-3)"	"unprognostic (1.90e-1)"	"unprognostic (2.57e-2)"	"prognostic unfavorable (3.20e-7)"	"unprognostic (2.80e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.63e-1)"	"unprognostic (4.17e-3)"	0.4	0.2	0.4	0.0	0.3	0.3	2.3	3.9	0.2	16.1	0.2	6.0	0.0	1.8	0.7	10.0	0.4	0.0	0.0	0.7	0.3	42.8	0.0	7.5	0.0	0.2	0.4	0.2	0.0	3.3	0.0	3.8	0.5	1.8	13.9	1.2	0.2	17.9	3.5	0.0	8.9	0.4	0.1	0.0	0.0	10.2	0.1	0.1	2.1	5.7	0.0	1.2	1.4	15.4	0.3	1.1	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	46.8	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	2.9	0.0	0.0	0.1	0.0	21.7	1.5	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.3	3.9	0.2	0.7	0.3	0.2	0.4	0.2	1.8	0.0	0.1	0.3	0.4	19.2	4.2	0.0	0.0	0.4	4.7	8.8	19.9	0.0	0.8	1.3	0.8	0.0	17.4	90.1	0.0	0.2	0.0	3.4	0.0	2.0	0.0	9.8	1.1	0.1	0.0	0.0	0.2	1.7	0.0	0.4	15.3	18.6	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.2	10.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.5	1.1	0.0	0.1	5.3	0.0	0.2	1.9	0.0	0.0	0.0	0.2	0.1	0.1	4.4	0.3	0.1	0.2	0.0	0.4	1.8
SLC9A4	NHE4	ENSG00000180251	"Solute carrier family 9 member A4"	Q6AI14	2	102473226-102533972	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Antiport, Ion transport, Sodium transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"stomach 1: 54.3"	"Group enriched"	"Detected in some"	12	"Collecting duct cells: 25.8;Gastric mucus-secreting cells: 54.0"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 2.1"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 2.3;OE19: 6.8;RT4: 4.1"	"Group enriched"	"Detected in some"	18	"hippocampal formation: 10.6;olfactory bulb: 6.8"	"Low region specificity"	"Detected in single"			HPA036096	Supported		Approved	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA036096: AB_2674939"	"unprognostic (1.41e-1)"	"unprognostic (3.76e-2)"	"unprognostic (9.31e-2)"	"unprognostic (3.09e-3)"	"unprognostic (7.58e-2)"	"unprognostic (1.46e-1)"		"unprognostic (7.17e-2)"	"unprognostic (5.35e-1)"	"unprognostic (9.44e-3)"	"unprognostic (3.26e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.46e-2)"	"unprognostic (3.12e-1)"	"unprognostic (5.04e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.98e-2)"	0.0	0.0	0.3	0.1	0.5	0.8	0.2	0.6	0.7	0.3	0.0	0.0	2.0	0.1	0.1	1.5	0.1	1.2	0.6	0.4	0.4	8.7	0.0	0.0	0.4	0.2	0.1	0.4	0.1	0.0	0.1	0.0	0.1	0.4	0.1	0.0	0.4	1.3	0.5	1.5	0.4	0.0	0.0	0.0	0.2	54.3	0.3	0.1	0.1	0.1	0.0	0.5	0.4	0.1	0.6	0.1	0.1	0.1	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.2	0.0	1.3	0.0	0.1	0.1	0.0	0.0	0.0	2.3	0.1	0.1	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.5	6.8	0.2	0.0	0.2	0.1	0.0	4.1	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.1	0.2	0.5	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.6	0.7	0.4	0.4	0.2	0.1	0.4	0.4	0.0	0.1	0.6	0.0	3.2	3.2	0.0	0.1	0.0	0.0	0.2	0.0	0.0	1.0	0.0	0.4	0.0	0.9	25.8	0.0	0.1	0.0	0.0	0.0	0.0	2.2	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	54.0	0.6	1.3	0.0	0.0	0.0	0.0	0.0	0.2	0.3	2.0	0.0	0.0	0.2	0.0	0.3	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.6	0.8	0.0	0.0	0.1	0.4	0.0	0.3	0.3
SLITRK6	FLJ22774	ENSG00000184564	"SLIT and NTRK like family member 6"	Q9H5Y7	13	85792790-85806683	"Disease related genes, Human disease related genes, Predicted membrane proteins"	"Hearing, Sensory transduction, Vision"		Deafness	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"salivary gland: 28.0;urinary bladder: 14.8"	"Cell type enhanced"	"Detected in some"		"Basal respiratory cells: 22.8;Bipolar cells: 41.7;Club cells: 27.4;Ionocytes: 16.2;Respiratory ciliated cells: 41.6"	"Cancer enhanced"	"Detected in many"		"breast cancer: 21.1;urothelial cancer: 18.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"hTCEpi: 28.8;OE19: 24.2;RT4: 101.4;WM-115: 23.7"	"Region enhanced"	"Detected in many"		"thalamus: 22.6"	"Low region specificity"	"Detected in many"			"HPA014491, HPA014513"	Uncertain		Supported	"Plasma membrane"		NA	NA		28000	"Plasma membrane"		"HPA014491: AB_10601603, HPA014513: AB_2669026"	"unprognostic (6.14e-2)"	"unprognostic (5.21e-3)"	"unprognostic (1.40e-1)"	"unprognostic (2.66e-2)"	"unprognostic (2.46e-2)"	"prognostic unfavorable (8.52e-4)"	"unprognostic (6.10e-2)"	"unprognostic (1.72e-2)"	"unprognostic (1.69e-1)"	"unprognostic (4.82e-2)"	"unprognostic (7.60e-2)"	"unprognostic (7.92e-2)"	"unprognostic (3.31e-5)"	"unprognostic (5.60e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.51e-2)"	0.1	0.2	1.0	0.9	3.0	0.0	3.2	1.9	1.4	1.2	0.1	5.6	3.5	1.0	2.5	1.9	0.5	1.4	1.5	0.1	1.8	0.1	0.9	3.4	0.0	0.9	2.3	0.3	0.0	0.2	0.0	0.1	0.9	1.4	7.7	6.9	4.8	28.0	2.2	0.0	5.6	5.8	0.4	0.3	0.1	1.5	0.3	4.4	0.2	0.3	0.1	0.1	14.8	1.4	0.9	0.0	2.9	0.1	0.5	0.0	0.0	0.0	2.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	4.9	0.0	0.0	0.0	0.0	0.7	0.0	0.7	0.0	0.0	0.0	28.8	0.0	3.3	2.7	0.0	0.0	0.0	0.1	0.0	3.3	0.0	0.0	0.0	24.2	1.9	0.2	0.0	0.0	0.0	101.4	1.0	1.2	0.5	0.1	0.1	1.7	0.5	0.0	0.0	0.3	1.0	0.0	0.1	0.0	0.0	0.0	0.9	0.0	23.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	3.0	1.9	1.4	0.1	1.8	0.9	2.3	0.3	1.4	0.3	4.4	0.9	0.1	0.0	1.8	0.0	0.0	3.8	5.0	22.8	0.0	41.7	5.3	1.5	0.4	0.0	27.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	1.2	4.3	0.3	0.0	0.0	0.1	0.0	0.0	2.0	0.0	2.7	0.0	2.2	2.2	0.0	0.2	0.0	0.4	1.7	16.2	0.0	0.6	0.0	9.6	0.1	0.0	1.0	0.0	0.6	0.0	0.0	0.0	1.8	0.0	0.4	0.0	1.5	0.0	0.1	41.6	2.0	0.0	0.0	0.8	0.0	0.1	3.8	2.4	0.0	0.2	0.1	0.5	4.5
SP6	"Epfn, KLF14"	ENSG00000189120	"Sp6 transcription factor"	Q3SY56	17	47844908-47855874	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 23.0;skin 1: 14.4"	"Group enriched"	"Detected in some"	5	"Cytotrophoblasts: 57.5;Syncytiotrophoblasts: 98.8"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 11.8"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	5	"BEWO: 92.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA024516, HPA044469"			Supported	"Nucleoplasm,Mitotic spindle,Centrosome"		Yes	No			Nucleoplasm	"Mitotic spindle, Centrosome"	"HPA024516: AB_10960551, HPA044469: AB_10966430"	"unprognostic (3.06e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.07e-2)"	"unprognostic (7.55e-3)"	"unprognostic (6.79e-2)"	"unprognostic (4.57e-2)"	"unprognostic (2.10e-1)"	"prognostic unfavorable (2.11e-6)"	"unprognostic (1.22e-1)"	"unprognostic (8.72e-2)"	"unprognostic (3.92e-3)"	"unprognostic (1.63e-1)"	"unprognostic (9.59e-3)"	"prognostic favorable (6.39e-4)"	"unprognostic (3.33e-1)"	"unprognostic (9.93e-2)"	"prognostic favorable (5.72e-4)"	0.7	0.9	0.1	0.6	0.2	0.0	3.9	0.5	0.3	0.9	0.1	1.0	1.6	0.3	3.9	5.5	1.1	0.1	0.3	0.1	0.3	0.7	0.0	3.1	0.6	0.6	0.4	0.1	0.9	0.4	6.2	0.2	23.0	1.0	1.8	0.7	0.1	0.9	10.3	0.1	14.4	4.8	0.3	0.4	0.9	0.3	0.2	0.2	1.1	1.1	0.1	1.9	2.7	3.9	0.6	6.8	0.8	0.0	0.0	0.0	0.0	92.3	0.4	0.4	1.8	0.4	20.1	1.9	0.0	0.6	0.0	1.3	2.8	0.1	3.4	0.5	0.2	0.7	0.1	1.5	0.6	0.1	0.0	0.0	0.1	1.8	0.0	1.8	0.2	0.2	0.2	4.7	0.1	0.1	1.8	0.0	0.1	0.0	8.2	1.6	0.0	0.0	0.2	0.5	11.9	2.9	0.1	0.1	11.9	0.0	16.8	4.8	0.0	6.3	0.4	2.6	0.0	0.5	0.8	0.0	0.1	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.3	0.1	0.3	0.6	0.4	0.1	1.0	0.4	0.2	0.6	1.3	0.0	0.0	1.0	0.2	0.1	2.6	4.6	4.0	0.0	6.0	6.1	0.5	0.0	0.8	1.8	0.0	57.5	0.3	5.2	0.0	0.7	0.1	0.4	0.1	2.7	1.8	0.0	0.2	0.8	3.9	0.7	0.0	0.7	0.0	0.2	0.7	0.1	4.1	0.0	0.2	2.7	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.8	3.2	0.0	0.1	3.8	13.4	0.0	1.0	0.0	0.0	0.0	0.2	0.3	0.6	1.1	0.9	98.8	0.3	0.1	3.3	6.3
SPANXC	"CT11.3, CTp11"	ENSG00000198573	"SPANX family member C"	Q9NY87	X	141241463-141242517	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	45	"testis: 31.3"	"Group enriched"	"Detected in some"	209	"Early spermatids: 468.6;Late spermatids: 1668.9"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"A-431: 11.8;U-2 OS: 6.2"									"HPA046423, HPA073647"	Supported		Supported	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"HPA046423: AB_2679660, HPA073647: AB_2732232"															"unprognostic (3.56e-1)"			0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	11.8	0.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	6.2	0.0	0.3	0.0	0.0	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.1	0.3	0.3	0.1	0.0	0.6	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	468.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1668.9	4.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SPTSSB	"ADMP, C3orf57, ssSPTb"	ENSG00000196542	"Serine palmitoyltransferase small subunit B"	Q8NFR3	3	161344792-161372880	"Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Sphingolipid metabolism"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skin 1: 43.4;stomach 1: 62.0;urinary bladder: 50.0"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 28.5;Exocrine glandular cells: 46.0;Gastric mucus-secreting cells: 37.2;Melanocytes: 46.2;Prostatic glandular cells: 74.6;Suprabasal keratinocytes: 36.4;Urothelial cells: 65.6"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 24.0"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in some"	13	"NK-cell: 353.6"	"Lineage enriched"	"Detected in many"	13	"NK-cells: 353.6"	"Group enriched"	"Detected in some"	10	"MCF7: 1167.1;RT4: 304.2"									HPA047712			Uncertain	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"HPA047712: AB_2680127"	"unprognostic (2.09e-1)"	"unprognostic (4.19e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.34e-2)"	"unprognostic (4.15e-2)"	"unprognostic (3.18e-2)"	"unprognostic (1.98e-1)"	"unprognostic (5.10e-2)"	"unprognostic (6.37e-3)"	"unprognostic (2.72e-1)"	"unprognostic (4.08e-2)"	"unprognostic (5.37e-4)"	"unprognostic (8.21e-2)"	"unprognostic (1.99e-1)"	"unprognostic (1.22e-2)"	"unprognostic (9.51e-3)"	1.9	0.1	3.9	0.6	2.3	0.4	8.4	5.5	8.0	4.9	2.4	0.8	0.3	1.0	0.1	8.7	0.4	1.3	0.4	2.8	1.9	0.6	0.5	0.1	1.2	2.7	6.4	2.1	0.2	0.8	0.1	0.4	0.0	5.1	14.8	0.7	2.5	11.5	0.1	0.1	43.4	0.3	0.2	0.5	1.3	62.0	0.0	7.4	0.4	0.3	1.5	2.0	50.0	11.1	4.9	0.0	2.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	2.9	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.4	0.0	0.0	0.1	0.1	2.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1167.1	0.0	0.0	4.3	71.5	13.4	0.0	0.0	0.5	0.0	304.2	1.9	11.9	0.0	40.6	0.0	0.1	64.7	0.0	0.0	0.0	0.2	0.3	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	7.1	0.2	26.2	0.1	0.9	2.5	0.0	0.1	0.3	0.4	0.9	353.6	0.0	0.2	0.0	2.5	3.9	2.3	5.5	8.0	2.8	1.9	2.7	6.4	2.1	5.1	0.5	7.4	4.9	0.2	0.0	0.0	4.2	0.1	3.8	16.6	19.6	1.8	1.4	16.6	8.4	0.4	1.5	22.5	3.7	0.0	0.0	3.6	0.1	0.0	1.3	0.0	0.5	0.2	0.8	0.0	0.0	28.5	46.0	0.0	0.7	37.2	1.2	0.0	4.3	0.0	0.0	0.2	0.0	14.2	2.5	6.1	0.0	0.8	0.0	0.0	0.4	46.2	1.0	0.1	0.6	7.2	5.0	1.5	27.6	0.0	0.0	0.4	74.6	0.0	0.0	4.1	1.4	0.0	0.1	2.2	0.0	0.0	6.8	36.4	0.1	3.2	0.0	0.0	65.6
TINAGL1	"ARG1, LCN7, LIECG3, P3ECSL, TINAGRP"	ENSG00000142910	"Tubulointerstitial nephritis antigen like 1"	Q9GZM7	1	31576485-31587686	"Enzymes, Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Cytotrophoblasts: 1235.1;Sertoli cells: 427.3;Syncytiotrophoblasts: 1946.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 87.8"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in single"		"basophil: 2.0"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 2.0"	"Cell line enhanced"	"Detected in many"		"BEWO: 322.7;CAPAN-2: 178.9;EFO-21: 403.6;HaCaT: 181.4;HBEC3-KT: 211.9;HUVEC TERT2: 173.4;TIME: 376.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048695	Approved				"Secreted to extracellular matrix"	NA	NA		370000			"HPA048695: AB_2680497"	"unprognostic (1.27e-1)"	"unprognostic (2.94e-2)"	"unprognostic (7.53e-2)"	"unprognostic (1.80e-3)"	"unprognostic (2.74e-1)"	"unprognostic (1.72e-3)"	"unprognostic (8.29e-3)"	"unprognostic (6.02e-3)"	"unprognostic (4.18e-1)"	"unprognostic (6.96e-2)"	"unprognostic (7.02e-3)"	"unprognostic (1.22e-1)"	"prognostic favorable (3.65e-6)"	"unprognostic (7.42e-2)"	"unprognostic (6.64e-2)"	"prognostic favorable (9.64e-4)"	"unprognostic (3.43e-2)"	173.6	41.1	18.7	18.7	16.4	1.0	151.8	16.5	20.0	84.4	19.6	80.7	27.0	102.6	10.8	31.3	83.2	24.1	168.1	13.8	16.4	178.9	22.9	86.5	8.6	18.3	17.0	12.2	39.1	31.3	13.3	25.5	185.1	17.4	71.8	16.7	1.1	64.4	41.0	47.0	33.3	52.0	36.9	14.7	120.6	66.9	6.2	19.1	3.8	116.1	30.9	5.3	89.1	70.8	17.1	96.6	0.2	0.0	0.5	0.8	0.2	322.7	14.9	1.9	0.7	0.4	44.5	178.9	0.2	403.6	13.4	7.0	181.4	0.2	211.9	0.1	0.7	0.1	0.1	7.3	11.5	4.5	0.1	0.5	0.2	37.9	0.0	7.6	0.1	173.4	0.1	2.4	0.4	0.0	0.0	0.7	0.6	0.9	52.6	6.1	0.4	0.1	0.4	57.0	72.6	0.4	0.5	38.0	125.6	4.2	18.8	7.5	0.3	376.6	0.3	91.6	0.7	2.8	0.4	0.5	1.6	0.2	0.2	3.3	2.0	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.1	0.0	0.3	0.2	0.2	0.8	0.4	0.1	0.1	0.1	0.0	18.7	16.4	16.5	20.0	13.8	16.4	18.3	17.0	12.2	17.4	14.7	19.1	17.1	345.4	9.6	5.8	0.7	2.7	11.0	121.5	244.1	8.0	0.0	32.0	73.0	46.7	37.1	28.6	132.4	0.0	1235.1	2.6	158.9	1.9	378.7	1.4	8.4	3.2	161.4	11.4	13.5	0.1	92.2	223.5	35.0	50.0	14.4	14.7	49.7	306.6	4.4	89.3	0.0	1.1	35.5	14.2	8.8	10.3	0.7	7.5	4.2	23.2	13.1	2.0	0.2	0.0	0.5	0.0	344.6	115.3	4.1	0.2	131.4	45.2	80.9	9.1	0.4	427.3	9.5	357.4	0.3	0.8	4.9	6.5	1946.1	3.8	2.7	59.7	219.4
TMEM40	FLJ11036	ENSG00000088726	"Transmembrane protein 40"	Q8WWA1	3	12733528-12769457	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"esophagus: 221.6;skin 1: 62.5;vagina: 80.8"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 104.7;Cytotrophoblasts: 128.3;Macrophages: 121.3;Squamous epithelial cells: 116.5;Suprabasal keratinocytes: 201.9;Syncytiotrophoblasts: 656.6;Urothelial cells: 157.9"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 13.3;urothelial cancer: 12.1"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in some"		"neutrophil: 6.0"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 6.0"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 244.9;hTCEpi: 56.1;hTERT-HME1: 68.0;RT4: 36.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA044165, HPA073122"	Enhanced		Approved	Cytosol		NA	NA		2500000	Cytosol		"HPA044165: AB_10961279, HPA073122: "	"unprognostic (2.51e-3)"	"unprognostic (1.96e-2)"	"unprognostic (2.64e-3)"	"unprognostic (8.25e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.92e-1)"	"unprognostic (5.15e-4)"	"unprognostic (5.96e-2)"	"unprognostic (3.15e-1)"	"unprognostic (2.60e-1)"	"unprognostic (1.81e-3)"	"unprognostic (2.47e-1)"	"unprognostic (1.20e-3)"	"unprognostic (1.41e-1)"	"unprognostic (1.70e-1)"	"unprognostic (1.46e-2)"	"unprognostic (6.77e-2)"	0.1	0.1	0.2	0.0	0.3	3.4	3.2	0.4	0.5	20.3	0.2	0.0	0.1	0.1	1.3	221.6	3.2	0.1	3.2	0.4	0.2	0.2	0.3	2.1	0.1	0.3	0.3	0.2	0.1	0.1	3.2	0.2	16.0	0.4	3.7	0.0	0.1	27.5	2.5	1.3	62.5	0.0	0.1	0.1	1.8	0.2	0.9	0.3	1.5	0.1	0.7	26.1	15.4	80.8	0.5	26.6	0.1	0.0	0.1	0.0	0.0	22.4	0.2	1.1	1.3	1.4	1.0	4.1	0.1	0.2	0.0	0.6	7.6	0.0	244.9	5.1	0.2	0.0	1.9	0.2	0.8	0.0	0.0	0.0	0.0	56.1	0.0	68.0	0.4	0.0	0.0	0.1	0.0	0.0	7.7	0.0	0.0	0.0	0.2	4.3	0.0	1.6	0.0	1.6	36.0	0.2	0.2	0.1	31.3	0.0	4.6	2.8	0.7	0.0	0.0	1.6	0.0	2.1	0.3	0.1	0.4	0.1	0.0	0.0	1.6	0.9	1.1	0.0	0.1	0.5	0.0	0.0	0.0	0.2	0.0	0.2	0.0	6.0	0.0	0.0	0.8	0.0	32.9	0.2	0.3	0.4	0.5	0.4	0.2	0.3	0.3	0.2	0.4	0.1	0.3	0.5	0.1	0.0	0.0	0.3	0.3	64.2	104.7	71.7	17.6	0.0	1.5	5.6	4.7	0.0	39.4	1.8	0.0	128.3	0.0	0.1	0.0	0.5	0.8	2.9	0.0	1.8	0.0	0.0	0.3	0.0	14.7	1.8	0.0	0.1	0.0	0.0	2.2	0.7	10.8	0.0	0.3	0.0	12.2	4.8	7.3	2.0	0.3	121.3	10.6	0.0	2.6	0.0	2.1	0.0	0.2	2.2	0.0	0.0	0.0	53.5	0.0	0.0	55.0	0.0	0.0	0.1	3.6	0.7	6.8	116.5	201.9	656.6	1.0	0.2	0.0	157.9
UGT1A10	UGT1J	ENSG00000242515	"UDP glucuronosyltransferase family 1 member A10"	Q9HAW8	2	233636454-233773305	"Cancer-related genes, Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"gallbladder: 22.2;intestine: 80.2;stomach 1: 33.0"	"Cell type enhanced"	"Detected in some"		"Distal enterocytes: 1.8;Gastric mucus-secreting cells: 3.6;Intestinal goblet cells: 1.0;Paneth cells: 1.4;Proximal enterocytes: 3.9;Squamous epithelial cells: 4.3"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 9.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	143	"RT4: 523.3"														"Intracellular and membrane"	NA	NA								"unprognostic (9.33e-2)"			"unprognostic (7.64e-2)"	"unprognostic (2.45e-3)"	"unprognostic (1.73e-1)"			"prognostic unfavorable (4.55e-4)"		"unprognostic (1.49e-10)"	"unprognostic (2.90e-1)"	"unprognostic (1.50e-1)"		"unprognostic (3.59e-3)"	0.1	0.0	0.0	3.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	50.0	80.2	0.1	0.0	14.8	0.0	22.2	0.0	0.0	0.0	0.3	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	36.8	0.0	0.9	0.0	0.0	0.9	53.5	2.0	0.0	0.0	33.0	1.5	0.0	0.0	0.0	0.0	0.3	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.3	1.4	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	523.3	0.0	0.1	3.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.3	0.3
VGLL3	VGL-3	ENSG00000206538	"Vestigial like family member 3"	A8MV65	3	86876388-86991149	"Predicted intracellular proteins"	"Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 40.5"	"Cell type enhanced"	"Detected in many"		"Early spermatids: 138.1;Extravillous trophoblasts: 178.1;Late spermatids: 71.8;Leydig cells: 132.3;Peritubular cells: 149.3;Skeletal myocytes: 65.9;Syncytiotrophoblasts: 80.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 7.9;urothelial cancer: 6.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	5	"U-2197: 518.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA054983	Approved		Approved	Nucleoli,Cytosol		NA	NA			"Nucleoli, Cytosol"		"HPA054983: AB_2682663"	"unprognostic (9.08e-2)"	"unprognostic (4.47e-3)"	"unprognostic (5.97e-2)"	"unprognostic (1.54e-1)"	"unprognostic (2.98e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.77e-2)"	"unprognostic (3.86e-2)"	"unprognostic (1.38e-2)"	"unprognostic (4.94e-2)"	"unprognostic (3.70e-2)"	"unprognostic (3.44e-2)"	"unprognostic (2.73e-8)"	"unprognostic (3.85e-3)"	"unprognostic (1.27e-1)"	"unprognostic (5.42e-3)"	"unprognostic (1.05e-1)"	21.2	1.5	5.8	3.3	1.6	0.4	7.5	0.5	1.6	5.5	7.1	5.3	1.1	8.1	1.4	3.0	5.5	9.6	3.5	2.0	5.3	1.5	0.6	16.1	2.3	0.9	2.1	0.3	14.4	4.0	1.2	0.3	40.5	1.0	11.1	2.3	1.1	1.6	4.2	1.7	3.6	2.2	9.1	0.7	2.0	2.6	3.5	3.1	0.5	3.1	1.5	0.8	9.4	4.1	0.7	8.1	13.1	69.5	0.2	90.5	112.2	1.1	48.6	34.0	40.8	50.8	15.2	3.1	0.0	0.1	76.9	4.6	6.9	4.8	4.6	55.9	28.4	0.1	3.6	4.8	0.3	41.3	0.5	0.2	86.6	7.6	60.1	26.9	21.8	6.1	0.1	0.0	0.1	51.5	0.1	0.5	0.4	1.4	0.1	0.3	0.1	91.7	0.4	0.0	8.3	0.2	0.1	20.8	0.7	0.1	2.4	0.2	0.3	2.8	90.3	13.4	518.3	1.6	0.2	0.2	0.0	16.8	0.0	3.8	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	5.8	1.6	0.5	1.6	2.0	5.3	0.9	2.1	0.3	1.0	0.7	3.1	0.7	2.5	3.2	2.2	0.0	0.0	8.0	11.1	2.1	4.0	0.0	0.9	4.6	1.2	1.5	3.3	11.0	0.0	35.6	0.1	0.0	0.0	13.4	138.1	1.3	31.0	1.7	0.0	0.0	0.4	2.6	178.1	33.4	1.1	1.2	0.0	0.1	2.5	0.0	7.5	0.0	2.0	0.0	2.0	0.0	10.3	71.8	132.3	0.7	3.6	6.5	0.0	17.1	0.0	0.0	1.4	13.2	0.0	149.3	0.0	17.7	0.0	0.1	3.2	0.3	13.1	65.9	21.8	1.1	1.4	1.8	5.3	80.7	0.5	23.1	0.0	4.5
VSIG2	"CTH, CTXL"	ENSG00000019102	"V-set and immunoglobulin domain containing 2"	Q96IQ7	11	124747474-124752255	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"stomach 1: 624.9"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 514.3;Gastric mucus-secreting cells: 623.4;Intestinal goblet cells: 285.6;Pancreatic endocrine cells: 260.2;Paneth cells: 509.9;Undifferentiated cells: 207.0;Urothelial cells: 285.3"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 87.4"	"Low region specificity"	"Detected in many"			"Low immune cell specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	6	"OE19: 429.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA035919, HPA050147"	Enhanced		Approved	Nucleoplasm		NA	NA		78000	Nucleoplasm		"HPA035919: AB_10669981, HPA050147: AB_2681032"	"unprognostic (1.64e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.10e-2)"	"unprognostic (1.90e-1)"	"unprognostic (2.00e-1)"	"unprognostic (2.18e-3)"	"unprognostic (2.16e-1)"	"unprognostic (2.22e-2)"	"unprognostic (3.47e-3)"	"unprognostic (2.02e-1)"	"unprognostic (6.01e-2)"	"unprognostic (2.78e-2)"	"unprognostic (2.99e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.36e-2)"	4.0	0.8	2.8	7.1	5.1	3.4	9.6	0.6	6.5	29.9	0.5	137.5	6.2	4.9	0.4	26.6	17.7	26.7	4.2	2.9	2.3	6.3	3.0	46.1	0.9	1.9	3.1	1.9	1.1	2.0	2.0	1.7	6.1	2.8	58.7	139.1	0.7	32.0	4.4	2.3	1.5	2.8	4.8	0.7	1.6	624.9	0.9	2.5	0.2	44.1	2.5	2.5	85.3	9.4	3.3	0.4	0.1	4.8	3.4	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.9	1.5	2.4	0.1	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.3	16.6	0.0	7.9	0.7	0.5	3.0	0.1	0.0	0.0	0.0	0.3	2.8	0.3	0.3	0.6	0.0	1.6	0.1	0.1	0.6	429.0	3.7	0.4	3.6	0.1	0.1	69.2	0.3	0.9	0.1	4.6	0.0	0.7	0.4	2.4	4.1	1.8	1.1	0.3	0.8	0.3	0.0	0.0	0.6	1.7	0.9	0.0	1.2	0.0	0.0	0.1	0.5	0.0	0.5	0.1	0.4	0.0	0.6	0.4	0.1	0.3	0.2	0.0	0.7	0.9	2.8	5.1	0.6	6.5	2.9	2.3	1.9	3.1	1.9	2.8	0.7	2.5	3.3	4.6	125.0	51.6	0.0	1.5	0.8	19.2	25.3	2.8	1.5	31.5	18.4	0.7	82.9	99.3	3.7	0.0	0.0	0.6	514.3	1.9	14.6	0.0	12.1	1.8	5.0	66.8	0.0	0.2	90.9	0.1	0.9	623.4	18.3	1.3	0.1	3.9	0.2	0.1	0.0	0.1	285.6	20.3	0.3	2.7	0.0	1.5	2.4	3.6	1.0	0.0	0.0	0.0	0.0	0.1	260.2	509.9	0.0	0.7	61.6	1.3	0.1	36.7	0.0	0.0	0.3	6.2	0.2	0.7	0.7	0.4	0.0	2.2	0.3	207.0	285.3
WASH6P	"CXYorf1, FAM39A"	ENSG00000182484	"WASP family homolog 6, pseudogene"		X	156020826-156025710	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"			"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	6	"granulocytes: 225.3"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 10.6"	"Low region specificity"	"Detected in many"			"Low immune cell specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Low cell line specificity"	"Detected in many"											HPA002689	Uncertain		Approved	Vesicles		NA	NA			Vesicles		"HPA002689: AB_1078803"	"unprognostic (2.01e-1)"	"unprognostic (3.42e-2)"	"unprognostic (1.06e-1)"	"prognostic unfavorable (7.56e-4)"	"unprognostic (4.69e-2)"	"unprognostic (4.20e-2)"	"unprognostic (1.53e-2)"	"unprognostic (2.23e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.93e-2)"	"unprognostic (1.33e-3)"	"unprognostic (3.94e-2)"	"unprognostic (8.18e-2)"	"unprognostic (2.11e-1)"	"unprognostic (2.15e-1)"	"unprognostic (1.45e-1)"	"unprognostic (5.86e-3)"	1.0	1.3	0.9	1.7	1.2	3.5	1.0	1.0	1.5	0.5	1.0	1.0	2.7	1.6	2.7	0.4	1.2	0.8	1.2	1.1	1.0	2.3	0.7	1.2	1.8	2.2	0.9	0.5	1.7	4.2	0.7		1.2	1.7	1.1	0.7	3.6	0.9	1.2	6.5	3.1	2.2	0.6	0.5	2.9	1.7	2.3	1.2	1.2	1.2	0.6	0.9	0.7		1.8	9.6	1.5	1.6	5.0	0.7	0.0	5.9	2.5	0.4	0.8	1.5	0.4	5.2	3.1	1.7	1.4	4.0	7.3	1.2	2.0	0.7	0.7	1.7	4.7	0.6	1.3	0.0	1.8	3.7	0.2	0.9	1.4	2.0	0.5	1.2	0.9	6.2	4.6	0.0	1.2	7.9	4.1	2.3	4.2	0.9	7.0	3.0	2.0	0.3	0.4	4.2	6.3	3.1	4.7	5.7	1.3	6.6	5.8	3.1	3.5	3.4	3.3	3.9	8.0	9.8	1.8	0.8	3.1	3.9	0.4	0.2	0.0	0.3	0.2	0.3	0.4	0.0	0.3	0.2	0.3	0.1	0.2	0.1	0.8	1.1	0.2	0.4	0.3	0.9	1.2	1.0	1.5	1.1	1.0	2.2	0.9	0.5	1.7	0.5	1.2	1.8	0.0	35.3	23.1	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	9.6	0.0	0.0	0.0	0.0	0.0	0.2	5.3	0.0	0.0	0.0	0.0	1.5	0.0	0.0	225.3	0.0	0.0	0.0	0.0	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.2	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	5.3	0.0
ZSCAN4	"FLJ35105, ZNF494"	ENSG00000180532	"Zinc finger and SCAN domain containing 4"	Q8NAM6	19	57668935-57679152	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in single"		"stomach 1: 2.8"	"Cell type enhanced"	"Detected in some"		"Collecting duct cells: 1.8;Microglial cells: 1.0;Syncytiotrophoblasts: 1.6"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA006491	Uncertain					NA	NA					"HPA006491: AB_10603385"	"unprognostic (1.96e-1)"	"unprognostic (2.55e-1)"		"unprognostic (2.52e-1)"	"unprognostic (1.44e-1)"	"unprognostic (2.75e-1)"		"unprognostic (4.04e-2)"	"unprognostic (2.59e-2)"	"unprognostic (2.85e-3)"	"unprognostic (1.06e-2)"	"unprognostic (7.26e-2)"	"unprognostic (1.45e-2)"	"unprognostic (3.33e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.69e-5)"	"unprognostic (1.73e-1)"	0.2	0.0	0.2	0.0	0.3	0.3	0.1	0.9	0.6	0.3	0.1	0.1	0.1	0.0	0.4	0.1	0.4	0.1	0.3	0.3	0.2	0.1	0.0	0.3	0.1	0.3	0.1	0.3	0.0	0.0	0.0	0.2	0.8	0.4	0.6	0.1	0.2	0.6	0.6	0.2	0.7	0.1	0.0	0.1	0.2	2.8	0.4	0.2	0.2	0.3	0.2	0.0	0.9	0.2	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.9	0.6	0.3	0.2	0.3	0.1	0.3	0.4	0.1	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.8	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.1	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.3
